<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
    <id>https://macwaneric.github.io/cancer.rss.feed/index.html</id>
    <title>CancerFeed</title>
    <updated>2023-02-19T01:04:29.136Z</updated>
    <generator>osmosfeed 1.15.1</generator>
    <link rel="alternate" href="https://macwaneric.github.io/cancer.rss.feed/index.html"/>
    <link rel="self" href="https://macwaneric.github.io/cancer.rss.feed/feed.atom"/>
    <entry>
        <title type="html"><![CDATA[Prevalence and Therapeutic Implications of Clonal Hematopoiesis of Indeterminate Potential in Young Patients With Stroke]]></title>
        <id>pubmed:36789775</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36789775/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230218200425&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Using genetic screening for myeloid disorders in patients with stroke of predominantly undetermined etiology, we found a 3-fold higher CHIP prevalence than in the general population. We identified high-risk CHIP and previously covert myeloproliferative neoplasms as potential stroke etiologies in 4.4% and 1% of patients, respectively. Our findings demonstrate the diagnostic and therapeutic yield of genetic screening in young patients with stroke. Future studies should investigate the...]]></summary>
        <author>
            <name>Ernst Mayerhofer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Landscape of Patients with Germline <em>RUNX1</em> Variants and Familial Platelet Disorder with Myeloid Malignancy]]></title>
        <id>pubmed:36789433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36789433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230218200425&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline RUNX1 mutations lead to familial platelet disorder with associated myeloid malignancies (FPDMM), which is characterized by thrombocytopenia and a life-long risk (35-45%) of hematological malignancies. We recently launched a longitudinal natural history study for patients with FPDMM at the NIH Clinical Center. Among 29 families with research genomic data, 28 different germline RUNX1 variants were detected. Besides missense mutations enriched in Runt homology domain and loss-of-function...]]></summary>
        <author>
            <name>Kai Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Investigation of the Impact of Clonal Hematopoiesis on Severity and Pathophysiology of COVID-19 in Rhesus Macaques]]></title>
        <id>pubmed:36789423</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36789423/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230218200425&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clinical manifestations of COVID-19 vary widely, ranging from asymptomatic to severe respiratory failure with profound inflammation. Although risk factors for severe illness have been identified, definitive determinants remain elusive. Clonal hematopoiesis (CH), the expansion of hematopoietic stem and progenitor cells bearing acquired somatic mutations, is associated with advanced age and hyperinflammation. Given the similar age range and hyperinflammatory phenotype between frequent CH and...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and Therapeutic Implications of Clonal Hematopoiesis of Indeterminate Potential in Young Patients With Stroke]]></title>
        <id>pubmed:36789775</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36789775/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Using genetic screening for myeloid disorders in patients with stroke of predominantly undetermined etiology, we found a 3-fold higher CHIP prevalence than in the general population. We identified high-risk CHIP and previously covert myeloproliferative neoplasms as potential stroke etiologies in 4.4% and 1% of patients, respectively. Our findings demonstrate the diagnostic and therapeutic yield of genetic screening in young patients with stroke. Future studies should investigate the...]]></summary>
        <author>
            <name>Ernst Mayerhofer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Landscape of Patients with Germline <em>RUNX1</em> Variants and Familial Platelet Disorder with Myeloid Malignancy]]></title>
        <id>pubmed:36789433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36789433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline RUNX1 mutations lead to familial platelet disorder with associated myeloid malignancies (FPDMM), which is characterized by thrombocytopenia and a life-long risk (35-45%) of hematological malignancies. We recently launched a longitudinal natural history study for patients with FPDMM at the NIH Clinical Center. Among 29 families with research genomic data, 28 different germline RUNX1 variants were detected. Besides missense mutations enriched in Runt homology domain and loss-of-function...]]></summary>
        <author>
            <name>Kai Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Investigation of the Impact of Clonal Hematopoiesis on Severity and Pathophysiology of COVID-19 in Rhesus Macaques]]></title>
        <id>pubmed:36789423</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36789423/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clinical manifestations of COVID-19 vary widely, ranging from asymptomatic to severe respiratory failure with profound inflammation. Although risk factors for severe illness have been identified, definitive determinants remain elusive. Clonal hematopoiesis (CH), the expansion of hematopoietic stem and progenitor cells bearing acquired somatic mutations, is associated with advanced age and hyperinflammation. Given the similar age range and hyperinflammatory phenotype between frequent CH and...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and Therapeutic Implications of Clonal Hematopoiesis of Indeterminate Potential in Young Patients With Stroke]]></title>
        <id>pubmed:36789775</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36789775/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Using genetic screening for myeloid disorders in patients with stroke of predominantly undetermined etiology, we found a 3-fold higher CHIP prevalence than in the general population. We identified high-risk CHIP and previously covert myeloproliferative neoplasms as potential stroke etiologies in 4.4% and 1% of patients, respectively. Our findings demonstrate the diagnostic and therapeutic yield of genetic screening in young patients with stroke. Future studies should investigate the...]]></summary>
        <author>
            <name>Ernst Mayerhofer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Landscape of Patients with Germline <em>RUNX1</em> Variants and Familial Platelet Disorder with Myeloid Malignancy]]></title>
        <id>pubmed:36789433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36789433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline RUNX1 mutations lead to familial platelet disorder with associated myeloid malignancies (FPDMM), which is characterized by thrombocytopenia and a life-long risk (35-45%) of hematological malignancies. We recently launched a longitudinal natural history study for patients with FPDMM at the NIH Clinical Center. Among 29 families with research genomic data, 28 different germline RUNX1 variants were detected. Besides missense mutations enriched in Runt homology domain and loss-of-function...]]></summary>
        <author>
            <name>Kai Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Investigation of the Impact of Clonal Hematopoiesis on Severity and Pathophysiology of COVID-19 in Rhesus Macaques]]></title>
        <id>pubmed:36789423</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36789423/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clinical manifestations of COVID-19 vary widely, ranging from asymptomatic to severe respiratory failure with profound inflammation. Although risk factors for severe illness have been identified, definitive determinants remain elusive. Clonal hematopoiesis (CH), the expansion of hematopoietic stem and progenitor cells bearing acquired somatic mutations, is associated with advanced age and hyperinflammation. Given the similar age range and hyperinflammatory phenotype between frequent CH and...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and Therapeutic Implications of Clonal Hematopoiesis of Indeterminate Potential in Young Patients With Stroke]]></title>
        <id>pubmed:36789775</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36789775/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Using genetic screening for myeloid disorders in patients with stroke of predominantly undetermined etiology, we found a 3-fold higher CHIP prevalence than in the general population. We identified high-risk CHIP and previously covert myeloproliferative neoplasms as potential stroke etiologies in 4.4% and 1% of patients, respectively. Our findings demonstrate the diagnostic and therapeutic yield of genetic screening in young patients with stroke. Future studies should investigate the...]]></summary>
        <author>
            <name>Ernst Mayerhofer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Landscape of Patients with Germline <em>RUNX1</em> Variants and Familial Platelet Disorder with Myeloid Malignancy]]></title>
        <id>pubmed:36789433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36789433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline RUNX1 mutations lead to familial platelet disorder with associated myeloid malignancies (FPDMM), which is characterized by thrombocytopenia and a life-long risk (35-45%) of hematological malignancies. We recently launched a longitudinal natural history study for patients with FPDMM at the NIH Clinical Center. Among 29 families with research genomic data, 28 different germline RUNX1 variants were detected. Besides missense mutations enriched in Runt homology domain and loss-of-function...]]></summary>
        <author>
            <name>Kai Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Investigation of the Impact of Clonal Hematopoiesis on Severity and Pathophysiology of COVID-19 in Rhesus Macaques]]></title>
        <id>pubmed:36789423</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36789423/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clinical manifestations of COVID-19 vary widely, ranging from asymptomatic to severe respiratory failure with profound inflammation. Although risk factors for severe illness have been identified, definitive determinants remain elusive. Clonal hematopoiesis (CH), the expansion of hematopoietic stem and progenitor cells bearing acquired somatic mutations, is associated with advanced age and hyperinflammation. Given the similar age range and hyperinflammatory phenotype between frequent CH and...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct Mutagenic Activity of APOBEC3G Cytidine Deaminase Identified in Bladder Cancer]]></title>
        <id>pubmed:36789568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36789568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230218200426&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The APOBEC cytidine deaminase enzyme family is linked to mutational signatures identified in cancer. While previous work has provided insights into the role of APOBEC3A and APOBEC3B in mutational processes in cancer, understanding of the mutational signatures induced by other APOBEC family members is limited. In this issue of Cancer Research, Liu and colleagues investigated the role of APOBEC3G (A3G) in bladder cancer. The authors revealed that transgenic expression of A3G in a murine bladder...]]></summary>
        <author>
            <name>Deborah Caswell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct Mutagenic Activity of APOBEC3G Cytidine Deaminase Identified in Bladder Cancer]]></title>
        <id>pubmed:36789568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36789568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The APOBEC cytidine deaminase enzyme family is linked to mutational signatures identified in cancer. While previous work has provided insights into the role of APOBEC3A and APOBEC3B in mutational processes in cancer, understanding of the mutational signatures induced by other APOBEC family members is limited. In this issue of Cancer Research, Liu and colleagues investigated the role of APOBEC3G (A3G) in bladder cancer. The authors revealed that transgenic expression of A3G in a murine bladder...]]></summary>
        <author>
            <name>Deborah Caswell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Distinct Mutagenic Activity of APOBEC3G Cytidine Deaminase Identified in Bladder Cancer]]></title>
        <id>pubmed:36789568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36789568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The APOBEC cytidine deaminase enzyme family is linked to mutational signatures identified in cancer. While previous work has provided insights into the role of APOBEC3A and APOBEC3B in mutational processes in cancer, understanding of the mutational signatures induced by other APOBEC family members is limited. In this issue of Cancer Research, Liu and colleagues investigated the role of APOBEC3G (A3G) in bladder cancer. The authors revealed that transgenic expression of A3G in a murine bladder...]]></summary>
        <author>
            <name>Deborah Caswell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Evolves from TP53-Mutated Clonal Hematopoiesis]]></title>
        <id>pubmed:36779909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36779909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230218200425&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low-hypodiploid acute lymphoblastic leukemia (LH-ALL) in both children and adults is characterized by biallelic TP53 alterations in virtually all cases. However, in contrast to a common germline origin of the TP53 mutations in pediatric cases, those in adult cases are mostly somatic and are derived from age-related clonal hematopoiesis (ARCH), highlighting the role of TP53-mutant ARCH in the development not only of myeloid leukemogenesis but also of LH-ALL in aged populations. See related...]]></summary>
        <author>
            <name>Ryunosuke Saiki</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients]]></title>
        <id>pubmed:36776372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36776372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230218200425&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Longitudinal monitoring using tumor-informed ctDNA testing shows high analytical sensitivity, low probability of false-positive results due to CH mutations, and improved sensitivity in detecting recurrence which may modify the clinical management of CRC.]]></summary>
        <author>
            <name>Hiu Ting Chan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Evolves from TP53-Mutated Clonal Hematopoiesis]]></title>
        <id>pubmed:36779909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36779909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low-hypodiploid acute lymphoblastic leukemia (LH-ALL) in both children and adults is characterized by biallelic TP53 alterations in virtually all cases. However, in contrast to a common germline origin of the TP53 mutations in pediatric cases, those in adult cases are mostly somatic and are derived from age-related clonal hematopoiesis (ARCH), highlighting the role of TP53-mutant ARCH in the development not only of myeloid leukemogenesis but also of LH-ALL in aged populations. See related...]]></summary>
        <author>
            <name>Ryunosuke Saiki</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients]]></title>
        <id>pubmed:36776372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36776372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Longitudinal monitoring using tumor-informed ctDNA testing shows high analytical sensitivity, low probability of false-positive results due to CH mutations, and improved sensitivity in detecting recurrence which may modify the clinical management of CRC.]]></summary>
        <author>
            <name>Hiu Ting Chan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Evolves from TP53-Mutated Clonal Hematopoiesis]]></title>
        <id>pubmed:36779909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36779909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low-hypodiploid acute lymphoblastic leukemia (LH-ALL) in both children and adults is characterized by biallelic TP53 alterations in virtually all cases. However, in contrast to a common germline origin of the TP53 mutations in pediatric cases, those in adult cases are mostly somatic and are derived from age-related clonal hematopoiesis (ARCH), highlighting the role of TP53-mutant ARCH in the development not only of myeloid leukemogenesis but also of LH-ALL in aged populations. See related...]]></summary>
        <author>
            <name>Ryunosuke Saiki</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients]]></title>
        <id>pubmed:36776372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36776372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Longitudinal monitoring using tumor-informed ctDNA testing shows high analytical sensitivity, low probability of false-positive results due to CH mutations, and improved sensitivity in detecting recurrence which may modify the clinical management of CRC.]]></summary>
        <author>
            <name>Hiu Ting Chan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Evolves from TP53-Mutated Clonal Hematopoiesis]]></title>
        <id>pubmed:36779909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36779909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low-hypodiploid acute lymphoblastic leukemia (LH-ALL) in both children and adults is characterized by biallelic TP53 alterations in virtually all cases. However, in contrast to a common germline origin of the TP53 mutations in pediatric cases, those in adult cases are mostly somatic and are derived from age-related clonal hematopoiesis (ARCH), highlighting the role of TP53-mutant ARCH in the development not only of myeloid leukemogenesis but also of LH-ALL in aged populations. See related...]]></summary>
        <author>
            <name>Ryunosuke Saiki</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients]]></title>
        <id>pubmed:36776372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36776372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Longitudinal monitoring using tumor-informed ctDNA testing shows high analytical sensitivity, low probability of false-positive results due to CH mutations, and improved sensitivity in detecting recurrence which may modify the clinical management of CRC.]]></summary>
        <author>
            <name>Hiu Ting Chan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Evolves from TP53-Mutated Clonal Hematopoiesis]]></title>
        <id>pubmed:36779909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36779909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low-hypodiploid acute lymphoblastic leukemia (LH-ALL) in both children and adults is characterized by biallelic TP53 alterations in virtually all cases. However, in contrast to a common germline origin of the TP53 mutations in pediatric cases, those in adult cases are mostly somatic and are derived from age-related clonal hematopoiesis (ARCH), highlighting the role of TP53-mutant ARCH in the development not only of myeloid leukemogenesis but also of LH-ALL in aged populations. See related...]]></summary>
        <author>
            <name>Ryunosuke Saiki</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients]]></title>
        <id>pubmed:36776372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36776372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Longitudinal monitoring using tumor-informed ctDNA testing shows high analytical sensitivity, low probability of false-positive results due to CH mutations, and improved sensitivity in detecting recurrence which may modify the clinical management of CRC.]]></summary>
        <author>
            <name>Hiu Ting Chan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Evolves from TP53-Mutated Clonal Hematopoiesis]]></title>
        <id>pubmed:36779909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36779909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low-hypodiploid acute lymphoblastic leukemia (LH-ALL) in both children and adults is characterized by biallelic TP53 alterations in virtually all cases. However, in contrast to a common germline origin of the TP53 mutations in pediatric cases, those in adult cases are mostly somatic and are derived from age-related clonal hematopoiesis (ARCH), highlighting the role of TP53-mutant ARCH in the development not only of myeloid leukemogenesis but also of LH-ALL in aged populations. See related...]]></summary>
        <author>
            <name>Ryunosuke Saiki</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients]]></title>
        <id>pubmed:36776372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36776372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Longitudinal monitoring using tumor-informed ctDNA testing shows high analytical sensitivity, low probability of false-positive results due to CH mutations, and improved sensitivity in detecting recurrence which may modify the clinical management of CRC.]]></summary>
        <author>
            <name>Hiu Ting Chan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:36778226</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36778226/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230218200426&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing mutational lineages in breast cancer by multi-patient-targeted single-cell DNA sequencing]]></title>
        <id>pubmed:36777188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36777188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230218200426&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell DNA sequencing (scDNA-seq) methods are powerful tools for profiling mutations in cancer cells; however, most genomic regions sequenced in single cells are non-informative. To overcome this issue, we developed a multi-patient-targeted (MPT) scDNA-seq method. MPT involves first performing bulk exome sequencing across a cohort of cancer patients to identify somatic mutations, which are then pooled together to develop a single custom targeted panel for high-throughput scDNA-seq using a...]]></summary>
        <author>
            <name>Jake Leighton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Patient-derived models: Advanced tools for precision medicine in neuroblastoma]]></title>
        <id>pubmed:36776363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36776363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230218200426&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma is a childhood cancer derived from the sympathetic nervous system. High-risk neuroblastoma patients have a poor overall survival and account for ~15% of childhood cancer deaths. There is thus a need for clinically relevant and authentic models of neuroblastoma that closely resemble the human disease to further interrogate underlying mechanisms and to develop novel therapeutic strategies. Here we review recent developments in patient-derived neuroblastoma xenograft models and in...]]></summary>
        <author>
            <name>Kristina Aaltonen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:36778226</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36778226/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing mutational lineages in breast cancer by multi-patient-targeted single-cell DNA sequencing]]></title>
        <id>pubmed:36777188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36777188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell DNA sequencing (scDNA-seq) methods are powerful tools for profiling mutations in cancer cells; however, most genomic regions sequenced in single cells are non-informative. To overcome this issue, we developed a multi-patient-targeted (MPT) scDNA-seq method. MPT involves first performing bulk exome sequencing across a cohort of cancer patients to identify somatic mutations, which are then pooled together to develop a single custom targeted panel for high-throughput scDNA-seq using a...]]></summary>
        <author>
            <name>Jake Leighton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Patient-derived models: Advanced tools for precision medicine in neuroblastoma]]></title>
        <id>pubmed:36776363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36776363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma is a childhood cancer derived from the sympathetic nervous system. High-risk neuroblastoma patients have a poor overall survival and account for ~15% of childhood cancer deaths. There is thus a need for clinically relevant and authentic models of neuroblastoma that closely resemble the human disease to further interrogate underlying mechanisms and to develop novel therapeutic strategies. Here we review recent developments in patient-derived neuroblastoma xenograft models and in...]]></summary>
        <author>
            <name>Kristina Aaltonen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:36778226</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36778226/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing mutational lineages in breast cancer by multi-patient-targeted single-cell DNA sequencing]]></title>
        <id>pubmed:36777188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36777188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell DNA sequencing (scDNA-seq) methods are powerful tools for profiling mutations in cancer cells; however, most genomic regions sequenced in single cells are non-informative. To overcome this issue, we developed a multi-patient-targeted (MPT) scDNA-seq method. MPT involves first performing bulk exome sequencing across a cohort of cancer patients to identify somatic mutations, which are then pooled together to develop a single custom targeted panel for high-throughput scDNA-seq using a...]]></summary>
        <author>
            <name>Jake Leighton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Patient-derived models: Advanced tools for precision medicine in neuroblastoma]]></title>
        <id>pubmed:36776363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36776363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma is a childhood cancer derived from the sympathetic nervous system. High-risk neuroblastoma patients have a poor overall survival and account for ~15% of childhood cancer deaths. There is thus a need for clinically relevant and authentic models of neuroblastoma that closely resemble the human disease to further interrogate underlying mechanisms and to develop novel therapeutic strategies. Here we review recent developments in patient-derived neuroblastoma xenograft models and in...]]></summary>
        <author>
            <name>Kristina Aaltonen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:36778226</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36778226/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing mutational lineages in breast cancer by multi-patient-targeted single-cell DNA sequencing]]></title>
        <id>pubmed:36777188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36777188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell DNA sequencing (scDNA-seq) methods are powerful tools for profiling mutations in cancer cells; however, most genomic regions sequenced in single cells are non-informative. To overcome this issue, we developed a multi-patient-targeted (MPT) scDNA-seq method. MPT involves first performing bulk exome sequencing across a cohort of cancer patients to identify somatic mutations, which are then pooled together to develop a single custom targeted panel for high-throughput scDNA-seq using a...]]></summary>
        <author>
            <name>Jake Leighton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Patient-derived models: Advanced tools for precision medicine in neuroblastoma]]></title>
        <id>pubmed:36776363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36776363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma is a childhood cancer derived from the sympathetic nervous system. High-risk neuroblastoma patients have a poor overall survival and account for ~15% of childhood cancer deaths. There is thus a need for clinically relevant and authentic models of neuroblastoma that closely resemble the human disease to further interrogate underlying mechanisms and to develop novel therapeutic strategies. Here we review recent developments in patient-derived neuroblastoma xenograft models and in...]]></summary>
        <author>
            <name>Kristina Aaltonen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:36778226</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36778226/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing mutational lineages in breast cancer by multi-patient-targeted single-cell DNA sequencing]]></title>
        <id>pubmed:36777188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36777188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell DNA sequencing (scDNA-seq) methods are powerful tools for profiling mutations in cancer cells; however, most genomic regions sequenced in single cells are non-informative. To overcome this issue, we developed a multi-patient-targeted (MPT) scDNA-seq method. MPT involves first performing bulk exome sequencing across a cohort of cancer patients to identify somatic mutations, which are then pooled together to develop a single custom targeted panel for high-throughput scDNA-seq using a...]]></summary>
        <author>
            <name>Jake Leighton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Patient-derived models: Advanced tools for precision medicine in neuroblastoma]]></title>
        <id>pubmed:36776363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36776363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma is a childhood cancer derived from the sympathetic nervous system. High-risk neuroblastoma patients have a poor overall survival and account for ~15% of childhood cancer deaths. There is thus a need for clinically relevant and authentic models of neuroblastoma that closely resemble the human disease to further interrogate underlying mechanisms and to develop novel therapeutic strategies. Here we review recent developments in patient-derived neuroblastoma xenograft models and in...]]></summary>
        <author>
            <name>Kristina Aaltonen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:36778226</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36778226/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing mutational lineages in breast cancer by multi-patient-targeted single-cell DNA sequencing]]></title>
        <id>pubmed:36777188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36777188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell DNA sequencing (scDNA-seq) methods are powerful tools for profiling mutations in cancer cells; however, most genomic regions sequenced in single cells are non-informative. To overcome this issue, we developed a multi-patient-targeted (MPT) scDNA-seq method. MPT involves first performing bulk exome sequencing across a cohort of cancer patients to identify somatic mutations, which are then pooled together to develop a single custom targeted panel for high-throughput scDNA-seq using a...]]></summary>
        <author>
            <name>Jake Leighton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Patient-derived models: Advanced tools for precision medicine in neuroblastoma]]></title>
        <id>pubmed:36776363</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36776363/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-13T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma is a childhood cancer derived from the sympathetic nervous system. High-risk neuroblastoma patients have a poor overall survival and account for ~15% of childhood cancer deaths. There is thus a need for clinically relevant and authentic models of neuroblastoma that closely resemble the human disease to further interrogate underlying mechanisms and to develop novel therapeutic strategies. Here we review recent developments in patient-derived neuroblastoma xenograft models and in...]]></summary>
        <author>
            <name>Kristina Aaltonen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shedding Light on the Pathogenesis of Splanchnic Vein Thrombosis]]></title>
        <id>pubmed:36768584</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36768584/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230218200425&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Splanchnic vein thrombosis is a rare but potentially life-threatening manifestation of venous thromboembolism, with challenging implications both at the pathological and therapeutic level. It is frequently associated with liver cirrhosis, but it could also be provoked by myeloproliferative disorders, cancer of various gastroenterological origin, abdominal infections and thrombophilia. A portion of splanchnic vein thrombosis is still classified as idiopathic. Here, we review the mechanisms of...]]></summary>
        <author>
            <name>Sofia Camerlo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shedding Light on the Pathogenesis of Splanchnic Vein Thrombosis]]></title>
        <id>pubmed:36768584</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36768584/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Splanchnic vein thrombosis is a rare but potentially life-threatening manifestation of venous thromboembolism, with challenging implications both at the pathological and therapeutic level. It is frequently associated with liver cirrhosis, but it could also be provoked by myeloproliferative disorders, cancer of various gastroenterological origin, abdominal infections and thrombophilia. A portion of splanchnic vein thrombosis is still classified as idiopathic. Here, we review the mechanisms of...]]></summary>
        <author>
            <name>Sofia Camerlo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shedding Light on the Pathogenesis of Splanchnic Vein Thrombosis]]></title>
        <id>pubmed:36768584</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36768584/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Splanchnic vein thrombosis is a rare but potentially life-threatening manifestation of venous thromboembolism, with challenging implications both at the pathological and therapeutic level. It is frequently associated with liver cirrhosis, but it could also be provoked by myeloproliferative disorders, cancer of various gastroenterological origin, abdominal infections and thrombophilia. A portion of splanchnic vein thrombosis is still classified as idiopathic. Here, we review the mechanisms of...]]></summary>
        <author>
            <name>Sofia Camerlo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shedding Light on the Pathogenesis of Splanchnic Vein Thrombosis]]></title>
        <id>pubmed:36768584</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36768584/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Splanchnic vein thrombosis is a rare but potentially life-threatening manifestation of venous thromboembolism, with challenging implications both at the pathological and therapeutic level. It is frequently associated with liver cirrhosis, but it could also be provoked by myeloproliferative disorders, cancer of various gastroenterological origin, abdominal infections and thrombophilia. A portion of splanchnic vein thrombosis is still classified as idiopathic. Here, we review the mechanisms of...]]></summary>
        <author>
            <name>Sofia Camerlo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shedding Light on the Pathogenesis of Splanchnic Vein Thrombosis]]></title>
        <id>pubmed:36768584</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36768584/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Splanchnic vein thrombosis is a rare but potentially life-threatening manifestation of venous thromboembolism, with challenging implications both at the pathological and therapeutic level. It is frequently associated with liver cirrhosis, but it could also be provoked by myeloproliferative disorders, cancer of various gastroenterological origin, abdominal infections and thrombophilia. A portion of splanchnic vein thrombosis is still classified as idiopathic. Here, we review the mechanisms of...]]></summary>
        <author>
            <name>Sofia Camerlo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shedding Light on the Pathogenesis of Splanchnic Vein Thrombosis]]></title>
        <id>pubmed:36768584</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36768584/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Splanchnic vein thrombosis is a rare but potentially life-threatening manifestation of venous thromboembolism, with challenging implications both at the pathological and therapeutic level. It is frequently associated with liver cirrhosis, but it could also be provoked by myeloproliferative disorders, cancer of various gastroenterological origin, abdominal infections and thrombophilia. A portion of splanchnic vein thrombosis is still classified as idiopathic. Here, we review the mechanisms of...]]></summary>
        <author>
            <name>Sofia Camerlo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shedding Light on the Pathogenesis of Splanchnic Vein Thrombosis]]></title>
        <id>pubmed:36768584</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36768584/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Splanchnic vein thrombosis is a rare but potentially life-threatening manifestation of venous thromboembolism, with challenging implications both at the pathological and therapeutic level. It is frequently associated with liver cirrhosis, but it could also be provoked by myeloproliferative disorders, cancer of various gastroenterological origin, abdominal infections and thrombophilia. A portion of splanchnic vein thrombosis is still classified as idiopathic. Here, we review the mechanisms of...]]></summary>
        <author>
            <name>Sofia Camerlo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shedding Light on the Pathogenesis of Splanchnic Vein Thrombosis]]></title>
        <id>pubmed:36768584</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36768584/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Splanchnic vein thrombosis is a rare but potentially life-threatening manifestation of venous thromboembolism, with challenging implications both at the pathological and therapeutic level. It is frequently associated with liver cirrhosis, but it could also be provoked by myeloproliferative disorders, cancer of various gastroenterological origin, abdominal infections and thrombophilia. A portion of splanchnic vein thrombosis is still classified as idiopathic. Here, we review the mechanisms of...]]></summary>
        <author>
            <name>Sofia Camerlo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of <em>TP53</em> in Adaptation and Evolution]]></title>
        <id>pubmed:36766853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36766853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230218200426&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The TP53 gene is a major player in cancer formation, and it is considered the most important tumor suppressor gene. The p53 protein acts as a transcription factor, and it is involved in DNA repair, senescence, cell-cycle control, autophagy, and apoptosis. Beyond cancer, there is evidence that TP53 is associated with fertility, aging, and longevity. Additionally, more evidence exists that genetic variants in TP53 are associated with environmental adaptation. Special TP53 amino-acid residues or...]]></summary>
        <author>
            <name>Konstantinos Voskarides</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options]]></title>
        <id>pubmed:36765799</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36765799/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230218200426&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The development of tyrosine kinase inhibitors (TKIs) targeting the mutant epidermal growth factor receptor (EGFR) protein initiated the success story of targeted therapies in non-small-cell lung cancer (NSCLC). Osimertinib, a third-generation EGFR-TKI, is currently indicated as first-line therapy in patients with NSCLC with sensitizing EGFR mutations, as second-line therapy in patients who present the resistance-associated mutation T790M after treatment with previous EGFR-TKIs, and as adjuvant...]]></summary>
        <author>
            <name>Georgia Gomatou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Is Reflex Germline <em>BRCA1/2</em> Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?]]></title>
        <id>pubmed:36765687</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36765687/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230218200426&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Women diagnosed with non-mucinous high-grade epithelial ovarian cancer (EOC) in England are often reflex-tested for germline and tumour BRCA1/2 variants. The value of germline BRCA1/2 testing in women diagnosed aged 80 is questionable. We performed an observational study of all women diagnosed with non-mucinous high-grade EOC who underwent germline and tumour BRCA1/2 testing by the North West of England Genomic Laboratory Hub. A subgroup of women also underwent germline testing using a panel of...]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of <em>TP53</em> in Adaptation and Evolution]]></title>
        <id>pubmed:36766853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36766853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The TP53 gene is a major player in cancer formation, and it is considered the most important tumor suppressor gene. The p53 protein acts as a transcription factor, and it is involved in DNA repair, senescence, cell-cycle control, autophagy, and apoptosis. Beyond cancer, there is evidence that TP53 is associated with fertility, aging, and longevity. Additionally, more evidence exists that genetic variants in TP53 are associated with environmental adaptation. Special TP53 amino-acid residues or...]]></summary>
        <author>
            <name>Konstantinos Voskarides</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options]]></title>
        <id>pubmed:36765799</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36765799/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The development of tyrosine kinase inhibitors (TKIs) targeting the mutant epidermal growth factor receptor (EGFR) protein initiated the success story of targeted therapies in non-small-cell lung cancer (NSCLC). Osimertinib, a third-generation EGFR-TKI, is currently indicated as first-line therapy in patients with NSCLC with sensitizing EGFR mutations, as second-line therapy in patients who present the resistance-associated mutation T790M after treatment with previous EGFR-TKIs, and as adjuvant...]]></summary>
        <author>
            <name>Georgia Gomatou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Is Reflex Germline <em>BRCA1/2</em> Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?]]></title>
        <id>pubmed:36765687</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36765687/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Women diagnosed with non-mucinous high-grade epithelial ovarian cancer (EOC) in England are often reflex-tested for germline and tumour BRCA1/2 variants. The value of germline BRCA1/2 testing in women diagnosed aged 80 is questionable. We performed an observational study of all women diagnosed with non-mucinous high-grade EOC who underwent germline and tumour BRCA1/2 testing by the North West of England Genomic Laboratory Hub. A subgroup of women also underwent germline testing using a panel of...]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of <em>TP53</em> in Adaptation and Evolution]]></title>
        <id>pubmed:36766853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36766853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The TP53 gene is a major player in cancer formation, and it is considered the most important tumor suppressor gene. The p53 protein acts as a transcription factor, and it is involved in DNA repair, senescence, cell-cycle control, autophagy, and apoptosis. Beyond cancer, there is evidence that TP53 is associated with fertility, aging, and longevity. Additionally, more evidence exists that genetic variants in TP53 are associated with environmental adaptation. Special TP53 amino-acid residues or...]]></summary>
        <author>
            <name>Konstantinos Voskarides</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options]]></title>
        <id>pubmed:36765799</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36765799/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The development of tyrosine kinase inhibitors (TKIs) targeting the mutant epidermal growth factor receptor (EGFR) protein initiated the success story of targeted therapies in non-small-cell lung cancer (NSCLC). Osimertinib, a third-generation EGFR-TKI, is currently indicated as first-line therapy in patients with NSCLC with sensitizing EGFR mutations, as second-line therapy in patients who present the resistance-associated mutation T790M after treatment with previous EGFR-TKIs, and as adjuvant...]]></summary>
        <author>
            <name>Georgia Gomatou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Is Reflex Germline <em>BRCA1/2</em> Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?]]></title>
        <id>pubmed:36765687</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36765687/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Women diagnosed with non-mucinous high-grade epithelial ovarian cancer (EOC) in England are often reflex-tested for germline and tumour BRCA1/2 variants. The value of germline BRCA1/2 testing in women diagnosed aged 80 is questionable. We performed an observational study of all women diagnosed with non-mucinous high-grade EOC who underwent germline and tumour BRCA1/2 testing by the North West of England Genomic Laboratory Hub. A subgroup of women also underwent germline testing using a panel of...]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of <em>TP53</em> in Adaptation and Evolution]]></title>
        <id>pubmed:36766853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36766853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The TP53 gene is a major player in cancer formation, and it is considered the most important tumor suppressor gene. The p53 protein acts as a transcription factor, and it is involved in DNA repair, senescence, cell-cycle control, autophagy, and apoptosis. Beyond cancer, there is evidence that TP53 is associated with fertility, aging, and longevity. Additionally, more evidence exists that genetic variants in TP53 are associated with environmental adaptation. Special TP53 amino-acid residues or...]]></summary>
        <author>
            <name>Konstantinos Voskarides</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options]]></title>
        <id>pubmed:36765799</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36765799/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The development of tyrosine kinase inhibitors (TKIs) targeting the mutant epidermal growth factor receptor (EGFR) protein initiated the success story of targeted therapies in non-small-cell lung cancer (NSCLC). Osimertinib, a third-generation EGFR-TKI, is currently indicated as first-line therapy in patients with NSCLC with sensitizing EGFR mutations, as second-line therapy in patients who present the resistance-associated mutation T790M after treatment with previous EGFR-TKIs, and as adjuvant...]]></summary>
        <author>
            <name>Georgia Gomatou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Is Reflex Germline <em>BRCA1/2</em> Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?]]></title>
        <id>pubmed:36765687</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36765687/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Women diagnosed with non-mucinous high-grade epithelial ovarian cancer (EOC) in England are often reflex-tested for germline and tumour BRCA1/2 variants. The value of germline BRCA1/2 testing in women diagnosed aged 80 is questionable. We performed an observational study of all women diagnosed with non-mucinous high-grade EOC who underwent germline and tumour BRCA1/2 testing by the North West of England Genomic Laboratory Hub. A subgroup of women also underwent germline testing using a panel of...]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of <em>TP53</em> in Adaptation and Evolution]]></title>
        <id>pubmed:36766853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36766853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The TP53 gene is a major player in cancer formation, and it is considered the most important tumor suppressor gene. The p53 protein acts as a transcription factor, and it is involved in DNA repair, senescence, cell-cycle control, autophagy, and apoptosis. Beyond cancer, there is evidence that TP53 is associated with fertility, aging, and longevity. Additionally, more evidence exists that genetic variants in TP53 are associated with environmental adaptation. Special TP53 amino-acid residues or...]]></summary>
        <author>
            <name>Konstantinos Voskarides</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options]]></title>
        <id>pubmed:36765799</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36765799/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The development of tyrosine kinase inhibitors (TKIs) targeting the mutant epidermal growth factor receptor (EGFR) protein initiated the success story of targeted therapies in non-small-cell lung cancer (NSCLC). Osimertinib, a third-generation EGFR-TKI, is currently indicated as first-line therapy in patients with NSCLC with sensitizing EGFR mutations, as second-line therapy in patients who present the resistance-associated mutation T790M after treatment with previous EGFR-TKIs, and as adjuvant...]]></summary>
        <author>
            <name>Georgia Gomatou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Is Reflex Germline <em>BRCA1/2</em> Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?]]></title>
        <id>pubmed:36765687</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36765687/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Women diagnosed with non-mucinous high-grade epithelial ovarian cancer (EOC) in England are often reflex-tested for germline and tumour BRCA1/2 variants. The value of germline BRCA1/2 testing in women diagnosed aged 80 is questionable. We performed an observational study of all women diagnosed with non-mucinous high-grade EOC who underwent germline and tumour BRCA1/2 testing by the North West of England Genomic Laboratory Hub. A subgroup of women also underwent germline testing using a panel of...]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of <em>TP53</em> in Adaptation and Evolution]]></title>
        <id>pubmed:36766853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36766853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The TP53 gene is a major player in cancer formation, and it is considered the most important tumor suppressor gene. The p53 protein acts as a transcription factor, and it is involved in DNA repair, senescence, cell-cycle control, autophagy, and apoptosis. Beyond cancer, there is evidence that TP53 is associated with fertility, aging, and longevity. Additionally, more evidence exists that genetic variants in TP53 are associated with environmental adaptation. Special TP53 amino-acid residues or...]]></summary>
        <author>
            <name>Konstantinos Voskarides</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options]]></title>
        <id>pubmed:36765799</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36765799/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The development of tyrosine kinase inhibitors (TKIs) targeting the mutant epidermal growth factor receptor (EGFR) protein initiated the success story of targeted therapies in non-small-cell lung cancer (NSCLC). Osimertinib, a third-generation EGFR-TKI, is currently indicated as first-line therapy in patients with NSCLC with sensitizing EGFR mutations, as second-line therapy in patients who present the resistance-associated mutation T790M after treatment with previous EGFR-TKIs, and as adjuvant...]]></summary>
        <author>
            <name>Georgia Gomatou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Is Reflex Germline <em>BRCA1/2</em> Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?]]></title>
        <id>pubmed:36765687</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36765687/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Women diagnosed with non-mucinous high-grade epithelial ovarian cancer (EOC) in England are often reflex-tested for germline and tumour BRCA1/2 variants. The value of germline BRCA1/2 testing in women diagnosed aged 80 is questionable. We performed an observational study of all women diagnosed with non-mucinous high-grade EOC who underwent germline and tumour BRCA1/2 testing by the North West of England Genomic Laboratory Hub. A subgroup of women also underwent germline testing using a panel of...]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of <em>TP53</em> in Adaptation and Evolution]]></title>
        <id>pubmed:36766853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36766853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The TP53 gene is a major player in cancer formation, and it is considered the most important tumor suppressor gene. The p53 protein acts as a transcription factor, and it is involved in DNA repair, senescence, cell-cycle control, autophagy, and apoptosis. Beyond cancer, there is evidence that TP53 is associated with fertility, aging, and longevity. Additionally, more evidence exists that genetic variants in TP53 are associated with environmental adaptation. Special TP53 amino-acid residues or...]]></summary>
        <author>
            <name>Konstantinos Voskarides</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options]]></title>
        <id>pubmed:36765799</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36765799/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The development of tyrosine kinase inhibitors (TKIs) targeting the mutant epidermal growth factor receptor (EGFR) protein initiated the success story of targeted therapies in non-small-cell lung cancer (NSCLC). Osimertinib, a third-generation EGFR-TKI, is currently indicated as first-line therapy in patients with NSCLC with sensitizing EGFR mutations, as second-line therapy in patients who present the resistance-associated mutation T790M after treatment with previous EGFR-TKIs, and as adjuvant...]]></summary>
        <author>
            <name>Georgia Gomatou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Is Reflex Germline <em>BRCA1/2</em> Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?]]></title>
        <id>pubmed:36765687</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36765687/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Women diagnosed with non-mucinous high-grade epithelial ovarian cancer (EOC) in England are often reflex-tested for germline and tumour BRCA1/2 variants. The value of germline BRCA1/2 testing in women diagnosed aged 80 is questionable. We performed an observational study of all women diagnosed with non-mucinous high-grade EOC who underwent germline and tumour BRCA1/2 testing by the North West of England Genomic Laboratory Hub. A subgroup of women also underwent germline testing using a panel of...]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of <em>TP53</em> in Adaptation and Evolution]]></title>
        <id>pubmed:36766853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36766853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The TP53 gene is a major player in cancer formation, and it is considered the most important tumor suppressor gene. The p53 protein acts as a transcription factor, and it is involved in DNA repair, senescence, cell-cycle control, autophagy, and apoptosis. Beyond cancer, there is evidence that TP53 is associated with fertility, aging, and longevity. Additionally, more evidence exists that genetic variants in TP53 are associated with environmental adaptation. Special TP53 amino-acid residues or...]]></summary>
        <author>
            <name>Konstantinos Voskarides</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options]]></title>
        <id>pubmed:36765799</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36765799/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The development of tyrosine kinase inhibitors (TKIs) targeting the mutant epidermal growth factor receptor (EGFR) protein initiated the success story of targeted therapies in non-small-cell lung cancer (NSCLC). Osimertinib, a third-generation EGFR-TKI, is currently indicated as first-line therapy in patients with NSCLC with sensitizing EGFR mutations, as second-line therapy in patients who present the resistance-associated mutation T790M after treatment with previous EGFR-TKIs, and as adjuvant...]]></summary>
        <author>
            <name>Georgia Gomatou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Is Reflex Germline <em>BRCA1/2</em> Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?]]></title>
        <id>pubmed:36765687</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36765687/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Women diagnosed with non-mucinous high-grade epithelial ovarian cancer (EOC) in England are often reflex-tested for germline and tumour BRCA1/2 variants. The value of germline BRCA1/2 testing in women diagnosed aged 80 is questionable. We performed an observational study of all women diagnosed with non-mucinous high-grade EOC who underwent germline and tumour BRCA1/2 testing by the North West of England Genomic Laboratory Hub. A subgroup of women also underwent germline testing using a panel of...]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomic diversity associated with APOBEC mutagenesis in squamous cell carcinoma arising from ovarian teratoma]]></title>
        <id>pubmed:36762791</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36762791/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230218200426&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although the gross and microscopic features of squamous cell carcinoma arising from ovarian mature cystic teratoma (MCT-SCC) vary from case to case, the spatially spreading of genomic alterations within the tumor remains unclear. To clarify the spatial genomic diversity in MCT-SCCs, we performed whole-exome sequencing by collecting 16 samples from histologically different parts of two MCT-SCCs. Both cases showed histological diversity within the tumors (case 1: nonkeratinizing and keratinizing...]]></summary>
        <author>
            <name>Ryo Tamura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomic diversity associated with APOBEC mutagenesis in squamous cell carcinoma arising from ovarian teratoma]]></title>
        <id>pubmed:36762791</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36762791/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although the gross and microscopic features of squamous cell carcinoma arising from ovarian mature cystic teratoma (MCT-SCC) vary from case to case, the spatially spreading of genomic alterations within the tumor remains unclear. To clarify the spatial genomic diversity in MCT-SCCs, we performed whole-exome sequencing by collecting 16 samples from histologically different parts of two MCT-SCCs. Both cases showed histological diversity within the tumors (case 1: nonkeratinizing and keratinizing...]]></summary>
        <author>
            <name>Ryo Tamura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomic diversity associated with APOBEC mutagenesis in squamous cell carcinoma arising from ovarian teratoma]]></title>
        <id>pubmed:36762791</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36762791/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although the gross and microscopic features of squamous cell carcinoma arising from ovarian mature cystic teratoma (MCT-SCC) vary from case to case, the spatially spreading of genomic alterations within the tumor remains unclear. To clarify the spatial genomic diversity in MCT-SCCs, we performed whole-exome sequencing by collecting 16 samples from histologically different parts of two MCT-SCCs. Both cases showed histological diversity within the tumors (case 1: nonkeratinizing and keratinizing...]]></summary>
        <author>
            <name>Ryo Tamura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomic diversity associated with APOBEC mutagenesis in squamous cell carcinoma arising from ovarian teratoma]]></title>
        <id>pubmed:36762791</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36762791/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although the gross and microscopic features of squamous cell carcinoma arising from ovarian mature cystic teratoma (MCT-SCC) vary from case to case, the spatially spreading of genomic alterations within the tumor remains unclear. To clarify the spatial genomic diversity in MCT-SCCs, we performed whole-exome sequencing by collecting 16 samples from histologically different parts of two MCT-SCCs. Both cases showed histological diversity within the tumors (case 1: nonkeratinizing and keratinizing...]]></summary>
        <author>
            <name>Ryo Tamura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomic diversity associated with APOBEC mutagenesis in squamous cell carcinoma arising from ovarian teratoma]]></title>
        <id>pubmed:36762791</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36762791/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although the gross and microscopic features of squamous cell carcinoma arising from ovarian mature cystic teratoma (MCT-SCC) vary from case to case, the spatially spreading of genomic alterations within the tumor remains unclear. To clarify the spatial genomic diversity in MCT-SCCs, we performed whole-exome sequencing by collecting 16 samples from histologically different parts of two MCT-SCCs. Both cases showed histological diversity within the tumors (case 1: nonkeratinizing and keratinizing...]]></summary>
        <author>
            <name>Ryo Tamura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomic diversity associated with APOBEC mutagenesis in squamous cell carcinoma arising from ovarian teratoma]]></title>
        <id>pubmed:36762791</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36762791/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although the gross and microscopic features of squamous cell carcinoma arising from ovarian mature cystic teratoma (MCT-SCC) vary from case to case, the spatially spreading of genomic alterations within the tumor remains unclear. To clarify the spatial genomic diversity in MCT-SCCs, we performed whole-exome sequencing by collecting 16 samples from histologically different parts of two MCT-SCCs. Both cases showed histological diversity within the tumors (case 1: nonkeratinizing and keratinizing...]]></summary>
        <author>
            <name>Ryo Tamura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomic diversity associated with APOBEC mutagenesis in squamous cell carcinoma arising from ovarian teratoma]]></title>
        <id>pubmed:36762791</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36762791/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although the gross and microscopic features of squamous cell carcinoma arising from ovarian mature cystic teratoma (MCT-SCC) vary from case to case, the spatially spreading of genomic alterations within the tumor remains unclear. To clarify the spatial genomic diversity in MCT-SCCs, we performed whole-exome sequencing by collecting 16 samples from histologically different parts of two MCT-SCCs. Both cases showed histological diversity within the tumors (case 1: nonkeratinizing and keratinizing...]]></summary>
        <author>
            <name>Ryo Tamura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomic diversity associated with APOBEC mutagenesis in squamous cell carcinoma arising from ovarian teratoma]]></title>
        <id>pubmed:36762791</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36762791/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although the gross and microscopic features of squamous cell carcinoma arising from ovarian mature cystic teratoma (MCT-SCC) vary from case to case, the spatially spreading of genomic alterations within the tumor remains unclear. To clarify the spatial genomic diversity in MCT-SCCs, we performed whole-exome sequencing by collecting 16 samples from histologically different parts of two MCT-SCCs. Both cases showed histological diversity within the tumors (case 1: nonkeratinizing and keratinizing...]]></summary>
        <author>
            <name>Ryo Tamura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomic diversity associated with APOBEC mutagenesis in squamous cell carcinoma arising from ovarian teratoma]]></title>
        <id>pubmed:36762791</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36762791/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although the gross and microscopic features of squamous cell carcinoma arising from ovarian mature cystic teratoma (MCT-SCC) vary from case to case, the spatially spreading of genomic alterations within the tumor remains unclear. To clarify the spatial genomic diversity in MCT-SCCs, we performed whole-exome sequencing by collecting 16 samples from histologically different parts of two MCT-SCCs. Both cases showed histological diversity within the tumors (case 1: nonkeratinizing and keratinizing...]]></summary>
        <author>
            <name>Ryo Tamura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Erdheim-Chester Disease with BRAF V600E Mutation and a Concomitant Myeloid Malignancy Sharing NRAS and IDH2 Mutations]]></title>
        <id>pubmed:36754028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36754028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230218200425&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Erdheim-Chester disease (ECD) is a rare clonal histiocytic process that is characterized by a foamy (xanthomatous) proliferation often associated with Touton giant cells. The diagnosis is often challenging and not exclusively a histologic diagnosis, as it requires correlation with unique clinical, radiographic and recently described molecular findings. Activating mutations involving the MAPK pathway including BRAF, ARAF, N/KRAS and MEK are recurrent in the disease. However, it is increasingly...]]></summary>
        <author>
            <name>Nitya Prabhakaran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamics of age- versus therapy-related clonal hematopoiesis in long-term survivors of pediatric cancer]]></title>
        <id>pubmed:36751942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36751942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230218200425&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the first comprehensive investigation of clonal hematopoiesis (CH) in 2,860 long-term survivors of pediatric cancer with a median follow-up time of 23.5 years. Deep-sequencing over 39 CH-related genes reveals mutations in 15% of the survivors, significantly higher than the 8.5% in 324 community controls. CH in survivors is associated with exposures to alkylating agents, radiation, and bleomycin. Therapy-related CH shows significant enrichment in STAT3, characterized as a CH-gene...]]></summary>
        <author>
            <name>Kohei Hagiwara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Erdheim-Chester Disease with BRAF V600E Mutation and a Concomitant Myeloid Malignancy Sharing NRAS and IDH2 Mutations]]></title>
        <id>pubmed:36754028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36754028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Erdheim-Chester disease (ECD) is a rare clonal histiocytic process that is characterized by a foamy (xanthomatous) proliferation often associated with Touton giant cells. The diagnosis is often challenging and not exclusively a histologic diagnosis, as it requires correlation with unique clinical, radiographic and recently described molecular findings. Activating mutations involving the MAPK pathway including BRAF, ARAF, N/KRAS and MEK are recurrent in the disease. However, it is increasingly...]]></summary>
        <author>
            <name>Nitya Prabhakaran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamics of age- versus therapy-related clonal hematopoiesis in long-term survivors of pediatric cancer]]></title>
        <id>pubmed:36751942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36751942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the first comprehensive investigation of clonal hematopoiesis (CH) in 2,860 long-term survivors of pediatric cancer with a median follow-up time of 23.5 years. Deep-sequencing over 39 CH-related genes reveals mutations in 15% of the survivors, significantly higher than the 8.5% in 324 community controls. CH in survivors is associated with exposures to alkylating agents, radiation, and bleomycin. Therapy-related CH shows significant enrichment in STAT3, characterized as a CH-gene...]]></summary>
        <author>
            <name>Kohei Hagiwara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Erdheim-Chester Disease with BRAF V600E Mutation and a Concomitant Myeloid Malignancy Sharing NRAS and IDH2 Mutations]]></title>
        <id>pubmed:36754028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36754028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Erdheim-Chester disease (ECD) is a rare clonal histiocytic process that is characterized by a foamy (xanthomatous) proliferation often associated with Touton giant cells. The diagnosis is often challenging and not exclusively a histologic diagnosis, as it requires correlation with unique clinical, radiographic and recently described molecular findings. Activating mutations involving the MAPK pathway including BRAF, ARAF, N/KRAS and MEK are recurrent in the disease. However, it is increasingly...]]></summary>
        <author>
            <name>Nitya Prabhakaran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamics of age- versus therapy-related clonal hematopoiesis in long-term survivors of pediatric cancer]]></title>
        <id>pubmed:36751942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36751942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the first comprehensive investigation of clonal hematopoiesis (CH) in 2,860 long-term survivors of pediatric cancer with a median follow-up time of 23.5 years. Deep-sequencing over 39 CH-related genes reveals mutations in 15% of the survivors, significantly higher than the 8.5% in 324 community controls. CH in survivors is associated with exposures to alkylating agents, radiation, and bleomycin. Therapy-related CH shows significant enrichment in STAT3, characterized as a CH-gene...]]></summary>
        <author>
            <name>Kohei Hagiwara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Erdheim-Chester Disease with BRAF V600E Mutation and a Concomitant Myeloid Malignancy Sharing NRAS and IDH2 Mutations]]></title>
        <id>pubmed:36754028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36754028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Erdheim-Chester disease (ECD) is a rare clonal histiocytic process that is characterized by a foamy (xanthomatous) proliferation often associated with Touton giant cells. The diagnosis is often challenging and not exclusively a histologic diagnosis, as it requires correlation with unique clinical, radiographic and recently described molecular findings. Activating mutations involving the MAPK pathway including BRAF, ARAF, N/KRAS and MEK are recurrent in the disease. However, it is increasingly...]]></summary>
        <author>
            <name>Nitya Prabhakaran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamics of age- versus therapy-related clonal hematopoiesis in long-term survivors of pediatric cancer]]></title>
        <id>pubmed:36751942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36751942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the first comprehensive investigation of clonal hematopoiesis (CH) in 2,860 long-term survivors of pediatric cancer with a median follow-up time of 23.5 years. Deep-sequencing over 39 CH-related genes reveals mutations in 15% of the survivors, significantly higher than the 8.5% in 324 community controls. CH in survivors is associated with exposures to alkylating agents, radiation, and bleomycin. Therapy-related CH shows significant enrichment in STAT3, characterized as a CH-gene...]]></summary>
        <author>
            <name>Kohei Hagiwara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Erdheim-Chester Disease with BRAF V600E Mutation and a Concomitant Myeloid Malignancy Sharing NRAS and IDH2 Mutations]]></title>
        <id>pubmed:36754028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36754028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Erdheim-Chester disease (ECD) is a rare clonal histiocytic process that is characterized by a foamy (xanthomatous) proliferation often associated with Touton giant cells. The diagnosis is often challenging and not exclusively a histologic diagnosis, as it requires correlation with unique clinical, radiographic and recently described molecular findings. Activating mutations involving the MAPK pathway including BRAF, ARAF, N/KRAS and MEK are recurrent in the disease. However, it is increasingly...]]></summary>
        <author>
            <name>Nitya Prabhakaran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamics of age- versus therapy-related clonal hematopoiesis in long-term survivors of pediatric cancer]]></title>
        <id>pubmed:36751942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36751942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the first comprehensive investigation of clonal hematopoiesis (CH) in 2,860 long-term survivors of pediatric cancer with a median follow-up time of 23.5 years. Deep-sequencing over 39 CH-related genes reveals mutations in 15% of the survivors, significantly higher than the 8.5% in 324 community controls. CH in survivors is associated with exposures to alkylating agents, radiation, and bleomycin. Therapy-related CH shows significant enrichment in STAT3, characterized as a CH-gene...]]></summary>
        <author>
            <name>Kohei Hagiwara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Erdheim-Chester Disease with BRAF V600E Mutation and a Concomitant Myeloid Malignancy Sharing NRAS and IDH2 Mutations]]></title>
        <id>pubmed:36754028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36754028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Erdheim-Chester disease (ECD) is a rare clonal histiocytic process that is characterized by a foamy (xanthomatous) proliferation often associated with Touton giant cells. The diagnosis is often challenging and not exclusively a histologic diagnosis, as it requires correlation with unique clinical, radiographic and recently described molecular findings. Activating mutations involving the MAPK pathway including BRAF, ARAF, N/KRAS and MEK are recurrent in the disease. However, it is increasingly...]]></summary>
        <author>
            <name>Nitya Prabhakaran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamics of age- versus therapy-related clonal hematopoiesis in long-term survivors of pediatric cancer]]></title>
        <id>pubmed:36751942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36751942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the first comprehensive investigation of clonal hematopoiesis (CH) in 2,860 long-term survivors of pediatric cancer with a median follow-up time of 23.5 years. Deep-sequencing over 39 CH-related genes reveals mutations in 15% of the survivors, significantly higher than the 8.5% in 324 community controls. CH in survivors is associated with exposures to alkylating agents, radiation, and bleomycin. Therapy-related CH shows significant enrichment in STAT3, characterized as a CH-gene...]]></summary>
        <author>
            <name>Kohei Hagiwara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Erdheim-Chester Disease with BRAF V600E Mutation and a Concomitant Myeloid Malignancy Sharing NRAS and IDH2 Mutations]]></title>
        <id>pubmed:36754028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36754028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Erdheim-Chester disease (ECD) is a rare clonal histiocytic process that is characterized by a foamy (xanthomatous) proliferation often associated with Touton giant cells. The diagnosis is often challenging and not exclusively a histologic diagnosis, as it requires correlation with unique clinical, radiographic and recently described molecular findings. Activating mutations involving the MAPK pathway including BRAF, ARAF, N/KRAS and MEK are recurrent in the disease. However, it is increasingly...]]></summary>
        <author>
            <name>Nitya Prabhakaran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamics of age- versus therapy-related clonal hematopoiesis in long-term survivors of pediatric cancer]]></title>
        <id>pubmed:36751942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36751942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the first comprehensive investigation of clonal hematopoiesis (CH) in 2,860 long-term survivors of pediatric cancer with a median follow-up time of 23.5 years. Deep-sequencing over 39 CH-related genes reveals mutations in 15% of the survivors, significantly higher than the 8.5% in 324 community controls. CH in survivors is associated with exposures to alkylating agents, radiation, and bleomycin. Therapy-related CH shows significant enrichment in STAT3, characterized as a CH-gene...]]></summary>
        <author>
            <name>Kohei Hagiwara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Erdheim-Chester Disease with BRAF V600E Mutation and a Concomitant Myeloid Malignancy Sharing NRAS and IDH2 Mutations]]></title>
        <id>pubmed:36754028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36754028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Erdheim-Chester disease (ECD) is a rare clonal histiocytic process that is characterized by a foamy (xanthomatous) proliferation often associated with Touton giant cells. The diagnosis is often challenging and not exclusively a histologic diagnosis, as it requires correlation with unique clinical, radiographic and recently described molecular findings. Activating mutations involving the MAPK pathway including BRAF, ARAF, N/KRAS and MEK are recurrent in the disease. However, it is increasingly...]]></summary>
        <author>
            <name>Nitya Prabhakaran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamics of age- versus therapy-related clonal hematopoiesis in long-term survivors of pediatric cancer]]></title>
        <id>pubmed:36751942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36751942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the first comprehensive investigation of clonal hematopoiesis (CH) in 2,860 long-term survivors of pediatric cancer with a median follow-up time of 23.5 years. Deep-sequencing over 39 CH-related genes reveals mutations in 15% of the survivors, significantly higher than the 8.5% in 324 community controls. CH in survivors is associated with exposures to alkylating agents, radiation, and bleomycin. Therapy-related CH shows significant enrichment in STAT3, characterized as a CH-gene...]]></summary>
        <author>
            <name>Kohei Hagiwara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Erdheim-Chester Disease with BRAF V600E Mutation and a Concomitant Myeloid Malignancy Sharing NRAS and IDH2 Mutations]]></title>
        <id>pubmed:36754028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36754028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Erdheim-Chester disease (ECD) is a rare clonal histiocytic process that is characterized by a foamy (xanthomatous) proliferation often associated with Touton giant cells. The diagnosis is often challenging and not exclusively a histologic diagnosis, as it requires correlation with unique clinical, radiographic and recently described molecular findings. Activating mutations involving the MAPK pathway including BRAF, ARAF, N/KRAS and MEK are recurrent in the disease. However, it is increasingly...]]></summary>
        <author>
            <name>Nitya Prabhakaran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamics of age- versus therapy-related clonal hematopoiesis in long-term survivors of pediatric cancer]]></title>
        <id>pubmed:36751942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36751942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the first comprehensive investigation of clonal hematopoiesis (CH) in 2,860 long-term survivors of pediatric cancer with a median follow-up time of 23.5 years. Deep-sequencing over 39 CH-related genes reveals mutations in 15% of the survivors, significantly higher than the 8.5% in 324 community controls. CH in survivors is associated with exposures to alkylating agents, radiation, and bleomycin. Therapy-related CH shows significant enrichment in STAT3, characterized as a CH-gene...]]></summary>
        <author>
            <name>Kohei Hagiwara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Erdheim-Chester Disease with BRAF V600E Mutation and a Concomitant Myeloid Malignancy Sharing NRAS and IDH2 Mutations]]></title>
        <id>pubmed:36754028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36754028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230209200537&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Erdheim-Chester disease (ECD) is a rare clonal histiocytic process that is characterized by a foamy (xanthomatous) proliferation often associated with Touton giant cells. The diagnosis is often challenging and not exclusively a histologic diagnosis, as it requires correlation with unique clinical, radiographic and recently described molecular findings. Activating mutations involving the MAPK pathway including BRAF, ARAF, N/KRAS and MEK are recurrent in the disease. However, it is increasingly...]]></summary>
        <author>
            <name>Nitya Prabhakaran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamics of age- versus therapy-related clonal hematopoiesis in long-term survivors of pediatric cancer]]></title>
        <id>pubmed:36751942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36751942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230209200537&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the first comprehensive investigation of clonal hematopoiesis (CH) in 2,860 long-term survivors of pediatric cancer with a median follow-up time of 23.5 years. Deep-sequencing over 39 CH-related genes reveals mutations in 15% of the survivors, significantly higher than the 8.5% in 324 community controls. CH in survivors is associated with exposures to alkylating agents, radiation, and bleomycin. Therapy-related CH shows significant enrichment in STAT3, characterized as a CH-gene...]]></summary>
        <author>
            <name>Kohei Hagiwara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamics of age- versus therapy-related clonal hematopoiesis in long-term survivors of pediatric cancer]]></title>
        <id>pubmed:36751942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36751942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230208200033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the first comprehensive investigation of clonal hematopoiesis (CH) in 2,860 long-term survivors of pediatric cancer with a median follow-up time of 23.5 years. Deep-sequencing over 39 CH-related genes reveals mutations in 15% of the survivors, significantly higher than the 8.5% in 324 community controls. CH in survivors is associated with exposures to alkylating agents, radiation, and bleomycin. Therapy-related CH shows significant enrichment in STAT3, characterized as a CH-gene...]]></summary>
        <author>
            <name>Kohei Hagiwara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Rapid, Shallow Whole Genome Sequencing Workflow Applicable to Limiting Amounts of Cell-Free DNA]]></title>
        <id>pubmed:36747279</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36747279/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230218200426&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The ReproSeq PGS assay is rapid, at approximately $120 per sample, providing both a sCNA profile and estimation of the tumor DNA fraction from limiting cfDNA template (300pg) and individual CTCs. The approach could be used to examine the copy number landscape over time to guide treatment decisions, support future trial designs, and be applied to low volume blood spot samples enabling remote monitoring.]]></summary>
        <author>
            <name>Rebecca C Allsopp</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Rapid, Shallow Whole Genome Sequencing Workflow Applicable to Limiting Amounts of Cell-Free DNA]]></title>
        <id>pubmed:36747279</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36747279/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The ReproSeq PGS assay is rapid, at approximately $120 per sample, providing both a sCNA profile and estimation of the tumor DNA fraction from limiting cfDNA template (300pg) and individual CTCs. The approach could be used to examine the copy number landscape over time to guide treatment decisions, support future trial designs, and be applied to low volume blood spot samples enabling remote monitoring.]]></summary>
        <author>
            <name>Rebecca C Allsopp</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Rapid, Shallow Whole Genome Sequencing Workflow Applicable to Limiting Amounts of Cell-Free DNA]]></title>
        <id>pubmed:36747279</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36747279/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The ReproSeq PGS assay is rapid, at approximately $120 per sample, providing both a sCNA profile and estimation of the tumor DNA fraction from limiting cfDNA template (300pg) and individual CTCs. The approach could be used to examine the copy number landscape over time to guide treatment decisions, support future trial designs, and be applied to low volume blood spot samples enabling remote monitoring.]]></summary>
        <author>
            <name>Rebecca C Allsopp</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Rapid, Shallow Whole Genome Sequencing Workflow Applicable to Limiting Amounts of Cell-Free DNA]]></title>
        <id>pubmed:36747279</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36747279/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The ReproSeq PGS assay is rapid, at approximately $120 per sample, providing both a sCNA profile and estimation of the tumor DNA fraction from limiting cfDNA template (300pg) and individual CTCs. The approach could be used to examine the copy number landscape over time to guide treatment decisions, support future trial designs, and be applied to low volume blood spot samples enabling remote monitoring.]]></summary>
        <author>
            <name>Rebecca C Allsopp</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Rapid, Shallow Whole Genome Sequencing Workflow Applicable to Limiting Amounts of Cell-Free DNA]]></title>
        <id>pubmed:36747279</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36747279/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The ReproSeq PGS assay is rapid, at approximately $120 per sample, providing both a sCNA profile and estimation of the tumor DNA fraction from limiting cfDNA template (300pg) and individual CTCs. The approach could be used to examine the copy number landscape over time to guide treatment decisions, support future trial designs, and be applied to low volume blood spot samples enabling remote monitoring.]]></summary>
        <author>
            <name>Rebecca C Allsopp</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Rapid, Shallow Whole Genome Sequencing Workflow Applicable to Limiting Amounts of Cell-Free DNA]]></title>
        <id>pubmed:36747279</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36747279/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The ReproSeq PGS assay is rapid, at approximately $120 per sample, providing both a sCNA profile and estimation of the tumor DNA fraction from limiting cfDNA template (300pg) and individual CTCs. The approach could be used to examine the copy number landscape over time to guide treatment decisions, support future trial designs, and be applied to low volume blood spot samples enabling remote monitoring.]]></summary>
        <author>
            <name>Rebecca C Allsopp</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Rapid, Shallow Whole Genome Sequencing Workflow Applicable to Limiting Amounts of Cell-Free DNA]]></title>
        <id>pubmed:36747279</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36747279/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The ReproSeq PGS assay is rapid, at approximately $120 per sample, providing both a sCNA profile and estimation of the tumor DNA fraction from limiting cfDNA template (300pg) and individual CTCs. The approach could be used to examine the copy number landscape over time to guide treatment decisions, support future trial designs, and be applied to low volume blood spot samples enabling remote monitoring.]]></summary>
        <author>
            <name>Rebecca C Allsopp</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Rapid, Shallow Whole Genome Sequencing Workflow Applicable to Limiting Amounts of Cell-Free DNA]]></title>
        <id>pubmed:36747279</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36747279/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The ReproSeq PGS assay is rapid, at approximately $120 per sample, providing both a sCNA profile and estimation of the tumor DNA fraction from limiting cfDNA template (300pg) and individual CTCs. The approach could be used to examine the copy number landscape over time to guide treatment decisions, support future trial designs, and be applied to low volume blood spot samples enabling remote monitoring.]]></summary>
        <author>
            <name>Rebecca C Allsopp</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Rapid, Shallow Whole Genome Sequencing Workflow Applicable to Limiting Amounts of Cell-Free DNA]]></title>
        <id>pubmed:36747279</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36747279/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The ReproSeq PGS assay is rapid, at approximately $120 per sample, providing both a sCNA profile and estimation of the tumor DNA fraction from limiting cfDNA template (300pg) and individual CTCs. The approach could be used to examine the copy number landscape over time to guide treatment decisions, support future trial designs, and be applied to low volume blood spot samples enabling remote monitoring.]]></summary>
        <author>
            <name>Rebecca C Allsopp</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Rapid, Shallow Whole Genome Sequencing Workflow Applicable to Limiting Amounts of Cell-Free DNA]]></title>
        <id>pubmed:36747279</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36747279/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230209200536&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The ReproSeq PGS assay is rapid, at approximately $120 per sample, providing both a sCNA profile and estimation of the tumor DNA fraction from limiting cfDNA template (300pg) and individual CTCs. The approach could be used to examine the copy number landscape over time to guide treatment decisions, support future trial designs, and be applied to low volume blood spot samples enabling remote monitoring.]]></summary>
        <author>
            <name>Rebecca C Allsopp</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Rapid, Shallow Whole Genome Sequencing Workflow Applicable to Limiting Amounts of Cell-Free DNA]]></title>
        <id>pubmed:36747279</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36747279/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230208200032&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The ReproSeq PGS assay is rapid, at approximately $120 per sample, providing both a sCNA profile and estimation of the tumor DNA fraction from limiting cfDNA template (300pg) and individual CTCs. The approach could be used to examine the copy number landscape over time to guide treatment decisions, support future trial designs, and be applied to low volume blood spot samples enabling remote monitoring.]]></summary>
        <author>
            <name>Rebecca C Allsopp</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Rapid, Shallow Whole Genome Sequencing Workflow Applicable to Limiting Amounts of Cell-Free DNA]]></title>
        <id>pubmed:36747279</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36747279/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The ReproSeq PGS assay is rapid, at approximately $120 per sample, providing both a sCNA profile and estimation of the tumor DNA fraction from limiting cfDNA template (300pg) and individual CTCs. The approach could be used to examine the copy number landscape over time to guide treatment decisions, support future trial designs, and be applied to low volume blood spot samples enabling remote monitoring.]]></summary>
        <author>
            <name>Rebecca C Allsopp</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review]]></title>
        <id>pubmed:36741006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36741006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230218200425&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We describe a case of HR-MDS, with deletion of chromosome 7 and acquisition of RUNX1 mutation, developing after CAR T-cell therapy in a patient with clonal hematopoiesis (CH). Previous chemotherapy favored MDS onset; however, we could not exclude the fact that the impairment of immunosurveillance related to either lymphodepletion or CAR T-cell infusion may play a role in MDS development. Thus, we designed a multicenter prospective study (ClonHema-CAR-T-Study) to investigate if...]]></summary>
        <author>
            <name>Eugenia Accorsi Buttini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review]]></title>
        <id>pubmed:36741006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36741006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We describe a case of HR-MDS, with deletion of chromosome 7 and acquisition of RUNX1 mutation, developing after CAR T-cell therapy in a patient with clonal hematopoiesis (CH). Previous chemotherapy favored MDS onset; however, we could not exclude the fact that the impairment of immunosurveillance related to either lymphodepletion or CAR T-cell infusion may play a role in MDS development. Thus, we designed a multicenter prospective study (ClonHema-CAR-T-Study) to investigate if...]]></summary>
        <author>
            <name>Eugenia Accorsi Buttini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review]]></title>
        <id>pubmed:36741006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36741006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We describe a case of HR-MDS, with deletion of chromosome 7 and acquisition of RUNX1 mutation, developing after CAR T-cell therapy in a patient with clonal hematopoiesis (CH). Previous chemotherapy favored MDS onset; however, we could not exclude the fact that the impairment of immunosurveillance related to either lymphodepletion or CAR T-cell infusion may play a role in MDS development. Thus, we designed a multicenter prospective study (ClonHema-CAR-T-Study) to investigate if...]]></summary>
        <author>
            <name>Eugenia Accorsi Buttini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review]]></title>
        <id>pubmed:36741006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36741006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We describe a case of HR-MDS, with deletion of chromosome 7 and acquisition of RUNX1 mutation, developing after CAR T-cell therapy in a patient with clonal hematopoiesis (CH). Previous chemotherapy favored MDS onset; however, we could not exclude the fact that the impairment of immunosurveillance related to either lymphodepletion or CAR T-cell infusion may play a role in MDS development. Thus, we designed a multicenter prospective study (ClonHema-CAR-T-Study) to investigate if...]]></summary>
        <author>
            <name>Eugenia Accorsi Buttini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review]]></title>
        <id>pubmed:36741006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36741006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We describe a case of HR-MDS, with deletion of chromosome 7 and acquisition of RUNX1 mutation, developing after CAR T-cell therapy in a patient with clonal hematopoiesis (CH). Previous chemotherapy favored MDS onset; however, we could not exclude the fact that the impairment of immunosurveillance related to either lymphodepletion or CAR T-cell infusion may play a role in MDS development. Thus, we designed a multicenter prospective study (ClonHema-CAR-T-Study) to investigate if...]]></summary>
        <author>
            <name>Eugenia Accorsi Buttini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review]]></title>
        <id>pubmed:36741006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36741006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We describe a case of HR-MDS, with deletion of chromosome 7 and acquisition of RUNX1 mutation, developing after CAR T-cell therapy in a patient with clonal hematopoiesis (CH). Previous chemotherapy favored MDS onset; however, we could not exclude the fact that the impairment of immunosurveillance related to either lymphodepletion or CAR T-cell infusion may play a role in MDS development. Thus, we designed a multicenter prospective study (ClonHema-CAR-T-Study) to investigate if...]]></summary>
        <author>
            <name>Eugenia Accorsi Buttini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review]]></title>
        <id>pubmed:36741006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36741006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We describe a case of HR-MDS, with deletion of chromosome 7 and acquisition of RUNX1 mutation, developing after CAR T-cell therapy in a patient with clonal hematopoiesis (CH). Previous chemotherapy favored MDS onset; however, we could not exclude the fact that the impairment of immunosurveillance related to either lymphodepletion or CAR T-cell infusion may play a role in MDS development. Thus, we designed a multicenter prospective study (ClonHema-CAR-T-Study) to investigate if...]]></summary>
        <author>
            <name>Eugenia Accorsi Buttini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review]]></title>
        <id>pubmed:36741006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36741006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We describe a case of HR-MDS, with deletion of chromosome 7 and acquisition of RUNX1 mutation, developing after CAR T-cell therapy in a patient with clonal hematopoiesis (CH). Previous chemotherapy favored MDS onset; however, we could not exclude the fact that the impairment of immunosurveillance related to either lymphodepletion or CAR T-cell infusion may play a role in MDS development. Thus, we designed a multicenter prospective study (ClonHema-CAR-T-Study) to investigate if...]]></summary>
        <author>
            <name>Eugenia Accorsi Buttini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review]]></title>
        <id>pubmed:36741006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36741006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We describe a case of HR-MDS, with deletion of chromosome 7 and acquisition of RUNX1 mutation, developing after CAR T-cell therapy in a patient with clonal hematopoiesis (CH). Previous chemotherapy favored MDS onset; however, we could not exclude the fact that the impairment of immunosurveillance related to either lymphodepletion or CAR T-cell infusion may play a role in MDS development. Thus, we designed a multicenter prospective study (ClonHema-CAR-T-Study) to investigate if...]]></summary>
        <author>
            <name>Eugenia Accorsi Buttini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review]]></title>
        <id>pubmed:36741006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36741006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230209200537&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We describe a case of HR-MDS, with deletion of chromosome 7 and acquisition of RUNX1 mutation, developing after CAR T-cell therapy in a patient with clonal hematopoiesis (CH). Previous chemotherapy favored MDS onset; however, we could not exclude the fact that the impairment of immunosurveillance related to either lymphodepletion or CAR T-cell infusion may play a role in MDS development. Thus, we designed a multicenter prospective study (ClonHema-CAR-T-Study) to investigate if...]]></summary>
        <author>
            <name>Eugenia Accorsi Buttini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review]]></title>
        <id>pubmed:36741006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36741006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230208200033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We describe a case of HR-MDS, with deletion of chromosome 7 and acquisition of RUNX1 mutation, developing after CAR T-cell therapy in a patient with clonal hematopoiesis (CH). Previous chemotherapy favored MDS onset; however, we could not exclude the fact that the impairment of immunosurveillance related to either lymphodepletion or CAR T-cell infusion may play a role in MDS development. Thus, we designed a multicenter prospective study (ClonHema-CAR-T-Study) to investigate if...]]></summary>
        <author>
            <name>Eugenia Accorsi Buttini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review]]></title>
        <id>pubmed:36741006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36741006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We describe a case of HR-MDS, with deletion of chromosome 7 and acquisition of RUNX1 mutation, developing after CAR T-cell therapy in a patient with clonal hematopoiesis (CH). Previous chemotherapy favored MDS onset; however, we could not exclude the fact that the impairment of immunosurveillance related to either lymphodepletion or CAR T-cell infusion may play a role in MDS development. Thus, we designed a multicenter prospective study (ClonHema-CAR-T-Study) to investigate if...]]></summary>
        <author>
            <name>Eugenia Accorsi Buttini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review]]></title>
        <id>pubmed:36741006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36741006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We describe a case of HR-MDS, with deletion of chromosome 7 and acquisition of RUNX1 mutation, developing after CAR T-cell therapy in a patient with clonal hematopoiesis (CH). Previous chemotherapy favored MDS onset; however, we could not exclude the fact that the impairment of immunosurveillance related to either lymphodepletion or CAR T-cell infusion may play a role in MDS development. Thus, we designed a multicenter prospective study (ClonHema-CAR-T-Study) to investigate if...]]></summary>
        <author>
            <name>Eugenia Accorsi Buttini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpreting variants in genes affected by clonal hematopoiesis in population data]]></title>
        <id>pubmed:36739343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230218200425&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reference population databases like the Genome Aggregation Database (gnomAD) have improved our ability to interpret the human genome. Variant frequencies and frequency-derived tools (such as depletion scores) have become fundamental to variant interpretation and the assessment of variant-gene-disease relationships. Clonal hematopoiesis (CH) obstructs variant interpretation as somatic variants that provide proliferative advantage will affect variant frequencies, depletion scores, and downstream...]]></summary>
        <author>
            <name>Sanna Gudmundsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpreting variants in genes affected by clonal hematopoiesis in population data]]></title>
        <id>pubmed:36739343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reference population databases like the Genome Aggregation Database (gnomAD) have improved our ability to interpret the human genome. Variant frequencies and frequency-derived tools (such as depletion scores) have become fundamental to variant interpretation and the assessment of variant-gene-disease relationships. Clonal hematopoiesis (CH) obstructs variant interpretation as somatic variants that provide proliferative advantage will affect variant frequencies, depletion scores, and downstream...]]></summary>
        <author>
            <name>Sanna Gudmundsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpreting variants in genes affected by clonal hematopoiesis in population data]]></title>
        <id>pubmed:36739343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reference population databases like the Genome Aggregation Database (gnomAD) have improved our ability to interpret the human genome. Variant frequencies and frequency-derived tools (such as depletion scores) have become fundamental to variant interpretation and the assessment of variant-gene-disease relationships. Clonal hematopoiesis (CH) obstructs variant interpretation as somatic variants that provide proliferative advantage will affect variant frequencies, depletion scores, and downstream...]]></summary>
        <author>
            <name>Sanna Gudmundsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpreting variants in genes affected by clonal hematopoiesis in population data]]></title>
        <id>pubmed:36739343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reference population databases like the Genome Aggregation Database (gnomAD) have improved our ability to interpret the human genome. Variant frequencies and frequency-derived tools (such as depletion scores) have become fundamental to variant interpretation and the assessment of variant-gene-disease relationships. Clonal hematopoiesis (CH) obstructs variant interpretation as somatic variants that provide proliferative advantage will affect variant frequencies, depletion scores, and downstream...]]></summary>
        <author>
            <name>Sanna Gudmundsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpreting variants in genes affected by clonal hematopoiesis in population data]]></title>
        <id>pubmed:36739343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reference population databases like the Genome Aggregation Database (gnomAD) have improved our ability to interpret the human genome. Variant frequencies and frequency-derived tools (such as depletion scores) have become fundamental to variant interpretation and the assessment of variant-gene-disease relationships. Clonal hematopoiesis (CH) obstructs variant interpretation as somatic variants that provide proliferative advantage will affect variant frequencies, depletion scores, and downstream...]]></summary>
        <author>
            <name>Sanna Gudmundsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpreting variants in genes affected by clonal hematopoiesis in population data]]></title>
        <id>pubmed:36739343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reference population databases like the Genome Aggregation Database (gnomAD) have improved our ability to interpret the human genome. Variant frequencies and frequency-derived tools (such as depletion scores) have become fundamental to variant interpretation and the assessment of variant-gene-disease relationships. Clonal hematopoiesis (CH) obstructs variant interpretation as somatic variants that provide proliferative advantage will affect variant frequencies, depletion scores, and downstream...]]></summary>
        <author>
            <name>Sanna Gudmundsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpreting variants in genes affected by clonal hematopoiesis in population data]]></title>
        <id>pubmed:36739343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reference population databases like the Genome Aggregation Database (gnomAD) have improved our ability to interpret the human genome. Variant frequencies and frequency-derived tools (such as depletion scores) have become fundamental to variant interpretation and the assessment of variant-gene-disease relationships. Clonal hematopoiesis (CH) obstructs variant interpretation as somatic variants that provide proliferative advantage will affect variant frequencies, depletion scores, and downstream...]]></summary>
        <author>
            <name>Sanna Gudmundsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpreting variants in genes affected by clonal hematopoiesis in population data]]></title>
        <id>pubmed:36739343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reference population databases like the Genome Aggregation Database (gnomAD) have improved our ability to interpret the human genome. Variant frequencies and frequency-derived tools (such as depletion scores) have become fundamental to variant interpretation and the assessment of variant-gene-disease relationships. Clonal hematopoiesis (CH) obstructs variant interpretation as somatic variants that provide proliferative advantage will affect variant frequencies, depletion scores, and downstream...]]></summary>
        <author>
            <name>Sanna Gudmundsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpreting variants in genes affected by clonal hematopoiesis in population data]]></title>
        <id>pubmed:36739343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reference population databases like the Genome Aggregation Database (gnomAD) have improved our ability to interpret the human genome. Variant frequencies and frequency-derived tools (such as depletion scores) have become fundamental to variant interpretation and the assessment of variant-gene-disease relationships. Clonal hematopoiesis (CH) obstructs variant interpretation as somatic variants that provide proliferative advantage will affect variant frequencies, depletion scores, and downstream...]]></summary>
        <author>
            <name>Sanna Gudmundsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpreting variants in genes affected by clonal hematopoiesis in population data]]></title>
        <id>pubmed:36739343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230209200537&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reference population databases like the Genome Aggregation Database (gnomAD) have improved our ability to interpret the human genome. Variant frequencies and frequency-derived tools (such as depletion scores) have become fundamental to variant interpretation and the assessment of variant-gene-disease relationships. Clonal hematopoiesis (CH) obstructs variant interpretation as somatic variants that provide proliferative advantage will affect variant frequencies, depletion scores, and downstream...]]></summary>
        <author>
            <name>Sanna Gudmundsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpreting variants in genes affected by clonal hematopoiesis in population data]]></title>
        <id>pubmed:36739343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230208200033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reference population databases like the Genome Aggregation Database (gnomAD) have improved our ability to interpret the human genome. Variant frequencies and frequency-derived tools (such as depletion scores) have become fundamental to variant interpretation and the assessment of variant-gene-disease relationships. Clonal hematopoiesis (CH) obstructs variant interpretation as somatic variants that provide proliferative advantage will affect variant frequencies, depletion scores, and downstream...]]></summary>
        <author>
            <name>Sanna Gudmundsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpreting variants in genes affected by clonal hematopoiesis in population data]]></title>
        <id>pubmed:36739343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reference population databases like the Genome Aggregation Database (gnomAD) have improved our ability to interpret the human genome. Variant frequencies and frequency-derived tools (such as depletion scores) have become fundamental to variant interpretation and the assessment of variant-gene-disease relationships. Clonal hematopoiesis (CH) obstructs variant interpretation as somatic variants that provide proliferative advantage will affect variant frequencies, depletion scores, and downstream...]]></summary>
        <author>
            <name>Sanna Gudmundsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpreting variants in genes affected by clonal hematopoiesis in population data]]></title>
        <id>pubmed:36739343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reference population databases like the Genome Aggregation Database (gnomAD) have improved our ability to interpret the human genome. Variant frequencies and frequency-derived tools (such as depletion scores) have become fundamental to variant interpretation and the assessment of variant-gene-disease relationships. Clonal hematopoiesis (CH) obstructs variant interpretation as somatic variants that provide proliferative advantage will affect variant frequencies, depletion scores, and downstream...]]></summary>
        <author>
            <name>Sanna Gudmundsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpreting variants in genes affected by clonal hematopoiesis in population data]]></title>
        <id>pubmed:36739343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Reference population databases like the Genome Aggregation Database (gnomAD) have improved our ability to interpret the human genome. Variant frequencies and frequency-derived tools (such as depletion scores) have become fundamental to variant interpretation and the assessment of variant-gene-disease relationships. Clonal hematopoiesis (CH) obstructs variant interpretation as somatic variants that provide proliferative advantage will affect variant frequencies, depletion scores, and downstream...]]></summary>
        <author>
            <name>Sanna Gudmundsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia]]></title>
        <id>pubmed:36739348</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739348/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230218200426&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Murine models offer a valuable tool to recapitulate genetically defined subtypes of AML, and to assess the potential of compound mutations and clonal evolution during disease progression. This is of particular importance for difficult to treat leukemias such as FLT3 internal tandem duplication (ITD) positive AML. While conditional gene targeting by Cre recombinase is a powerful technology that has revolutionized biomedical research, consequences of Cre expression such as lack of fidelity,...]]></summary>
        <author>
            <name>Jasmin Straube</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia]]></title>
        <id>pubmed:36739348</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739348/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Murine models offer a valuable tool to recapitulate genetically defined subtypes of AML, and to assess the potential of compound mutations and clonal evolution during disease progression. This is of particular importance for difficult to treat leukemias such as FLT3 internal tandem duplication (ITD) positive AML. While conditional gene targeting by Cre recombinase is a powerful technology that has revolutionized biomedical research, consequences of Cre expression such as lack of fidelity,...]]></summary>
        <author>
            <name>Jasmin Straube</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia]]></title>
        <id>pubmed:36739348</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739348/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Murine models offer a valuable tool to recapitulate genetically defined subtypes of AML, and to assess the potential of compound mutations and clonal evolution during disease progression. This is of particular importance for difficult to treat leukemias such as FLT3 internal tandem duplication (ITD) positive AML. While conditional gene targeting by Cre recombinase is a powerful technology that has revolutionized biomedical research, consequences of Cre expression such as lack of fidelity,...]]></summary>
        <author>
            <name>Jasmin Straube</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia]]></title>
        <id>pubmed:36739348</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739348/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Murine models offer a valuable tool to recapitulate genetically defined subtypes of AML, and to assess the potential of compound mutations and clonal evolution during disease progression. This is of particular importance for difficult to treat leukemias such as FLT3 internal tandem duplication (ITD) positive AML. While conditional gene targeting by Cre recombinase is a powerful technology that has revolutionized biomedical research, consequences of Cre expression such as lack of fidelity,...]]></summary>
        <author>
            <name>Jasmin Straube</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia]]></title>
        <id>pubmed:36739348</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739348/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Murine models offer a valuable tool to recapitulate genetically defined subtypes of AML, and to assess the potential of compound mutations and clonal evolution during disease progression. This is of particular importance for difficult to treat leukemias such as FLT3 internal tandem duplication (ITD) positive AML. While conditional gene targeting by Cre recombinase is a powerful technology that has revolutionized biomedical research, consequences of Cre expression such as lack of fidelity,...]]></summary>
        <author>
            <name>Jasmin Straube</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia]]></title>
        <id>pubmed:36739348</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739348/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Murine models offer a valuable tool to recapitulate genetically defined subtypes of AML, and to assess the potential of compound mutations and clonal evolution during disease progression. This is of particular importance for difficult to treat leukemias such as FLT3 internal tandem duplication (ITD) positive AML. While conditional gene targeting by Cre recombinase is a powerful technology that has revolutionized biomedical research, consequences of Cre expression such as lack of fidelity,...]]></summary>
        <author>
            <name>Jasmin Straube</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia]]></title>
        <id>pubmed:36739348</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739348/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Murine models offer a valuable tool to recapitulate genetically defined subtypes of AML, and to assess the potential of compound mutations and clonal evolution during disease progression. This is of particular importance for difficult to treat leukemias such as FLT3 internal tandem duplication (ITD) positive AML. While conditional gene targeting by Cre recombinase is a powerful technology that has revolutionized biomedical research, consequences of Cre expression such as lack of fidelity,...]]></summary>
        <author>
            <name>Jasmin Straube</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia]]></title>
        <id>pubmed:36739348</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739348/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Murine models offer a valuable tool to recapitulate genetically defined subtypes of AML, and to assess the potential of compound mutations and clonal evolution during disease progression. This is of particular importance for difficult to treat leukemias such as FLT3 internal tandem duplication (ITD) positive AML. While conditional gene targeting by Cre recombinase is a powerful technology that has revolutionized biomedical research, consequences of Cre expression such as lack of fidelity,...]]></summary>
        <author>
            <name>Jasmin Straube</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia]]></title>
        <id>pubmed:36739348</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739348/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Murine models offer a valuable tool to recapitulate genetically defined subtypes of AML, and to assess the potential of compound mutations and clonal evolution during disease progression. This is of particular importance for difficult to treat leukemias such as FLT3 internal tandem duplication (ITD) positive AML. While conditional gene targeting by Cre recombinase is a powerful technology that has revolutionized biomedical research, consequences of Cre expression such as lack of fidelity,...]]></summary>
        <author>
            <name>Jasmin Straube</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia]]></title>
        <id>pubmed:36739348</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739348/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230209200536&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Murine models offer a valuable tool to recapitulate genetically defined subtypes of AML, and to assess the potential of compound mutations and clonal evolution during disease progression. This is of particular importance for difficult to treat leukemias such as FLT3 internal tandem duplication (ITD) positive AML. While conditional gene targeting by Cre recombinase is a powerful technology that has revolutionized biomedical research, consequences of Cre expression such as lack of fidelity,...]]></summary>
        <author>
            <name>Jasmin Straube</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia]]></title>
        <id>pubmed:36739348</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739348/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230208200032&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Murine models offer a valuable tool to recapitulate genetically defined subtypes of AML, and to assess the potential of compound mutations and clonal evolution during disease progression. This is of particular importance for difficult to treat leukemias such as FLT3 internal tandem duplication (ITD) positive AML. While conditional gene targeting by Cre recombinase is a powerful technology that has revolutionized biomedical research, consequences of Cre expression such as lack of fidelity,...]]></summary>
        <author>
            <name>Jasmin Straube</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia]]></title>
        <id>pubmed:36739348</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739348/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Murine models offer a valuable tool to recapitulate genetically defined subtypes of AML, and to assess the potential of compound mutations and clonal evolution during disease progression. This is of particular importance for difficult to treat leukemias such as FLT3 internal tandem duplication (ITD) positive AML. While conditional gene targeting by Cre recombinase is a powerful technology that has revolutionized biomedical research, consequences of Cre expression such as lack of fidelity,...]]></summary>
        <author>
            <name>Jasmin Straube</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia]]></title>
        <id>pubmed:36739348</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739348/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Murine models offer a valuable tool to recapitulate genetically defined subtypes of AML, and to assess the potential of compound mutations and clonal evolution during disease progression. This is of particular importance for difficult to treat leukemias such as FLT3 internal tandem duplication (ITD) positive AML. While conditional gene targeting by Cre recombinase is a powerful technology that has revolutionized biomedical research, consequences of Cre expression such as lack of fidelity,...]]></summary>
        <author>
            <name>Jasmin Straube</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia]]></title>
        <id>pubmed:36739348</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36739348/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Murine models offer a valuable tool to recapitulate genetically defined subtypes of AML, and to assess the potential of compound mutations and clonal evolution during disease progression. This is of particular importance for difficult to treat leukemias such as FLT3 internal tandem duplication (ITD) positive AML. While conditional gene targeting by Cre recombinase is a powerful technology that has revolutionized biomedical research, consequences of Cre expression such as lack of fidelity,...]]></summary>
        <author>
            <name>Jasmin Straube</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting somatic mutations to decipher human blood production: a natural lineage-tracing strategy]]></title>
        <id>pubmed:36736573</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736573/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230218200425&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lineage tracing using fluorescent proteins, genetic barcodes, and various other strategies have provided critical insights into the dynamics of both fetal and adult hematopoiesis in model organisms. However, these technologies cannot be readily utilized to study hematopoiesis in humans. Therefore, there is a critical need to develop strategies to assess cellular dynamics within human hematopoietic tissues in vivo. Recently, researchers have utilized naturally acquired somatic mutations, coupled...]]></summary>
        <author>
            <name>Mackenzie Bloom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230218200425&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Rare Pattern of Myelodysplastic Syndrome (MDS) with Serum Monoclonal Immunoglobulin: Case Report]]></title>
        <id>pubmed:36735715</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36735715/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230218200425&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The combination of plasma cell disease and myeloid malignancy may increase mortality. This is uncommon and may be easily misdiagnosed if not detected early. When a myeloid neoplasm tests positive for MDS and serum M protein, clinicians should evaluate for other plasma cell disease.]]></summary>
        <author>
            <name>Yating Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting somatic mutations to decipher human blood production: a natural lineage-tracing strategy]]></title>
        <id>pubmed:36736573</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736573/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lineage tracing using fluorescent proteins, genetic barcodes, and various other strategies have provided critical insights into the dynamics of both fetal and adult hematopoiesis in model organisms. However, these technologies cannot be readily utilized to study hematopoiesis in humans. Therefore, there is a critical need to develop strategies to assess cellular dynamics within human hematopoietic tissues in vivo. Recently, researchers have utilized naturally acquired somatic mutations, coupled...]]></summary>
        <author>
            <name>Mackenzie Bloom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Rare Pattern of Myelodysplastic Syndrome (MDS) with Serum Monoclonal Immunoglobulin: Case Report]]></title>
        <id>pubmed:36735715</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36735715/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The combination of plasma cell disease and myeloid malignancy may increase mortality. This is uncommon and may be easily misdiagnosed if not detected early. When a myeloid neoplasm tests positive for MDS and serum M protein, clinicians should evaluate for other plasma cell disease.]]></summary>
        <author>
            <name>Yating Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting somatic mutations to decipher human blood production: a natural lineage-tracing strategy]]></title>
        <id>pubmed:36736573</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736573/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lineage tracing using fluorescent proteins, genetic barcodes, and various other strategies have provided critical insights into the dynamics of both fetal and adult hematopoiesis in model organisms. However, these technologies cannot be readily utilized to study hematopoiesis in humans. Therefore, there is a critical need to develop strategies to assess cellular dynamics within human hematopoietic tissues in vivo. Recently, researchers have utilized naturally acquired somatic mutations, coupled...]]></summary>
        <author>
            <name>Mackenzie Bloom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Rare Pattern of Myelodysplastic Syndrome (MDS) with Serum Monoclonal Immunoglobulin: Case Report]]></title>
        <id>pubmed:36735715</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36735715/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The combination of plasma cell disease and myeloid malignancy may increase mortality. This is uncommon and may be easily misdiagnosed if not detected early. When a myeloid neoplasm tests positive for MDS and serum M protein, clinicians should evaluate for other plasma cell disease.]]></summary>
        <author>
            <name>Yating Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting somatic mutations to decipher human blood production: a natural lineage-tracing strategy]]></title>
        <id>pubmed:36736573</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736573/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lineage tracing using fluorescent proteins, genetic barcodes, and various other strategies have provided critical insights into the dynamics of both fetal and adult hematopoiesis in model organisms. However, these technologies cannot be readily utilized to study hematopoiesis in humans. Therefore, there is a critical need to develop strategies to assess cellular dynamics within human hematopoietic tissues in vivo. Recently, researchers have utilized naturally acquired somatic mutations, coupled...]]></summary>
        <author>
            <name>Mackenzie Bloom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Rare Pattern of Myelodysplastic Syndrome (MDS) with Serum Monoclonal Immunoglobulin: Case Report]]></title>
        <id>pubmed:36735715</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36735715/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The combination of plasma cell disease and myeloid malignancy may increase mortality. This is uncommon and may be easily misdiagnosed if not detected early. When a myeloid neoplasm tests positive for MDS and serum M protein, clinicians should evaluate for other plasma cell disease.]]></summary>
        <author>
            <name>Yating Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting somatic mutations to decipher human blood production: a natural lineage-tracing strategy]]></title>
        <id>pubmed:36736573</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736573/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lineage tracing using fluorescent proteins, genetic barcodes, and various other strategies have provided critical insights into the dynamics of both fetal and adult hematopoiesis in model organisms. However, these technologies cannot be readily utilized to study hematopoiesis in humans. Therefore, there is a critical need to develop strategies to assess cellular dynamics within human hematopoietic tissues in vivo. Recently, researchers have utilized naturally acquired somatic mutations, coupled...]]></summary>
        <author>
            <name>Mackenzie Bloom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Rare Pattern of Myelodysplastic Syndrome (MDS) with Serum Monoclonal Immunoglobulin: Case Report]]></title>
        <id>pubmed:36735715</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36735715/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The combination of plasma cell disease and myeloid malignancy may increase mortality. This is uncommon and may be easily misdiagnosed if not detected early. When a myeloid neoplasm tests positive for MDS and serum M protein, clinicians should evaluate for other plasma cell disease.]]></summary>
        <author>
            <name>Yating Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting somatic mutations to decipher human blood production: a natural lineage-tracing strategy]]></title>
        <id>pubmed:36736573</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736573/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lineage tracing using fluorescent proteins, genetic barcodes, and various other strategies have provided critical insights into the dynamics of both fetal and adult hematopoiesis in model organisms. However, these technologies cannot be readily utilized to study hematopoiesis in humans. Therefore, there is a critical need to develop strategies to assess cellular dynamics within human hematopoietic tissues in vivo. Recently, researchers have utilized naturally acquired somatic mutations, coupled...]]></summary>
        <author>
            <name>Mackenzie Bloom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Rare Pattern of Myelodysplastic Syndrome (MDS) with Serum Monoclonal Immunoglobulin: Case Report]]></title>
        <id>pubmed:36735715</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36735715/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The combination of plasma cell disease and myeloid malignancy may increase mortality. This is uncommon and may be easily misdiagnosed if not detected early. When a myeloid neoplasm tests positive for MDS and serum M protein, clinicians should evaluate for other plasma cell disease.]]></summary>
        <author>
            <name>Yating Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting somatic mutations to decipher human blood production: a natural lineage-tracing strategy]]></title>
        <id>pubmed:36736573</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736573/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lineage tracing using fluorescent proteins, genetic barcodes, and various other strategies have provided critical insights into the dynamics of both fetal and adult hematopoiesis in model organisms. However, these technologies cannot be readily utilized to study hematopoiesis in humans. Therefore, there is a critical need to develop strategies to assess cellular dynamics within human hematopoietic tissues in vivo. Recently, researchers have utilized naturally acquired somatic mutations, coupled...]]></summary>
        <author>
            <name>Mackenzie Bloom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Rare Pattern of Myelodysplastic Syndrome (MDS) with Serum Monoclonal Immunoglobulin: Case Report]]></title>
        <id>pubmed:36735715</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36735715/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The combination of plasma cell disease and myeloid malignancy may increase mortality. This is uncommon and may be easily misdiagnosed if not detected early. When a myeloid neoplasm tests positive for MDS and serum M protein, clinicians should evaluate for other plasma cell disease.]]></summary>
        <author>
            <name>Yating Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting somatic mutations to decipher human blood production: a natural lineage-tracing strategy]]></title>
        <id>pubmed:36736573</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736573/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lineage tracing using fluorescent proteins, genetic barcodes, and various other strategies have provided critical insights into the dynamics of both fetal and adult hematopoiesis in model organisms. However, these technologies cannot be readily utilized to study hematopoiesis in humans. Therefore, there is a critical need to develop strategies to assess cellular dynamics within human hematopoietic tissues in vivo. Recently, researchers have utilized naturally acquired somatic mutations, coupled...]]></summary>
        <author>
            <name>Mackenzie Bloom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Rare Pattern of Myelodysplastic Syndrome (MDS) with Serum Monoclonal Immunoglobulin: Case Report]]></title>
        <id>pubmed:36735715</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36735715/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The combination of plasma cell disease and myeloid malignancy may increase mortality. This is uncommon and may be easily misdiagnosed if not detected early. When a myeloid neoplasm tests positive for MDS and serum M protein, clinicians should evaluate for other plasma cell disease.]]></summary>
        <author>
            <name>Yating Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting somatic mutations to decipher human blood production: a natural lineage-tracing strategy]]></title>
        <id>pubmed:36736573</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736573/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lineage tracing using fluorescent proteins, genetic barcodes, and various other strategies have provided critical insights into the dynamics of both fetal and adult hematopoiesis in model organisms. However, these technologies cannot be readily utilized to study hematopoiesis in humans. Therefore, there is a critical need to develop strategies to assess cellular dynamics within human hematopoietic tissues in vivo. Recently, researchers have utilized naturally acquired somatic mutations, coupled...]]></summary>
        <author>
            <name>Mackenzie Bloom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Rare Pattern of Myelodysplastic Syndrome (MDS) with Serum Monoclonal Immunoglobulin: Case Report]]></title>
        <id>pubmed:36735715</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36735715/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The combination of plasma cell disease and myeloid malignancy may increase mortality. This is uncommon and may be easily misdiagnosed if not detected early. When a myeloid neoplasm tests positive for MDS and serum M protein, clinicians should evaluate for other plasma cell disease.]]></summary>
        <author>
            <name>Yating Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting somatic mutations to decipher human blood production: a natural lineage-tracing strategy]]></title>
        <id>pubmed:36736573</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736573/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230209200537&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lineage tracing using fluorescent proteins, genetic barcodes, and various other strategies have provided critical insights into the dynamics of both fetal and adult hematopoiesis in model organisms. However, these technologies cannot be readily utilized to study hematopoiesis in humans. Therefore, there is a critical need to develop strategies to assess cellular dynamics within human hematopoietic tissues in vivo. Recently, researchers have utilized naturally acquired somatic mutations, coupled...]]></summary>
        <author>
            <name>Mackenzie Bloom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230209200537&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Rare Pattern of Myelodysplastic Syndrome (MDS) with Serum Monoclonal Immunoglobulin: Case Report]]></title>
        <id>pubmed:36735715</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36735715/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230209200537&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The combination of plasma cell disease and myeloid malignancy may increase mortality. This is uncommon and may be easily misdiagnosed if not detected early. When a myeloid neoplasm tests positive for MDS and serum M protein, clinicians should evaluate for other plasma cell disease.]]></summary>
        <author>
            <name>Yating Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting somatic mutations to decipher human blood production: a natural lineage-tracing strategy]]></title>
        <id>pubmed:36736573</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736573/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230208200033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lineage tracing using fluorescent proteins, genetic barcodes, and various other strategies have provided critical insights into the dynamics of both fetal and adult hematopoiesis in model organisms. However, these technologies cannot be readily utilized to study hematopoiesis in humans. Therefore, there is a critical need to develop strategies to assess cellular dynamics within human hematopoietic tissues in vivo. Recently, researchers have utilized naturally acquired somatic mutations, coupled...]]></summary>
        <author>
            <name>Mackenzie Bloom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230208200033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Rare Pattern of Myelodysplastic Syndrome (MDS) with Serum Monoclonal Immunoglobulin: Case Report]]></title>
        <id>pubmed:36735715</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36735715/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230208200033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The combination of plasma cell disease and myeloid malignancy may increase mortality. This is uncommon and may be easily misdiagnosed if not detected early. When a myeloid neoplasm tests positive for MDS and serum M protein, clinicians should evaluate for other plasma cell disease.]]></summary>
        <author>
            <name>Yating Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting somatic mutations to decipher human blood production: a natural lineage-tracing strategy]]></title>
        <id>pubmed:36736573</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736573/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lineage tracing using fluorescent proteins, genetic barcodes, and various other strategies have provided critical insights into the dynamics of both fetal and adult hematopoiesis in model organisms. However, these technologies cannot be readily utilized to study hematopoiesis in humans. Therefore, there is a critical need to develop strategies to assess cellular dynamics within human hematopoietic tissues in vivo. Recently, researchers have utilized naturally acquired somatic mutations, coupled...]]></summary>
        <author>
            <name>Mackenzie Bloom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Rare Pattern of Myelodysplastic Syndrome (MDS) with Serum Monoclonal Immunoglobulin: Case Report]]></title>
        <id>pubmed:36735715</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36735715/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The combination of plasma cell disease and myeloid malignancy may increase mortality. This is uncommon and may be easily misdiagnosed if not detected early. When a myeloid neoplasm tests positive for MDS and serum M protein, clinicians should evaluate for other plasma cell disease.]]></summary>
        <author>
            <name>Yating Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting somatic mutations to decipher human blood production: a natural lineage-tracing strategy]]></title>
        <id>pubmed:36736573</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736573/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lineage tracing using fluorescent proteins, genetic barcodes, and various other strategies have provided critical insights into the dynamics of both fetal and adult hematopoiesis in model organisms. However, these technologies cannot be readily utilized to study hematopoiesis in humans. Therefore, there is a critical need to develop strategies to assess cellular dynamics within human hematopoietic tissues in vivo. Recently, researchers have utilized naturally acquired somatic mutations, coupled...]]></summary>
        <author>
            <name>Mackenzie Bloom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Rare Pattern of Myelodysplastic Syndrome (MDS) with Serum Monoclonal Immunoglobulin: Case Report]]></title>
        <id>pubmed:36735715</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36735715/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The combination of plasma cell disease and myeloid malignancy may increase mortality. This is uncommon and may be easily misdiagnosed if not detected early. When a myeloid neoplasm tests positive for MDS and serum M protein, clinicians should evaluate for other plasma cell disease.]]></summary>
        <author>
            <name>Yating Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting somatic mutations to decipher human blood production: a natural lineage-tracing strategy]]></title>
        <id>pubmed:36736573</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736573/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lineage tracing using fluorescent proteins, genetic barcodes, and various other strategies have provided critical insights into the dynamics of both fetal and adult hematopoiesis in model organisms. However, these technologies cannot be readily utilized to study hematopoiesis in humans. Therefore, there is a critical need to develop strategies to assess cellular dynamics within human hematopoietic tissues in vivo. Recently, researchers have utilized naturally acquired somatic mutations, coupled...]]></summary>
        <author>
            <name>Mackenzie Bloom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Rare Pattern of Myelodysplastic Syndrome (MDS) with Serum Monoclonal Immunoglobulin: Case Report]]></title>
        <id>pubmed:36735715</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36735715/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The combination of plasma cell disease and myeloid malignancy may increase mortality. This is uncommon and may be easily misdiagnosed if not detected early. When a myeloid neoplasm tests positive for MDS and serum M protein, clinicians should evaluate for other plasma cell disease.]]></summary>
        <author>
            <name>Yating Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting somatic mutations to decipher human blood production: a natural lineage-tracing strategy]]></title>
        <id>pubmed:36736573</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736573/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lineage tracing using fluorescent proteins, genetic barcodes, and various other strategies have provided critical insights into the dynamics of both fetal and adult hematopoiesis in model organisms. However, these technologies cannot be readily utilized to study hematopoiesis in humans. Therefore, there is a critical need to develop strategies to assess cellular dynamics within human hematopoietic tissues in vivo. Recently, researchers have utilized naturally acquired somatic mutations, coupled...]]></summary>
        <author>
            <name>Mackenzie Bloom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Rare Pattern of Myelodysplastic Syndrome (MDS) with Serum Monoclonal Immunoglobulin: Case Report]]></title>
        <id>pubmed:36735715</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36735715/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The combination of plasma cell disease and myeloid malignancy may increase mortality. This is uncommon and may be easily misdiagnosed if not detected early. When a myeloid neoplasm tests positive for MDS and serum M protein, clinicians should evaluate for other plasma cell disease.]]></summary>
        <author>
            <name>Yating Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Rare Pattern of Myelodysplastic Syndrome (MDS) with Serum Monoclonal Immunoglobulin: Case Report]]></title>
        <id>pubmed:36735715</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36735715/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The combination of plasma cell disease and myeloid malignancy may increase mortality. This is uncommon and may be easily misdiagnosed if not detected early. When a myeloid neoplasm tests positive for MDS and serum M protein, clinicians should evaluate for other plasma cell disease.]]></summary>
        <author>
            <name>Yating Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230218200426&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230209200536&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230208200032&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia]]></title>
        <id>pubmed:36736290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36736290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated...]]></summary>
        <author>
            <name>Marie Sebert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cord Blood Transplantation in 2 Infants Presenting Monosomy 7 Clonal Hematopoiesis; SAMD9/SAMD9L Germline Mutation]]></title>
        <id>pubmed:36730951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36730951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230218200425&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recently, germline mutations in SAMD9 and SAMD9L were increasingly found in children with monosomy 7. We report the outcomes in 2 infants with the SAMD9/SAMD9L variant, who presented with anemia and thrombocytopenia (patient 1), and neutropenia and nonsymptomatic white-matter-encephalopathy (patient 2). Both patients received cord blood transplantation and experienced critical post-cord blood transplantation adverse events; patients 1 and 2 developed fulminant engraftment syndrome and...]]></summary>
        <author>
            <name>Maiko Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230218200425&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cord Blood Transplantation in 2 Infants Presenting Monosomy 7 Clonal Hematopoiesis; SAMD9/SAMD9L Germline Mutation]]></title>
        <id>pubmed:36730951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36730951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recently, germline mutations in SAMD9 and SAMD9L were increasingly found in children with monosomy 7. We report the outcomes in 2 infants with the SAMD9/SAMD9L variant, who presented with anemia and thrombocytopenia (patient 1), and neutropenia and nonsymptomatic white-matter-encephalopathy (patient 2). Both patients received cord blood transplantation and experienced critical post-cord blood transplantation adverse events; patients 1 and 2 developed fulminant engraftment syndrome and...]]></summary>
        <author>
            <name>Maiko Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cord Blood Transplantation in 2 Infants Presenting Monosomy 7 Clonal Hematopoiesis; SAMD9/SAMD9L Germline Mutation]]></title>
        <id>pubmed:36730951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36730951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recently, germline mutations in SAMD9 and SAMD9L were increasingly found in children with monosomy 7. We report the outcomes in 2 infants with the SAMD9/SAMD9L variant, who presented with anemia and thrombocytopenia (patient 1), and neutropenia and nonsymptomatic white-matter-encephalopathy (patient 2). Both patients received cord blood transplantation and experienced critical post-cord blood transplantation adverse events; patients 1 and 2 developed fulminant engraftment syndrome and...]]></summary>
        <author>
            <name>Maiko Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cord Blood Transplantation in 2 Infants Presenting Monosomy 7 Clonal Hematopoiesis; SAMD9/SAMD9L Germline Mutation]]></title>
        <id>pubmed:36730951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36730951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recently, germline mutations in SAMD9 and SAMD9L were increasingly found in children with monosomy 7. We report the outcomes in 2 infants with the SAMD9/SAMD9L variant, who presented with anemia and thrombocytopenia (patient 1), and neutropenia and nonsymptomatic white-matter-encephalopathy (patient 2). Both patients received cord blood transplantation and experienced critical post-cord blood transplantation adverse events; patients 1 and 2 developed fulminant engraftment syndrome and...]]></summary>
        <author>
            <name>Maiko Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cord Blood Transplantation in 2 Infants Presenting Monosomy 7 Clonal Hematopoiesis; SAMD9/SAMD9L Germline Mutation]]></title>
        <id>pubmed:36730951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36730951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recently, germline mutations in SAMD9 and SAMD9L were increasingly found in children with monosomy 7. We report the outcomes in 2 infants with the SAMD9/SAMD9L variant, who presented with anemia and thrombocytopenia (patient 1), and neutropenia and nonsymptomatic white-matter-encephalopathy (patient 2). Both patients received cord blood transplantation and experienced critical post-cord blood transplantation adverse events; patients 1 and 2 developed fulminant engraftment syndrome and...]]></summary>
        <author>
            <name>Maiko Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from 13-year followup]]></title>
        <id>pubmed:36727396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36727396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Donor clonal hematopoiesis may be transferred to the recipient through allogeneic hematopoietic stem cell transplantation (HCT), but the potential for adverse long-term impact on transplant outcomes remains unknown. A total of 744 samples from 372 recipients who received HCT and the corresponding donors were included. Bar-coded error-corrected sequencing using a modified molecular inversion probe capture protocol was performed, which targeted 34 genes covering mutations involved in clonal...]]></summary>
        <author>
            <name>Kyoung Ha Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[When Clinico-Morphological and Molecular Studies Tell Different Stories: A Case of Myelodysplastic Syndrome]]></title>
        <id>pubmed:36726663</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726663/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic stem cell disorders characterized by cytopenias, dysplasia in one or more of the major myeloid cell lines, ineffective hematopoiesis, with cellular marrow, and risk for leukemic transformation. We present a case of a 66-year-old male with a history of multiple packed red blood cell (PRBC) transfusions. Routine investigations, bone marrow aspiration, and biopsy were done. The clinical and morphological findings raised suspicion of MDS with...]]></summary>
        <author>
            <name>Niharika Jain</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cord Blood Transplantation in 2 Infants Presenting Monosomy 7 Clonal Hematopoiesis; SAMD9/SAMD9L Germline Mutation]]></title>
        <id>pubmed:36730951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36730951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recently, germline mutations in SAMD9 and SAMD9L were increasingly found in children with monosomy 7. We report the outcomes in 2 infants with the SAMD9/SAMD9L variant, who presented with anemia and thrombocytopenia (patient 1), and neutropenia and nonsymptomatic white-matter-encephalopathy (patient 2). Both patients received cord blood transplantation and experienced critical post-cord blood transplantation adverse events; patients 1 and 2 developed fulminant engraftment syndrome and...]]></summary>
        <author>
            <name>Maiko Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from 13-year followup]]></title>
        <id>pubmed:36727396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36727396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Donor clonal hematopoiesis may be transferred to the recipient through allogeneic hematopoietic stem cell transplantation (HCT), but the potential for adverse long-term impact on transplant outcomes remains unknown. A total of 744 samples from 372 recipients who received HCT and the corresponding donors were included. Bar-coded error-corrected sequencing using a modified molecular inversion probe capture protocol was performed, which targeted 34 genes covering mutations involved in clonal...]]></summary>
        <author>
            <name>Kyoung Ha Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[When Clinico-Morphological and Molecular Studies Tell Different Stories: A Case of Myelodysplastic Syndrome]]></title>
        <id>pubmed:36726663</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726663/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic stem cell disorders characterized by cytopenias, dysplasia in one or more of the major myeloid cell lines, ineffective hematopoiesis, with cellular marrow, and risk for leukemic transformation. We present a case of a 66-year-old male with a history of multiple packed red blood cell (PRBC) transfusions. Routine investigations, bone marrow aspiration, and biopsy were done. The clinical and morphological findings raised suspicion of MDS with...]]></summary>
        <author>
            <name>Niharika Jain</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cord Blood Transplantation in 2 Infants Presenting Monosomy 7 Clonal Hematopoiesis; SAMD9/SAMD9L Germline Mutation]]></title>
        <id>pubmed:36730951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36730951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recently, germline mutations in SAMD9 and SAMD9L were increasingly found in children with monosomy 7. We report the outcomes in 2 infants with the SAMD9/SAMD9L variant, who presented with anemia and thrombocytopenia (patient 1), and neutropenia and nonsymptomatic white-matter-encephalopathy (patient 2). Both patients received cord blood transplantation and experienced critical post-cord blood transplantation adverse events; patients 1 and 2 developed fulminant engraftment syndrome and...]]></summary>
        <author>
            <name>Maiko Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from 13-year followup]]></title>
        <id>pubmed:36727396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36727396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Donor clonal hematopoiesis may be transferred to the recipient through allogeneic hematopoietic stem cell transplantation (HCT), but the potential for adverse long-term impact on transplant outcomes remains unknown. A total of 744 samples from 372 recipients who received HCT and the corresponding donors were included. Bar-coded error-corrected sequencing using a modified molecular inversion probe capture protocol was performed, which targeted 34 genes covering mutations involved in clonal...]]></summary>
        <author>
            <name>Kyoung Ha Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[When Clinico-Morphological and Molecular Studies Tell Different Stories: A Case of Myelodysplastic Syndrome]]></title>
        <id>pubmed:36726663</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726663/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic stem cell disorders characterized by cytopenias, dysplasia in one or more of the major myeloid cell lines, ineffective hematopoiesis, with cellular marrow, and risk for leukemic transformation. We present a case of a 66-year-old male with a history of multiple packed red blood cell (PRBC) transfusions. Routine investigations, bone marrow aspiration, and biopsy were done. The clinical and morphological findings raised suspicion of MDS with...]]></summary>
        <author>
            <name>Niharika Jain</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cord Blood Transplantation in 2 Infants Presenting Monosomy 7 Clonal Hematopoiesis; SAMD9/SAMD9L Germline Mutation]]></title>
        <id>pubmed:36730951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36730951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recently, germline mutations in SAMD9 and SAMD9L were increasingly found in children with monosomy 7. We report the outcomes in 2 infants with the SAMD9/SAMD9L variant, who presented with anemia and thrombocytopenia (patient 1), and neutropenia and nonsymptomatic white-matter-encephalopathy (patient 2). Both patients received cord blood transplantation and experienced critical post-cord blood transplantation adverse events; patients 1 and 2 developed fulminant engraftment syndrome and...]]></summary>
        <author>
            <name>Maiko Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from 13-year followup]]></title>
        <id>pubmed:36727396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36727396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Donor clonal hematopoiesis may be transferred to the recipient through allogeneic hematopoietic stem cell transplantation (HCT), but the potential for adverse long-term impact on transplant outcomes remains unknown. A total of 744 samples from 372 recipients who received HCT and the corresponding donors were included. Bar-coded error-corrected sequencing using a modified molecular inversion probe capture protocol was performed, which targeted 34 genes covering mutations involved in clonal...]]></summary>
        <author>
            <name>Kyoung Ha Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[When Clinico-Morphological and Molecular Studies Tell Different Stories: A Case of Myelodysplastic Syndrome]]></title>
        <id>pubmed:36726663</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726663/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic stem cell disorders characterized by cytopenias, dysplasia in one or more of the major myeloid cell lines, ineffective hematopoiesis, with cellular marrow, and risk for leukemic transformation. We present a case of a 66-year-old male with a history of multiple packed red blood cell (PRBC) transfusions. Routine investigations, bone marrow aspiration, and biopsy were done. The clinical and morphological findings raised suspicion of MDS with...]]></summary>
        <author>
            <name>Niharika Jain</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cord Blood Transplantation in 2 Infants Presenting Monosomy 7 Clonal Hematopoiesis; SAMD9/SAMD9L Germline Mutation]]></title>
        <id>pubmed:36730951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36730951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recently, germline mutations in SAMD9 and SAMD9L were increasingly found in children with monosomy 7. We report the outcomes in 2 infants with the SAMD9/SAMD9L variant, who presented with anemia and thrombocytopenia (patient 1), and neutropenia and nonsymptomatic white-matter-encephalopathy (patient 2). Both patients received cord blood transplantation and experienced critical post-cord blood transplantation adverse events; patients 1 and 2 developed fulminant engraftment syndrome and...]]></summary>
        <author>
            <name>Maiko Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from 13-year followup]]></title>
        <id>pubmed:36727396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36727396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Donor clonal hematopoiesis may be transferred to the recipient through allogeneic hematopoietic stem cell transplantation (HCT), but the potential for adverse long-term impact on transplant outcomes remains unknown. A total of 744 samples from 372 recipients who received HCT and the corresponding donors were included. Bar-coded error-corrected sequencing using a modified molecular inversion probe capture protocol was performed, which targeted 34 genes covering mutations involved in clonal...]]></summary>
        <author>
            <name>Kyoung Ha Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[When Clinico-Morphological and Molecular Studies Tell Different Stories: A Case of Myelodysplastic Syndrome]]></title>
        <id>pubmed:36726663</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726663/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic stem cell disorders characterized by cytopenias, dysplasia in one or more of the major myeloid cell lines, ineffective hematopoiesis, with cellular marrow, and risk for leukemic transformation. We present a case of a 66-year-old male with a history of multiple packed red blood cell (PRBC) transfusions. Routine investigations, bone marrow aspiration, and biopsy were done. The clinical and morphological findings raised suspicion of MDS with...]]></summary>
        <author>
            <name>Niharika Jain</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cord Blood Transplantation in 2 Infants Presenting Monosomy 7 Clonal Hematopoiesis; SAMD9/SAMD9L Germline Mutation]]></title>
        <id>pubmed:36730951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36730951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230209200537&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recently, germline mutations in SAMD9 and SAMD9L were increasingly found in children with monosomy 7. We report the outcomes in 2 infants with the SAMD9/SAMD9L variant, who presented with anemia and thrombocytopenia (patient 1), and neutropenia and nonsymptomatic white-matter-encephalopathy (patient 2). Both patients received cord blood transplantation and experienced critical post-cord blood transplantation adverse events; patients 1 and 2 developed fulminant engraftment syndrome and...]]></summary>
        <author>
            <name>Maiko Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230209200537&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from 13-year followup]]></title>
        <id>pubmed:36727396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36727396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230209200537&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Donor clonal hematopoiesis may be transferred to the recipient through allogeneic hematopoietic stem cell transplantation (HCT), but the potential for adverse long-term impact on transplant outcomes remains unknown. A total of 744 samples from 372 recipients who received HCT and the corresponding donors were included. Bar-coded error-corrected sequencing using a modified molecular inversion probe capture protocol was performed, which targeted 34 genes covering mutations involved in clonal...]]></summary>
        <author>
            <name>Kyoung Ha Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[When Clinico-Morphological and Molecular Studies Tell Different Stories: A Case of Myelodysplastic Syndrome]]></title>
        <id>pubmed:36726663</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726663/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230209200537&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic stem cell disorders characterized by cytopenias, dysplasia in one or more of the major myeloid cell lines, ineffective hematopoiesis, with cellular marrow, and risk for leukemic transformation. We present a case of a 66-year-old male with a history of multiple packed red blood cell (PRBC) transfusions. Routine investigations, bone marrow aspiration, and biopsy were done. The clinical and morphological findings raised suspicion of MDS with...]]></summary>
        <author>
            <name>Niharika Jain</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cord Blood Transplantation in 2 Infants Presenting Monosomy 7 Clonal Hematopoiesis; SAMD9/SAMD9L Germline Mutation]]></title>
        <id>pubmed:36730951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36730951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230208200033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recently, germline mutations in SAMD9 and SAMD9L were increasingly found in children with monosomy 7. We report the outcomes in 2 infants with the SAMD9/SAMD9L variant, who presented with anemia and thrombocytopenia (patient 1), and neutropenia and nonsymptomatic white-matter-encephalopathy (patient 2). Both patients received cord blood transplantation and experienced critical post-cord blood transplantation adverse events; patients 1 and 2 developed fulminant engraftment syndrome and...]]></summary>
        <author>
            <name>Maiko Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230208200033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from 13-year followup]]></title>
        <id>pubmed:36727396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36727396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230208200033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Donor clonal hematopoiesis may be transferred to the recipient through allogeneic hematopoietic stem cell transplantation (HCT), but the potential for adverse long-term impact on transplant outcomes remains unknown. A total of 744 samples from 372 recipients who received HCT and the corresponding donors were included. Bar-coded error-corrected sequencing using a modified molecular inversion probe capture protocol was performed, which targeted 34 genes covering mutations involved in clonal...]]></summary>
        <author>
            <name>Kyoung Ha Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[When Clinico-Morphological and Molecular Studies Tell Different Stories: A Case of Myelodysplastic Syndrome]]></title>
        <id>pubmed:36726663</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726663/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230208200033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic stem cell disorders characterized by cytopenias, dysplasia in one or more of the major myeloid cell lines, ineffective hematopoiesis, with cellular marrow, and risk for leukemic transformation. We present a case of a 66-year-old male with a history of multiple packed red blood cell (PRBC) transfusions. Routine investigations, bone marrow aspiration, and biopsy were done. The clinical and morphological findings raised suspicion of MDS with...]]></summary>
        <author>
            <name>Niharika Jain</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cord Blood Transplantation in 2 Infants Presenting Monosomy 7 Clonal Hematopoiesis; SAMD9/SAMD9L Germline Mutation]]></title>
        <id>pubmed:36730951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36730951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recently, germline mutations in SAMD9 and SAMD9L were increasingly found in children with monosomy 7. We report the outcomes in 2 infants with the SAMD9/SAMD9L variant, who presented with anemia and thrombocytopenia (patient 1), and neutropenia and nonsymptomatic white-matter-encephalopathy (patient 2). Both patients received cord blood transplantation and experienced critical post-cord blood transplantation adverse events; patients 1 and 2 developed fulminant engraftment syndrome and...]]></summary>
        <author>
            <name>Maiko Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from 13-year followup]]></title>
        <id>pubmed:36727396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36727396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Donor clonal hematopoiesis may be transferred to the recipient through allogeneic hematopoietic stem cell transplantation (HCT), but the potential for adverse long-term impact on transplant outcomes remains unknown. A total of 744 samples from 372 recipients who received HCT and the corresponding donors were included. Bar-coded error-corrected sequencing using a modified molecular inversion probe capture protocol was performed, which targeted 34 genes covering mutations involved in clonal...]]></summary>
        <author>
            <name>Kyoung Ha Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[When Clinico-Morphological and Molecular Studies Tell Different Stories: A Case of Myelodysplastic Syndrome]]></title>
        <id>pubmed:36726663</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726663/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic stem cell disorders characterized by cytopenias, dysplasia in one or more of the major myeloid cell lines, ineffective hematopoiesis, with cellular marrow, and risk for leukemic transformation. We present a case of a 66-year-old male with a history of multiple packed red blood cell (PRBC) transfusions. Routine investigations, bone marrow aspiration, and biopsy were done. The clinical and morphological findings raised suspicion of MDS with...]]></summary>
        <author>
            <name>Niharika Jain</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cord Blood Transplantation in 2 Infants Presenting Monosomy 7 Clonal Hematopoiesis; SAMD9/SAMD9L Germline Mutation]]></title>
        <id>pubmed:36730951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36730951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recently, germline mutations in SAMD9 and SAMD9L were increasingly found in children with monosomy 7. We report the outcomes in 2 infants with the SAMD9/SAMD9L variant, who presented with anemia and thrombocytopenia (patient 1), and neutropenia and nonsymptomatic white-matter-encephalopathy (patient 2). Both patients received cord blood transplantation and experienced critical post-cord blood transplantation adverse events; patients 1 and 2 developed fulminant engraftment syndrome and...]]></summary>
        <author>
            <name>Maiko Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from 13-year followup]]></title>
        <id>pubmed:36727396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36727396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Donor clonal hematopoiesis may be transferred to the recipient through allogeneic hematopoietic stem cell transplantation (HCT), but the potential for adverse long-term impact on transplant outcomes remains unknown. A total of 744 samples from 372 recipients who received HCT and the corresponding donors were included. Bar-coded error-corrected sequencing using a modified molecular inversion probe capture protocol was performed, which targeted 34 genes covering mutations involved in clonal...]]></summary>
        <author>
            <name>Kyoung Ha Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[When Clinico-Morphological and Molecular Studies Tell Different Stories: A Case of Myelodysplastic Syndrome]]></title>
        <id>pubmed:36726663</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726663/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic stem cell disorders characterized by cytopenias, dysplasia in one or more of the major myeloid cell lines, ineffective hematopoiesis, with cellular marrow, and risk for leukemic transformation. We present a case of a 66-year-old male with a history of multiple packed red blood cell (PRBC) transfusions. Routine investigations, bone marrow aspiration, and biopsy were done. The clinical and morphological findings raised suspicion of MDS with...]]></summary>
        <author>
            <name>Niharika Jain</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cord Blood Transplantation in 2 Infants Presenting Monosomy 7 Clonal Hematopoiesis; SAMD9/SAMD9L Germline Mutation]]></title>
        <id>pubmed:36730951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36730951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recently, germline mutations in SAMD9 and SAMD9L were increasingly found in children with monosomy 7. We report the outcomes in 2 infants with the SAMD9/SAMD9L variant, who presented with anemia and thrombocytopenia (patient 1), and neutropenia and nonsymptomatic white-matter-encephalopathy (patient 2). Both patients received cord blood transplantation and experienced critical post-cord blood transplantation adverse events; patients 1 and 2 developed fulminant engraftment syndrome and...]]></summary>
        <author>
            <name>Maiko Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from 13-year followup]]></title>
        <id>pubmed:36727396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36727396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Donor clonal hematopoiesis may be transferred to the recipient through allogeneic hematopoietic stem cell transplantation (HCT), but the potential for adverse long-term impact on transplant outcomes remains unknown. A total of 744 samples from 372 recipients who received HCT and the corresponding donors were included. Bar-coded error-corrected sequencing using a modified molecular inversion probe capture protocol was performed, which targeted 34 genes covering mutations involved in clonal...]]></summary>
        <author>
            <name>Kyoung Ha Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[When Clinico-Morphological and Molecular Studies Tell Different Stories: A Case of Myelodysplastic Syndrome]]></title>
        <id>pubmed:36726663</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726663/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic stem cell disorders characterized by cytopenias, dysplasia in one or more of the major myeloid cell lines, ineffective hematopoiesis, with cellular marrow, and risk for leukemic transformation. We present a case of a 66-year-old male with a history of multiple packed red blood cell (PRBC) transfusions. Routine investigations, bone marrow aspiration, and biopsy were done. The clinical and morphological findings raised suspicion of MDS with...]]></summary>
        <author>
            <name>Niharika Jain</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cord Blood Transplantation in 2 Infants Presenting Monosomy 7 Clonal Hematopoiesis; SAMD9/SAMD9L Germline Mutation]]></title>
        <id>pubmed:36730951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36730951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recently, germline mutations in SAMD9 and SAMD9L were increasingly found in children with monosomy 7. We report the outcomes in 2 infants with the SAMD9/SAMD9L variant, who presented with anemia and thrombocytopenia (patient 1), and neutropenia and nonsymptomatic white-matter-encephalopathy (patient 2). Both patients received cord blood transplantation and experienced critical post-cord blood transplantation adverse events; patients 1 and 2 developed fulminant engraftment syndrome and...]]></summary>
        <author>
            <name>Maiko Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from 13-year followup]]></title>
        <id>pubmed:36727396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36727396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Donor clonal hematopoiesis may be transferred to the recipient through allogeneic hematopoietic stem cell transplantation (HCT), but the potential for adverse long-term impact on transplant outcomes remains unknown. A total of 744 samples from 372 recipients who received HCT and the corresponding donors were included. Bar-coded error-corrected sequencing using a modified molecular inversion probe capture protocol was performed, which targeted 34 genes covering mutations involved in clonal...]]></summary>
        <author>
            <name>Kyoung Ha Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[When Clinico-Morphological and Molecular Studies Tell Different Stories: A Case of Myelodysplastic Syndrome]]></title>
        <id>pubmed:36726663</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726663/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic stem cell disorders characterized by cytopenias, dysplasia in one or more of the major myeloid cell lines, ineffective hematopoiesis, with cellular marrow, and risk for leukemic transformation. We present a case of a 66-year-old male with a history of multiple packed red blood cell (PRBC) transfusions. Routine investigations, bone marrow aspiration, and biopsy were done. The clinical and morphological findings raised suspicion of MDS with...]]></summary>
        <author>
            <name>Niharika Jain</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cord Blood Transplantation in 2 Infants Presenting Monosomy 7 Clonal Hematopoiesis; SAMD9/SAMD9L Germline Mutation]]></title>
        <id>pubmed:36730951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36730951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recently, germline mutations in SAMD9 and SAMD9L were increasingly found in children with monosomy 7. We report the outcomes in 2 infants with the SAMD9/SAMD9L variant, who presented with anemia and thrombocytopenia (patient 1), and neutropenia and nonsymptomatic white-matter-encephalopathy (patient 2). Both patients received cord blood transplantation and experienced critical post-cord blood transplantation adverse events; patients 1 and 2 developed fulminant engraftment syndrome and...]]></summary>
        <author>
            <name>Maiko Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from 13-year followup]]></title>
        <id>pubmed:36727396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36727396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Donor clonal hematopoiesis may be transferred to the recipient through allogeneic hematopoietic stem cell transplantation (HCT), but the potential for adverse long-term impact on transplant outcomes remains unknown. A total of 744 samples from 372 recipients who received HCT and the corresponding donors were included. Bar-coded error-corrected sequencing using a modified molecular inversion probe capture protocol was performed, which targeted 34 genes covering mutations involved in clonal...]]></summary>
        <author>
            <name>Kyoung Ha Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[When Clinico-Morphological and Molecular Studies Tell Different Stories: A Case of Myelodysplastic Syndrome]]></title>
        <id>pubmed:36726663</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726663/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic stem cell disorders characterized by cytopenias, dysplasia in one or more of the major myeloid cell lines, ineffective hematopoiesis, with cellular marrow, and risk for leukemic transformation. We present a case of a 66-year-old male with a history of multiple packed red blood cell (PRBC) transfusions. Routine investigations, bone marrow aspiration, and biopsy were done. The clinical and morphological findings raised suspicion of MDS with...]]></summary>
        <author>
            <name>Niharika Jain</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cord Blood Transplantation in 2 Infants Presenting Monosomy 7 Clonal Hematopoiesis; SAMD9/SAMD9L Germline Mutation]]></title>
        <id>pubmed:36730951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36730951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recently, germline mutations in SAMD9 and SAMD9L were increasingly found in children with monosomy 7. We report the outcomes in 2 infants with the SAMD9/SAMD9L variant, who presented with anemia and thrombocytopenia (patient 1), and neutropenia and nonsymptomatic white-matter-encephalopathy (patient 2). Both patients received cord blood transplantation and experienced critical post-cord blood transplantation adverse events; patients 1 and 2 developed fulminant engraftment syndrome and...]]></summary>
        <author>
            <name>Maiko Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from 13-year followup]]></title>
        <id>pubmed:36727396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36727396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Donor clonal hematopoiesis may be transferred to the recipient through allogeneic hematopoietic stem cell transplantation (HCT), but the potential for adverse long-term impact on transplant outcomes remains unknown. A total of 744 samples from 372 recipients who received HCT and the corresponding donors were included. Bar-coded error-corrected sequencing using a modified molecular inversion probe capture protocol was performed, which targeted 34 genes covering mutations involved in clonal...]]></summary>
        <author>
            <name>Kyoung Ha Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[When Clinico-Morphological and Molecular Studies Tell Different Stories: A Case of Myelodysplastic Syndrome]]></title>
        <id>pubmed:36726663</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726663/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic stem cell disorders characterized by cytopenias, dysplasia in one or more of the major myeloid cell lines, ineffective hematopoiesis, with cellular marrow, and risk for leukemic transformation. We present a case of a 66-year-old male with a history of multiple packed red blood cell (PRBC) transfusions. Routine investigations, bone marrow aspiration, and biopsy were done. The clinical and morphological findings raised suspicion of MDS with...]]></summary>
        <author>
            <name>Niharika Jain</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteogenomics decodes the evolution of human ipsilateral breast cancer]]></title>
        <id>pubmed:36732562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36732562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230218200426&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ipsilateral breast tumor recurrence (IBTR) is a clinically important event, where an isolated in-breast recurrence is a potentially curable event but associated with an increased risk of distant metastasis and breast cancer death. It remains unclear if IBTRs are associated with molecular changes that can be explored as a resource for precision medicine strategies. Here, we employed proteogenomics to analyze a cohort of 27 primary breast cancers and their matched IBTRs to define proteogenomic...]]></summary>
        <author>
            <name>Tommaso De Marchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230218200426&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Candidate targets of copy number deletion events across 17 cancer types]]></title>
        <id>pubmed:36726722</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726722/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230218200426&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome variation is the direct cause of cancer and driver of its clonal evolution. While the impact of many point mutations can be evaluated through their modification of individual genomic elements, even a single copy number aberration (CNA) may encompass hundreds of genes and therefore pose challenges to untangle potentially complex functional effects. However, consistent, recurring and disease-specific patterns in the genome-wide CNA landscape imply that particular CNA may promote...]]></summary>
        <author>
            <name>Qingyao Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteogenomics decodes the evolution of human ipsilateral breast cancer]]></title>
        <id>pubmed:36732562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36732562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ipsilateral breast tumor recurrence (IBTR) is a clinically important event, where an isolated in-breast recurrence is a potentially curable event but associated with an increased risk of distant metastasis and breast cancer death. It remains unclear if IBTRs are associated with molecular changes that can be explored as a resource for precision medicine strategies. Here, we employed proteogenomics to analyze a cohort of 27 primary breast cancers and their matched IBTRs to define proteogenomic...]]></summary>
        <author>
            <name>Tommaso De Marchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Candidate targets of copy number deletion events across 17 cancer types]]></title>
        <id>pubmed:36726722</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726722/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome variation is the direct cause of cancer and driver of its clonal evolution. While the impact of many point mutations can be evaluated through their modification of individual genomic elements, even a single copy number aberration (CNA) may encompass hundreds of genes and therefore pose challenges to untangle potentially complex functional effects. However, consistent, recurring and disease-specific patterns in the genome-wide CNA landscape imply that particular CNA may promote...]]></summary>
        <author>
            <name>Qingyao Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteogenomics decodes the evolution of human ipsilateral breast cancer]]></title>
        <id>pubmed:36732562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36732562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ipsilateral breast tumor recurrence (IBTR) is a clinically important event, where an isolated in-breast recurrence is a potentially curable event but associated with an increased risk of distant metastasis and breast cancer death. It remains unclear if IBTRs are associated with molecular changes that can be explored as a resource for precision medicine strategies. Here, we employed proteogenomics to analyze a cohort of 27 primary breast cancers and their matched IBTRs to define proteogenomic...]]></summary>
        <author>
            <name>Tommaso De Marchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Candidate targets of copy number deletion events across 17 cancer types]]></title>
        <id>pubmed:36726722</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726722/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome variation is the direct cause of cancer and driver of its clonal evolution. While the impact of many point mutations can be evaluated through their modification of individual genomic elements, even a single copy number aberration (CNA) may encompass hundreds of genes and therefore pose challenges to untangle potentially complex functional effects. However, consistent, recurring and disease-specific patterns in the genome-wide CNA landscape imply that particular CNA may promote...]]></summary>
        <author>
            <name>Qingyao Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteogenomics decodes the evolution of human ipsilateral breast cancer]]></title>
        <id>pubmed:36732562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36732562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ipsilateral breast tumor recurrence (IBTR) is a clinically important event, where an isolated in-breast recurrence is a potentially curable event but associated with an increased risk of distant metastasis and breast cancer death. It remains unclear if IBTRs are associated with molecular changes that can be explored as a resource for precision medicine strategies. Here, we employed proteogenomics to analyze a cohort of 27 primary breast cancers and their matched IBTRs to define proteogenomic...]]></summary>
        <author>
            <name>Tommaso De Marchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Candidate targets of copy number deletion events across 17 cancer types]]></title>
        <id>pubmed:36726722</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726722/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome variation is the direct cause of cancer and driver of its clonal evolution. While the impact of many point mutations can be evaluated through their modification of individual genomic elements, even a single copy number aberration (CNA) may encompass hundreds of genes and therefore pose challenges to untangle potentially complex functional effects. However, consistent, recurring and disease-specific patterns in the genome-wide CNA landscape imply that particular CNA may promote...]]></summary>
        <author>
            <name>Qingyao Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteogenomics decodes the evolution of human ipsilateral breast cancer]]></title>
        <id>pubmed:36732562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36732562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ipsilateral breast tumor recurrence (IBTR) is a clinically important event, where an isolated in-breast recurrence is a potentially curable event but associated with an increased risk of distant metastasis and breast cancer death. It remains unclear if IBTRs are associated with molecular changes that can be explored as a resource for precision medicine strategies. Here, we employed proteogenomics to analyze a cohort of 27 primary breast cancers and their matched IBTRs to define proteogenomic...]]></summary>
        <author>
            <name>Tommaso De Marchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Candidate targets of copy number deletion events across 17 cancer types]]></title>
        <id>pubmed:36726722</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726722/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome variation is the direct cause of cancer and driver of its clonal evolution. While the impact of many point mutations can be evaluated through their modification of individual genomic elements, even a single copy number aberration (CNA) may encompass hundreds of genes and therefore pose challenges to untangle potentially complex functional effects. However, consistent, recurring and disease-specific patterns in the genome-wide CNA landscape imply that particular CNA may promote...]]></summary>
        <author>
            <name>Qingyao Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteogenomics decodes the evolution of human ipsilateral breast cancer]]></title>
        <id>pubmed:36732562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36732562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ipsilateral breast tumor recurrence (IBTR) is a clinically important event, where an isolated in-breast recurrence is a potentially curable event but associated with an increased risk of distant metastasis and breast cancer death. It remains unclear if IBTRs are associated with molecular changes that can be explored as a resource for precision medicine strategies. Here, we employed proteogenomics to analyze a cohort of 27 primary breast cancers and their matched IBTRs to define proteogenomic...]]></summary>
        <author>
            <name>Tommaso De Marchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Candidate targets of copy number deletion events across 17 cancer types]]></title>
        <id>pubmed:36726722</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726722/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome variation is the direct cause of cancer and driver of its clonal evolution. While the impact of many point mutations can be evaluated through their modification of individual genomic elements, even a single copy number aberration (CNA) may encompass hundreds of genes and therefore pose challenges to untangle potentially complex functional effects. However, consistent, recurring and disease-specific patterns in the genome-wide CNA landscape imply that particular CNA may promote...]]></summary>
        <author>
            <name>Qingyao Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteogenomics decodes the evolution of human ipsilateral breast cancer]]></title>
        <id>pubmed:36732562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36732562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ipsilateral breast tumor recurrence (IBTR) is a clinically important event, where an isolated in-breast recurrence is a potentially curable event but associated with an increased risk of distant metastasis and breast cancer death. It remains unclear if IBTRs are associated with molecular changes that can be explored as a resource for precision medicine strategies. Here, we employed proteogenomics to analyze a cohort of 27 primary breast cancers and their matched IBTRs to define proteogenomic...]]></summary>
        <author>
            <name>Tommaso De Marchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Candidate targets of copy number deletion events across 17 cancer types]]></title>
        <id>pubmed:36726722</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726722/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome variation is the direct cause of cancer and driver of its clonal evolution. While the impact of many point mutations can be evaluated through their modification of individual genomic elements, even a single copy number aberration (CNA) may encompass hundreds of genes and therefore pose challenges to untangle potentially complex functional effects. However, consistent, recurring and disease-specific patterns in the genome-wide CNA landscape imply that particular CNA may promote...]]></summary>
        <author>
            <name>Qingyao Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteogenomics decodes the evolution of human ipsilateral breast cancer]]></title>
        <id>pubmed:36732562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36732562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ipsilateral breast tumor recurrence (IBTR) is a clinically important event, where an isolated in-breast recurrence is a potentially curable event but associated with an increased risk of distant metastasis and breast cancer death. It remains unclear if IBTRs are associated with molecular changes that can be explored as a resource for precision medicine strategies. Here, we employed proteogenomics to analyze a cohort of 27 primary breast cancers and their matched IBTRs to define proteogenomic...]]></summary>
        <author>
            <name>Tommaso De Marchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Candidate targets of copy number deletion events across 17 cancer types]]></title>
        <id>pubmed:36726722</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726722/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome variation is the direct cause of cancer and driver of its clonal evolution. While the impact of many point mutations can be evaluated through their modification of individual genomic elements, even a single copy number aberration (CNA) may encompass hundreds of genes and therefore pose challenges to untangle potentially complex functional effects. However, consistent, recurring and disease-specific patterns in the genome-wide CNA landscape imply that particular CNA may promote...]]></summary>
        <author>
            <name>Qingyao Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteogenomics decodes the evolution of human ipsilateral breast cancer]]></title>
        <id>pubmed:36732562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36732562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ipsilateral breast tumor recurrence (IBTR) is a clinically important event, where an isolated in-breast recurrence is a potentially curable event but associated with an increased risk of distant metastasis and breast cancer death. It remains unclear if IBTRs are associated with molecular changes that can be explored as a resource for precision medicine strategies. Here, we employed proteogenomics to analyze a cohort of 27 primary breast cancers and their matched IBTRs to define proteogenomic...]]></summary>
        <author>
            <name>Tommaso De Marchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Candidate targets of copy number deletion events across 17 cancer types]]></title>
        <id>pubmed:36726722</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726722/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome variation is the direct cause of cancer and driver of its clonal evolution. While the impact of many point mutations can be evaluated through their modification of individual genomic elements, even a single copy number aberration (CNA) may encompass hundreds of genes and therefore pose challenges to untangle potentially complex functional effects. However, consistent, recurring and disease-specific patterns in the genome-wide CNA landscape imply that particular CNA may promote...]]></summary>
        <author>
            <name>Qingyao Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteogenomics decodes the evolution of human ipsilateral breast cancer]]></title>
        <id>pubmed:36732562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36732562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230209200536&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ipsilateral breast tumor recurrence (IBTR) is a clinically important event, where an isolated in-breast recurrence is a potentially curable event but associated with an increased risk of distant metastasis and breast cancer death. It remains unclear if IBTRs are associated with molecular changes that can be explored as a resource for precision medicine strategies. Here, we employed proteogenomics to analyze a cohort of 27 primary breast cancers and their matched IBTRs to define proteogenomic...]]></summary>
        <author>
            <name>Tommaso De Marchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230209200536&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Candidate targets of copy number deletion events across 17 cancer types]]></title>
        <id>pubmed:36726722</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726722/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230209200536&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome variation is the direct cause of cancer and driver of its clonal evolution. While the impact of many point mutations can be evaluated through their modification of individual genomic elements, even a single copy number aberration (CNA) may encompass hundreds of genes and therefore pose challenges to untangle potentially complex functional effects. However, consistent, recurring and disease-specific patterns in the genome-wide CNA landscape imply that particular CNA may promote...]]></summary>
        <author>
            <name>Qingyao Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteogenomics decodes the evolution of human ipsilateral breast cancer]]></title>
        <id>pubmed:36732562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36732562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230208200032&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ipsilateral breast tumor recurrence (IBTR) is a clinically important event, where an isolated in-breast recurrence is a potentially curable event but associated with an increased risk of distant metastasis and breast cancer death. It remains unclear if IBTRs are associated with molecular changes that can be explored as a resource for precision medicine strategies. Here, we employed proteogenomics to analyze a cohort of 27 primary breast cancers and their matched IBTRs to define proteogenomic...]]></summary>
        <author>
            <name>Tommaso De Marchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230208200032&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Candidate targets of copy number deletion events across 17 cancer types]]></title>
        <id>pubmed:36726722</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726722/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230208200032&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome variation is the direct cause of cancer and driver of its clonal evolution. While the impact of many point mutations can be evaluated through their modification of individual genomic elements, even a single copy number aberration (CNA) may encompass hundreds of genes and therefore pose challenges to untangle potentially complex functional effects. However, consistent, recurring and disease-specific patterns in the genome-wide CNA landscape imply that particular CNA may promote...]]></summary>
        <author>
            <name>Qingyao Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteogenomics decodes the evolution of human ipsilateral breast cancer]]></title>
        <id>pubmed:36732562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36732562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ipsilateral breast tumor recurrence (IBTR) is a clinically important event, where an isolated in-breast recurrence is a potentially curable event but associated with an increased risk of distant metastasis and breast cancer death. It remains unclear if IBTRs are associated with molecular changes that can be explored as a resource for precision medicine strategies. Here, we employed proteogenomics to analyze a cohort of 27 primary breast cancers and their matched IBTRs to define proteogenomic...]]></summary>
        <author>
            <name>Tommaso De Marchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Candidate targets of copy number deletion events across 17 cancer types]]></title>
        <id>pubmed:36726722</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726722/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome variation is the direct cause of cancer and driver of its clonal evolution. While the impact of many point mutations can be evaluated through their modification of individual genomic elements, even a single copy number aberration (CNA) may encompass hundreds of genes and therefore pose challenges to untangle potentially complex functional effects. However, consistent, recurring and disease-specific patterns in the genome-wide CNA landscape imply that particular CNA may promote...]]></summary>
        <author>
            <name>Qingyao Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteogenomics decodes the evolution of human ipsilateral breast cancer]]></title>
        <id>pubmed:36732562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36732562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ipsilateral breast tumor recurrence (IBTR) is a clinically important event, where an isolated in-breast recurrence is a potentially curable event but associated with an increased risk of distant metastasis and breast cancer death. It remains unclear if IBTRs are associated with molecular changes that can be explored as a resource for precision medicine strategies. Here, we employed proteogenomics to analyze a cohort of 27 primary breast cancers and their matched IBTRs to define proteogenomic...]]></summary>
        <author>
            <name>Tommaso De Marchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers]]></title>
        <id>pubmed:36729457</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36729457/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.]]></summary>
        <author>
            <name>Bill H Diplas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Candidate targets of copy number deletion events across 17 cancer types]]></title>
        <id>pubmed:36726722</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726722/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome variation is the direct cause of cancer and driver of its clonal evolution. While the impact of many point mutations can be evaluated through their modification of individual genomic elements, even a single copy number aberration (CNA) may encompass hundreds of genes and therefore pose challenges to untangle potentially complex functional effects. However, consistent, recurring and disease-specific patterns in the genome-wide CNA landscape imply that particular CNA may promote...]]></summary>
        <author>
            <name>Qingyao Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteogenomics decodes the evolution of human ipsilateral breast cancer]]></title>
        <id>pubmed:36732562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36732562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ipsilateral breast tumor recurrence (IBTR) is a clinically important event, where an isolated in-breast recurrence is a potentially curable event but associated with an increased risk of distant metastasis and breast cancer death. It remains unclear if IBTRs are associated with molecular changes that can be explored as a resource for precision medicine strategies. Here, we employed proteogenomics to analyze a cohort of 27 primary breast cancers and their matched IBTRs to define proteogenomic...]]></summary>
        <author>
            <name>Tommaso De Marchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Candidate targets of copy number deletion events across 17 cancer types]]></title>
        <id>pubmed:36726722</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726722/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome variation is the direct cause of cancer and driver of its clonal evolution. While the impact of many point mutations can be evaluated through their modification of individual genomic elements, even a single copy number aberration (CNA) may encompass hundreds of genes and therefore pose challenges to untangle potentially complex functional effects. However, consistent, recurring and disease-specific patterns in the genome-wide CNA landscape imply that particular CNA may promote...]]></summary>
        <author>
            <name>Qingyao Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteogenomics decodes the evolution of human ipsilateral breast cancer]]></title>
        <id>pubmed:36732562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36732562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ipsilateral breast tumor recurrence (IBTR) is a clinically important event, where an isolated in-breast recurrence is a potentially curable event but associated with an increased risk of distant metastasis and breast cancer death. It remains unclear if IBTRs are associated with molecular changes that can be explored as a resource for precision medicine strategies. Here, we employed proteogenomics to analyze a cohort of 27 primary breast cancers and their matched IBTRs to define proteogenomic...]]></summary>
        <author>
            <name>Tommaso De Marchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Candidate targets of copy number deletion events across 17 cancer types]]></title>
        <id>pubmed:36726722</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726722/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome variation is the direct cause of cancer and driver of its clonal evolution. While the impact of many point mutations can be evaluated through their modification of individual genomic elements, even a single copy number aberration (CNA) may encompass hundreds of genes and therefore pose challenges to untangle potentially complex functional effects. However, consistent, recurring and disease-specific patterns in the genome-wide CNA landscape imply that particular CNA may promote...]]></summary>
        <author>
            <name>Qingyao Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteogenomics decodes the evolution of human ipsilateral breast cancer]]></title>
        <id>pubmed:36732562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36732562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ipsilateral breast tumor recurrence (IBTR) is a clinically important event, where an isolated in-breast recurrence is a potentially curable event but associated with an increased risk of distant metastasis and breast cancer death. It remains unclear if IBTRs are associated with molecular changes that can be explored as a resource for precision medicine strategies. Here, we employed proteogenomics to analyze a cohort of 27 primary breast cancers and their matched IBTRs to define proteogenomic...]]></summary>
        <author>
            <name>Tommaso De Marchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Candidate targets of copy number deletion events across 17 cancer types]]></title>
        <id>pubmed:36726722</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726722/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome variation is the direct cause of cancer and driver of its clonal evolution. While the impact of many point mutations can be evaluated through their modification of individual genomic elements, even a single copy number aberration (CNA) may encompass hundreds of genes and therefore pose challenges to untangle potentially complex functional effects. However, consistent, recurring and disease-specific patterns in the genome-wide CNA landscape imply that particular CNA may promote...]]></summary>
        <author>
            <name>Qingyao Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Candidate targets of copy number deletion events across 17 cancer types]]></title>
        <id>pubmed:36726722</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36726722/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-02-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome variation is the direct cause of cancer and driver of its clonal evolution. While the impact of many point mutations can be evaluated through their modification of individual genomic elements, even a single copy number aberration (CNA) may encompass hundreds of genes and therefore pose challenges to untangle potentially complex functional effects. However, consistent, recurring and disease-specific patterns in the genome-wide CNA landscape imply that particular CNA may promote...]]></summary>
        <author>
            <name>Qingyao Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Causes of Clonal Hematopoiesis: a Review]]></title>
        <id>pubmed:36719597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36719597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Clonal hematopoiesis (CH) is an age-dependent process detectable using advanced sequencing technologies and is associated with multiple adverse health outcomes including cardiovascular disease and cancer. The purpose of this review is to summarize known causes of CH mutations and to identify key areas and considerations for future research on CH.]]></summary>
        <author>
            <name>LiJin Joo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Causes of Clonal Hematopoiesis: a Review]]></title>
        <id>pubmed:36719597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36719597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Clonal hematopoiesis (CH) is an age-dependent process detectable using advanced sequencing technologies and is associated with multiple adverse health outcomes including cardiovascular disease and cancer. The purpose of this review is to summarize known causes of CH mutations and to identify key areas and considerations for future research on CH.]]></summary>
        <author>
            <name>LiJin Joo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Causes of Clonal Hematopoiesis: a Review]]></title>
        <id>pubmed:36719597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36719597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Clonal hematopoiesis (CH) is an age-dependent process detectable using advanced sequencing technologies and is associated with multiple adverse health outcomes including cardiovascular disease and cancer. The purpose of this review is to summarize known causes of CH mutations and to identify key areas and considerations for future research on CH.]]></summary>
        <author>
            <name>LiJin Joo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Causes of Clonal Hematopoiesis: a Review]]></title>
        <id>pubmed:36719597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36719597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Clonal hematopoiesis (CH) is an age-dependent process detectable using advanced sequencing technologies and is associated with multiple adverse health outcomes including cardiovascular disease and cancer. The purpose of this review is to summarize known causes of CH mutations and to identify key areas and considerations for future research on CH.]]></summary>
        <author>
            <name>LiJin Joo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Causes of Clonal Hematopoiesis: a Review]]></title>
        <id>pubmed:36719597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36719597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Clonal hematopoiesis (CH) is an age-dependent process detectable using advanced sequencing technologies and is associated with multiple adverse health outcomes including cardiovascular disease and cancer. The purpose of this review is to summarize known causes of CH mutations and to identify key areas and considerations for future research on CH.]]></summary>
        <author>
            <name>LiJin Joo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Causes of Clonal Hematopoiesis: a Review]]></title>
        <id>pubmed:36719597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36719597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230209200537&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Clonal hematopoiesis (CH) is an age-dependent process detectable using advanced sequencing technologies and is associated with multiple adverse health outcomes including cardiovascular disease and cancer. The purpose of this review is to summarize known causes of CH mutations and to identify key areas and considerations for future research on CH.]]></summary>
        <author>
            <name>LiJin Joo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Causes of Clonal Hematopoiesis: a Review]]></title>
        <id>pubmed:36719597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36719597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230208200033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Clonal hematopoiesis (CH) is an age-dependent process detectable using advanced sequencing technologies and is associated with multiple adverse health outcomes including cardiovascular disease and cancer. The purpose of this review is to summarize known causes of CH mutations and to identify key areas and considerations for future research on CH.]]></summary>
        <author>
            <name>LiJin Joo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Causes of Clonal Hematopoiesis: a Review]]></title>
        <id>pubmed:36719597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36719597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Clonal hematopoiesis (CH) is an age-dependent process detectable using advanced sequencing technologies and is associated with multiple adverse health outcomes including cardiovascular disease and cancer. The purpose of this review is to summarize known causes of CH mutations and to identify key areas and considerations for future research on CH.]]></summary>
        <author>
            <name>LiJin Joo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Causes of Clonal Hematopoiesis: a Review]]></title>
        <id>pubmed:36719597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36719597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Clonal hematopoiesis (CH) is an age-dependent process detectable using advanced sequencing technologies and is associated with multiple adverse health outcomes including cardiovascular disease and cancer. The purpose of this review is to summarize known causes of CH mutations and to identify key areas and considerations for future research on CH.]]></summary>
        <author>
            <name>LiJin Joo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Causes of Clonal Hematopoiesis: a Review]]></title>
        <id>pubmed:36719597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36719597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Clonal hematopoiesis (CH) is an age-dependent process detectable using advanced sequencing technologies and is associated with multiple adverse health outcomes including cardiovascular disease and cancer. The purpose of this review is to summarize known causes of CH mutations and to identify key areas and considerations for future research on CH.]]></summary>
        <author>
            <name>LiJin Joo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Causes of Clonal Hematopoiesis: a Review]]></title>
        <id>pubmed:36719597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36719597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Clonal hematopoiesis (CH) is an age-dependent process detectable using advanced sequencing technologies and is associated with multiple adverse health outcomes including cardiovascular disease and cancer. The purpose of this review is to summarize known causes of CH mutations and to identify key areas and considerations for future research on CH.]]></summary>
        <author>
            <name>LiJin Joo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Causes of Clonal Hematopoiesis: a Review]]></title>
        <id>pubmed:36719597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36719597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Clonal hematopoiesis (CH) is an age-dependent process detectable using advanced sequencing technologies and is associated with multiple adverse health outcomes including cardiovascular disease and cancer. The purpose of this review is to summarize known causes of CH mutations and to identify key areas and considerations for future research on CH.]]></summary>
        <author>
            <name>LiJin Joo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Causes of Clonal Hematopoiesis: a Review]]></title>
        <id>pubmed:36719597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36719597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Clonal hematopoiesis (CH) is an age-dependent process detectable using advanced sequencing technologies and is associated with multiple adverse health outcomes including cardiovascular disease and cancer. The purpose of this review is to summarize known causes of CH mutations and to identify key areas and considerations for future research on CH.]]></summary>
        <author>
            <name>LiJin Joo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Causes of Clonal Hematopoiesis: a Review]]></title>
        <id>pubmed:36719597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36719597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Clonal hematopoiesis (CH) is an age-dependent process detectable using advanced sequencing technologies and is associated with multiple adverse health outcomes including cardiovascular disease and cancer. The purpose of this review is to summarize known causes of CH mutations and to identify key areas and considerations for future research on CH.]]></summary>
        <author>
            <name>LiJin Joo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Causes of Clonal Hematopoiesis: a Review]]></title>
        <id>pubmed:36719597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36719597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Clonal hematopoiesis (CH) is an age-dependent process detectable using advanced sequencing technologies and is associated with multiple adverse health outcomes including cardiovascular disease and cancer. The purpose of this review is to summarize known causes of CH mutations and to identify key areas and considerations for future research on CH.]]></summary>
        <author>
            <name>LiJin Joo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonality relatedness and molecular characteristics of Richter transformation]]></title>
        <id>pubmed:36709198</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709198/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230218200426&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To investigate the clinical, genetic, and clonality related aspects of individuals with Richter transformation (RT) . Methods: From January 2019 to December 2021, 18 RT patients with diagnoses at the First Affiliated Hospital of Nanjing Medical University (Pukou CLL center) were retrospectively examined. The immunoglobin heavy variable (IGHV) gene usage and IGHV-D-J rearrangement pattern of diagnosed CLL/SLL and transformed diffuse large B-cell lymphoma (DLBCL) were compared to...]]></summary>
        <author>
            <name>Y Q Sha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonality relatedness and molecular characteristics of Richter transformation]]></title>
        <id>pubmed:36709198</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709198/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230217200212&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To investigate the clinical, genetic, and clonality related aspects of individuals with Richter transformation (RT) . Methods: From January 2019 to December 2021, 18 RT patients with diagnoses at the First Affiliated Hospital of Nanjing Medical University (Pukou CLL center) were retrospectively examined. The immunoglobin heavy variable (IGHV) gene usage and IGHV-D-J rearrangement pattern of diagnosed CLL/SLL and transformed diffuse large B-cell lymphoma (DLBCL) were compared to...]]></summary>
        <author>
            <name>Y Q Sha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonality relatedness and molecular characteristics of Richter transformation]]></title>
        <id>pubmed:36709198</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709198/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230216200633&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To investigate the clinical, genetic, and clonality related aspects of individuals with Richter transformation (RT) . Methods: From January 2019 to December 2021, 18 RT patients with diagnoses at the First Affiliated Hospital of Nanjing Medical University (Pukou CLL center) were retrospectively examined. The immunoglobin heavy variable (IGHV) gene usage and IGHV-D-J rearrangement pattern of diagnosed CLL/SLL and transformed diffuse large B-cell lymphoma (DLBCL) were compared to...]]></summary>
        <author>
            <name>Y Q Sha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonality relatedness and molecular characteristics of Richter transformation]]></title>
        <id>pubmed:36709198</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709198/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To investigate the clinical, genetic, and clonality related aspects of individuals with Richter transformation (RT) . Methods: From January 2019 to December 2021, 18 RT patients with diagnoses at the First Affiliated Hospital of Nanjing Medical University (Pukou CLL center) were retrospectively examined. The immunoglobin heavy variable (IGHV) gene usage and IGHV-D-J rearrangement pattern of diagnosed CLL/SLL and transformed diffuse large B-cell lymphoma (DLBCL) were compared to...]]></summary>
        <author>
            <name>Y Q Sha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk factors for leukemia transformation in patients with myelodysplastic syndromes]]></title>
        <id>pubmed:36709195</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709195/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230215200329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To explore the risk factors in leukemia transformation (LT) in those with myelodysplastic syndromes (MDS) . Methods: From January 2012 to December 2020,data on 320 patients with newly diagnosed primary MDS were gathered from the MDS center. The clinical features and molecular characteristics are explored. Additionally, a retrospective analysis of risk factors for the development of acute leukemia from MDS was done. Results: The median follow-up was13.6 (0.4-107.3) months. 23.4%...]]></summary>
        <author>
            <name>S Y Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonality relatedness and molecular characteristics of Richter transformation]]></title>
        <id>pubmed:36709198</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709198/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To investigate the clinical, genetic, and clonality related aspects of individuals with Richter transformation (RT) . Methods: From January 2019 to December 2021, 18 RT patients with diagnoses at the First Affiliated Hospital of Nanjing Medical University (Pukou CLL center) were retrospectively examined. The immunoglobin heavy variable (IGHV) gene usage and IGHV-D-J rearrangement pattern of diagnosed CLL/SLL and transformed diffuse large B-cell lymphoma (DLBCL) were compared to...]]></summary>
        <author>
            <name>Y Q Sha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk factors for leukemia transformation in patients with myelodysplastic syndromes]]></title>
        <id>pubmed:36709195</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709195/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230214200334&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To explore the risk factors in leukemia transformation (LT) in those with myelodysplastic syndromes (MDS) . Methods: From January 2012 to December 2020,data on 320 patients with newly diagnosed primary MDS were gathered from the MDS center. The clinical features and molecular characteristics are explored. Additionally, a retrospective analysis of risk factors for the development of acute leukemia from MDS was done. Results: The median follow-up was13.6 (0.4-107.3) months. 23.4%...]]></summary>
        <author>
            <name>S Y Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonality relatedness and molecular characteristics of Richter transformation]]></title>
        <id>pubmed:36709198</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709198/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To investigate the clinical, genetic, and clonality related aspects of individuals with Richter transformation (RT) . Methods: From January 2019 to December 2021, 18 RT patients with diagnoses at the First Affiliated Hospital of Nanjing Medical University (Pukou CLL center) were retrospectively examined. The immunoglobin heavy variable (IGHV) gene usage and IGHV-D-J rearrangement pattern of diagnosed CLL/SLL and transformed diffuse large B-cell lymphoma (DLBCL) were compared to...]]></summary>
        <author>
            <name>Y Q Sha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk factors for leukemia transformation in patients with myelodysplastic syndromes]]></title>
        <id>pubmed:36709195</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709195/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230213200355&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To explore the risk factors in leukemia transformation (LT) in those with myelodysplastic syndromes (MDS) . Methods: From January 2012 to December 2020,data on 320 patients with newly diagnosed primary MDS were gathered from the MDS center. The clinical features and molecular characteristics are explored. Additionally, a retrospective analysis of risk factors for the development of acute leukemia from MDS was done. Results: The median follow-up was13.6 (0.4-107.3) months. 23.4%...]]></summary>
        <author>
            <name>S Y Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonality relatedness and molecular characteristics of Richter transformation]]></title>
        <id>pubmed:36709198</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709198/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To investigate the clinical, genetic, and clonality related aspects of individuals with Richter transformation (RT) . Methods: From January 2019 to December 2021, 18 RT patients with diagnoses at the First Affiliated Hospital of Nanjing Medical University (Pukou CLL center) were retrospectively examined. The immunoglobin heavy variable (IGHV) gene usage and IGHV-D-J rearrangement pattern of diagnosed CLL/SLL and transformed diffuse large B-cell lymphoma (DLBCL) were compared to...]]></summary>
        <author>
            <name>Y Q Sha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk factors for leukemia transformation in patients with myelodysplastic syndromes]]></title>
        <id>pubmed:36709195</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709195/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To explore the risk factors in leukemia transformation (LT) in those with myelodysplastic syndromes (MDS) . Methods: From January 2012 to December 2020,data on 320 patients with newly diagnosed primary MDS were gathered from the MDS center. The clinical features and molecular characteristics are explored. Additionally, a retrospective analysis of risk factors for the development of acute leukemia from MDS was done. Results: The median follow-up was13.6 (0.4-107.3) months. 23.4%...]]></summary>
        <author>
            <name>S Y Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonality relatedness and molecular characteristics of Richter transformation]]></title>
        <id>pubmed:36709198</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709198/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To investigate the clinical, genetic, and clonality related aspects of individuals with Richter transformation (RT) . Methods: From January 2019 to December 2021, 18 RT patients with diagnoses at the First Affiliated Hospital of Nanjing Medical University (Pukou CLL center) were retrospectively examined. The immunoglobin heavy variable (IGHV) gene usage and IGHV-D-J rearrangement pattern of diagnosed CLL/SLL and transformed diffuse large B-cell lymphoma (DLBCL) were compared to...]]></summary>
        <author>
            <name>Y Q Sha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk factors for leukemia transformation in patients with myelodysplastic syndromes]]></title>
        <id>pubmed:36709195</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709195/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To explore the risk factors in leukemia transformation (LT) in those with myelodysplastic syndromes (MDS) . Methods: From January 2012 to December 2020,data on 320 patients with newly diagnosed primary MDS were gathered from the MDS center. The clinical features and molecular characteristics are explored. Additionally, a retrospective analysis of risk factors for the development of acute leukemia from MDS was done. Results: The median follow-up was13.6 (0.4-107.3) months. 23.4%...]]></summary>
        <author>
            <name>S Y Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonality relatedness and molecular characteristics of Richter transformation]]></title>
        <id>pubmed:36709198</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709198/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To investigate the clinical, genetic, and clonality related aspects of individuals with Richter transformation (RT) . Methods: From January 2019 to December 2021, 18 RT patients with diagnoses at the First Affiliated Hospital of Nanjing Medical University (Pukou CLL center) were retrospectively examined. The immunoglobin heavy variable (IGHV) gene usage and IGHV-D-J rearrangement pattern of diagnosed CLL/SLL and transformed diffuse large B-cell lymphoma (DLBCL) were compared to...]]></summary>
        <author>
            <name>Y Q Sha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk factors for leukemia transformation in patients with myelodysplastic syndromes]]></title>
        <id>pubmed:36709195</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709195/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To explore the risk factors in leukemia transformation (LT) in those with myelodysplastic syndromes (MDS) . Methods: From January 2012 to December 2020,data on 320 patients with newly diagnosed primary MDS were gathered from the MDS center. The clinical features and molecular characteristics are explored. Additionally, a retrospective analysis of risk factors for the development of acute leukemia from MDS was done. Results: The median follow-up was13.6 (0.4-107.3) months. 23.4%...]]></summary>
        <author>
            <name>S Y Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonality relatedness and molecular characteristics of Richter transformation]]></title>
        <id>pubmed:36709198</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709198/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230209200536&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To investigate the clinical, genetic, and clonality related aspects of individuals with Richter transformation (RT) . Methods: From January 2019 to December 2021, 18 RT patients with diagnoses at the First Affiliated Hospital of Nanjing Medical University (Pukou CLL center) were retrospectively examined. The immunoglobin heavy variable (IGHV) gene usage and IGHV-D-J rearrangement pattern of diagnosed CLL/SLL and transformed diffuse large B-cell lymphoma (DLBCL) were compared to...]]></summary>
        <author>
            <name>Y Q Sha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk factors for leukemia transformation in patients with myelodysplastic syndromes]]></title>
        <id>pubmed:36709195</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709195/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230209200536&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To explore the risk factors in leukemia transformation (LT) in those with myelodysplastic syndromes (MDS) . Methods: From January 2012 to December 2020,data on 320 patients with newly diagnosed primary MDS were gathered from the MDS center. The clinical features and molecular characteristics are explored. Additionally, a retrospective analysis of risk factors for the development of acute leukemia from MDS was done. Results: The median follow-up was13.6 (0.4-107.3) months. 23.4%...]]></summary>
        <author>
            <name>S Y Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonality relatedness and molecular characteristics of Richter transformation]]></title>
        <id>pubmed:36709198</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709198/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230208200032&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To investigate the clinical, genetic, and clonality related aspects of individuals with Richter transformation (RT) . Methods: From January 2019 to December 2021, 18 RT patients with diagnoses at the First Affiliated Hospital of Nanjing Medical University (Pukou CLL center) were retrospectively examined. The immunoglobin heavy variable (IGHV) gene usage and IGHV-D-J rearrangement pattern of diagnosed CLL/SLL and transformed diffuse large B-cell lymphoma (DLBCL) were compared to...]]></summary>
        <author>
            <name>Y Q Sha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk factors for leukemia transformation in patients with myelodysplastic syndromes]]></title>
        <id>pubmed:36709195</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709195/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230208200032&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To explore the risk factors in leukemia transformation (LT) in those with myelodysplastic syndromes (MDS) . Methods: From January 2012 to December 2020,data on 320 patients with newly diagnosed primary MDS were gathered from the MDS center. The clinical features and molecular characteristics are explored. Additionally, a retrospective analysis of risk factors for the development of acute leukemia from MDS was done. Results: The median follow-up was13.6 (0.4-107.3) months. 23.4%...]]></summary>
        <author>
            <name>S Y Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonality relatedness and molecular characteristics of Richter transformation]]></title>
        <id>pubmed:36709198</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709198/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To investigate the clinical, genetic, and clonality related aspects of individuals with Richter transformation (RT) . Methods: From January 2019 to December 2021, 18 RT patients with diagnoses at the First Affiliated Hospital of Nanjing Medical University (Pukou CLL center) were retrospectively examined. The immunoglobin heavy variable (IGHV) gene usage and IGHV-D-J rearrangement pattern of diagnosed CLL/SLL and transformed diffuse large B-cell lymphoma (DLBCL) were compared to...]]></summary>
        <author>
            <name>Y Q Sha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk factors for leukemia transformation in patients with myelodysplastic syndromes]]></title>
        <id>pubmed:36709195</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709195/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To explore the risk factors in leukemia transformation (LT) in those with myelodysplastic syndromes (MDS) . Methods: From January 2012 to December 2020,data on 320 patients with newly diagnosed primary MDS were gathered from the MDS center. The clinical features and molecular characteristics are explored. Additionally, a retrospective analysis of risk factors for the development of acute leukemia from MDS was done. Results: The median follow-up was13.6 (0.4-107.3) months. 23.4%...]]></summary>
        <author>
            <name>S Y Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonality relatedness and molecular characteristics of Richter transformation]]></title>
        <id>pubmed:36709198</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709198/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To investigate the clinical, genetic, and clonality related aspects of individuals with Richter transformation (RT) . Methods: From January 2019 to December 2021, 18 RT patients with diagnoses at the First Affiliated Hospital of Nanjing Medical University (Pukou CLL center) were retrospectively examined. The immunoglobin heavy variable (IGHV) gene usage and IGHV-D-J rearrangement pattern of diagnosed CLL/SLL and transformed diffuse large B-cell lymphoma (DLBCL) were compared to...]]></summary>
        <author>
            <name>Y Q Sha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk factors for leukemia transformation in patients with myelodysplastic syndromes]]></title>
        <id>pubmed:36709195</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709195/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To explore the risk factors in leukemia transformation (LT) in those with myelodysplastic syndromes (MDS) . Methods: From January 2012 to December 2020,data on 320 patients with newly diagnosed primary MDS were gathered from the MDS center. The clinical features and molecular characteristics are explored. Additionally, a retrospective analysis of risk factors for the development of acute leukemia from MDS was done. Results: The median follow-up was13.6 (0.4-107.3) months. 23.4%...]]></summary>
        <author>
            <name>S Y Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonality relatedness and molecular characteristics of Richter transformation]]></title>
        <id>pubmed:36709198</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709198/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To investigate the clinical, genetic, and clonality related aspects of individuals with Richter transformation (RT) . Methods: From January 2019 to December 2021, 18 RT patients with diagnoses at the First Affiliated Hospital of Nanjing Medical University (Pukou CLL center) were retrospectively examined. The immunoglobin heavy variable (IGHV) gene usage and IGHV-D-J rearrangement pattern of diagnosed CLL/SLL and transformed diffuse large B-cell lymphoma (DLBCL) were compared to...]]></summary>
        <author>
            <name>Y Q Sha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk factors for leukemia transformation in patients with myelodysplastic syndromes]]></title>
        <id>pubmed:36709195</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709195/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To explore the risk factors in leukemia transformation (LT) in those with myelodysplastic syndromes (MDS) . Methods: From January 2012 to December 2020,data on 320 patients with newly diagnosed primary MDS were gathered from the MDS center. The clinical features and molecular characteristics are explored. Additionally, a retrospective analysis of risk factors for the development of acute leukemia from MDS was done. Results: The median follow-up was13.6 (0.4-107.3) months. 23.4%...]]></summary>
        <author>
            <name>S Y Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonality relatedness and molecular characteristics of Richter transformation]]></title>
        <id>pubmed:36709198</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709198/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To investigate the clinical, genetic, and clonality related aspects of individuals with Richter transformation (RT) . Methods: From January 2019 to December 2021, 18 RT patients with diagnoses at the First Affiliated Hospital of Nanjing Medical University (Pukou CLL center) were retrospectively examined. The immunoglobin heavy variable (IGHV) gene usage and IGHV-D-J rearrangement pattern of diagnosed CLL/SLL and transformed diffuse large B-cell lymphoma (DLBCL) were compared to...]]></summary>
        <author>
            <name>Y Q Sha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk factors for leukemia transformation in patients with myelodysplastic syndromes]]></title>
        <id>pubmed:36709195</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709195/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To explore the risk factors in leukemia transformation (LT) in those with myelodysplastic syndromes (MDS) . Methods: From January 2012 to December 2020,data on 320 patients with newly diagnosed primary MDS were gathered from the MDS center. The clinical features and molecular characteristics are explored. Additionally, a retrospective analysis of risk factors for the development of acute leukemia from MDS was done. Results: The median follow-up was13.6 (0.4-107.3) months. 23.4%...]]></summary>
        <author>
            <name>S Y Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonality relatedness and molecular characteristics of Richter transformation]]></title>
        <id>pubmed:36709198</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709198/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To investigate the clinical, genetic, and clonality related aspects of individuals with Richter transformation (RT) . Methods: From January 2019 to December 2021, 18 RT patients with diagnoses at the First Affiliated Hospital of Nanjing Medical University (Pukou CLL center) were retrospectively examined. The immunoglobin heavy variable (IGHV) gene usage and IGHV-D-J rearrangement pattern of diagnosed CLL/SLL and transformed diffuse large B-cell lymphoma (DLBCL) were compared to...]]></summary>
        <author>
            <name>Y Q Sha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk factors for leukemia transformation in patients with myelodysplastic syndromes]]></title>
        <id>pubmed:36709195</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709195/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To explore the risk factors in leukemia transformation (LT) in those with myelodysplastic syndromes (MDS) . Methods: From January 2012 to December 2020,data on 320 patients with newly diagnosed primary MDS were gathered from the MDS center. The clinical features and molecular characteristics are explored. Additionally, a retrospective analysis of risk factors for the development of acute leukemia from MDS was done. Results: The median follow-up was13.6 (0.4-107.3) months. 23.4%...]]></summary>
        <author>
            <name>S Y Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonality relatedness and molecular characteristics of Richter transformation]]></title>
        <id>pubmed:36709198</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709198/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To investigate the clinical, genetic, and clonality related aspects of individuals with Richter transformation (RT) . Methods: From January 2019 to December 2021, 18 RT patients with diagnoses at the First Affiliated Hospital of Nanjing Medical University (Pukou CLL center) were retrospectively examined. The immunoglobin heavy variable (IGHV) gene usage and IGHV-D-J rearrangement pattern of diagnosed CLL/SLL and transformed diffuse large B-cell lymphoma (DLBCL) were compared to...]]></summary>
        <author>
            <name>Y Q Sha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk factors for leukemia transformation in patients with myelodysplastic syndromes]]></title>
        <id>pubmed:36709195</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709195/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To explore the risk factors in leukemia transformation (LT) in those with myelodysplastic syndromes (MDS) . Methods: From January 2012 to December 2020,data on 320 patients with newly diagnosed primary MDS were gathered from the MDS center. The clinical features and molecular characteristics are explored. Additionally, a retrospective analysis of risk factors for the development of acute leukemia from MDS was done. Results: The median follow-up was13.6 (0.4-107.3) months. 23.4%...]]></summary>
        <author>
            <name>S Y Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonality relatedness and molecular characteristics of Richter transformation]]></title>
        <id>pubmed:36709198</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709198/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To investigate the clinical, genetic, and clonality related aspects of individuals with Richter transformation (RT) . Methods: From January 2019 to December 2021, 18 RT patients with diagnoses at the First Affiliated Hospital of Nanjing Medical University (Pukou CLL center) were retrospectively examined. The immunoglobin heavy variable (IGHV) gene usage and IGHV-D-J rearrangement pattern of diagnosed CLL/SLL and transformed diffuse large B-cell lymphoma (DLBCL) were compared to...]]></summary>
        <author>
            <name>Y Q Sha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk factors for leukemia transformation in patients with myelodysplastic syndromes]]></title>
        <id>pubmed:36709195</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709195/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To explore the risk factors in leukemia transformation (LT) in those with myelodysplastic syndromes (MDS) . Methods: From January 2012 to December 2020,data on 320 patients with newly diagnosed primary MDS were gathered from the MDS center. The clinical features and molecular characteristics are explored. Additionally, a retrospective analysis of risk factors for the development of acute leukemia from MDS was done. Results: The median follow-up was13.6 (0.4-107.3) months. 23.4%...]]></summary>
        <author>
            <name>S Y Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonality relatedness and molecular characteristics of Richter transformation]]></title>
        <id>pubmed:36709198</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709198/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To investigate the clinical, genetic, and clonality related aspects of individuals with Richter transformation (RT) . Methods: From January 2019 to December 2021, 18 RT patients with diagnoses at the First Affiliated Hospital of Nanjing Medical University (Pukou CLL center) were retrospectively examined. The immunoglobin heavy variable (IGHV) gene usage and IGHV-D-J rearrangement pattern of diagnosed CLL/SLL and transformed diffuse large B-cell lymphoma (DLBCL) were compared to...]]></summary>
        <author>
            <name>Y Q Sha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk factors for leukemia transformation in patients with myelodysplastic syndromes]]></title>
        <id>pubmed:36709195</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36709195/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Objective: To explore the risk factors in leukemia transformation (LT) in those with myelodysplastic syndromes (MDS) . Methods: From January 2012 to December 2020,data on 320 patients with newly diagnosed primary MDS were gathered from the MDS center. The clinical features and molecular characteristics are explored. Additionally, a retrospective analysis of risk factors for the development of acute leukemia from MDS was done. Results: The median follow-up was13.6 (0.4-107.3) months. 23.4%...]]></summary>
        <author>
            <name>S Y Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis due to mosaic chromosomal alterations: Impact on disease risk and mortality]]></title>
        <id>pubmed:36706615</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36706615/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) are the clonal expansion of large somatically acquired structural chromosomal changes present on the autosomes and sex chromosomes. Most studies of mCAs use existing genotype array intensity data from large populations to investigate potential risk factors and disease outcomes associated with mCAs. In this review, we perform a comprehensive examination of existing evidence for mCA disease and mortality associations and provide a framework for interpreting...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis due to mosaic chromosomal alterations: Impact on disease risk and mortality]]></title>
        <id>pubmed:36706615</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36706615/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) are the clonal expansion of large somatically acquired structural chromosomal changes present on the autosomes and sex chromosomes. Most studies of mCAs use existing genotype array intensity data from large populations to investigate potential risk factors and disease outcomes associated with mCAs. In this review, we perform a comprehensive examination of existing evidence for mCA disease and mortality associations and provide a framework for interpreting...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis due to mosaic chromosomal alterations: Impact on disease risk and mortality]]></title>
        <id>pubmed:36706615</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36706615/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) are the clonal expansion of large somatically acquired structural chromosomal changes present on the autosomes and sex chromosomes. Most studies of mCAs use existing genotype array intensity data from large populations to investigate potential risk factors and disease outcomes associated with mCAs. In this review, we perform a comprehensive examination of existing evidence for mCA disease and mortality associations and provide a framework for interpreting...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis due to mosaic chromosomal alterations: Impact on disease risk and mortality]]></title>
        <id>pubmed:36706615</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36706615/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230209200537&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) are the clonal expansion of large somatically acquired structural chromosomal changes present on the autosomes and sex chromosomes. Most studies of mCAs use existing genotype array intensity data from large populations to investigate potential risk factors and disease outcomes associated with mCAs. In this review, we perform a comprehensive examination of existing evidence for mCA disease and mortality associations and provide a framework for interpreting...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis due to mosaic chromosomal alterations: Impact on disease risk and mortality]]></title>
        <id>pubmed:36706615</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36706615/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230208200033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) are the clonal expansion of large somatically acquired structural chromosomal changes present on the autosomes and sex chromosomes. Most studies of mCAs use existing genotype array intensity data from large populations to investigate potential risk factors and disease outcomes associated with mCAs. In this review, we perform a comprehensive examination of existing evidence for mCA disease and mortality associations and provide a framework for interpreting...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis due to mosaic chromosomal alterations: Impact on disease risk and mortality]]></title>
        <id>pubmed:36706615</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36706615/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) are the clonal expansion of large somatically acquired structural chromosomal changes present on the autosomes and sex chromosomes. Most studies of mCAs use existing genotype array intensity data from large populations to investigate potential risk factors and disease outcomes associated with mCAs. In this review, we perform a comprehensive examination of existing evidence for mCA disease and mortality associations and provide a framework for interpreting...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis due to mosaic chromosomal alterations: Impact on disease risk and mortality]]></title>
        <id>pubmed:36706615</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36706615/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) are the clonal expansion of large somatically acquired structural chromosomal changes present on the autosomes and sex chromosomes. Most studies of mCAs use existing genotype array intensity data from large populations to investigate potential risk factors and disease outcomes associated with mCAs. In this review, we perform a comprehensive examination of existing evidence for mCA disease and mortality associations and provide a framework for interpreting...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis due to mosaic chromosomal alterations: Impact on disease risk and mortality]]></title>
        <id>pubmed:36706615</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36706615/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) are the clonal expansion of large somatically acquired structural chromosomal changes present on the autosomes and sex chromosomes. Most studies of mCAs use existing genotype array intensity data from large populations to investigate potential risk factors and disease outcomes associated with mCAs. In this review, we perform a comprehensive examination of existing evidence for mCA disease and mortality associations and provide a framework for interpreting...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis due to mosaic chromosomal alterations: Impact on disease risk and mortality]]></title>
        <id>pubmed:36706615</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36706615/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) are the clonal expansion of large somatically acquired structural chromosomal changes present on the autosomes and sex chromosomes. Most studies of mCAs use existing genotype array intensity data from large populations to investigate potential risk factors and disease outcomes associated with mCAs. In this review, we perform a comprehensive examination of existing evidence for mCA disease and mortality associations and provide a framework for interpreting...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis due to mosaic chromosomal alterations: Impact on disease risk and mortality]]></title>
        <id>pubmed:36706615</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36706615/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) are the clonal expansion of large somatically acquired structural chromosomal changes present on the autosomes and sex chromosomes. Most studies of mCAs use existing genotype array intensity data from large populations to investigate potential risk factors and disease outcomes associated with mCAs. In this review, we perform a comprehensive examination of existing evidence for mCA disease and mortality associations and provide a framework for interpreting...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis due to mosaic chromosomal alterations: Impact on disease risk and mortality]]></title>
        <id>pubmed:36706615</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36706615/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) are the clonal expansion of large somatically acquired structural chromosomal changes present on the autosomes and sex chromosomes. Most studies of mCAs use existing genotype array intensity data from large populations to investigate potential risk factors and disease outcomes associated with mCAs. In this review, we perform a comprehensive examination of existing evidence for mCA disease and mortality associations and provide a framework for interpreting...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis due to mosaic chromosomal alterations: Impact on disease risk and mortality]]></title>
        <id>pubmed:36706615</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36706615/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) are the clonal expansion of large somatically acquired structural chromosomal changes present on the autosomes and sex chromosomes. Most studies of mCAs use existing genotype array intensity data from large populations to investigate potential risk factors and disease outcomes associated with mCAs. In this review, we perform a comprehensive examination of existing evidence for mCA disease and mortality associations and provide a framework for interpreting...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis due to mosaic chromosomal alterations: Impact on disease risk and mortality]]></title>
        <id>pubmed:36706615</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36706615/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) are the clonal expansion of large somatically acquired structural chromosomal changes present on the autosomes and sex chromosomes. Most studies of mCAs use existing genotype array intensity data from large populations to investigate potential risk factors and disease outcomes associated with mCAs. In this review, we perform a comprehensive examination of existing evidence for mCA disease and mortality associations and provide a framework for interpreting...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis due to mosaic chromosomal alterations: Impact on disease risk and mortality]]></title>
        <id>pubmed:36706615</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36706615/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) are the clonal expansion of large somatically acquired structural chromosomal changes present on the autosomes and sex chromosomes. Most studies of mCAs use existing genotype array intensity data from large populations to investigate potential risk factors and disease outcomes associated with mCAs. In this review, we perform a comprehensive examination of existing evidence for mCA disease and mortality associations and provide a framework for interpreting...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis due to mosaic chromosomal alterations: Impact on disease risk and mortality]]></title>
        <id>pubmed:36706615</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36706615/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) are the clonal expansion of large somatically acquired structural chromosomal changes present on the autosomes and sex chromosomes. Most studies of mCAs use existing genotype array intensity data from large populations to investigate potential risk factors and disease outcomes associated with mCAs. In this review, we perform a comprehensive examination of existing evidence for mCA disease and mortality associations and provide a framework for interpreting...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis due to mosaic chromosomal alterations: Impact on disease risk and mortality]]></title>
        <id>pubmed:36706615</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36706615/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) are the clonal expansion of large somatically acquired structural chromosomal changes present on the autosomes and sex chromosomes. Most studies of mCAs use existing genotype array intensity data from large populations to investigate potential risk factors and disease outcomes associated with mCAs. In this review, we perform a comprehensive examination of existing evidence for mCA disease and mortality associations and provide a framework for interpreting...]]></summary>
        <author>
            <name>Aubrey K Hubbard</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Abnormal Platelet Counts and Clonal Hematopoiesis in the General Population]]></title>
        <id>pubmed:36698617</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36698617/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations that may cause clonal expansion of hematopoietic cells. Here, we investigated the association between platelet count abnormalities, CH and consequences on overall survival and the development of hematological malignancies. Individuals with thrombocytopenia (n = 631) or thrombocytosis (n = 178) 60 years, and their age- and sex-matched controls, were selected within the population-based Lifelines cohort (n = 167,729)....]]></summary>
        <author>
            <name>Priscilla Kamphuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Abnormal Platelet Counts and Clonal Hematopoiesis in the General Population]]></title>
        <id>pubmed:36698617</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36698617/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations that may cause clonal expansion of hematopoietic cells. Here, we investigated the association between platelet count abnormalities, CH and consequences on overall survival and the development of hematological malignancies. Individuals with thrombocytopenia (n = 631) or thrombocytosis (n = 178) 60 years, and their age- and sex-matched controls, were selected within the population-based Lifelines cohort (n = 167,729)....]]></summary>
        <author>
            <name>Priscilla Kamphuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Abnormal Platelet Counts and Clonal Hematopoiesis in the General Population]]></title>
        <id>pubmed:36698617</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36698617/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations that may cause clonal expansion of hematopoietic cells. Here, we investigated the association between platelet count abnormalities, CH and consequences on overall survival and the development of hematological malignancies. Individuals with thrombocytopenia (n = 631) or thrombocytosis (n = 178) 60 years, and their age- and sex-matched controls, were selected within the population-based Lifelines cohort (n = 167,729)....]]></summary>
        <author>
            <name>Priscilla Kamphuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Abnormal Platelet Counts and Clonal Hematopoiesis in the General Population]]></title>
        <id>pubmed:36698617</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36698617/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230209200537&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations that may cause clonal expansion of hematopoietic cells. Here, we investigated the association between platelet count abnormalities, CH and consequences on overall survival and the development of hematological malignancies. Individuals with thrombocytopenia (n = 631) or thrombocytosis (n = 178) 60 years, and their age- and sex-matched controls, were selected within the population-based Lifelines cohort (n = 167,729)....]]></summary>
        <author>
            <name>Priscilla Kamphuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Abnormal Platelet Counts and Clonal Hematopoiesis in the General Population]]></title>
        <id>pubmed:36698617</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36698617/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230208200033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations that may cause clonal expansion of hematopoietic cells. Here, we investigated the association between platelet count abnormalities, CH and consequences on overall survival and the development of hematological malignancies. Individuals with thrombocytopenia (n = 631) or thrombocytosis (n = 178) 60 years, and their age- and sex-matched controls, were selected within the population-based Lifelines cohort (n = 167,729)....]]></summary>
        <author>
            <name>Priscilla Kamphuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Abnormal Platelet Counts and Clonal Hematopoiesis in the General Population]]></title>
        <id>pubmed:36698617</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36698617/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations that may cause clonal expansion of hematopoietic cells. Here, we investigated the association between platelet count abnormalities, CH and consequences on overall survival and the development of hematological malignancies. Individuals with thrombocytopenia (n = 631) or thrombocytosis (n = 178) 60 years, and their age- and sex-matched controls, were selected within the population-based Lifelines cohort (n = 167,729)....]]></summary>
        <author>
            <name>Priscilla Kamphuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Abnormal Platelet Counts and Clonal Hematopoiesis in the General Population]]></title>
        <id>pubmed:36698617</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36698617/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations that may cause clonal expansion of hematopoietic cells. Here, we investigated the association between platelet count abnormalities, CH and consequences on overall survival and the development of hematological malignancies. Individuals with thrombocytopenia (n = 631) or thrombocytosis (n = 178) 60 years, and their age- and sex-matched controls, were selected within the population-based Lifelines cohort (n = 167,729)....]]></summary>
        <author>
            <name>Priscilla Kamphuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Abnormal Platelet Counts and Clonal Hematopoiesis in the General Population]]></title>
        <id>pubmed:36698617</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36698617/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations that may cause clonal expansion of hematopoietic cells. Here, we investigated the association between platelet count abnormalities, CH and consequences on overall survival and the development of hematological malignancies. Individuals with thrombocytopenia (n = 631) or thrombocytosis (n = 178) 60 years, and their age- and sex-matched controls, were selected within the population-based Lifelines cohort (n = 167,729)....]]></summary>
        <author>
            <name>Priscilla Kamphuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Abnormal Platelet Counts and Clonal Hematopoiesis in the General Population]]></title>
        <id>pubmed:36698617</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36698617/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations that may cause clonal expansion of hematopoietic cells. Here, we investigated the association between platelet count abnormalities, CH and consequences on overall survival and the development of hematological malignancies. Individuals with thrombocytopenia (n = 631) or thrombocytosis (n = 178) 60 years, and their age- and sex-matched controls, were selected within the population-based Lifelines cohort (n = 167,729)....]]></summary>
        <author>
            <name>Priscilla Kamphuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Abnormal Platelet Counts and Clonal Hematopoiesis in the General Population]]></title>
        <id>pubmed:36698617</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36698617/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations that may cause clonal expansion of hematopoietic cells. Here, we investigated the association between platelet count abnormalities, CH and consequences on overall survival and the development of hematological malignancies. Individuals with thrombocytopenia (n = 631) or thrombocytosis (n = 178) 60 years, and their age- and sex-matched controls, were selected within the population-based Lifelines cohort (n = 167,729)....]]></summary>
        <author>
            <name>Priscilla Kamphuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Abnormal Platelet Counts and Clonal Hematopoiesis in the General Population]]></title>
        <id>pubmed:36698617</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36698617/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations that may cause clonal expansion of hematopoietic cells. Here, we investigated the association between platelet count abnormalities, CH and consequences on overall survival and the development of hematological malignancies. Individuals with thrombocytopenia (n = 631) or thrombocytosis (n = 178) 60 years, and their age- and sex-matched controls, were selected within the population-based Lifelines cohort (n = 167,729)....]]></summary>
        <author>
            <name>Priscilla Kamphuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Abnormal Platelet Counts and Clonal Hematopoiesis in the General Population]]></title>
        <id>pubmed:36698617</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36698617/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations that may cause clonal expansion of hematopoietic cells. Here, we investigated the association between platelet count abnormalities, CH and consequences on overall survival and the development of hematological malignancies. Individuals with thrombocytopenia (n = 631) or thrombocytosis (n = 178) 60 years, and their age- and sex-matched controls, were selected within the population-based Lifelines cohort (n = 167,729)....]]></summary>
        <author>
            <name>Priscilla Kamphuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Abnormal Platelet Counts and Clonal Hematopoiesis in the General Population]]></title>
        <id>pubmed:36698617</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36698617/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations that may cause clonal expansion of hematopoietic cells. Here, we investigated the association between platelet count abnormalities, CH and consequences on overall survival and the development of hematological malignancies. Individuals with thrombocytopenia (n = 631) or thrombocytosis (n = 178) 60 years, and their age- and sex-matched controls, were selected within the population-based Lifelines cohort (n = 167,729)....]]></summary>
        <author>
            <name>Priscilla Kamphuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Abnormal Platelet Counts and Clonal Hematopoiesis in the General Population]]></title>
        <id>pubmed:36698617</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36698617/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations that may cause clonal expansion of hematopoietic cells. Here, we investigated the association between platelet count abnormalities, CH and consequences on overall survival and the development of hematological malignancies. Individuals with thrombocytopenia (n = 631) or thrombocytosis (n = 178) 60 years, and their age- and sex-matched controls, were selected within the population-based Lifelines cohort (n = 167,729)....]]></summary>
        <author>
            <name>Priscilla Kamphuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Abnormal Platelet Counts and Clonal Hematopoiesis in the General Population]]></title>
        <id>pubmed:36698617</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36698617/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations that may cause clonal expansion of hematopoietic cells. Here, we investigated the association between platelet count abnormalities, CH and consequences on overall survival and the development of hematological malignancies. Individuals with thrombocytopenia (n = 631) or thrombocytosis (n = 178) 60 years, and their age- and sex-matched controls, were selected within the population-based Lifelines cohort (n = 167,729)....]]></summary>
        <author>
            <name>Priscilla Kamphuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Abnormal Platelet Counts and Clonal Hematopoiesis in the General Population]]></title>
        <id>pubmed:36698617</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36698617/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations that may cause clonal expansion of hematopoietic cells. Here, we investigated the association between platelet count abnormalities, CH and consequences on overall survival and the development of hematological malignancies. Individuals with thrombocytopenia (n = 631) or thrombocytosis (n = 178) 60 years, and their age- and sex-matched controls, were selected within the population-based Lifelines cohort (n = 167,729)....]]></summary>
        <author>
            <name>Priscilla Kamphuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Abnormal Platelet Counts and Clonal Hematopoiesis in the General Population]]></title>
        <id>pubmed:36698617</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36698617/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations that may cause clonal expansion of hematopoietic cells. Here, we investigated the association between platelet count abnormalities, CH and consequences on overall survival and the development of hematological malignancies. Individuals with thrombocytopenia (n = 631) or thrombocytosis (n = 178) 60 years, and their age- and sex-matched controls, were selected within the population-based Lifelines cohort (n = 167,729)....]]></summary>
        <author>
            <name>Priscilla Kamphuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Abnormal Platelet Counts and Clonal Hematopoiesis in the General Population]]></title>
        <id>pubmed:36698617</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36698617/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations that may cause clonal expansion of hematopoietic cells. Here, we investigated the association between platelet count abnormalities, CH and consequences on overall survival and the development of hematological malignancies. Individuals with thrombocytopenia (n = 631) or thrombocytosis (n = 178) 60 years, and their age- and sex-matched controls, were selected within the population-based Lifelines cohort (n = 167,729)....]]></summary>
        <author>
            <name>Priscilla Kamphuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230209200537&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230208200033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230209200536&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230208200032&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms]]></title>
        <id>pubmed:36696829</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36696829/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to the considerable sequencing efforts performed for de novo myeloid neoplasms. Until recently, targeted deep sequencing (TDS) or whole exome sequencing (WES) have been the primary technologies utilized and thus limited the ability to explore the landscape of structural variants and...]]></summary>
        <author>
            <name>Jacob Jahn</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma]]></title>
        <id>pubmed:36689560</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689560/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CDDP resistance and development of distant metastasis are associated with dysregulated and epigenetically reprogrammed KEAP1-NRF2 signaling pathway. A strategy targeting KEAP1/NRF2 pathway or glutamine metabolism deserves further clinical investigation in patients with CDDP resistant head and neck tumors.]]></summary>
        <author>
            <name>Abdullah A Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction]]></title>
        <id>pubmed:36689467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230212200407&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The phenotypic efficacy of somatic copy number alterations (SCNAs) stems from their incidence per base pair of the genome, which is orders of magnitudes greater than that of point mutations. One mitotic event stands out in its potential to significantly change a cell's SCNA burden-a chromosome missegregation. A stochastic model of chromosome mis-segregations has been previously developed to describe the evolution of SCNAs of a single chromosome type. Building upon this work, we derive a general...]]></summary>
        <author>
            <name>Gregory J Kimmel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma]]></title>
        <id>pubmed:36689560</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689560/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CDDP resistance and development of distant metastasis are associated with dysregulated and epigenetically reprogrammed KEAP1-NRF2 signaling pathway. A strategy targeting KEAP1/NRF2 pathway or glutamine metabolism deserves further clinical investigation in patients with CDDP resistant head and neck tumors.]]></summary>
        <author>
            <name>Abdullah A Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction]]></title>
        <id>pubmed:36689467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230211200623&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The phenotypic efficacy of somatic copy number alterations (SCNAs) stems from their incidence per base pair of the genome, which is orders of magnitudes greater than that of point mutations. One mitotic event stands out in its potential to significantly change a cell's SCNA burden-a chromosome missegregation. A stochastic model of chromosome mis-segregations has been previously developed to describe the evolution of SCNAs of a single chromosome type. Building upon this work, we derive a general...]]></summary>
        <author>
            <name>Gregory J Kimmel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma]]></title>
        <id>pubmed:36689560</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689560/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CDDP resistance and development of distant metastasis are associated with dysregulated and epigenetically reprogrammed KEAP1-NRF2 signaling pathway. A strategy targeting KEAP1/NRF2 pathway or glutamine metabolism deserves further clinical investigation in patients with CDDP resistant head and neck tumors.]]></summary>
        <author>
            <name>Abdullah A Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction]]></title>
        <id>pubmed:36689467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The phenotypic efficacy of somatic copy number alterations (SCNAs) stems from their incidence per base pair of the genome, which is orders of magnitudes greater than that of point mutations. One mitotic event stands out in its potential to significantly change a cell's SCNA burden-a chromosome missegregation. A stochastic model of chromosome mis-segregations has been previously developed to describe the evolution of SCNAs of a single chromosome type. Building upon this work, we derive a general...]]></summary>
        <author>
            <name>Gregory J Kimmel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New developments in targeted therapy for metastatic colorectal cancer]]></title>
        <id>pubmed:36687386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36687386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is the second most lethal cancer worldwide and the prognosis of metastatic CRC (mCRC) remains poor. Recent advancements in translational research have led to the identification of several new therapeutic targets and improved the treatment outcome of patients with tumours harbouring BRAF V600E mutation, (HER2) ErBB2 alterations, NTRK gene fusions and KRAS(G12C) mutation. Improved understanding towards the mechanism of resistance to targeted therapy such as anti-epidermal...]]></summary>
        <author>
            <name>Ambrose H N Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma]]></title>
        <id>pubmed:36689560</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689560/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230209200536&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CDDP resistance and development of distant metastasis are associated with dysregulated and epigenetically reprogrammed KEAP1-NRF2 signaling pathway. A strategy targeting KEAP1/NRF2 pathway or glutamine metabolism deserves further clinical investigation in patients with CDDP resistant head and neck tumors.]]></summary>
        <author>
            <name>Abdullah A Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction]]></title>
        <id>pubmed:36689467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230209200536&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The phenotypic efficacy of somatic copy number alterations (SCNAs) stems from their incidence per base pair of the genome, which is orders of magnitudes greater than that of point mutations. One mitotic event stands out in its potential to significantly change a cell's SCNA burden-a chromosome missegregation. A stochastic model of chromosome mis-segregations has been previously developed to describe the evolution of SCNAs of a single chromosome type. Building upon this work, we derive a general...]]></summary>
        <author>
            <name>Gregory J Kimmel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New developments in targeted therapy for metastatic colorectal cancer]]></title>
        <id>pubmed:36687386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36687386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230209200536&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is the second most lethal cancer worldwide and the prognosis of metastatic CRC (mCRC) remains poor. Recent advancements in translational research have led to the identification of several new therapeutic targets and improved the treatment outcome of patients with tumours harbouring BRAF V600E mutation, (HER2) ErBB2 alterations, NTRK gene fusions and KRAS(G12C) mutation. Improved understanding towards the mechanism of resistance to targeted therapy such as anti-epidermal...]]></summary>
        <author>
            <name>Ambrose H N Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma]]></title>
        <id>pubmed:36689560</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689560/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230208200032&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CDDP resistance and development of distant metastasis are associated with dysregulated and epigenetically reprogrammed KEAP1-NRF2 signaling pathway. A strategy targeting KEAP1/NRF2 pathway or glutamine metabolism deserves further clinical investigation in patients with CDDP resistant head and neck tumors.]]></summary>
        <author>
            <name>Abdullah A Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction]]></title>
        <id>pubmed:36689467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230208200032&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The phenotypic efficacy of somatic copy number alterations (SCNAs) stems from their incidence per base pair of the genome, which is orders of magnitudes greater than that of point mutations. One mitotic event stands out in its potential to significantly change a cell's SCNA burden-a chromosome missegregation. A stochastic model of chromosome mis-segregations has been previously developed to describe the evolution of SCNAs of a single chromosome type. Building upon this work, we derive a general...]]></summary>
        <author>
            <name>Gregory J Kimmel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New developments in targeted therapy for metastatic colorectal cancer]]></title>
        <id>pubmed:36687386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36687386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230208200032&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is the second most lethal cancer worldwide and the prognosis of metastatic CRC (mCRC) remains poor. Recent advancements in translational research have led to the identification of several new therapeutic targets and improved the treatment outcome of patients with tumours harbouring BRAF V600E mutation, (HER2) ErBB2 alterations, NTRK gene fusions and KRAS(G12C) mutation. Improved understanding towards the mechanism of resistance to targeted therapy such as anti-epidermal...]]></summary>
        <author>
            <name>Ambrose H N Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma]]></title>
        <id>pubmed:36689560</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689560/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CDDP resistance and development of distant metastasis are associated with dysregulated and epigenetically reprogrammed KEAP1-NRF2 signaling pathway. A strategy targeting KEAP1/NRF2 pathway or glutamine metabolism deserves further clinical investigation in patients with CDDP resistant head and neck tumors.]]></summary>
        <author>
            <name>Abdullah A Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction]]></title>
        <id>pubmed:36689467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The phenotypic efficacy of somatic copy number alterations (SCNAs) stems from their incidence per base pair of the genome, which is orders of magnitudes greater than that of point mutations. One mitotic event stands out in its potential to significantly change a cell's SCNA burden-a chromosome missegregation. A stochastic model of chromosome mis-segregations has been previously developed to describe the evolution of SCNAs of a single chromosome type. Building upon this work, we derive a general...]]></summary>
        <author>
            <name>Gregory J Kimmel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New developments in targeted therapy for metastatic colorectal cancer]]></title>
        <id>pubmed:36687386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36687386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is the second most lethal cancer worldwide and the prognosis of metastatic CRC (mCRC) remains poor. Recent advancements in translational research have led to the identification of several new therapeutic targets and improved the treatment outcome of patients with tumours harbouring BRAF V600E mutation, (HER2) ErBB2 alterations, NTRK gene fusions and KRAS(G12C) mutation. Improved understanding towards the mechanism of resistance to targeted therapy such as anti-epidermal...]]></summary>
        <author>
            <name>Ambrose H N Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma]]></title>
        <id>pubmed:36689560</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689560/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CDDP resistance and development of distant metastasis are associated with dysregulated and epigenetically reprogrammed KEAP1-NRF2 signaling pathway. A strategy targeting KEAP1/NRF2 pathway or glutamine metabolism deserves further clinical investigation in patients with CDDP resistant head and neck tumors.]]></summary>
        <author>
            <name>Abdullah A Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction]]></title>
        <id>pubmed:36689467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The phenotypic efficacy of somatic copy number alterations (SCNAs) stems from their incidence per base pair of the genome, which is orders of magnitudes greater than that of point mutations. One mitotic event stands out in its potential to significantly change a cell's SCNA burden-a chromosome missegregation. A stochastic model of chromosome mis-segregations has been previously developed to describe the evolution of SCNAs of a single chromosome type. Building upon this work, we derive a general...]]></summary>
        <author>
            <name>Gregory J Kimmel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New developments in targeted therapy for metastatic colorectal cancer]]></title>
        <id>pubmed:36687386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36687386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is the second most lethal cancer worldwide and the prognosis of metastatic CRC (mCRC) remains poor. Recent advancements in translational research have led to the identification of several new therapeutic targets and improved the treatment outcome of patients with tumours harbouring BRAF V600E mutation, (HER2) ErBB2 alterations, NTRK gene fusions and KRAS(G12C) mutation. Improved understanding towards the mechanism of resistance to targeted therapy such as anti-epidermal...]]></summary>
        <author>
            <name>Ambrose H N Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma]]></title>
        <id>pubmed:36689560</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689560/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CDDP resistance and development of distant metastasis are associated with dysregulated and epigenetically reprogrammed KEAP1-NRF2 signaling pathway. A strategy targeting KEAP1/NRF2 pathway or glutamine metabolism deserves further clinical investigation in patients with CDDP resistant head and neck tumors.]]></summary>
        <author>
            <name>Abdullah A Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction]]></title>
        <id>pubmed:36689467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The phenotypic efficacy of somatic copy number alterations (SCNAs) stems from their incidence per base pair of the genome, which is orders of magnitudes greater than that of point mutations. One mitotic event stands out in its potential to significantly change a cell's SCNA burden-a chromosome missegregation. A stochastic model of chromosome mis-segregations has been previously developed to describe the evolution of SCNAs of a single chromosome type. Building upon this work, we derive a general...]]></summary>
        <author>
            <name>Gregory J Kimmel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New developments in targeted therapy for metastatic colorectal cancer]]></title>
        <id>pubmed:36687386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36687386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is the second most lethal cancer worldwide and the prognosis of metastatic CRC (mCRC) remains poor. Recent advancements in translational research have led to the identification of several new therapeutic targets and improved the treatment outcome of patients with tumours harbouring BRAF V600E mutation, (HER2) ErBB2 alterations, NTRK gene fusions and KRAS(G12C) mutation. Improved understanding towards the mechanism of resistance to targeted therapy such as anti-epidermal...]]></summary>
        <author>
            <name>Ambrose H N Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma]]></title>
        <id>pubmed:36689560</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689560/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CDDP resistance and development of distant metastasis are associated with dysregulated and epigenetically reprogrammed KEAP1-NRF2 signaling pathway. A strategy targeting KEAP1/NRF2 pathway or glutamine metabolism deserves further clinical investigation in patients with CDDP resistant head and neck tumors.]]></summary>
        <author>
            <name>Abdullah A Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction]]></title>
        <id>pubmed:36689467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The phenotypic efficacy of somatic copy number alterations (SCNAs) stems from their incidence per base pair of the genome, which is orders of magnitudes greater than that of point mutations. One mitotic event stands out in its potential to significantly change a cell's SCNA burden-a chromosome missegregation. A stochastic model of chromosome mis-segregations has been previously developed to describe the evolution of SCNAs of a single chromosome type. Building upon this work, we derive a general...]]></summary>
        <author>
            <name>Gregory J Kimmel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New developments in targeted therapy for metastatic colorectal cancer]]></title>
        <id>pubmed:36687386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36687386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is the second most lethal cancer worldwide and the prognosis of metastatic CRC (mCRC) remains poor. Recent advancements in translational research have led to the identification of several new therapeutic targets and improved the treatment outcome of patients with tumours harbouring BRAF V600E mutation, (HER2) ErBB2 alterations, NTRK gene fusions and KRAS(G12C) mutation. Improved understanding towards the mechanism of resistance to targeted therapy such as anti-epidermal...]]></summary>
        <author>
            <name>Ambrose H N Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma]]></title>
        <id>pubmed:36689560</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689560/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CDDP resistance and development of distant metastasis are associated with dysregulated and epigenetically reprogrammed KEAP1-NRF2 signaling pathway. A strategy targeting KEAP1/NRF2 pathway or glutamine metabolism deserves further clinical investigation in patients with CDDP resistant head and neck tumors.]]></summary>
        <author>
            <name>Abdullah A Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction]]></title>
        <id>pubmed:36689467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The phenotypic efficacy of somatic copy number alterations (SCNAs) stems from their incidence per base pair of the genome, which is orders of magnitudes greater than that of point mutations. One mitotic event stands out in its potential to significantly change a cell's SCNA burden-a chromosome missegregation. A stochastic model of chromosome mis-segregations has been previously developed to describe the evolution of SCNAs of a single chromosome type. Building upon this work, we derive a general...]]></summary>
        <author>
            <name>Gregory J Kimmel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New developments in targeted therapy for metastatic colorectal cancer]]></title>
        <id>pubmed:36687386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36687386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is the second most lethal cancer worldwide and the prognosis of metastatic CRC (mCRC) remains poor. Recent advancements in translational research have led to the identification of several new therapeutic targets and improved the treatment outcome of patients with tumours harbouring BRAF V600E mutation, (HER2) ErBB2 alterations, NTRK gene fusions and KRAS(G12C) mutation. Improved understanding towards the mechanism of resistance to targeted therapy such as anti-epidermal...]]></summary>
        <author>
            <name>Ambrose H N Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma]]></title>
        <id>pubmed:36689560</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689560/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CDDP resistance and development of distant metastasis are associated with dysregulated and epigenetically reprogrammed KEAP1-NRF2 signaling pathway. A strategy targeting KEAP1/NRF2 pathway or glutamine metabolism deserves further clinical investigation in patients with CDDP resistant head and neck tumors.]]></summary>
        <author>
            <name>Abdullah A Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction]]></title>
        <id>pubmed:36689467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The phenotypic efficacy of somatic copy number alterations (SCNAs) stems from their incidence per base pair of the genome, which is orders of magnitudes greater than that of point mutations. One mitotic event stands out in its potential to significantly change a cell's SCNA burden-a chromosome missegregation. A stochastic model of chromosome mis-segregations has been previously developed to describe the evolution of SCNAs of a single chromosome type. Building upon this work, we derive a general...]]></summary>
        <author>
            <name>Gregory J Kimmel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New developments in targeted therapy for metastatic colorectal cancer]]></title>
        <id>pubmed:36687386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36687386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is the second most lethal cancer worldwide and the prognosis of metastatic CRC (mCRC) remains poor. Recent advancements in translational research have led to the identification of several new therapeutic targets and improved the treatment outcome of patients with tumours harbouring BRAF V600E mutation, (HER2) ErBB2 alterations, NTRK gene fusions and KRAS(G12C) mutation. Improved understanding towards the mechanism of resistance to targeted therapy such as anti-epidermal...]]></summary>
        <author>
            <name>Ambrose H N Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma]]></title>
        <id>pubmed:36689560</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689560/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CDDP resistance and development of distant metastasis are associated with dysregulated and epigenetically reprogrammed KEAP1-NRF2 signaling pathway. A strategy targeting KEAP1/NRF2 pathway or glutamine metabolism deserves further clinical investigation in patients with CDDP resistant head and neck tumors.]]></summary>
        <author>
            <name>Abdullah A Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction]]></title>
        <id>pubmed:36689467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The phenotypic efficacy of somatic copy number alterations (SCNAs) stems from their incidence per base pair of the genome, which is orders of magnitudes greater than that of point mutations. One mitotic event stands out in its potential to significantly change a cell's SCNA burden-a chromosome missegregation. A stochastic model of chromosome mis-segregations has been previously developed to describe the evolution of SCNAs of a single chromosome type. Building upon this work, we derive a general...]]></summary>
        <author>
            <name>Gregory J Kimmel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New developments in targeted therapy for metastatic colorectal cancer]]></title>
        <id>pubmed:36687386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36687386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is the second most lethal cancer worldwide and the prognosis of metastatic CRC (mCRC) remains poor. Recent advancements in translational research have led to the identification of several new therapeutic targets and improved the treatment outcome of patients with tumours harbouring BRAF V600E mutation, (HER2) ErBB2 alterations, NTRK gene fusions and KRAS(G12C) mutation. Improved understanding towards the mechanism of resistance to targeted therapy such as anti-epidermal...]]></summary>
        <author>
            <name>Ambrose H N Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma]]></title>
        <id>pubmed:36689560</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689560/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CDDP resistance and development of distant metastasis are associated with dysregulated and epigenetically reprogrammed KEAP1-NRF2 signaling pathway. A strategy targeting KEAP1/NRF2 pathway or glutamine metabolism deserves further clinical investigation in patients with CDDP resistant head and neck tumors.]]></summary>
        <author>
            <name>Abdullah A Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction]]></title>
        <id>pubmed:36689467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The phenotypic efficacy of somatic copy number alterations (SCNAs) stems from their incidence per base pair of the genome, which is orders of magnitudes greater than that of point mutations. One mitotic event stands out in its potential to significantly change a cell's SCNA burden-a chromosome missegregation. A stochastic model of chromosome mis-segregations has been previously developed to describe the evolution of SCNAs of a single chromosome type. Building upon this work, we derive a general...]]></summary>
        <author>
            <name>Gregory J Kimmel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New developments in targeted therapy for metastatic colorectal cancer]]></title>
        <id>pubmed:36687386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36687386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is the second most lethal cancer worldwide and the prognosis of metastatic CRC (mCRC) remains poor. Recent advancements in translational research have led to the identification of several new therapeutic targets and improved the treatment outcome of patients with tumours harbouring BRAF V600E mutation, (HER2) ErBB2 alterations, NTRK gene fusions and KRAS(G12C) mutation. Improved understanding towards the mechanism of resistance to targeted therapy such as anti-epidermal...]]></summary>
        <author>
            <name>Ambrose H N Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma]]></title>
        <id>pubmed:36689560</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689560/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CDDP resistance and development of distant metastasis are associated with dysregulated and epigenetically reprogrammed KEAP1-NRF2 signaling pathway. A strategy targeting KEAP1/NRF2 pathway or glutamine metabolism deserves further clinical investigation in patients with CDDP resistant head and neck tumors.]]></summary>
        <author>
            <name>Abdullah A Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction]]></title>
        <id>pubmed:36689467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The phenotypic efficacy of somatic copy number alterations (SCNAs) stems from their incidence per base pair of the genome, which is orders of magnitudes greater than that of point mutations. One mitotic event stands out in its potential to significantly change a cell's SCNA burden-a chromosome missegregation. A stochastic model of chromosome mis-segregations has been previously developed to describe the evolution of SCNAs of a single chromosome type. Building upon this work, we derive a general...]]></summary>
        <author>
            <name>Gregory J Kimmel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New developments in targeted therapy for metastatic colorectal cancer]]></title>
        <id>pubmed:36687386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36687386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is the second most lethal cancer worldwide and the prognosis of metastatic CRC (mCRC) remains poor. Recent advancements in translational research have led to the identification of several new therapeutic targets and improved the treatment outcome of patients with tumours harbouring BRAF V600E mutation, (HER2) ErBB2 alterations, NTRK gene fusions and KRAS(G12C) mutation. Improved understanding towards the mechanism of resistance to targeted therapy such as anti-epidermal...]]></summary>
        <author>
            <name>Ambrose H N Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma]]></title>
        <id>pubmed:36689560</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689560/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CDDP resistance and development of distant metastasis are associated with dysregulated and epigenetically reprogrammed KEAP1-NRF2 signaling pathway. A strategy targeting KEAP1/NRF2 pathway or glutamine metabolism deserves further clinical investigation in patients with CDDP resistant head and neck tumors.]]></summary>
        <author>
            <name>Abdullah A Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction]]></title>
        <id>pubmed:36689467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The phenotypic efficacy of somatic copy number alterations (SCNAs) stems from their incidence per base pair of the genome, which is orders of magnitudes greater than that of point mutations. One mitotic event stands out in its potential to significantly change a cell's SCNA burden-a chromosome missegregation. A stochastic model of chromosome mis-segregations has been previously developed to describe the evolution of SCNAs of a single chromosome type. Building upon this work, we derive a general...]]></summary>
        <author>
            <name>Gregory J Kimmel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New developments in targeted therapy for metastatic colorectal cancer]]></title>
        <id>pubmed:36687386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36687386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is the second most lethal cancer worldwide and the prognosis of metastatic CRC (mCRC) remains poor. Recent advancements in translational research have led to the identification of several new therapeutic targets and improved the treatment outcome of patients with tumours harbouring BRAF V600E mutation, (HER2) ErBB2 alterations, NTRK gene fusions and KRAS(G12C) mutation. Improved understanding towards the mechanism of resistance to targeted therapy such as anti-epidermal...]]></summary>
        <author>
            <name>Ambrose H N Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma]]></title>
        <id>pubmed:36689560</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689560/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CDDP resistance and development of distant metastasis are associated with dysregulated and epigenetically reprogrammed KEAP1-NRF2 signaling pathway. A strategy targeting KEAP1/NRF2 pathway or glutamine metabolism deserves further clinical investigation in patients with CDDP resistant head and neck tumors.]]></summary>
        <author>
            <name>Abdullah A Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction]]></title>
        <id>pubmed:36689467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The phenotypic efficacy of somatic copy number alterations (SCNAs) stems from their incidence per base pair of the genome, which is orders of magnitudes greater than that of point mutations. One mitotic event stands out in its potential to significantly change a cell's SCNA burden-a chromosome missegregation. A stochastic model of chromosome mis-segregations has been previously developed to describe the evolution of SCNAs of a single chromosome type. Building upon this work, we derive a general...]]></summary>
        <author>
            <name>Gregory J Kimmel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New developments in targeted therapy for metastatic colorectal cancer]]></title>
        <id>pubmed:36687386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36687386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is the second most lethal cancer worldwide and the prognosis of metastatic CRC (mCRC) remains poor. Recent advancements in translational research have led to the identification of several new therapeutic targets and improved the treatment outcome of patients with tumours harbouring BRAF V600E mutation, (HER2) ErBB2 alterations, NTRK gene fusions and KRAS(G12C) mutation. Improved understanding towards the mechanism of resistance to targeted therapy such as anti-epidermal...]]></summary>
        <author>
            <name>Ambrose H N Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma]]></title>
        <id>pubmed:36689560</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689560/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CDDP resistance and development of distant metastasis are associated with dysregulated and epigenetically reprogrammed KEAP1-NRF2 signaling pathway. A strategy targeting KEAP1/NRF2 pathway or glutamine metabolism deserves further clinical investigation in patients with CDDP resistant head and neck tumors.]]></summary>
        <author>
            <name>Abdullah A Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction]]></title>
        <id>pubmed:36689467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The phenotypic efficacy of somatic copy number alterations (SCNAs) stems from their incidence per base pair of the genome, which is orders of magnitudes greater than that of point mutations. One mitotic event stands out in its potential to significantly change a cell's SCNA burden-a chromosome missegregation. A stochastic model of chromosome mis-segregations has been previously developed to describe the evolution of SCNAs of a single chromosome type. Building upon this work, we derive a general...]]></summary>
        <author>
            <name>Gregory J Kimmel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New developments in targeted therapy for metastatic colorectal cancer]]></title>
        <id>pubmed:36687386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36687386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is the second most lethal cancer worldwide and the prognosis of metastatic CRC (mCRC) remains poor. Recent advancements in translational research have led to the identification of several new therapeutic targets and improved the treatment outcome of patients with tumours harbouring BRAF V600E mutation, (HER2) ErBB2 alterations, NTRK gene fusions and KRAS(G12C) mutation. Improved understanding towards the mechanism of resistance to targeted therapy such as anti-epidermal...]]></summary>
        <author>
            <name>Ambrose H N Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma]]></title>
        <id>pubmed:36689560</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689560/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CDDP resistance and development of distant metastasis are associated with dysregulated and epigenetically reprogrammed KEAP1-NRF2 signaling pathway. A strategy targeting KEAP1/NRF2 pathway or glutamine metabolism deserves further clinical investigation in patients with CDDP resistant head and neck tumors.]]></summary>
        <author>
            <name>Abdullah A Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction]]></title>
        <id>pubmed:36689467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The phenotypic efficacy of somatic copy number alterations (SCNAs) stems from their incidence per base pair of the genome, which is orders of magnitudes greater than that of point mutations. One mitotic event stands out in its potential to significantly change a cell's SCNA burden-a chromosome missegregation. A stochastic model of chromosome mis-segregations has been previously developed to describe the evolution of SCNAs of a single chromosome type. Building upon this work, we derive a general...]]></summary>
        <author>
            <name>Gregory J Kimmel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New developments in targeted therapy for metastatic colorectal cancer]]></title>
        <id>pubmed:36687386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36687386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is the second most lethal cancer worldwide and the prognosis of metastatic CRC (mCRC) remains poor. Recent advancements in translational research have led to the identification of several new therapeutic targets and improved the treatment outcome of patients with tumours harbouring BRAF V600E mutation, (HER2) ErBB2 alterations, NTRK gene fusions and KRAS(G12C) mutation. Improved understanding towards the mechanism of resistance to targeted therapy such as anti-epidermal...]]></summary>
        <author>
            <name>Ambrose H N Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma]]></title>
        <id>pubmed:36689560</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689560/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CDDP resistance and development of distant metastasis are associated with dysregulated and epigenetically reprogrammed KEAP1-NRF2 signaling pathway. A strategy targeting KEAP1/NRF2 pathway or glutamine metabolism deserves further clinical investigation in patients with CDDP resistant head and neck tumors.]]></summary>
        <author>
            <name>Abdullah A Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction]]></title>
        <id>pubmed:36689467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The phenotypic efficacy of somatic copy number alterations (SCNAs) stems from their incidence per base pair of the genome, which is orders of magnitudes greater than that of point mutations. One mitotic event stands out in its potential to significantly change a cell's SCNA burden-a chromosome missegregation. A stochastic model of chromosome mis-segregations has been previously developed to describe the evolution of SCNAs of a single chromosome type. Building upon this work, we derive a general...]]></summary>
        <author>
            <name>Gregory J Kimmel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New developments in targeted therapy for metastatic colorectal cancer]]></title>
        <id>pubmed:36687386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36687386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is the second most lethal cancer worldwide and the prognosis of metastatic CRC (mCRC) remains poor. Recent advancements in translational research have led to the identification of several new therapeutic targets and improved the treatment outcome of patients with tumours harbouring BRAF V600E mutation, (HER2) ErBB2 alterations, NTRK gene fusions and KRAS(G12C) mutation. Improved understanding towards the mechanism of resistance to targeted therapy such as anti-epidermal...]]></summary>
        <author>
            <name>Ambrose H N Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma]]></title>
        <id>pubmed:36689560</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689560/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CDDP resistance and development of distant metastasis are associated with dysregulated and epigenetically reprogrammed KEAP1-NRF2 signaling pathway. A strategy targeting KEAP1/NRF2 pathway or glutamine metabolism deserves further clinical investigation in patients with CDDP resistant head and neck tumors.]]></summary>
        <author>
            <name>Abdullah A Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction]]></title>
        <id>pubmed:36689467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The phenotypic efficacy of somatic copy number alterations (SCNAs) stems from their incidence per base pair of the genome, which is orders of magnitudes greater than that of point mutations. One mitotic event stands out in its potential to significantly change a cell's SCNA burden-a chromosome missegregation. A stochastic model of chromosome mis-segregations has been previously developed to describe the evolution of SCNAs of a single chromosome type. Building upon this work, we derive a general...]]></summary>
        <author>
            <name>Gregory J Kimmel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New developments in targeted therapy for metastatic colorectal cancer]]></title>
        <id>pubmed:36687386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36687386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is the second most lethal cancer worldwide and the prognosis of metastatic CRC (mCRC) remains poor. Recent advancements in translational research have led to the identification of several new therapeutic targets and improved the treatment outcome of patients with tumours harbouring BRAF V600E mutation, (HER2) ErBB2 alterations, NTRK gene fusions and KRAS(G12C) mutation. Improved understanding towards the mechanism of resistance to targeted therapy such as anti-epidermal...]]></summary>
        <author>
            <name>Ambrose H N Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma]]></title>
        <id>pubmed:36689560</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689560/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CDDP resistance and development of distant metastasis are associated with dysregulated and epigenetically reprogrammed KEAP1-NRF2 signaling pathway. A strategy targeting KEAP1/NRF2 pathway or glutamine metabolism deserves further clinical investigation in patients with CDDP resistant head and neck tumors.]]></summary>
        <author>
            <name>Abdullah A Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction]]></title>
        <id>pubmed:36689467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36689467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The phenotypic efficacy of somatic copy number alterations (SCNAs) stems from their incidence per base pair of the genome, which is orders of magnitudes greater than that of point mutations. One mitotic event stands out in its potential to significantly change a cell's SCNA burden-a chromosome missegregation. A stochastic model of chromosome mis-segregations has been previously developed to describe the evolution of SCNAs of a single chromosome type. Building upon this work, we derive a general...]]></summary>
        <author>
            <name>Gregory J Kimmel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New developments in targeted therapy for metastatic colorectal cancer]]></title>
        <id>pubmed:36687386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36687386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) is the second most lethal cancer worldwide and the prognosis of metastatic CRC (mCRC) remains poor. Recent advancements in translational research have led to the identification of several new therapeutic targets and improved the treatment outcome of patients with tumours harbouring BRAF V600E mutation, (HER2) ErBB2 alterations, NTRK gene fusions and KRAS(G12C) mutation. Improved understanding towards the mechanism of resistance to targeted therapy such as anti-epidermal...]]></summary>
        <author>
            <name>Ambrose H N Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes]]></title>
        <id>pubmed:36682988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36682988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230208200033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[MDS is a clonal stem cell neoplasm with a spectrum from lower risk disease to short term life threatening higher risk disease. The disease risk is dictated by clinical and molecular features. Majority of MDS patients including lower risk disease unfortunately succumb from disease related complications namely cytopenia. While cytopenias may be mild early upon diagnosis and can be surveilled, ultimately treatment is required. Anemia is the hall mark of disease and most common indication to treat...]]></summary>
        <author>
            <name>Virginia O Volpe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes]]></title>
        <id>pubmed:36682988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36682988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[MDS is a clonal stem cell neoplasm with a spectrum from lower risk disease to short term life threatening higher risk disease. The disease risk is dictated by clinical and molecular features. Majority of MDS patients including lower risk disease unfortunately succumb from disease related complications namely cytopenia. While cytopenias may be mild early upon diagnosis and can be surveilled, ultimately treatment is required. Anemia is the hall mark of disease and most common indication to treat...]]></summary>
        <author>
            <name>Virginia O Volpe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes]]></title>
        <id>pubmed:36682988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36682988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[MDS is a clonal stem cell neoplasm with a spectrum from lower risk disease to short term life threatening higher risk disease. The disease risk is dictated by clinical and molecular features. Majority of MDS patients including lower risk disease unfortunately succumb from disease related complications namely cytopenia. While cytopenias may be mild early upon diagnosis and can be surveilled, ultimately treatment is required. Anemia is the hall mark of disease and most common indication to treat...]]></summary>
        <author>
            <name>Virginia O Volpe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes]]></title>
        <id>pubmed:36682988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36682988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[MDS is a clonal stem cell neoplasm with a spectrum from lower risk disease to short term life threatening higher risk disease. The disease risk is dictated by clinical and molecular features. Majority of MDS patients including lower risk disease unfortunately succumb from disease related complications namely cytopenia. While cytopenias may be mild early upon diagnosis and can be surveilled, ultimately treatment is required. Anemia is the hall mark of disease and most common indication to treat...]]></summary>
        <author>
            <name>Virginia O Volpe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes]]></title>
        <id>pubmed:36682988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36682988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[MDS is a clonal stem cell neoplasm with a spectrum from lower risk disease to short term life threatening higher risk disease. The disease risk is dictated by clinical and molecular features. Majority of MDS patients including lower risk disease unfortunately succumb from disease related complications namely cytopenia. While cytopenias may be mild early upon diagnosis and can be surveilled, ultimately treatment is required. Anemia is the hall mark of disease and most common indication to treat...]]></summary>
        <author>
            <name>Virginia O Volpe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes]]></title>
        <id>pubmed:36682988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36682988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[MDS is a clonal stem cell neoplasm with a spectrum from lower risk disease to short term life threatening higher risk disease. The disease risk is dictated by clinical and molecular features. Majority of MDS patients including lower risk disease unfortunately succumb from disease related complications namely cytopenia. While cytopenias may be mild early upon diagnosis and can be surveilled, ultimately treatment is required. Anemia is the hall mark of disease and most common indication to treat...]]></summary>
        <author>
            <name>Virginia O Volpe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes]]></title>
        <id>pubmed:36682988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36682988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[MDS is a clonal stem cell neoplasm with a spectrum from lower risk disease to short term life threatening higher risk disease. The disease risk is dictated by clinical and molecular features. Majority of MDS patients including lower risk disease unfortunately succumb from disease related complications namely cytopenia. While cytopenias may be mild early upon diagnosis and can be surveilled, ultimately treatment is required. Anemia is the hall mark of disease and most common indication to treat...]]></summary>
        <author>
            <name>Virginia O Volpe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes]]></title>
        <id>pubmed:36682988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36682988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[MDS is a clonal stem cell neoplasm with a spectrum from lower risk disease to short term life threatening higher risk disease. The disease risk is dictated by clinical and molecular features. Majority of MDS patients including lower risk disease unfortunately succumb from disease related complications namely cytopenia. While cytopenias may be mild early upon diagnosis and can be surveilled, ultimately treatment is required. Anemia is the hall mark of disease and most common indication to treat...]]></summary>
        <author>
            <name>Virginia O Volpe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes]]></title>
        <id>pubmed:36682988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36682988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[MDS is a clonal stem cell neoplasm with a spectrum from lower risk disease to short term life threatening higher risk disease. The disease risk is dictated by clinical and molecular features. Majority of MDS patients including lower risk disease unfortunately succumb from disease related complications namely cytopenia. While cytopenias may be mild early upon diagnosis and can be surveilled, ultimately treatment is required. Anemia is the hall mark of disease and most common indication to treat...]]></summary>
        <author>
            <name>Virginia O Volpe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes]]></title>
        <id>pubmed:36682988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36682988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[MDS is a clonal stem cell neoplasm with a spectrum from lower risk disease to short term life threatening higher risk disease. The disease risk is dictated by clinical and molecular features. Majority of MDS patients including lower risk disease unfortunately succumb from disease related complications namely cytopenia. While cytopenias may be mild early upon diagnosis and can be surveilled, ultimately treatment is required. Anemia is the hall mark of disease and most common indication to treat...]]></summary>
        <author>
            <name>Virginia O Volpe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes]]></title>
        <id>pubmed:36682988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36682988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[MDS is a clonal stem cell neoplasm with a spectrum from lower risk disease to short term life threatening higher risk disease. The disease risk is dictated by clinical and molecular features. Majority of MDS patients including lower risk disease unfortunately succumb from disease related complications namely cytopenia. While cytopenias may be mild early upon diagnosis and can be surveilled, ultimately treatment is required. Anemia is the hall mark of disease and most common indication to treat...]]></summary>
        <author>
            <name>Virginia O Volpe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes]]></title>
        <id>pubmed:36682988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36682988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[MDS is a clonal stem cell neoplasm with a spectrum from lower risk disease to short term life threatening higher risk disease. The disease risk is dictated by clinical and molecular features. Majority of MDS patients including lower risk disease unfortunately succumb from disease related complications namely cytopenia. While cytopenias may be mild early upon diagnosis and can be surveilled, ultimately treatment is required. Anemia is the hall mark of disease and most common indication to treat...]]></summary>
        <author>
            <name>Virginia O Volpe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes]]></title>
        <id>pubmed:36682988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36682988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[MDS is a clonal stem cell neoplasm with a spectrum from lower risk disease to short term life threatening higher risk disease. The disease risk is dictated by clinical and molecular features. Majority of MDS patients including lower risk disease unfortunately succumb from disease related complications namely cytopenia. While cytopenias may be mild early upon diagnosis and can be surveilled, ultimately treatment is required. Anemia is the hall mark of disease and most common indication to treat...]]></summary>
        <author>
            <name>Virginia O Volpe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes]]></title>
        <id>pubmed:36682988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36682988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[MDS is a clonal stem cell neoplasm with a spectrum from lower risk disease to short term life threatening higher risk disease. The disease risk is dictated by clinical and molecular features. Majority of MDS patients including lower risk disease unfortunately succumb from disease related complications namely cytopenia. While cytopenias may be mild early upon diagnosis and can be surveilled, ultimately treatment is required. Anemia is the hall mark of disease and most common indication to treat...]]></summary>
        <author>
            <name>Virginia O Volpe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes]]></title>
        <id>pubmed:36682988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36682988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[MDS is a clonal stem cell neoplasm with a spectrum from lower risk disease to short term life threatening higher risk disease. The disease risk is dictated by clinical and molecular features. Majority of MDS patients including lower risk disease unfortunately succumb from disease related complications namely cytopenia. While cytopenias may be mild early upon diagnosis and can be surveilled, ultimately treatment is required. Anemia is the hall mark of disease and most common indication to treat...]]></summary>
        <author>
            <name>Virginia O Volpe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes]]></title>
        <id>pubmed:36682988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36682988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[MDS is a clonal stem cell neoplasm with a spectrum from lower risk disease to short term life threatening higher risk disease. The disease risk is dictated by clinical and molecular features. Majority of MDS patients including lower risk disease unfortunately succumb from disease related complications namely cytopenia. While cytopenias may be mild early upon diagnosis and can be surveilled, ultimately treatment is required. Anemia is the hall mark of disease and most common indication to treat...]]></summary>
        <author>
            <name>Virginia O Volpe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes]]></title>
        <id>pubmed:36682988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36682988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[MDS is a clonal stem cell neoplasm with a spectrum from lower risk disease to short term life threatening higher risk disease. The disease risk is dictated by clinical and molecular features. Majority of MDS patients including lower risk disease unfortunately succumb from disease related complications namely cytopenia. While cytopenias may be mild early upon diagnosis and can be surveilled, ultimately treatment is required. Anemia is the hall mark of disease and most common indication to treat...]]></summary>
        <author>
            <name>Virginia O Volpe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term risk associated with clonal hematopoiesis in patients with severe aortic valve stenosis undergoing TAVR]]></title>
        <id>pubmed:36680616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: DNMT3A- and TET2-CHIP-driver mutations are associated with long-term mortality in patients with aortic valve stenosis even after a successful TAVR. The association is also present in never smokers, in whom no biasing effect from smoking on DNA methylation is to be expected.]]></summary>
        <author>
            <name>Silvia Mas-Peiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term risk associated with clonal hematopoiesis in patients with severe aortic valve stenosis undergoing TAVR]]></title>
        <id>pubmed:36680616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: DNMT3A- and TET2-CHIP-driver mutations are associated with long-term mortality in patients with aortic valve stenosis even after a successful TAVR. The association is also present in never smokers, in whom no biasing effect from smoking on DNA methylation is to be expected.]]></summary>
        <author>
            <name>Silvia Mas-Peiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term risk associated with clonal hematopoiesis in patients with severe aortic valve stenosis undergoing TAVR]]></title>
        <id>pubmed:36680616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: DNMT3A- and TET2-CHIP-driver mutations are associated with long-term mortality in patients with aortic valve stenosis even after a successful TAVR. The association is also present in never smokers, in whom no biasing effect from smoking on DNA methylation is to be expected.]]></summary>
        <author>
            <name>Silvia Mas-Peiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management]]></title>
        <id>pubmed:36680511</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680511/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow reticulin/collagen fibrosis, aberrant inflammatory cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, risk of leukemic progression, and shortened survival.]]></summary>
        <author>
            <name>Ayalew Tefferi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term risk associated with clonal hematopoiesis in patients with severe aortic valve stenosis undergoing TAVR]]></title>
        <id>pubmed:36680616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: DNMT3A- and TET2-CHIP-driver mutations are associated with long-term mortality in patients with aortic valve stenosis even after a successful TAVR. The association is also present in never smokers, in whom no biasing effect from smoking on DNA methylation is to be expected.]]></summary>
        <author>
            <name>Silvia Mas-Peiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management]]></title>
        <id>pubmed:36680511</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680511/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow reticulin/collagen fibrosis, aberrant inflammatory cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, risk of leukemic progression, and shortened survival.]]></summary>
        <author>
            <name>Ayalew Tefferi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term risk associated with clonal hematopoiesis in patients with severe aortic valve stenosis undergoing TAVR]]></title>
        <id>pubmed:36680616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: DNMT3A- and TET2-CHIP-driver mutations are associated with long-term mortality in patients with aortic valve stenosis even after a successful TAVR. The association is also present in never smokers, in whom no biasing effect from smoking on DNA methylation is to be expected.]]></summary>
        <author>
            <name>Silvia Mas-Peiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management]]></title>
        <id>pubmed:36680511</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680511/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow reticulin/collagen fibrosis, aberrant inflammatory cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, risk of leukemic progression, and shortened survival.]]></summary>
        <author>
            <name>Ayalew Tefferi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term risk associated with clonal hematopoiesis in patients with severe aortic valve stenosis undergoing TAVR]]></title>
        <id>pubmed:36680616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: DNMT3A- and TET2-CHIP-driver mutations are associated with long-term mortality in patients with aortic valve stenosis even after a successful TAVR. The association is also present in never smokers, in whom no biasing effect from smoking on DNA methylation is to be expected.]]></summary>
        <author>
            <name>Silvia Mas-Peiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management]]></title>
        <id>pubmed:36680511</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680511/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow reticulin/collagen fibrosis, aberrant inflammatory cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, risk of leukemic progression, and shortened survival.]]></summary>
        <author>
            <name>Ayalew Tefferi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term risk associated with clonal hematopoiesis in patients with severe aortic valve stenosis undergoing TAVR]]></title>
        <id>pubmed:36680616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: DNMT3A- and TET2-CHIP-driver mutations are associated with long-term mortality in patients with aortic valve stenosis even after a successful TAVR. The association is also present in never smokers, in whom no biasing effect from smoking on DNA methylation is to be expected.]]></summary>
        <author>
            <name>Silvia Mas-Peiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management]]></title>
        <id>pubmed:36680511</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680511/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow reticulin/collagen fibrosis, aberrant inflammatory cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, risk of leukemic progression, and shortened survival.]]></summary>
        <author>
            <name>Ayalew Tefferi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term risk associated with clonal hematopoiesis in patients with severe aortic valve stenosis undergoing TAVR]]></title>
        <id>pubmed:36680616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: DNMT3A- and TET2-CHIP-driver mutations are associated with long-term mortality in patients with aortic valve stenosis even after a successful TAVR. The association is also present in never smokers, in whom no biasing effect from smoking on DNA methylation is to be expected.]]></summary>
        <author>
            <name>Silvia Mas-Peiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management]]></title>
        <id>pubmed:36680511</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680511/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow reticulin/collagen fibrosis, aberrant inflammatory cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, risk of leukemic progression, and shortened survival.]]></summary>
        <author>
            <name>Ayalew Tefferi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term risk associated with clonal hematopoiesis in patients with severe aortic valve stenosis undergoing TAVR]]></title>
        <id>pubmed:36680616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: DNMT3A- and TET2-CHIP-driver mutations are associated with long-term mortality in patients with aortic valve stenosis even after a successful TAVR. The association is also present in never smokers, in whom no biasing effect from smoking on DNA methylation is to be expected.]]></summary>
        <author>
            <name>Silvia Mas-Peiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management]]></title>
        <id>pubmed:36680511</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680511/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow reticulin/collagen fibrosis, aberrant inflammatory cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, risk of leukemic progression, and shortened survival.]]></summary>
        <author>
            <name>Ayalew Tefferi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term risk associated with clonal hematopoiesis in patients with severe aortic valve stenosis undergoing TAVR]]></title>
        <id>pubmed:36680616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: DNMT3A- and TET2-CHIP-driver mutations are associated with long-term mortality in patients with aortic valve stenosis even after a successful TAVR. The association is also present in never smokers, in whom no biasing effect from smoking on DNA methylation is to be expected.]]></summary>
        <author>
            <name>Silvia Mas-Peiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management]]></title>
        <id>pubmed:36680511</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680511/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow reticulin/collagen fibrosis, aberrant inflammatory cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, risk of leukemic progression, and shortened survival.]]></summary>
        <author>
            <name>Ayalew Tefferi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term risk associated with clonal hematopoiesis in patients with severe aortic valve stenosis undergoing TAVR]]></title>
        <id>pubmed:36680616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: DNMT3A- and TET2-CHIP-driver mutations are associated with long-term mortality in patients with aortic valve stenosis even after a successful TAVR. The association is also present in never smokers, in whom no biasing effect from smoking on DNA methylation is to be expected.]]></summary>
        <author>
            <name>Silvia Mas-Peiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management]]></title>
        <id>pubmed:36680511</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680511/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow reticulin/collagen fibrosis, aberrant inflammatory cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, risk of leukemic progression, and shortened survival.]]></summary>
        <author>
            <name>Ayalew Tefferi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term risk associated with clonal hematopoiesis in patients with severe aortic valve stenosis undergoing TAVR]]></title>
        <id>pubmed:36680616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: DNMT3A- and TET2-CHIP-driver mutations are associated with long-term mortality in patients with aortic valve stenosis even after a successful TAVR. The association is also present in never smokers, in whom no biasing effect from smoking on DNA methylation is to be expected.]]></summary>
        <author>
            <name>Silvia Mas-Peiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management]]></title>
        <id>pubmed:36680511</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680511/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow reticulin/collagen fibrosis, aberrant inflammatory cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, risk of leukemic progression, and shortened survival.]]></summary>
        <author>
            <name>Ayalew Tefferi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term risk associated with clonal hematopoiesis in patients with severe aortic valve stenosis undergoing TAVR]]></title>
        <id>pubmed:36680616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: DNMT3A- and TET2-CHIP-driver mutations are associated with long-term mortality in patients with aortic valve stenosis even after a successful TAVR. The association is also present in never smokers, in whom no biasing effect from smoking on DNA methylation is to be expected.]]></summary>
        <author>
            <name>Silvia Mas-Peiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management]]></title>
        <id>pubmed:36680511</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680511/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow reticulin/collagen fibrosis, aberrant inflammatory cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, risk of leukemic progression, and shortened survival.]]></summary>
        <author>
            <name>Ayalew Tefferi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term risk associated with clonal hematopoiesis in patients with severe aortic valve stenosis undergoing TAVR]]></title>
        <id>pubmed:36680616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: DNMT3A- and TET2-CHIP-driver mutations are associated with long-term mortality in patients with aortic valve stenosis even after a successful TAVR. The association is also present in never smokers, in whom no biasing effect from smoking on DNA methylation is to be expected.]]></summary>
        <author>
            <name>Silvia Mas-Peiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management]]></title>
        <id>pubmed:36680511</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680511/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow reticulin/collagen fibrosis, aberrant inflammatory cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, risk of leukemic progression, and shortened survival.]]></summary>
        <author>
            <name>Ayalew Tefferi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term risk associated with clonal hematopoiesis in patients with severe aortic valve stenosis undergoing TAVR]]></title>
        <id>pubmed:36680616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: DNMT3A- and TET2-CHIP-driver mutations are associated with long-term mortality in patients with aortic valve stenosis even after a successful TAVR. The association is also present in never smokers, in whom no biasing effect from smoking on DNA methylation is to be expected.]]></summary>
        <author>
            <name>Silvia Mas-Peiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management]]></title>
        <id>pubmed:36680511</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680511/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow reticulin/collagen fibrosis, aberrant inflammatory cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, risk of leukemic progression, and shortened survival.]]></summary>
        <author>
            <name>Ayalew Tefferi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term risk associated with clonal hematopoiesis in patients with severe aortic valve stenosis undergoing TAVR]]></title>
        <id>pubmed:36680616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: DNMT3A- and TET2-CHIP-driver mutations are associated with long-term mortality in patients with aortic valve stenosis even after a successful TAVR. The association is also present in never smokers, in whom no biasing effect from smoking on DNA methylation is to be expected.]]></summary>
        <author>
            <name>Silvia Mas-Peiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management]]></title>
        <id>pubmed:36680511</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680511/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow reticulin/collagen fibrosis, aberrant inflammatory cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, risk of leukemic progression, and shortened survival.]]></summary>
        <author>
            <name>Ayalew Tefferi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term risk associated with clonal hematopoiesis in patients with severe aortic valve stenosis undergoing TAVR]]></title>
        <id>pubmed:36680616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: DNMT3A- and TET2-CHIP-driver mutations are associated with long-term mortality in patients with aortic valve stenosis even after a successful TAVR. The association is also present in never smokers, in whom no biasing effect from smoking on DNA methylation is to be expected.]]></summary>
        <author>
            <name>Silvia Mas-Peiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management]]></title>
        <id>pubmed:36680511</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680511/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow reticulin/collagen fibrosis, aberrant inflammatory cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, risk of leukemic progression, and shortened survival.]]></summary>
        <author>
            <name>Ayalew Tefferi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term risk associated with clonal hematopoiesis in patients with severe aortic valve stenosis undergoing TAVR]]></title>
        <id>pubmed:36680616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: DNMT3A- and TET2-CHIP-driver mutations are associated with long-term mortality in patients with aortic valve stenosis even after a successful TAVR. The association is also present in never smokers, in whom no biasing effect from smoking on DNA methylation is to be expected.]]></summary>
        <author>
            <name>Silvia Mas-Peiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management]]></title>
        <id>pubmed:36680511</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36680511/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow reticulin/collagen fibrosis, aberrant inflammatory cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, risk of leukemic progression, and shortened survival.]]></summary>
        <author>
            <name>Ayalew Tefferi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Meiotic chromosome organization and its role in recombination and cancer]]></title>
        <id>pubmed:36681479</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36681479/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomes adopt specific conformations to regulate various cellular processes. A well-documented chromosome configuration is the highly compacted chromosome structure during metaphase. More regional chromatin conformations have also been reported, including topologically associated domains encompassing mega-bases of DNA and local chromatin loops formed by kilo-bases of DNA. In this review, we discuss the changes in chromatin conformation taking place between somatic and meiotic cells, with a...]]></summary>
        <author>
            <name>Chris Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230210195718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Meiotic chromosome organization and its role in recombination and cancer]]></title>
        <id>pubmed:36681479</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36681479/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230209200536&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomes adopt specific conformations to regulate various cellular processes. A well-documented chromosome configuration is the highly compacted chromosome structure during metaphase. More regional chromatin conformations have also been reported, including topologically associated domains encompassing mega-bases of DNA and local chromatin loops formed by kilo-bases of DNA. In this review, we discuss the changes in chromatin conformation taking place between somatic and meiotic cells, with a...]]></summary>
        <author>
            <name>Chris Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230209200536&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer]]></title>
        <id>pubmed:36672453</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36672453/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230209200536&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted therapy also favors the emergence of drug tolerant or resistant cells, ultimately resulting in tumor relapse. Recently, cellular barcoding strategies have arisen as a powerful tool to investigate the...]]></summary>
        <author>
            <name>Houssein Chhouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Meiotic chromosome organization and its role in recombination and cancer]]></title>
        <id>pubmed:36681479</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36681479/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230208200032&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomes adopt specific conformations to regulate various cellular processes. A well-documented chromosome configuration is the highly compacted chromosome structure during metaphase. More regional chromatin conformations have also been reported, including topologically associated domains encompassing mega-bases of DNA and local chromatin loops formed by kilo-bases of DNA. In this review, we discuss the changes in chromatin conformation taking place between somatic and meiotic cells, with a...]]></summary>
        <author>
            <name>Chris Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230208200032&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer]]></title>
        <id>pubmed:36672453</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36672453/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230208200032&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted therapy also favors the emergence of drug tolerant or resistant cells, ultimately resulting in tumor relapse. Recently, cellular barcoding strategies have arisen as a powerful tool to investigate the...]]></summary>
        <author>
            <name>Houssein Chhouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Meiotic chromosome organization and its role in recombination and cancer]]></title>
        <id>pubmed:36681479</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36681479/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomes adopt specific conformations to regulate various cellular processes. A well-documented chromosome configuration is the highly compacted chromosome structure during metaphase. More regional chromatin conformations have also been reported, including topologically associated domains encompassing mega-bases of DNA and local chromatin loops formed by kilo-bases of DNA. In this review, we discuss the changes in chromatin conformation taking place between somatic and meiotic cells, with a...]]></summary>
        <author>
            <name>Chris Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer]]></title>
        <id>pubmed:36672453</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36672453/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230207200158&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted therapy also favors the emergence of drug tolerant or resistant cells, ultimately resulting in tumor relapse. Recently, cellular barcoding strategies have arisen as a powerful tool to investigate the...]]></summary>
        <author>
            <name>Houssein Chhouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Meiotic chromosome organization and its role in recombination and cancer]]></title>
        <id>pubmed:36681479</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36681479/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomes adopt specific conformations to regulate various cellular processes. A well-documented chromosome configuration is the highly compacted chromosome structure during metaphase. More regional chromatin conformations have also been reported, including topologically associated domains encompassing mega-bases of DNA and local chromatin loops formed by kilo-bases of DNA. In this review, we discuss the changes in chromatin conformation taking place between somatic and meiotic cells, with a...]]></summary>
        <author>
            <name>Chris Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer]]></title>
        <id>pubmed:36672453</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36672453/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted therapy also favors the emergence of drug tolerant or resistant cells, ultimately resulting in tumor relapse. Recently, cellular barcoding strategies have arisen as a powerful tool to investigate the...]]></summary>
        <author>
            <name>Houssein Chhouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Meiotic chromosome organization and its role in recombination and cancer]]></title>
        <id>pubmed:36681479</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36681479/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomes adopt specific conformations to regulate various cellular processes. A well-documented chromosome configuration is the highly compacted chromosome structure during metaphase. More regional chromatin conformations have also been reported, including topologically associated domains encompassing mega-bases of DNA and local chromatin loops formed by kilo-bases of DNA. In this review, we discuss the changes in chromatin conformation taking place between somatic and meiotic cells, with a...]]></summary>
        <author>
            <name>Chris Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer]]></title>
        <id>pubmed:36672453</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36672453/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted therapy also favors the emergence of drug tolerant or resistant cells, ultimately resulting in tumor relapse. Recently, cellular barcoding strategies have arisen as a powerful tool to investigate the...]]></summary>
        <author>
            <name>Houssein Chhouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Meiotic chromosome organization and its role in recombination and cancer]]></title>
        <id>pubmed:36681479</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36681479/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomes adopt specific conformations to regulate various cellular processes. A well-documented chromosome configuration is the highly compacted chromosome structure during metaphase. More regional chromatin conformations have also been reported, including topologically associated domains encompassing mega-bases of DNA and local chromatin loops formed by kilo-bases of DNA. In this review, we discuss the changes in chromatin conformation taking place between somatic and meiotic cells, with a...]]></summary>
        <author>
            <name>Chris Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer]]></title>
        <id>pubmed:36672453</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36672453/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted therapy also favors the emergence of drug tolerant or resistant cells, ultimately resulting in tumor relapse. Recently, cellular barcoding strategies have arisen as a powerful tool to investigate the...]]></summary>
        <author>
            <name>Houssein Chhouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Meiotic chromosome organization and its role in recombination and cancer]]></title>
        <id>pubmed:36681479</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36681479/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomes adopt specific conformations to regulate various cellular processes. A well-documented chromosome configuration is the highly compacted chromosome structure during metaphase. More regional chromatin conformations have also been reported, including topologically associated domains encompassing mega-bases of DNA and local chromatin loops formed by kilo-bases of DNA. In this review, we discuss the changes in chromatin conformation taking place between somatic and meiotic cells, with a...]]></summary>
        <author>
            <name>Chris Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer]]></title>
        <id>pubmed:36672453</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36672453/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted therapy also favors the emergence of drug tolerant or resistant cells, ultimately resulting in tumor relapse. Recently, cellular barcoding strategies have arisen as a powerful tool to investigate the...]]></summary>
        <author>
            <name>Houssein Chhouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Meiotic chromosome organization and its role in recombination and cancer]]></title>
        <id>pubmed:36681479</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36681479/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomes adopt specific conformations to regulate various cellular processes. A well-documented chromosome configuration is the highly compacted chromosome structure during metaphase. More regional chromatin conformations have also been reported, including topologically associated domains encompassing mega-bases of DNA and local chromatin loops formed by kilo-bases of DNA. In this review, we discuss the changes in chromatin conformation taking place between somatic and meiotic cells, with a...]]></summary>
        <author>
            <name>Chris Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer]]></title>
        <id>pubmed:36672453</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36672453/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted therapy also favors the emergence of drug tolerant or resistant cells, ultimately resulting in tumor relapse. Recently, cellular barcoding strategies have arisen as a powerful tool to investigate the...]]></summary>
        <author>
            <name>Houssein Chhouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Meiotic chromosome organization and its role in recombination and cancer]]></title>
        <id>pubmed:36681479</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36681479/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomes adopt specific conformations to regulate various cellular processes. A well-documented chromosome configuration is the highly compacted chromosome structure during metaphase. More regional chromatin conformations have also been reported, including topologically associated domains encompassing mega-bases of DNA and local chromatin loops formed by kilo-bases of DNA. In this review, we discuss the changes in chromatin conformation taking place between somatic and meiotic cells, with a...]]></summary>
        <author>
            <name>Chris Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer]]></title>
        <id>pubmed:36672453</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36672453/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted therapy also favors the emergence of drug tolerant or resistant cells, ultimately resulting in tumor relapse. Recently, cellular barcoding strategies have arisen as a powerful tool to investigate the...]]></summary>
        <author>
            <name>Houssein Chhouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Meiotic chromosome organization and its role in recombination and cancer]]></title>
        <id>pubmed:36681479</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36681479/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomes adopt specific conformations to regulate various cellular processes. A well-documented chromosome configuration is the highly compacted chromosome structure during metaphase. More regional chromatin conformations have also been reported, including topologically associated domains encompassing mega-bases of DNA and local chromatin loops formed by kilo-bases of DNA. In this review, we discuss the changes in chromatin conformation taking place between somatic and meiotic cells, with a...]]></summary>
        <author>
            <name>Chris Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer]]></title>
        <id>pubmed:36672453</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36672453/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted therapy also favors the emergence of drug tolerant or resistant cells, ultimately resulting in tumor relapse. Recently, cellular barcoding strategies have arisen as a powerful tool to investigate the...]]></summary>
        <author>
            <name>Houssein Chhouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Meiotic chromosome organization and its role in recombination and cancer]]></title>
        <id>pubmed:36681479</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36681479/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomes adopt specific conformations to regulate various cellular processes. A well-documented chromosome configuration is the highly compacted chromosome structure during metaphase. More regional chromatin conformations have also been reported, including topologically associated domains encompassing mega-bases of DNA and local chromatin loops formed by kilo-bases of DNA. In this review, we discuss the changes in chromatin conformation taking place between somatic and meiotic cells, with a...]]></summary>
        <author>
            <name>Chris Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer]]></title>
        <id>pubmed:36672453</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36672453/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted therapy also favors the emergence of drug tolerant or resistant cells, ultimately resulting in tumor relapse. Recently, cellular barcoding strategies have arisen as a powerful tool to investigate the...]]></summary>
        <author>
            <name>Houssein Chhouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Meiotic chromosome organization and its role in recombination and cancer]]></title>
        <id>pubmed:36681479</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36681479/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomes adopt specific conformations to regulate various cellular processes. A well-documented chromosome configuration is the highly compacted chromosome structure during metaphase. More regional chromatin conformations have also been reported, including topologically associated domains encompassing mega-bases of DNA and local chromatin loops formed by kilo-bases of DNA. In this review, we discuss the changes in chromatin conformation taking place between somatic and meiotic cells, with a...]]></summary>
        <author>
            <name>Chris Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer]]></title>
        <id>pubmed:36672453</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36672453/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted therapy also favors the emergence of drug tolerant or resistant cells, ultimately resulting in tumor relapse. Recently, cellular barcoding strategies have arisen as a powerful tool to investigate the...]]></summary>
        <author>
            <name>Houssein Chhouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Meiotic chromosome organization and its role in recombination and cancer]]></title>
        <id>pubmed:36681479</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36681479/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomes adopt specific conformations to regulate various cellular processes. A well-documented chromosome configuration is the highly compacted chromosome structure during metaphase. More regional chromatin conformations have also been reported, including topologically associated domains encompassing mega-bases of DNA and local chromatin loops formed by kilo-bases of DNA. In this review, we discuss the changes in chromatin conformation taking place between somatic and meiotic cells, with a...]]></summary>
        <author>
            <name>Chris Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer]]></title>
        <id>pubmed:36672453</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36672453/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted therapy also favors the emergence of drug tolerant or resistant cells, ultimately resulting in tumor relapse. Recently, cellular barcoding strategies have arisen as a powerful tool to investigate the...]]></summary>
        <author>
            <name>Houssein Chhouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Meiotic chromosome organization and its role in recombination and cancer]]></title>
        <id>pubmed:36681479</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36681479/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomes adopt specific conformations to regulate various cellular processes. A well-documented chromosome configuration is the highly compacted chromosome structure during metaphase. More regional chromatin conformations have also been reported, including topologically associated domains encompassing mega-bases of DNA and local chromatin loops formed by kilo-bases of DNA. In this review, we discuss the changes in chromatin conformation taking place between somatic and meiotic cells, with a...]]></summary>
        <author>
            <name>Chris Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer]]></title>
        <id>pubmed:36672453</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36672453/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted therapy also favors the emergence of drug tolerant or resistant cells, ultimately resulting in tumor relapse. Recently, cellular barcoding strategies have arisen as a powerful tool to investigate the...]]></summary>
        <author>
            <name>Houssein Chhouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Meiotic chromosome organization and its role in recombination and cancer]]></title>
        <id>pubmed:36681479</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36681479/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomes adopt specific conformations to regulate various cellular processes. A well-documented chromosome configuration is the highly compacted chromosome structure during metaphase. More regional chromatin conformations have also been reported, including topologically associated domains encompassing mega-bases of DNA and local chromatin loops formed by kilo-bases of DNA. In this review, we discuss the changes in chromatin conformation taking place between somatic and meiotic cells, with a...]]></summary>
        <author>
            <name>Chris Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer]]></title>
        <id>pubmed:36672453</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36672453/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted therapy also favors the emergence of drug tolerant or resistant cells, ultimately resulting in tumor relapse. Recently, cellular barcoding strategies have arisen as a powerful tool to investigate the...]]></summary>
        <author>
            <name>Houssein Chhouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Meiotic chromosome organization and its role in recombination and cancer]]></title>
        <id>pubmed:36681479</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36681479/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomes adopt specific conformations to regulate various cellular processes. A well-documented chromosome configuration is the highly compacted chromosome structure during metaphase. More regional chromatin conformations have also been reported, including topologically associated domains encompassing mega-bases of DNA and local chromatin loops formed by kilo-bases of DNA. In this review, we discuss the changes in chromatin conformation taking place between somatic and meiotic cells, with a...]]></summary>
        <author>
            <name>Chris Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer]]></title>
        <id>pubmed:36672453</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36672453/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted therapy also favors the emergence of drug tolerant or resistant cells, ultimately resulting in tumor relapse. Recently, cellular barcoding strategies have arisen as a powerful tool to investigate the...]]></summary>
        <author>
            <name>Houssein Chhouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Meiotic chromosome organization and its role in recombination and cancer]]></title>
        <id>pubmed:36681479</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36681479/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomes adopt specific conformations to regulate various cellular processes. A well-documented chromosome configuration is the highly compacted chromosome structure during metaphase. More regional chromatin conformations have also been reported, including topologically associated domains encompassing mega-bases of DNA and local chromatin loops formed by kilo-bases of DNA. In this review, we discuss the changes in chromatin conformation taking place between somatic and meiotic cells, with a...]]></summary>
        <author>
            <name>Chris Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation]]></title>
        <id>pubmed:36675240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36675240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The mammalian DNA methylation landscape is established and maintained by the combined activities of the two key epigenetic modifiers, DNA methyltransferases (DNMT) and Ten-eleven-translocation (TET) enzymes. Once DNMTs produce 5-methylcytosine (5mC), TET proteins fine-tune the DNA methylation status by consecutively oxidizing 5mC to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives. The 5mC and oxidized methylcytosines are essential for the maintenance of cellular identity and...]]></summary>
        <author>
            <name>Jungeun An</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer]]></title>
        <id>pubmed:36672453</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36672453/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted therapy also favors the emergence of drug tolerant or resistant cells, ultimately resulting in tumor relapse. Recently, cellular barcoding strategies have arisen as a powerful tool to investigate the...]]></summary>
        <author>
            <name>Houssein Chhouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer]]></title>
        <id>pubmed:36672453</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36672453/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted therapy also favors the emergence of drug tolerant or resistant cells, ultimately resulting in tumor relapse. Recently, cellular barcoding strategies have arisen as a powerful tool to investigate the...]]></summary>
        <author>
            <name>Houssein Chhouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer]]></title>
        <id>pubmed:36672453</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36672453/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted therapy also favors the emergence of drug tolerant or resistant cells, ultimately resulting in tumor relapse. Recently, cellular barcoding strategies have arisen as a powerful tool to investigate the...]]></summary>
        <author>
            <name>Houssein Chhouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer]]></title>
        <id>pubmed:36672453</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36672453/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-small cell lung cancers (NSCLC) harboring activating mutations of the epidermal growth factor receptor (EGFR) are treated with specific tyrosine kinase inhibitors (EGFR-TKIs) of this receptor, resulting in clinically responses that can generally last several months. Unfortunately, EGFR-targeted therapy also favors the emergence of drug tolerant or resistant cells, ultimately resulting in tumor relapse. Recently, cellular barcoding strategies have arisen as a powerful tool to investigate the...]]></summary>
        <author>
            <name>Houssein Chhouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy]]></title>
        <id>pubmed:36661736</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36661736/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing a small TP53-mutated clone. As a third-line therapy, the patient was treated with CAR-T cells, which resulted in complete remission. However, this treatment also led to the expansion of the TP53-mutated clone and therapy-related myelodysplasia with a complex aberrant karyotype....]]></summary>
        <author>
            <name>Lea Naomi Eder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy]]></title>
        <id>pubmed:36661736</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36661736/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing a small TP53-mutated clone. As a third-line therapy, the patient was treated with CAR-T cells, which resulted in complete remission. However, this treatment also led to the expansion of the TP53-mutated clone and therapy-related myelodysplasia with a complex aberrant karyotype....]]></summary>
        <author>
            <name>Lea Naomi Eder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy]]></title>
        <id>pubmed:36661736</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36661736/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing a small TP53-mutated clone. As a third-line therapy, the patient was treated with CAR-T cells, which resulted in complete remission. However, this treatment also led to the expansion of the TP53-mutated clone and therapy-related myelodysplasia with a complex aberrant karyotype....]]></summary>
        <author>
            <name>Lea Naomi Eder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy]]></title>
        <id>pubmed:36661736</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36661736/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing a small TP53-mutated clone. As a third-line therapy, the patient was treated with CAR-T cells, which resulted in complete remission. However, this treatment also led to the expansion of the TP53-mutated clone and therapy-related myelodysplasia with a complex aberrant karyotype....]]></summary>
        <author>
            <name>Lea Naomi Eder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy]]></title>
        <id>pubmed:36661736</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36661736/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing a small TP53-mutated clone. As a third-line therapy, the patient was treated with CAR-T cells, which resulted in complete remission. However, this treatment also led to the expansion of the TP53-mutated clone and therapy-related myelodysplasia with a complex aberrant karyotype....]]></summary>
        <author>
            <name>Lea Naomi Eder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy]]></title>
        <id>pubmed:36661736</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36661736/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing a small TP53-mutated clone. As a third-line therapy, the patient was treated with CAR-T cells, which resulted in complete remission. However, this treatment also led to the expansion of the TP53-mutated clone and therapy-related myelodysplasia with a complex aberrant karyotype....]]></summary>
        <author>
            <name>Lea Naomi Eder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy]]></title>
        <id>pubmed:36661736</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36661736/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing a small TP53-mutated clone. As a third-line therapy, the patient was treated with CAR-T cells, which resulted in complete remission. However, this treatment also led to the expansion of the TP53-mutated clone and therapy-related myelodysplasia with a complex aberrant karyotype....]]></summary>
        <author>
            <name>Lea Naomi Eder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy]]></title>
        <id>pubmed:36661736</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36661736/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing a small TP53-mutated clone. As a third-line therapy, the patient was treated with CAR-T cells, which resulted in complete remission. However, this treatment also led to the expansion of the TP53-mutated clone and therapy-related myelodysplasia with a complex aberrant karyotype....]]></summary>
        <author>
            <name>Lea Naomi Eder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy]]></title>
        <id>pubmed:36661736</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36661736/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing a small TP53-mutated clone. As a third-line therapy, the patient was treated with CAR-T cells, which resulted in complete remission. However, this treatment also led to the expansion of the TP53-mutated clone and therapy-related myelodysplasia with a complex aberrant karyotype....]]></summary>
        <author>
            <name>Lea Naomi Eder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy]]></title>
        <id>pubmed:36661736</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36661736/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing a small TP53-mutated clone. As a third-line therapy, the patient was treated with CAR-T cells, which resulted in complete remission. However, this treatment also led to the expansion of the TP53-mutated clone and therapy-related myelodysplasia with a complex aberrant karyotype....]]></summary>
        <author>
            <name>Lea Naomi Eder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy]]></title>
        <id>pubmed:36661736</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36661736/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing a small TP53-mutated clone. As a third-line therapy, the patient was treated with CAR-T cells, which resulted in complete remission. However, this treatment also led to the expansion of the TP53-mutated clone and therapy-related myelodysplasia with a complex aberrant karyotype....]]></summary>
        <author>
            <name>Lea Naomi Eder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy]]></title>
        <id>pubmed:36661736</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36661736/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing a small TP53-mutated clone. As a third-line therapy, the patient was treated with CAR-T cells, which resulted in complete remission. However, this treatment also led to the expansion of the TP53-mutated clone and therapy-related myelodysplasia with a complex aberrant karyotype....]]></summary>
        <author>
            <name>Lea Naomi Eder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy]]></title>
        <id>pubmed:36661736</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36661736/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing a small TP53-mutated clone. As a third-line therapy, the patient was treated with CAR-T cells, which resulted in complete remission. However, this treatment also led to the expansion of the TP53-mutated clone and therapy-related myelodysplasia with a complex aberrant karyotype....]]></summary>
        <author>
            <name>Lea Naomi Eder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy]]></title>
        <id>pubmed:36661736</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36661736/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing a small TP53-mutated clone. As a third-line therapy, the patient was treated with CAR-T cells, which resulted in complete remission. However, this treatment also led to the expansion of the TP53-mutated clone and therapy-related myelodysplasia with a complex aberrant karyotype....]]></summary>
        <author>
            <name>Lea Naomi Eder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy]]></title>
        <id>pubmed:36661736</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36661736/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing a small TP53-mutated clone. As a third-line therapy, the patient was treated with CAR-T cells, which resulted in complete remission. However, this treatment also led to the expansion of the TP53-mutated clone and therapy-related myelodysplasia with a complex aberrant karyotype....]]></summary>
        <author>
            <name>Lea Naomi Eder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidermotropic B-Cell Lymphoma: A Case of Secondary Cutaneous Splenic Marginal Zone B-Cell Lymphoma With Autoinvolutive and Recurrent Cutaneous Lesions]]></title>
        <id>pubmed:36669069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36669069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An 84-year-old woman presented with a 3-month history of a papular rash on the trunk, abdomen, and back. Histopathological examination revealed atypical lymphoid deep and band-like dermal infiltrates with marked epidermotropism. Neoplastic cells expressed B-cell markers (CD20), and clonal immunoglobulin gene rearrangement was observed. A complete peripheral blood study revealed aberrant circulating villous lymphocytes with the expression of B-cell markers (CD20, CD22, and CD79a) and aberrant...]]></summary>
        <author>
            <name>Roger Rovira-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230206200034&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidermotropic B-Cell Lymphoma: A Case of Secondary Cutaneous Splenic Marginal Zone B-Cell Lymphoma With Autoinvolutive and Recurrent Cutaneous Lesions]]></title>
        <id>pubmed:36669069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36669069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An 84-year-old woman presented with a 3-month history of a papular rash on the trunk, abdomen, and back. Histopathological examination revealed atypical lymphoid deep and band-like dermal infiltrates with marked epidermotropism. Neoplastic cells expressed B-cell markers (CD20), and clonal immunoglobulin gene rearrangement was observed. A complete peripheral blood study revealed aberrant circulating villous lymphocytes with the expression of B-cell markers (CD20, CD22, and CD79a) and aberrant...]]></summary>
        <author>
            <name>Roger Rovira-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidermotropic B-Cell Lymphoma: A Case of Secondary Cutaneous Splenic Marginal Zone B-Cell Lymphoma With Autoinvolutive and Recurrent Cutaneous Lesions]]></title>
        <id>pubmed:36669069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36669069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An 84-year-old woman presented with a 3-month history of a papular rash on the trunk, abdomen, and back. Histopathological examination revealed atypical lymphoid deep and band-like dermal infiltrates with marked epidermotropism. Neoplastic cells expressed B-cell markers (CD20), and clonal immunoglobulin gene rearrangement was observed. A complete peripheral blood study revealed aberrant circulating villous lymphocytes with the expression of B-cell markers (CD20, CD22, and CD79a) and aberrant...]]></summary>
        <author>
            <name>Roger Rovira-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidermotropic B-Cell Lymphoma: A Case of Secondary Cutaneous Splenic Marginal Zone B-Cell Lymphoma With Autoinvolutive and Recurrent Cutaneous Lesions]]></title>
        <id>pubmed:36669069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36669069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An 84-year-old woman presented with a 3-month history of a papular rash on the trunk, abdomen, and back. Histopathological examination revealed atypical lymphoid deep and band-like dermal infiltrates with marked epidermotropism. Neoplastic cells expressed B-cell markers (CD20), and clonal immunoglobulin gene rearrangement was observed. A complete peripheral blood study revealed aberrant circulating villous lymphocytes with the expression of B-cell markers (CD20, CD22, and CD79a) and aberrant...]]></summary>
        <author>
            <name>Roger Rovira-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidermotropic B-Cell Lymphoma: A Case of Secondary Cutaneous Splenic Marginal Zone B-Cell Lymphoma With Autoinvolutive and Recurrent Cutaneous Lesions]]></title>
        <id>pubmed:36669069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36669069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An 84-year-old woman presented with a 3-month history of a papular rash on the trunk, abdomen, and back. Histopathological examination revealed atypical lymphoid deep and band-like dermal infiltrates with marked epidermotropism. Neoplastic cells expressed B-cell markers (CD20), and clonal immunoglobulin gene rearrangement was observed. A complete peripheral blood study revealed aberrant circulating villous lymphocytes with the expression of B-cell markers (CD20, CD22, and CD79a) and aberrant...]]></summary>
        <author>
            <name>Roger Rovira-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidermotropic B-Cell Lymphoma: A Case of Secondary Cutaneous Splenic Marginal Zone B-Cell Lymphoma With Autoinvolutive and Recurrent Cutaneous Lesions]]></title>
        <id>pubmed:36669069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36669069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An 84-year-old woman presented with a 3-month history of a papular rash on the trunk, abdomen, and back. Histopathological examination revealed atypical lymphoid deep and band-like dermal infiltrates with marked epidermotropism. Neoplastic cells expressed B-cell markers (CD20), and clonal immunoglobulin gene rearrangement was observed. A complete peripheral blood study revealed aberrant circulating villous lymphocytes with the expression of B-cell markers (CD20, CD22, and CD79a) and aberrant...]]></summary>
        <author>
            <name>Roger Rovira-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidermotropic B-Cell Lymphoma: A Case of Secondary Cutaneous Splenic Marginal Zone B-Cell Lymphoma With Autoinvolutive and Recurrent Cutaneous Lesions]]></title>
        <id>pubmed:36669069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36669069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An 84-year-old woman presented with a 3-month history of a papular rash on the trunk, abdomen, and back. Histopathological examination revealed atypical lymphoid deep and band-like dermal infiltrates with marked epidermotropism. Neoplastic cells expressed B-cell markers (CD20), and clonal immunoglobulin gene rearrangement was observed. A complete peripheral blood study revealed aberrant circulating villous lymphocytes with the expression of B-cell markers (CD20, CD22, and CD79a) and aberrant...]]></summary>
        <author>
            <name>Roger Rovira-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidermotropic B-Cell Lymphoma: A Case of Secondary Cutaneous Splenic Marginal Zone B-Cell Lymphoma With Autoinvolutive and Recurrent Cutaneous Lesions]]></title>
        <id>pubmed:36669069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36669069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An 84-year-old woman presented with a 3-month history of a papular rash on the trunk, abdomen, and back. Histopathological examination revealed atypical lymphoid deep and band-like dermal infiltrates with marked epidermotropism. Neoplastic cells expressed B-cell markers (CD20), and clonal immunoglobulin gene rearrangement was observed. A complete peripheral blood study revealed aberrant circulating villous lymphocytes with the expression of B-cell markers (CD20, CD22, and CD79a) and aberrant...]]></summary>
        <author>
            <name>Roger Rovira-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidermotropic B-Cell Lymphoma: A Case of Secondary Cutaneous Splenic Marginal Zone B-Cell Lymphoma With Autoinvolutive and Recurrent Cutaneous Lesions]]></title>
        <id>pubmed:36669069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36669069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An 84-year-old woman presented with a 3-month history of a papular rash on the trunk, abdomen, and back. Histopathological examination revealed atypical lymphoid deep and band-like dermal infiltrates with marked epidermotropism. Neoplastic cells expressed B-cell markers (CD20), and clonal immunoglobulin gene rearrangement was observed. A complete peripheral blood study revealed aberrant circulating villous lymphocytes with the expression of B-cell markers (CD20, CD22, and CD79a) and aberrant...]]></summary>
        <author>
            <name>Roger Rovira-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidermotropic B-Cell Lymphoma: A Case of Secondary Cutaneous Splenic Marginal Zone B-Cell Lymphoma With Autoinvolutive and Recurrent Cutaneous Lesions]]></title>
        <id>pubmed:36669069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36669069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An 84-year-old woman presented with a 3-month history of a papular rash on the trunk, abdomen, and back. Histopathological examination revealed atypical lymphoid deep and band-like dermal infiltrates with marked epidermotropism. Neoplastic cells expressed B-cell markers (CD20), and clonal immunoglobulin gene rearrangement was observed. A complete peripheral blood study revealed aberrant circulating villous lymphocytes with the expression of B-cell markers (CD20, CD22, and CD79a) and aberrant...]]></summary>
        <author>
            <name>Roger Rovira-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidermotropic B-Cell Lymphoma: A Case of Secondary Cutaneous Splenic Marginal Zone B-Cell Lymphoma With Autoinvolutive and Recurrent Cutaneous Lesions]]></title>
        <id>pubmed:36669069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36669069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An 84-year-old woman presented with a 3-month history of a papular rash on the trunk, abdomen, and back. Histopathological examination revealed atypical lymphoid deep and band-like dermal infiltrates with marked epidermotropism. Neoplastic cells expressed B-cell markers (CD20), and clonal immunoglobulin gene rearrangement was observed. A complete peripheral blood study revealed aberrant circulating villous lymphocytes with the expression of B-cell markers (CD20, CD22, and CD79a) and aberrant...]]></summary>
        <author>
            <name>Roger Rovira-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis: causes and clinical implications]]></title>
        <id>pubmed:36662242</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36662242/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of...]]></summary>
        <author>
            <name>Andreas Burchert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidermotropic B-Cell Lymphoma: A Case of Secondary Cutaneous Splenic Marginal Zone B-Cell Lymphoma With Autoinvolutive and Recurrent Cutaneous Lesions]]></title>
        <id>pubmed:36669069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36669069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An 84-year-old woman presented with a 3-month history of a papular rash on the trunk, abdomen, and back. Histopathological examination revealed atypical lymphoid deep and band-like dermal infiltrates with marked epidermotropism. Neoplastic cells expressed B-cell markers (CD20), and clonal immunoglobulin gene rearrangement was observed. A complete peripheral blood study revealed aberrant circulating villous lymphocytes with the expression of B-cell markers (CD20, CD22, and CD79a) and aberrant...]]></summary>
        <author>
            <name>Roger Rovira-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidermotropic B-Cell Lymphoma: A Case of Secondary Cutaneous Splenic Marginal Zone B-Cell Lymphoma With Autoinvolutive and Recurrent Cutaneous Lesions]]></title>
        <id>pubmed:36669069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36669069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An 84-year-old woman presented with a 3-month history of a papular rash on the trunk, abdomen, and back. Histopathological examination revealed atypical lymphoid deep and band-like dermal infiltrates with marked epidermotropism. Neoplastic cells expressed B-cell markers (CD20), and clonal immunoglobulin gene rearrangement was observed. A complete peripheral blood study revealed aberrant circulating villous lymphocytes with the expression of B-cell markers (CD20, CD22, and CD79a) and aberrant...]]></summary>
        <author>
            <name>Roger Rovira-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidermotropic B-Cell Lymphoma: A Case of Secondary Cutaneous Splenic Marginal Zone B-Cell Lymphoma With Autoinvolutive and Recurrent Cutaneous Lesions]]></title>
        <id>pubmed:36669069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36669069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An 84-year-old woman presented with a 3-month history of a papular rash on the trunk, abdomen, and back. Histopathological examination revealed atypical lymphoid deep and band-like dermal infiltrates with marked epidermotropism. Neoplastic cells expressed B-cell markers (CD20), and clonal immunoglobulin gene rearrangement was observed. A complete peripheral blood study revealed aberrant circulating villous lymphocytes with the expression of B-cell markers (CD20, CD22, and CD79a) and aberrant...]]></summary>
        <author>
            <name>Roger Rovira-Lpez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow inflammatory memory in cardiometabolic disease and inflammatory comorbidities]]></title>
        <id>pubmed:36655373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36655373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiometabolic disorders are chief causes of morbidity and mortality, with chronic inflammation playing a crucial role in their pathogenesis. The release of differentiated myeloid cells with elevated pro-inflammatory potential, as a result of maladaptively trained myelopoiesis may be a crucial factor for the perpetuation of inflammation. Several cardiovascular risk factors, including sedentary lifestyle, unhealthy diet, hypercholesterolemia and hyperglycemia, may modulate bone marrow...]]></summary>
        <author>
            <name>Ioannis Mitroulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow inflammatory memory in cardiometabolic disease and inflammatory comorbidities]]></title>
        <id>pubmed:36655373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36655373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiometabolic disorders are chief causes of morbidity and mortality, with chronic inflammation playing a crucial role in their pathogenesis. The release of differentiated myeloid cells with elevated pro-inflammatory potential, as a result of maladaptively trained myelopoiesis may be a crucial factor for the perpetuation of inflammation. Several cardiovascular risk factors, including sedentary lifestyle, unhealthy diet, hypercholesterolemia and hyperglycemia, may modulate bone marrow...]]></summary>
        <author>
            <name>Ioannis Mitroulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow inflammatory memory in cardiometabolic disease and inflammatory comorbidities]]></title>
        <id>pubmed:36655373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36655373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiometabolic disorders are chief causes of morbidity and mortality, with chronic inflammation playing a crucial role in their pathogenesis. The release of differentiated myeloid cells with elevated pro-inflammatory potential, as a result of maladaptively trained myelopoiesis may be a crucial factor for the perpetuation of inflammation. Several cardiovascular risk factors, including sedentary lifestyle, unhealthy diet, hypercholesterolemia and hyperglycemia, may modulate bone marrow...]]></summary>
        <author>
            <name>Ioannis Mitroulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow inflammatory memory in cardiometabolic disease and inflammatory comorbidities]]></title>
        <id>pubmed:36655373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36655373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiometabolic disorders are chief causes of morbidity and mortality, with chronic inflammation playing a crucial role in their pathogenesis. The release of differentiated myeloid cells with elevated pro-inflammatory potential, as a result of maladaptively trained myelopoiesis may be a crucial factor for the perpetuation of inflammation. Several cardiovascular risk factors, including sedentary lifestyle, unhealthy diet, hypercholesterolemia and hyperglycemia, may modulate bone marrow...]]></summary>
        <author>
            <name>Ioannis Mitroulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow inflammatory memory in cardiometabolic disease and inflammatory comorbidities]]></title>
        <id>pubmed:36655373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36655373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiometabolic disorders are chief causes of morbidity and mortality, with chronic inflammation playing a crucial role in their pathogenesis. The release of differentiated myeloid cells with elevated pro-inflammatory potential, as a result of maladaptively trained myelopoiesis may be a crucial factor for the perpetuation of inflammation. Several cardiovascular risk factors, including sedentary lifestyle, unhealthy diet, hypercholesterolemia and hyperglycemia, may modulate bone marrow...]]></summary>
        <author>
            <name>Ioannis Mitroulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow inflammatory memory in cardiometabolic disease and inflammatory comorbidities]]></title>
        <id>pubmed:36655373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36655373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiometabolic disorders are chief causes of morbidity and mortality, with chronic inflammation playing a crucial role in their pathogenesis. The release of differentiated myeloid cells with elevated pro-inflammatory potential, as a result of maladaptively trained myelopoiesis may be a crucial factor for the perpetuation of inflammation. Several cardiovascular risk factors, including sedentary lifestyle, unhealthy diet, hypercholesterolemia and hyperglycemia, may modulate bone marrow...]]></summary>
        <author>
            <name>Ioannis Mitroulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow inflammatory memory in cardiometabolic disease and inflammatory comorbidities]]></title>
        <id>pubmed:36655373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36655373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiometabolic disorders are chief causes of morbidity and mortality, with chronic inflammation playing a crucial role in their pathogenesis. The release of differentiated myeloid cells with elevated pro-inflammatory potential, as a result of maladaptively trained myelopoiesis may be a crucial factor for the perpetuation of inflammation. Several cardiovascular risk factors, including sedentary lifestyle, unhealthy diet, hypercholesterolemia and hyperglycemia, may modulate bone marrow...]]></summary>
        <author>
            <name>Ioannis Mitroulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow inflammatory memory in cardiometabolic disease and inflammatory comorbidities]]></title>
        <id>pubmed:36655373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36655373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiometabolic disorders are chief causes of morbidity and mortality, with chronic inflammation playing a crucial role in their pathogenesis. The release of differentiated myeloid cells with elevated pro-inflammatory potential, as a result of maladaptively trained myelopoiesis may be a crucial factor for the perpetuation of inflammation. Several cardiovascular risk factors, including sedentary lifestyle, unhealthy diet, hypercholesterolemia and hyperglycemia, may modulate bone marrow...]]></summary>
        <author>
            <name>Ioannis Mitroulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow inflammatory memory in cardiometabolic disease and inflammatory comorbidities]]></title>
        <id>pubmed:36655373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36655373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiometabolic disorders are chief causes of morbidity and mortality, with chronic inflammation playing a crucial role in their pathogenesis. The release of differentiated myeloid cells with elevated pro-inflammatory potential, as a result of maladaptively trained myelopoiesis may be a crucial factor for the perpetuation of inflammation. Several cardiovascular risk factors, including sedentary lifestyle, unhealthy diet, hypercholesterolemia and hyperglycemia, may modulate bone marrow...]]></summary>
        <author>
            <name>Ioannis Mitroulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow inflammatory memory in cardiometabolic disease and inflammatory comorbidities]]></title>
        <id>pubmed:36655373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36655373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiometabolic disorders are chief causes of morbidity and mortality, with chronic inflammation playing a crucial role in their pathogenesis. The release of differentiated myeloid cells with elevated pro-inflammatory potential, as a result of maladaptively trained myelopoiesis may be a crucial factor for the perpetuation of inflammation. Several cardiovascular risk factors, including sedentary lifestyle, unhealthy diet, hypercholesterolemia and hyperglycemia, may modulate bone marrow...]]></summary>
        <author>
            <name>Ioannis Mitroulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow inflammatory memory in cardiometabolic disease and inflammatory comorbidities]]></title>
        <id>pubmed:36655373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36655373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiometabolic disorders are chief causes of morbidity and mortality, with chronic inflammation playing a crucial role in their pathogenesis. The release of differentiated myeloid cells with elevated pro-inflammatory potential, as a result of maladaptively trained myelopoiesis may be a crucial factor for the perpetuation of inflammation. Several cardiovascular risk factors, including sedentary lifestyle, unhealthy diet, hypercholesterolemia and hyperglycemia, may modulate bone marrow...]]></summary>
        <author>
            <name>Ioannis Mitroulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow inflammatory memory in cardiometabolic disease and inflammatory comorbidities]]></title>
        <id>pubmed:36655373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36655373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiometabolic disorders are chief causes of morbidity and mortality, with chronic inflammation playing a crucial role in their pathogenesis. The release of differentiated myeloid cells with elevated pro-inflammatory potential, as a result of maladaptively trained myelopoiesis may be a crucial factor for the perpetuation of inflammation. Several cardiovascular risk factors, including sedentary lifestyle, unhealthy diet, hypercholesterolemia and hyperglycemia, may modulate bone marrow...]]></summary>
        <author>
            <name>Ioannis Mitroulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow inflammatory memory in cardiometabolic disease and inflammatory comorbidities]]></title>
        <id>pubmed:36655373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36655373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiometabolic disorders are chief causes of morbidity and mortality, with chronic inflammation playing a crucial role in their pathogenesis. The release of differentiated myeloid cells with elevated pro-inflammatory potential, as a result of maladaptively trained myelopoiesis may be a crucial factor for the perpetuation of inflammation. Several cardiovascular risk factors, including sedentary lifestyle, unhealthy diet, hypercholesterolemia and hyperglycemia, may modulate bone marrow...]]></summary>
        <author>
            <name>Ioannis Mitroulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow inflammatory memory in cardiometabolic disease and inflammatory comorbidities]]></title>
        <id>pubmed:36655373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36655373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiometabolic disorders are chief causes of morbidity and mortality, with chronic inflammation playing a crucial role in their pathogenesis. The release of differentiated myeloid cells with elevated pro-inflammatory potential, as a result of maladaptively trained myelopoiesis may be a crucial factor for the perpetuation of inflammation. Several cardiovascular risk factors, including sedentary lifestyle, unhealthy diet, hypercholesterolemia and hyperglycemia, may modulate bone marrow...]]></summary>
        <author>
            <name>Ioannis Mitroulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow inflammatory memory in cardiometabolic disease and inflammatory comorbidities]]></title>
        <id>pubmed:36655373</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36655373/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiometabolic disorders are chief causes of morbidity and mortality, with chronic inflammation playing a crucial role in their pathogenesis. The release of differentiated myeloid cells with elevated pro-inflammatory potential, as a result of maladaptively trained myelopoiesis may be a crucial factor for the perpetuation of inflammation. Several cardiovascular risk factors, including sedentary lifestyle, unhealthy diet, hypercholesterolemia and hyperglycemia, may modulate bone marrow...]]></summary>
        <author>
            <name>Ioannis Mitroulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy]]></title>
        <id>pubmed:36657818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36657818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230205195945&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden and provide unique insights into the evolving molecular landscape of cancers under the selective pressure of immunotherapy. Tracking the landscape of genomic alterations detected in ctDNA may reveal the clonal architecture of the metastatic cascade and thus improve our understanding of the molecular wiring of therapeutic responses. While liquid biopsies may provide a rapid and accurate evaluation of tumor...]]></summary>
        <author>
            <name>Lavanya Sivapalan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy]]></title>
        <id>pubmed:36657818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36657818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden and provide unique insights into the evolving molecular landscape of cancers under the selective pressure of immunotherapy. Tracking the landscape of genomic alterations detected in ctDNA may reveal the clonal architecture of the metastatic cascade and thus improve our understanding of the molecular wiring of therapeutic responses. While liquid biopsies may provide a rapid and accurate evaluation of tumor...]]></summary>
        <author>
            <name>Lavanya Sivapalan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proliferative advantage of specific aneuploid cells drives evolution of tumor karyotypes]]></title>
        <id>pubmed:36654508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36654508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230204200547&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most tumors have abnormal karyotypes, which arise from mistakes during mitotic division of healthy euploid cells and evolve through numerous complex mechanisms. In a recent mouse model with increased chromosome missegregation, chromosome gains dominate over losses both in pretumor and tumor tissues, whereas T-cell lymphomas are characterized by gains of chromosomes 14 and 15. However, the quantitative understanding of clonal selection leading to tumor karyotype evolution remains unknown. Here we...]]></summary>
        <author>
            <name>Ivana Ban</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy]]></title>
        <id>pubmed:36657818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36657818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden and provide unique insights into the evolving molecular landscape of cancers under the selective pressure of immunotherapy. Tracking the landscape of genomic alterations detected in ctDNA may reveal the clonal architecture of the metastatic cascade and thus improve our understanding of the molecular wiring of therapeutic responses. While liquid biopsies may provide a rapid and accurate evaluation of tumor...]]></summary>
        <author>
            <name>Lavanya Sivapalan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proliferative advantage of specific aneuploid cells drives evolution of tumor karyotypes]]></title>
        <id>pubmed:36654508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36654508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230203195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most tumors have abnormal karyotypes, which arise from mistakes during mitotic division of healthy euploid cells and evolve through numerous complex mechanisms. In a recent mouse model with increased chromosome missegregation, chromosome gains dominate over losses both in pretumor and tumor tissues, whereas T-cell lymphomas are characterized by gains of chromosomes 14 and 15. However, the quantitative understanding of clonal selection leading to tumor karyotype evolution remains unknown. Here we...]]></summary>
        <author>
            <name>Ivana Ban</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy]]></title>
        <id>pubmed:36657818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36657818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden and provide unique insights into the evolving molecular landscape of cancers under the selective pressure of immunotherapy. Tracking the landscape of genomic alterations detected in ctDNA may reveal the clonal architecture of the metastatic cascade and thus improve our understanding of the molecular wiring of therapeutic responses. While liquid biopsies may provide a rapid and accurate evaluation of tumor...]]></summary>
        <author>
            <name>Lavanya Sivapalan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proliferative advantage of specific aneuploid cells drives evolution of tumor karyotypes]]></title>
        <id>pubmed:36654508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36654508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most tumors have abnormal karyotypes, which arise from mistakes during mitotic division of healthy euploid cells and evolve through numerous complex mechanisms. In a recent mouse model with increased chromosome missegregation, chromosome gains dominate over losses both in pretumor and tumor tissues, whereas T-cell lymphomas are characterized by gains of chromosomes 14 and 15. However, the quantitative understanding of clonal selection leading to tumor karyotype evolution remains unknown. Here we...]]></summary>
        <author>
            <name>Ivana Ban</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy]]></title>
        <id>pubmed:36657818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36657818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden and provide unique insights into the evolving molecular landscape of cancers under the selective pressure of immunotherapy. Tracking the landscape of genomic alterations detected in ctDNA may reveal the clonal architecture of the metastatic cascade and thus improve our understanding of the molecular wiring of therapeutic responses. While liquid biopsies may provide a rapid and accurate evaluation of tumor...]]></summary>
        <author>
            <name>Lavanya Sivapalan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proliferative advantage of specific aneuploid cells drives evolution of tumor karyotypes]]></title>
        <id>pubmed:36654508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36654508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most tumors have abnormal karyotypes, which arise from mistakes during mitotic division of healthy euploid cells and evolve through numerous complex mechanisms. In a recent mouse model with increased chromosome missegregation, chromosome gains dominate over losses both in pretumor and tumor tissues, whereas T-cell lymphomas are characterized by gains of chromosomes 14 and 15. However, the quantitative understanding of clonal selection leading to tumor karyotype evolution remains unknown. Here we...]]></summary>
        <author>
            <name>Ivana Ban</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy]]></title>
        <id>pubmed:36657818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36657818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden and provide unique insights into the evolving molecular landscape of cancers under the selective pressure of immunotherapy. Tracking the landscape of genomic alterations detected in ctDNA may reveal the clonal architecture of the metastatic cascade and thus improve our understanding of the molecular wiring of therapeutic responses. While liquid biopsies may provide a rapid and accurate evaluation of tumor...]]></summary>
        <author>
            <name>Lavanya Sivapalan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proliferative advantage of specific aneuploid cells drives evolution of tumor karyotypes]]></title>
        <id>pubmed:36654508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36654508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most tumors have abnormal karyotypes, which arise from mistakes during mitotic division of healthy euploid cells and evolve through numerous complex mechanisms. In a recent mouse model with increased chromosome missegregation, chromosome gains dominate over losses both in pretumor and tumor tissues, whereas T-cell lymphomas are characterized by gains of chromosomes 14 and 15. However, the quantitative understanding of clonal selection leading to tumor karyotype evolution remains unknown. Here we...]]></summary>
        <author>
            <name>Ivana Ban</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy]]></title>
        <id>pubmed:36657818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36657818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden and provide unique insights into the evolving molecular landscape of cancers under the selective pressure of immunotherapy. Tracking the landscape of genomic alterations detected in ctDNA may reveal the clonal architecture of the metastatic cascade and thus improve our understanding of the molecular wiring of therapeutic responses. While liquid biopsies may provide a rapid and accurate evaluation of tumor...]]></summary>
        <author>
            <name>Lavanya Sivapalan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proliferative advantage of specific aneuploid cells drives evolution of tumor karyotypes]]></title>
        <id>pubmed:36654508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36654508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most tumors have abnormal karyotypes, which arise from mistakes during mitotic division of healthy euploid cells and evolve through numerous complex mechanisms. In a recent mouse model with increased chromosome missegregation, chromosome gains dominate over losses both in pretumor and tumor tissues, whereas T-cell lymphomas are characterized by gains of chromosomes 14 and 15. However, the quantitative understanding of clonal selection leading to tumor karyotype evolution remains unknown. Here we...]]></summary>
        <author>
            <name>Ivana Ban</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy]]></title>
        <id>pubmed:36657818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36657818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden and provide unique insights into the evolving molecular landscape of cancers under the selective pressure of immunotherapy. Tracking the landscape of genomic alterations detected in ctDNA may reveal the clonal architecture of the metastatic cascade and thus improve our understanding of the molecular wiring of therapeutic responses. While liquid biopsies may provide a rapid and accurate evaluation of tumor...]]></summary>
        <author>
            <name>Lavanya Sivapalan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proliferative advantage of specific aneuploid cells drives evolution of tumor karyotypes]]></title>
        <id>pubmed:36654508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36654508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most tumors have abnormal karyotypes, which arise from mistakes during mitotic division of healthy euploid cells and evolve through numerous complex mechanisms. In a recent mouse model with increased chromosome missegregation, chromosome gains dominate over losses both in pretumor and tumor tissues, whereas T-cell lymphomas are characterized by gains of chromosomes 14 and 15. However, the quantitative understanding of clonal selection leading to tumor karyotype evolution remains unknown. Here we...]]></summary>
        <author>
            <name>Ivana Ban</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy]]></title>
        <id>pubmed:36657818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36657818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden and provide unique insights into the evolving molecular landscape of cancers under the selective pressure of immunotherapy. Tracking the landscape of genomic alterations detected in ctDNA may reveal the clonal architecture of the metastatic cascade and thus improve our understanding of the molecular wiring of therapeutic responses. While liquid biopsies may provide a rapid and accurate evaluation of tumor...]]></summary>
        <author>
            <name>Lavanya Sivapalan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proliferative advantage of specific aneuploid cells drives evolution of tumor karyotypes]]></title>
        <id>pubmed:36654508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36654508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most tumors have abnormal karyotypes, which arise from mistakes during mitotic division of healthy euploid cells and evolve through numerous complex mechanisms. In a recent mouse model with increased chromosome missegregation, chromosome gains dominate over losses both in pretumor and tumor tissues, whereas T-cell lymphomas are characterized by gains of chromosomes 14 and 15. However, the quantitative understanding of clonal selection leading to tumor karyotype evolution remains unknown. Here we...]]></summary>
        <author>
            <name>Ivana Ban</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy]]></title>
        <id>pubmed:36657818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36657818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden and provide unique insights into the evolving molecular landscape of cancers under the selective pressure of immunotherapy. Tracking the landscape of genomic alterations detected in ctDNA may reveal the clonal architecture of the metastatic cascade and thus improve our understanding of the molecular wiring of therapeutic responses. While liquid biopsies may provide a rapid and accurate evaluation of tumor...]]></summary>
        <author>
            <name>Lavanya Sivapalan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proliferative advantage of specific aneuploid cells drives evolution of tumor karyotypes]]></title>
        <id>pubmed:36654508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36654508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most tumors have abnormal karyotypes, which arise from mistakes during mitotic division of healthy euploid cells and evolve through numerous complex mechanisms. In a recent mouse model with increased chromosome missegregation, chromosome gains dominate over losses both in pretumor and tumor tissues, whereas T-cell lymphomas are characterized by gains of chromosomes 14 and 15. However, the quantitative understanding of clonal selection leading to tumor karyotype evolution remains unknown. Here we...]]></summary>
        <author>
            <name>Ivana Ban</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy]]></title>
        <id>pubmed:36657818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36657818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden and provide unique insights into the evolving molecular landscape of cancers under the selective pressure of immunotherapy. Tracking the landscape of genomic alterations detected in ctDNA may reveal the clonal architecture of the metastatic cascade and thus improve our understanding of the molecular wiring of therapeutic responses. While liquid biopsies may provide a rapid and accurate evaluation of tumor...]]></summary>
        <author>
            <name>Lavanya Sivapalan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proliferative advantage of specific aneuploid cells drives evolution of tumor karyotypes]]></title>
        <id>pubmed:36654508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36654508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most tumors have abnormal karyotypes, which arise from mistakes during mitotic division of healthy euploid cells and evolve through numerous complex mechanisms. In a recent mouse model with increased chromosome missegregation, chromosome gains dominate over losses both in pretumor and tumor tissues, whereas T-cell lymphomas are characterized by gains of chromosomes 14 and 15. However, the quantitative understanding of clonal selection leading to tumor karyotype evolution remains unknown. Here we...]]></summary>
        <author>
            <name>Ivana Ban</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy]]></title>
        <id>pubmed:36657818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36657818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden and provide unique insights into the evolving molecular landscape of cancers under the selective pressure of immunotherapy. Tracking the landscape of genomic alterations detected in ctDNA may reveal the clonal architecture of the metastatic cascade and thus improve our understanding of the molecular wiring of therapeutic responses. While liquid biopsies may provide a rapid and accurate evaluation of tumor...]]></summary>
        <author>
            <name>Lavanya Sivapalan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proliferative advantage of specific aneuploid cells drives evolution of tumor karyotypes]]></title>
        <id>pubmed:36654508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36654508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most tumors have abnormal karyotypes, which arise from mistakes during mitotic division of healthy euploid cells and evolve through numerous complex mechanisms. In a recent mouse model with increased chromosome missegregation, chromosome gains dominate over losses both in pretumor and tumor tissues, whereas T-cell lymphomas are characterized by gains of chromosomes 14 and 15. However, the quantitative understanding of clonal selection leading to tumor karyotype evolution remains unknown. Here we...]]></summary>
        <author>
            <name>Ivana Ban</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy]]></title>
        <id>pubmed:36657818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36657818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden and provide unique insights into the evolving molecular landscape of cancers under the selective pressure of immunotherapy. Tracking the landscape of genomic alterations detected in ctDNA may reveal the clonal architecture of the metastatic cascade and thus improve our understanding of the molecular wiring of therapeutic responses. While liquid biopsies may provide a rapid and accurate evaluation of tumor...]]></summary>
        <author>
            <name>Lavanya Sivapalan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proliferative advantage of specific aneuploid cells drives evolution of tumor karyotypes]]></title>
        <id>pubmed:36654508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36654508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most tumors have abnormal karyotypes, which arise from mistakes during mitotic division of healthy euploid cells and evolve through numerous complex mechanisms. In a recent mouse model with increased chromosome missegregation, chromosome gains dominate over losses both in pretumor and tumor tissues, whereas T-cell lymphomas are characterized by gains of chromosomes 14 and 15. However, the quantitative understanding of clonal selection leading to tumor karyotype evolution remains unknown. Here we...]]></summary>
        <author>
            <name>Ivana Ban</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy]]></title>
        <id>pubmed:36657818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36657818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden and provide unique insights into the evolving molecular landscape of cancers under the selective pressure of immunotherapy. Tracking the landscape of genomic alterations detected in ctDNA may reveal the clonal architecture of the metastatic cascade and thus improve our understanding of the molecular wiring of therapeutic responses. While liquid biopsies may provide a rapid and accurate evaluation of tumor...]]></summary>
        <author>
            <name>Lavanya Sivapalan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proliferative advantage of specific aneuploid cells drives evolution of tumor karyotypes]]></title>
        <id>pubmed:36654508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36654508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most tumors have abnormal karyotypes, which arise from mistakes during mitotic division of healthy euploid cells and evolve through numerous complex mechanisms. In a recent mouse model with increased chromosome missegregation, chromosome gains dominate over losses both in pretumor and tumor tissues, whereas T-cell lymphomas are characterized by gains of chromosomes 14 and 15. However, the quantitative understanding of clonal selection leading to tumor karyotype evolution remains unknown. Here we...]]></summary>
        <author>
            <name>Ivana Ban</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy]]></title>
        <id>pubmed:36657818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36657818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden and provide unique insights into the evolving molecular landscape of cancers under the selective pressure of immunotherapy. Tracking the landscape of genomic alterations detected in ctDNA may reveal the clonal architecture of the metastatic cascade and thus improve our understanding of the molecular wiring of therapeutic responses. While liquid biopsies may provide a rapid and accurate evaluation of tumor...]]></summary>
        <author>
            <name>Lavanya Sivapalan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proliferative advantage of specific aneuploid cells drives evolution of tumor karyotypes]]></title>
        <id>pubmed:36654508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36654508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most tumors have abnormal karyotypes, which arise from mistakes during mitotic division of healthy euploid cells and evolve through numerous complex mechanisms. In a recent mouse model with increased chromosome missegregation, chromosome gains dominate over losses both in pretumor and tumor tissues, whereas T-cell lymphomas are characterized by gains of chromosomes 14 and 15. However, the quantitative understanding of clonal selection leading to tumor karyotype evolution remains unknown. Here we...]]></summary>
        <author>
            <name>Ivana Ban</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy]]></title>
        <id>pubmed:36657818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36657818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden and provide unique insights into the evolving molecular landscape of cancers under the selective pressure of immunotherapy. Tracking the landscape of genomic alterations detected in ctDNA may reveal the clonal architecture of the metastatic cascade and thus improve our understanding of the molecular wiring of therapeutic responses. While liquid biopsies may provide a rapid and accurate evaluation of tumor...]]></summary>
        <author>
            <name>Lavanya Sivapalan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proliferative advantage of specific aneuploid cells drives evolution of tumor karyotypes]]></title>
        <id>pubmed:36654508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36654508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most tumors have abnormal karyotypes, which arise from mistakes during mitotic division of healthy euploid cells and evolve through numerous complex mechanisms. In a recent mouse model with increased chromosome missegregation, chromosome gains dominate over losses both in pretumor and tumor tissues, whereas T-cell lymphomas are characterized by gains of chromosomes 14 and 15. However, the quantitative understanding of clonal selection leading to tumor karyotype evolution remains unknown. Here we...]]></summary>
        <author>
            <name>Ivana Ban</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy]]></title>
        <id>pubmed:36657818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36657818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden and provide unique insights into the evolving molecular landscape of cancers under the selective pressure of immunotherapy. Tracking the landscape of genomic alterations detected in ctDNA may reveal the clonal architecture of the metastatic cascade and thus improve our understanding of the molecular wiring of therapeutic responses. While liquid biopsies may provide a rapid and accurate evaluation of tumor...]]></summary>
        <author>
            <name>Lavanya Sivapalan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proliferative advantage of specific aneuploid cells drives evolution of tumor karyotypes]]></title>
        <id>pubmed:36654508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36654508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most tumors have abnormal karyotypes, which arise from mistakes during mitotic division of healthy euploid cells and evolve through numerous complex mechanisms. In a recent mouse model with increased chromosome missegregation, chromosome gains dominate over losses both in pretumor and tumor tissues, whereas T-cell lymphomas are characterized by gains of chromosomes 14 and 15. However, the quantitative understanding of clonal selection leading to tumor karyotype evolution remains unknown. Here we...]]></summary>
        <author>
            <name>Ivana Ban</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proliferative advantage of specific aneuploid cells drives evolution of tumor karyotypes]]></title>
        <id>pubmed:36654508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36654508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most tumors have abnormal karyotypes, which arise from mistakes during mitotic division of healthy euploid cells and evolve through numerous complex mechanisms. In a recent mouse model with increased chromosome missegregation, chromosome gains dominate over losses both in pretumor and tumor tissues, whereas T-cell lymphomas are characterized by gains of chromosomes 14 and 15. However, the quantitative understanding of clonal selection leading to tumor karyotype evolution remains unknown. Here we...]]></summary>
        <author>
            <name>Ivana Ban</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic datasets]]></title>
        <id>pubmed:36652671</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36652671/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is a common form of age-related somatic mosaicism that is associated with significant morbidity and mortality. CHIP mutations can be identified in peripheral blood samples sequenced using approaches that cover the whole genome, whole exome or targeted genetic regions; however, differentiating true CHIP mutations from sequencing artifacts and germline variants is a considerable bioinformatic challenge. We present a stepwise method that...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic datasets]]></title>
        <id>pubmed:36652671</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36652671/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is a common form of age-related somatic mosaicism that is associated with significant morbidity and mortality. CHIP mutations can be identified in peripheral blood samples sequenced using approaches that cover the whole genome, whole exome or targeted genetic regions; however, differentiating true CHIP mutations from sequencing artifacts and germline variants is a considerable bioinformatic challenge. We present a stepwise method that...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic datasets]]></title>
        <id>pubmed:36652671</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36652671/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is a common form of age-related somatic mosaicism that is associated with significant morbidity and mortality. CHIP mutations can be identified in peripheral blood samples sequenced using approaches that cover the whole genome, whole exome or targeted genetic regions; however, differentiating true CHIP mutations from sequencing artifacts and germline variants is a considerable bioinformatic challenge. We present a stepwise method that...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic datasets]]></title>
        <id>pubmed:36652671</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36652671/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is a common form of age-related somatic mosaicism that is associated with significant morbidity and mortality. CHIP mutations can be identified in peripheral blood samples sequenced using approaches that cover the whole genome, whole exome or targeted genetic regions; however, differentiating true CHIP mutations from sequencing artifacts and germline variants is a considerable bioinformatic challenge. We present a stepwise method that...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic datasets]]></title>
        <id>pubmed:36652671</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36652671/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is a common form of age-related somatic mosaicism that is associated with significant morbidity and mortality. CHIP mutations can be identified in peripheral blood samples sequenced using approaches that cover the whole genome, whole exome or targeted genetic regions; however, differentiating true CHIP mutations from sequencing artifacts and germline variants is a considerable bioinformatic challenge. We present a stepwise method that...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic datasets]]></title>
        <id>pubmed:36652671</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36652671/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is a common form of age-related somatic mosaicism that is associated with significant morbidity and mortality. CHIP mutations can be identified in peripheral blood samples sequenced using approaches that cover the whole genome, whole exome or targeted genetic regions; however, differentiating true CHIP mutations from sequencing artifacts and germline variants is a considerable bioinformatic challenge. We present a stepwise method that...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic datasets]]></title>
        <id>pubmed:36652671</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36652671/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is a common form of age-related somatic mosaicism that is associated with significant morbidity and mortality. CHIP mutations can be identified in peripheral blood samples sequenced using approaches that cover the whole genome, whole exome or targeted genetic regions; however, differentiating true CHIP mutations from sequencing artifacts and germline variants is a considerable bioinformatic challenge. We present a stepwise method that...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic datasets]]></title>
        <id>pubmed:36652671</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36652671/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is a common form of age-related somatic mosaicism that is associated with significant morbidity and mortality. CHIP mutations can be identified in peripheral blood samples sequenced using approaches that cover the whole genome, whole exome or targeted genetic regions; however, differentiating true CHIP mutations from sequencing artifacts and germline variants is a considerable bioinformatic challenge. We present a stepwise method that...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic datasets]]></title>
        <id>pubmed:36652671</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36652671/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is a common form of age-related somatic mosaicism that is associated with significant morbidity and mortality. CHIP mutations can be identified in peripheral blood samples sequenced using approaches that cover the whole genome, whole exome or targeted genetic regions; however, differentiating true CHIP mutations from sequencing artifacts and germline variants is a considerable bioinformatic challenge. We present a stepwise method that...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic datasets]]></title>
        <id>pubmed:36652671</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36652671/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is a common form of age-related somatic mosaicism that is associated with significant morbidity and mortality. CHIP mutations can be identified in peripheral blood samples sequenced using approaches that cover the whole genome, whole exome or targeted genetic regions; however, differentiating true CHIP mutations from sequencing artifacts and germline variants is a considerable bioinformatic challenge. We present a stepwise method that...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic datasets]]></title>
        <id>pubmed:36652671</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36652671/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is a common form of age-related somatic mosaicism that is associated with significant morbidity and mortality. CHIP mutations can be identified in peripheral blood samples sequenced using approaches that cover the whole genome, whole exome or targeted genetic regions; however, differentiating true CHIP mutations from sequencing artifacts and germline variants is a considerable bioinformatic challenge. We present a stepwise method that...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic datasets]]></title>
        <id>pubmed:36652671</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36652671/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is a common form of age-related somatic mosaicism that is associated with significant morbidity and mortality. CHIP mutations can be identified in peripheral blood samples sequenced using approaches that cover the whole genome, whole exome or targeted genetic regions; however, differentiating true CHIP mutations from sequencing artifacts and germline variants is a considerable bioinformatic challenge. We present a stepwise method that...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic datasets]]></title>
        <id>pubmed:36652671</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36652671/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is a common form of age-related somatic mosaicism that is associated with significant morbidity and mortality. CHIP mutations can be identified in peripheral blood samples sequenced using approaches that cover the whole genome, whole exome or targeted genetic regions; however, differentiating true CHIP mutations from sequencing artifacts and germline variants is a considerable bioinformatic challenge. We present a stepwise method that...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic datasets]]></title>
        <id>pubmed:36652671</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36652671/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is a common form of age-related somatic mosaicism that is associated with significant morbidity and mortality. CHIP mutations can be identified in peripheral blood samples sequenced using approaches that cover the whole genome, whole exome or targeted genetic regions; however, differentiating true CHIP mutations from sequencing artifacts and germline variants is a considerable bioinformatic challenge. We present a stepwise method that...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis]]></title>
        <id>pubmed:36653483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36653483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230202200409&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple primary lung cancer (MPLC) with lymph node metastasis (LNM) is a rare phenomenon of multifocal lung cancer. The genomic landscapes of MPLC and the clonal evolution pattern between primary lung lesions and lymph node metastasis haven't been fully illustrated. We performed whole-exome sequencing (WES) on 52 FFPE (Formalin-fixed Paraffin-Embedded) samples from 11 patients diagnosed with MPLC with LNM. Genomic profiling and phylogenetic analysis were conducted to infer the evolutional...]]></summary>
        <author>
            <name>He Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis]]></title>
        <id>pubmed:36653483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36653483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple primary lung cancer (MPLC) with lymph node metastasis (LNM) is a rare phenomenon of multifocal lung cancer. The genomic landscapes of MPLC and the clonal evolution pattern between primary lung lesions and lymph node metastasis haven't been fully illustrated. We performed whole-exome sequencing (WES) on 52 FFPE (Formalin-fixed Paraffin-Embedded) samples from 11 patients diagnosed with MPLC with LNM. Genomic profiling and phylogenetic analysis were conducted to infer the evolutional...]]></summary>
        <author>
            <name>He Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms]]></title>
        <id>pubmed:36651780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36651780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The management of patients with acute myeloid leukemia (blast phase) secondary to myeloproliferative neoplasms (MPNs) is extremely challenging and the outcome dismal, with a median overall survival of about 3-6 months. Effective therapeutic approaches are lacking, especially when intensive strategies followed by allogeneic transplantation are not feasible. The combination of venetoclax and hypomethylating agents has recently been established as standard for newly diagnosed, unfit patients with...]]></summary>
        <author>
            <name>Francesco Mannelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis]]></title>
        <id>pubmed:36653483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36653483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple primary lung cancer (MPLC) with lymph node metastasis (LNM) is a rare phenomenon of multifocal lung cancer. The genomic landscapes of MPLC and the clonal evolution pattern between primary lung lesions and lymph node metastasis haven't been fully illustrated. We performed whole-exome sequencing (WES) on 52 FFPE (Formalin-fixed Paraffin-Embedded) samples from 11 patients diagnosed with MPLC with LNM. Genomic profiling and phylogenetic analysis were conducted to infer the evolutional...]]></summary>
        <author>
            <name>He Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms]]></title>
        <id>pubmed:36651780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36651780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The management of patients with acute myeloid leukemia (blast phase) secondary to myeloproliferative neoplasms (MPNs) is extremely challenging and the outcome dismal, with a median overall survival of about 3-6 months. Effective therapeutic approaches are lacking, especially when intensive strategies followed by allogeneic transplantation are not feasible. The combination of venetoclax and hypomethylating agents has recently been established as standard for newly diagnosed, unfit patients with...]]></summary>
        <author>
            <name>Francesco Mannelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis]]></title>
        <id>pubmed:36653483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36653483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple primary lung cancer (MPLC) with lymph node metastasis (LNM) is a rare phenomenon of multifocal lung cancer. The genomic landscapes of MPLC and the clonal evolution pattern between primary lung lesions and lymph node metastasis haven't been fully illustrated. We performed whole-exome sequencing (WES) on 52 FFPE (Formalin-fixed Paraffin-Embedded) samples from 11 patients diagnosed with MPLC with LNM. Genomic profiling and phylogenetic analysis were conducted to infer the evolutional...]]></summary>
        <author>
            <name>He Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms]]></title>
        <id>pubmed:36651780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36651780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The management of patients with acute myeloid leukemia (blast phase) secondary to myeloproliferative neoplasms (MPNs) is extremely challenging and the outcome dismal, with a median overall survival of about 3-6 months. Effective therapeutic approaches are lacking, especially when intensive strategies followed by allogeneic transplantation are not feasible. The combination of venetoclax and hypomethylating agents has recently been established as standard for newly diagnosed, unfit patients with...]]></summary>
        <author>
            <name>Francesco Mannelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis]]></title>
        <id>pubmed:36653483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36653483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple primary lung cancer (MPLC) with lymph node metastasis (LNM) is a rare phenomenon of multifocal lung cancer. The genomic landscapes of MPLC and the clonal evolution pattern between primary lung lesions and lymph node metastasis haven't been fully illustrated. We performed whole-exome sequencing (WES) on 52 FFPE (Formalin-fixed Paraffin-Embedded) samples from 11 patients diagnosed with MPLC with LNM. Genomic profiling and phylogenetic analysis were conducted to infer the evolutional...]]></summary>
        <author>
            <name>He Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms]]></title>
        <id>pubmed:36651780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36651780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The management of patients with acute myeloid leukemia (blast phase) secondary to myeloproliferative neoplasms (MPNs) is extremely challenging and the outcome dismal, with a median overall survival of about 3-6 months. Effective therapeutic approaches are lacking, especially when intensive strategies followed by allogeneic transplantation are not feasible. The combination of venetoclax and hypomethylating agents has recently been established as standard for newly diagnosed, unfit patients with...]]></summary>
        <author>
            <name>Francesco Mannelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis]]></title>
        <id>pubmed:36653483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36653483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple primary lung cancer (MPLC) with lymph node metastasis (LNM) is a rare phenomenon of multifocal lung cancer. The genomic landscapes of MPLC and the clonal evolution pattern between primary lung lesions and lymph node metastasis haven't been fully illustrated. We performed whole-exome sequencing (WES) on 52 FFPE (Formalin-fixed Paraffin-Embedded) samples from 11 patients diagnosed with MPLC with LNM. Genomic profiling and phylogenetic analysis were conducted to infer the evolutional...]]></summary>
        <author>
            <name>He Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms]]></title>
        <id>pubmed:36651780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36651780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The management of patients with acute myeloid leukemia (blast phase) secondary to myeloproliferative neoplasms (MPNs) is extremely challenging and the outcome dismal, with a median overall survival of about 3-6 months. Effective therapeutic approaches are lacking, especially when intensive strategies followed by allogeneic transplantation are not feasible. The combination of venetoclax and hypomethylating agents has recently been established as standard for newly diagnosed, unfit patients with...]]></summary>
        <author>
            <name>Francesco Mannelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis]]></title>
        <id>pubmed:36653483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36653483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple primary lung cancer (MPLC) with lymph node metastasis (LNM) is a rare phenomenon of multifocal lung cancer. The genomic landscapes of MPLC and the clonal evolution pattern between primary lung lesions and lymph node metastasis haven't been fully illustrated. We performed whole-exome sequencing (WES) on 52 FFPE (Formalin-fixed Paraffin-Embedded) samples from 11 patients diagnosed with MPLC with LNM. Genomic profiling and phylogenetic analysis were conducted to infer the evolutional...]]></summary>
        <author>
            <name>He Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms]]></title>
        <id>pubmed:36651780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36651780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The management of patients with acute myeloid leukemia (blast phase) secondary to myeloproliferative neoplasms (MPNs) is extremely challenging and the outcome dismal, with a median overall survival of about 3-6 months. Effective therapeutic approaches are lacking, especially when intensive strategies followed by allogeneic transplantation are not feasible. The combination of venetoclax and hypomethylating agents has recently been established as standard for newly diagnosed, unfit patients with...]]></summary>
        <author>
            <name>Francesco Mannelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis]]></title>
        <id>pubmed:36653483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36653483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple primary lung cancer (MPLC) with lymph node metastasis (LNM) is a rare phenomenon of multifocal lung cancer. The genomic landscapes of MPLC and the clonal evolution pattern between primary lung lesions and lymph node metastasis haven't been fully illustrated. We performed whole-exome sequencing (WES) on 52 FFPE (Formalin-fixed Paraffin-Embedded) samples from 11 patients diagnosed with MPLC with LNM. Genomic profiling and phylogenetic analysis were conducted to infer the evolutional...]]></summary>
        <author>
            <name>He Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms]]></title>
        <id>pubmed:36651780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36651780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The management of patients with acute myeloid leukemia (blast phase) secondary to myeloproliferative neoplasms (MPNs) is extremely challenging and the outcome dismal, with a median overall survival of about 3-6 months. Effective therapeutic approaches are lacking, especially when intensive strategies followed by allogeneic transplantation are not feasible. The combination of venetoclax and hypomethylating agents has recently been established as standard for newly diagnosed, unfit patients with...]]></summary>
        <author>
            <name>Francesco Mannelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis]]></title>
        <id>pubmed:36653483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36653483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple primary lung cancer (MPLC) with lymph node metastasis (LNM) is a rare phenomenon of multifocal lung cancer. The genomic landscapes of MPLC and the clonal evolution pattern between primary lung lesions and lymph node metastasis haven't been fully illustrated. We performed whole-exome sequencing (WES) on 52 FFPE (Formalin-fixed Paraffin-Embedded) samples from 11 patients diagnosed with MPLC with LNM. Genomic profiling and phylogenetic analysis were conducted to infer the evolutional...]]></summary>
        <author>
            <name>He Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms]]></title>
        <id>pubmed:36651780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36651780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The management of patients with acute myeloid leukemia (blast phase) secondary to myeloproliferative neoplasms (MPNs) is extremely challenging and the outcome dismal, with a median overall survival of about 3-6 months. Effective therapeutic approaches are lacking, especially when intensive strategies followed by allogeneic transplantation are not feasible. The combination of venetoclax and hypomethylating agents has recently been established as standard for newly diagnosed, unfit patients with...]]></summary>
        <author>
            <name>Francesco Mannelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis]]></title>
        <id>pubmed:36653483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36653483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple primary lung cancer (MPLC) with lymph node metastasis (LNM) is a rare phenomenon of multifocal lung cancer. The genomic landscapes of MPLC and the clonal evolution pattern between primary lung lesions and lymph node metastasis haven't been fully illustrated. We performed whole-exome sequencing (WES) on 52 FFPE (Formalin-fixed Paraffin-Embedded) samples from 11 patients diagnosed with MPLC with LNM. Genomic profiling and phylogenetic analysis were conducted to infer the evolutional...]]></summary>
        <author>
            <name>He Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms]]></title>
        <id>pubmed:36651780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36651780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The management of patients with acute myeloid leukemia (blast phase) secondary to myeloproliferative neoplasms (MPNs) is extremely challenging and the outcome dismal, with a median overall survival of about 3-6 months. Effective therapeutic approaches are lacking, especially when intensive strategies followed by allogeneic transplantation are not feasible. The combination of venetoclax and hypomethylating agents has recently been established as standard for newly diagnosed, unfit patients with...]]></summary>
        <author>
            <name>Francesco Mannelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis]]></title>
        <id>pubmed:36653483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36653483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple primary lung cancer (MPLC) with lymph node metastasis (LNM) is a rare phenomenon of multifocal lung cancer. The genomic landscapes of MPLC and the clonal evolution pattern between primary lung lesions and lymph node metastasis haven't been fully illustrated. We performed whole-exome sequencing (WES) on 52 FFPE (Formalin-fixed Paraffin-Embedded) samples from 11 patients diagnosed with MPLC with LNM. Genomic profiling and phylogenetic analysis were conducted to infer the evolutional...]]></summary>
        <author>
            <name>He Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms]]></title>
        <id>pubmed:36651780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36651780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The management of patients with acute myeloid leukemia (blast phase) secondary to myeloproliferative neoplasms (MPNs) is extremely challenging and the outcome dismal, with a median overall survival of about 3-6 months. Effective therapeutic approaches are lacking, especially when intensive strategies followed by allogeneic transplantation are not feasible. The combination of venetoclax and hypomethylating agents has recently been established as standard for newly diagnosed, unfit patients with...]]></summary>
        <author>
            <name>Francesco Mannelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis]]></title>
        <id>pubmed:36653483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36653483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple primary lung cancer (MPLC) with lymph node metastasis (LNM) is a rare phenomenon of multifocal lung cancer. The genomic landscapes of MPLC and the clonal evolution pattern between primary lung lesions and lymph node metastasis haven't been fully illustrated. We performed whole-exome sequencing (WES) on 52 FFPE (Formalin-fixed Paraffin-Embedded) samples from 11 patients diagnosed with MPLC with LNM. Genomic profiling and phylogenetic analysis were conducted to infer the evolutional...]]></summary>
        <author>
            <name>He Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms]]></title>
        <id>pubmed:36651780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36651780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The management of patients with acute myeloid leukemia (blast phase) secondary to myeloproliferative neoplasms (MPNs) is extremely challenging and the outcome dismal, with a median overall survival of about 3-6 months. Effective therapeutic approaches are lacking, especially when intensive strategies followed by allogeneic transplantation are not feasible. The combination of venetoclax and hypomethylating agents has recently been established as standard for newly diagnosed, unfit patients with...]]></summary>
        <author>
            <name>Francesco Mannelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis]]></title>
        <id>pubmed:36653483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36653483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple primary lung cancer (MPLC) with lymph node metastasis (LNM) is a rare phenomenon of multifocal lung cancer. The genomic landscapes of MPLC and the clonal evolution pattern between primary lung lesions and lymph node metastasis haven't been fully illustrated. We performed whole-exome sequencing (WES) on 52 FFPE (Formalin-fixed Paraffin-Embedded) samples from 11 patients diagnosed with MPLC with LNM. Genomic profiling and phylogenetic analysis were conducted to infer the evolutional...]]></summary>
        <author>
            <name>He Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms]]></title>
        <id>pubmed:36651780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36651780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The management of patients with acute myeloid leukemia (blast phase) secondary to myeloproliferative neoplasms (MPNs) is extremely challenging and the outcome dismal, with a median overall survival of about 3-6 months. Effective therapeutic approaches are lacking, especially when intensive strategies followed by allogeneic transplantation are not feasible. The combination of venetoclax and hypomethylating agents has recently been established as standard for newly diagnosed, unfit patients with...]]></summary>
        <author>
            <name>Francesco Mannelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis]]></title>
        <id>pubmed:36653483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36653483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple primary lung cancer (MPLC) with lymph node metastasis (LNM) is a rare phenomenon of multifocal lung cancer. The genomic landscapes of MPLC and the clonal evolution pattern between primary lung lesions and lymph node metastasis haven't been fully illustrated. We performed whole-exome sequencing (WES) on 52 FFPE (Formalin-fixed Paraffin-Embedded) samples from 11 patients diagnosed with MPLC with LNM. Genomic profiling and phylogenetic analysis were conducted to infer the evolutional...]]></summary>
        <author>
            <name>He Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms]]></title>
        <id>pubmed:36651780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36651780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The management of patients with acute myeloid leukemia (blast phase) secondary to myeloproliferative neoplasms (MPNs) is extremely challenging and the outcome dismal, with a median overall survival of about 3-6 months. Effective therapeutic approaches are lacking, especially when intensive strategies followed by allogeneic transplantation are not feasible. The combination of venetoclax and hypomethylating agents has recently been established as standard for newly diagnosed, unfit patients with...]]></summary>
        <author>
            <name>Francesco Mannelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis]]></title>
        <id>pubmed:36653483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36653483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple primary lung cancer (MPLC) with lymph node metastasis (LNM) is a rare phenomenon of multifocal lung cancer. The genomic landscapes of MPLC and the clonal evolution pattern between primary lung lesions and lymph node metastasis haven't been fully illustrated. We performed whole-exome sequencing (WES) on 52 FFPE (Formalin-fixed Paraffin-Embedded) samples from 11 patients diagnosed with MPLC with LNM. Genomic profiling and phylogenetic analysis were conducted to infer the evolutional...]]></summary>
        <author>
            <name>He Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms]]></title>
        <id>pubmed:36651780</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36651780/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The management of patients with acute myeloid leukemia (blast phase) secondary to myeloproliferative neoplasms (MPNs) is extremely challenging and the outcome dismal, with a median overall survival of about 3-6 months. Effective therapeutic approaches are lacking, especially when intensive strategies followed by allogeneic transplantation are not feasible. The combination of venetoclax and hypomethylating agents has recently been established as standard for newly diagnosed, unfit patients with...]]></summary>
        <author>
            <name>Francesco Mannelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era]]></title>
        <id>pubmed:36649045</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36649045/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the last ten years, liquid biopsy has been slowly joining the traditional invasive techniques for the diagnosis and monitoring of tumors. Liquid biopsies allow easy repeated sampling of blood, reflect the tumor scenario, and make personalized therapy real for the patient. Liquid biopsies isolate and utilize different substrates present in patients' body fluids such as circulating tumor cells, circulating tumor DNA, tumor extracellular vesicles, etc. One of the most-used solid cancers in the...]]></summary>
        <author>
            <name>Maria Palmieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again]]></title>
        <id>pubmed:36648882</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36648882/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is an incurable hematologic malignancy characterized by a multistep evolutionary pathway, with an initial phase called monoclonal gammopathy of undetermined significance (MGUS), potentially evolving into the symptomatic disease, often preceded by an intermediate phase called "smoldering" MM (sMM). From a biological point of view, genomic alterations (translocations/deletions/mutations) are already present at the MGUS phase, thus rendering their role in disease evolution...]]></summary>
        <author>
            <name>Federica Plano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era]]></title>
        <id>pubmed:36649045</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36649045/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the last ten years, liquid biopsy has been slowly joining the traditional invasive techniques for the diagnosis and monitoring of tumors. Liquid biopsies allow easy repeated sampling of blood, reflect the tumor scenario, and make personalized therapy real for the patient. Liquid biopsies isolate and utilize different substrates present in patients' body fluids such as circulating tumor cells, circulating tumor DNA, tumor extracellular vesicles, etc. One of the most-used solid cancers in the...]]></summary>
        <author>
            <name>Maria Palmieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again]]></title>
        <id>pubmed:36648882</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36648882/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is an incurable hematologic malignancy characterized by a multistep evolutionary pathway, with an initial phase called monoclonal gammopathy of undetermined significance (MGUS), potentially evolving into the symptomatic disease, often preceded by an intermediate phase called "smoldering" MM (sMM). From a biological point of view, genomic alterations (translocations/deletions/mutations) are already present at the MGUS phase, thus rendering their role in disease evolution...]]></summary>
        <author>
            <name>Federica Plano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era]]></title>
        <id>pubmed:36649045</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36649045/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the last ten years, liquid biopsy has been slowly joining the traditional invasive techniques for the diagnosis and monitoring of tumors. Liquid biopsies allow easy repeated sampling of blood, reflect the tumor scenario, and make personalized therapy real for the patient. Liquid biopsies isolate and utilize different substrates present in patients' body fluids such as circulating tumor cells, circulating tumor DNA, tumor extracellular vesicles, etc. One of the most-used solid cancers in the...]]></summary>
        <author>
            <name>Maria Palmieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again]]></title>
        <id>pubmed:36648882</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36648882/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is an incurable hematologic malignancy characterized by a multistep evolutionary pathway, with an initial phase called monoclonal gammopathy of undetermined significance (MGUS), potentially evolving into the symptomatic disease, often preceded by an intermediate phase called "smoldering" MM (sMM). From a biological point of view, genomic alterations (translocations/deletions/mutations) are already present at the MGUS phase, thus rendering their role in disease evolution...]]></summary>
        <author>
            <name>Federica Plano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era]]></title>
        <id>pubmed:36649045</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36649045/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the last ten years, liquid biopsy has been slowly joining the traditional invasive techniques for the diagnosis and monitoring of tumors. Liquid biopsies allow easy repeated sampling of blood, reflect the tumor scenario, and make personalized therapy real for the patient. Liquid biopsies isolate and utilize different substrates present in patients' body fluids such as circulating tumor cells, circulating tumor DNA, tumor extracellular vesicles, etc. One of the most-used solid cancers in the...]]></summary>
        <author>
            <name>Maria Palmieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again]]></title>
        <id>pubmed:36648882</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36648882/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is an incurable hematologic malignancy characterized by a multistep evolutionary pathway, with an initial phase called monoclonal gammopathy of undetermined significance (MGUS), potentially evolving into the symptomatic disease, often preceded by an intermediate phase called "smoldering" MM (sMM). From a biological point of view, genomic alterations (translocations/deletions/mutations) are already present at the MGUS phase, thus rendering their role in disease evolution...]]></summary>
        <author>
            <name>Federica Plano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era]]></title>
        <id>pubmed:36649045</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36649045/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the last ten years, liquid biopsy has been slowly joining the traditional invasive techniques for the diagnosis and monitoring of tumors. Liquid biopsies allow easy repeated sampling of blood, reflect the tumor scenario, and make personalized therapy real for the patient. Liquid biopsies isolate and utilize different substrates present in patients' body fluids such as circulating tumor cells, circulating tumor DNA, tumor extracellular vesicles, etc. One of the most-used solid cancers in the...]]></summary>
        <author>
            <name>Maria Palmieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again]]></title>
        <id>pubmed:36648882</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36648882/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is an incurable hematologic malignancy characterized by a multistep evolutionary pathway, with an initial phase called monoclonal gammopathy of undetermined significance (MGUS), potentially evolving into the symptomatic disease, often preceded by an intermediate phase called "smoldering" MM (sMM). From a biological point of view, genomic alterations (translocations/deletions/mutations) are already present at the MGUS phase, thus rendering their role in disease evolution...]]></summary>
        <author>
            <name>Federica Plano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era]]></title>
        <id>pubmed:36649045</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36649045/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the last ten years, liquid biopsy has been slowly joining the traditional invasive techniques for the diagnosis and monitoring of tumors. Liquid biopsies allow easy repeated sampling of blood, reflect the tumor scenario, and make personalized therapy real for the patient. Liquid biopsies isolate and utilize different substrates present in patients' body fluids such as circulating tumor cells, circulating tumor DNA, tumor extracellular vesicles, etc. One of the most-used solid cancers in the...]]></summary>
        <author>
            <name>Maria Palmieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again]]></title>
        <id>pubmed:36648882</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36648882/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is an incurable hematologic malignancy characterized by a multistep evolutionary pathway, with an initial phase called monoclonal gammopathy of undetermined significance (MGUS), potentially evolving into the symptomatic disease, often preceded by an intermediate phase called "smoldering" MM (sMM). From a biological point of view, genomic alterations (translocations/deletions/mutations) are already present at the MGUS phase, thus rendering their role in disease evolution...]]></summary>
        <author>
            <name>Federica Plano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era]]></title>
        <id>pubmed:36649045</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36649045/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the last ten years, liquid biopsy has been slowly joining the traditional invasive techniques for the diagnosis and monitoring of tumors. Liquid biopsies allow easy repeated sampling of blood, reflect the tumor scenario, and make personalized therapy real for the patient. Liquid biopsies isolate and utilize different substrates present in patients' body fluids such as circulating tumor cells, circulating tumor DNA, tumor extracellular vesicles, etc. One of the most-used solid cancers in the...]]></summary>
        <author>
            <name>Maria Palmieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again]]></title>
        <id>pubmed:36648882</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36648882/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is an incurable hematologic malignancy characterized by a multistep evolutionary pathway, with an initial phase called monoclonal gammopathy of undetermined significance (MGUS), potentially evolving into the symptomatic disease, often preceded by an intermediate phase called "smoldering" MM (sMM). From a biological point of view, genomic alterations (translocations/deletions/mutations) are already present at the MGUS phase, thus rendering their role in disease evolution...]]></summary>
        <author>
            <name>Federica Plano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era]]></title>
        <id>pubmed:36649045</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36649045/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the last ten years, liquid biopsy has been slowly joining the traditional invasive techniques for the diagnosis and monitoring of tumors. Liquid biopsies allow easy repeated sampling of blood, reflect the tumor scenario, and make personalized therapy real for the patient. Liquid biopsies isolate and utilize different substrates present in patients' body fluids such as circulating tumor cells, circulating tumor DNA, tumor extracellular vesicles, etc. One of the most-used solid cancers in the...]]></summary>
        <author>
            <name>Maria Palmieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again]]></title>
        <id>pubmed:36648882</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36648882/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is an incurable hematologic malignancy characterized by a multistep evolutionary pathway, with an initial phase called monoclonal gammopathy of undetermined significance (MGUS), potentially evolving into the symptomatic disease, often preceded by an intermediate phase called "smoldering" MM (sMM). From a biological point of view, genomic alterations (translocations/deletions/mutations) are already present at the MGUS phase, thus rendering their role in disease evolution...]]></summary>
        <author>
            <name>Federica Plano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era]]></title>
        <id>pubmed:36649045</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36649045/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the last ten years, liquid biopsy has been slowly joining the traditional invasive techniques for the diagnosis and monitoring of tumors. Liquid biopsies allow easy repeated sampling of blood, reflect the tumor scenario, and make personalized therapy real for the patient. Liquid biopsies isolate and utilize different substrates present in patients' body fluids such as circulating tumor cells, circulating tumor DNA, tumor extracellular vesicles, etc. One of the most-used solid cancers in the...]]></summary>
        <author>
            <name>Maria Palmieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again]]></title>
        <id>pubmed:36648882</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36648882/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is an incurable hematologic malignancy characterized by a multistep evolutionary pathway, with an initial phase called monoclonal gammopathy of undetermined significance (MGUS), potentially evolving into the symptomatic disease, often preceded by an intermediate phase called "smoldering" MM (sMM). From a biological point of view, genomic alterations (translocations/deletions/mutations) are already present at the MGUS phase, thus rendering their role in disease evolution...]]></summary>
        <author>
            <name>Federica Plano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era]]></title>
        <id>pubmed:36649045</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36649045/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the last ten years, liquid biopsy has been slowly joining the traditional invasive techniques for the diagnosis and monitoring of tumors. Liquid biopsies allow easy repeated sampling of blood, reflect the tumor scenario, and make personalized therapy real for the patient. Liquid biopsies isolate and utilize different substrates present in patients' body fluids such as circulating tumor cells, circulating tumor DNA, tumor extracellular vesicles, etc. One of the most-used solid cancers in the...]]></summary>
        <author>
            <name>Maria Palmieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again]]></title>
        <id>pubmed:36648882</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36648882/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is an incurable hematologic malignancy characterized by a multistep evolutionary pathway, with an initial phase called monoclonal gammopathy of undetermined significance (MGUS), potentially evolving into the symptomatic disease, often preceded by an intermediate phase called "smoldering" MM (sMM). From a biological point of view, genomic alterations (translocations/deletions/mutations) are already present at the MGUS phase, thus rendering their role in disease evolution...]]></summary>
        <author>
            <name>Federica Plano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era]]></title>
        <id>pubmed:36649045</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36649045/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the last ten years, liquid biopsy has been slowly joining the traditional invasive techniques for the diagnosis and monitoring of tumors. Liquid biopsies allow easy repeated sampling of blood, reflect the tumor scenario, and make personalized therapy real for the patient. Liquid biopsies isolate and utilize different substrates present in patients' body fluids such as circulating tumor cells, circulating tumor DNA, tumor extracellular vesicles, etc. One of the most-used solid cancers in the...]]></summary>
        <author>
            <name>Maria Palmieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again]]></title>
        <id>pubmed:36648882</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36648882/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is an incurable hematologic malignancy characterized by a multistep evolutionary pathway, with an initial phase called monoclonal gammopathy of undetermined significance (MGUS), potentially evolving into the symptomatic disease, often preceded by an intermediate phase called "smoldering" MM (sMM). From a biological point of view, genomic alterations (translocations/deletions/mutations) are already present at the MGUS phase, thus rendering their role in disease evolution...]]></summary>
        <author>
            <name>Federica Plano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era]]></title>
        <id>pubmed:36649045</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36649045/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the last ten years, liquid biopsy has been slowly joining the traditional invasive techniques for the diagnosis and monitoring of tumors. Liquid biopsies allow easy repeated sampling of blood, reflect the tumor scenario, and make personalized therapy real for the patient. Liquid biopsies isolate and utilize different substrates present in patients' body fluids such as circulating tumor cells, circulating tumor DNA, tumor extracellular vesicles, etc. One of the most-used solid cancers in the...]]></summary>
        <author>
            <name>Maria Palmieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again]]></title>
        <id>pubmed:36648882</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36648882/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is an incurable hematologic malignancy characterized by a multistep evolutionary pathway, with an initial phase called monoclonal gammopathy of undetermined significance (MGUS), potentially evolving into the symptomatic disease, often preceded by an intermediate phase called "smoldering" MM (sMM). From a biological point of view, genomic alterations (translocations/deletions/mutations) are already present at the MGUS phase, thus rendering their role in disease evolution...]]></summary>
        <author>
            <name>Federica Plano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era]]></title>
        <id>pubmed:36649045</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36649045/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the last ten years, liquid biopsy has been slowly joining the traditional invasive techniques for the diagnosis and monitoring of tumors. Liquid biopsies allow easy repeated sampling of blood, reflect the tumor scenario, and make personalized therapy real for the patient. Liquid biopsies isolate and utilize different substrates present in patients' body fluids such as circulating tumor cells, circulating tumor DNA, tumor extracellular vesicles, etc. One of the most-used solid cancers in the...]]></summary>
        <author>
            <name>Maria Palmieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again]]></title>
        <id>pubmed:36648882</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36648882/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is an incurable hematologic malignancy characterized by a multistep evolutionary pathway, with an initial phase called monoclonal gammopathy of undetermined significance (MGUS), potentially evolving into the symptomatic disease, often preceded by an intermediate phase called "smoldering" MM (sMM). From a biological point of view, genomic alterations (translocations/deletions/mutations) are already present at the MGUS phase, thus rendering their role in disease evolution...]]></summary>
        <author>
            <name>Federica Plano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era]]></title>
        <id>pubmed:36649045</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36649045/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the last ten years, liquid biopsy has been slowly joining the traditional invasive techniques for the diagnosis and monitoring of tumors. Liquid biopsies allow easy repeated sampling of blood, reflect the tumor scenario, and make personalized therapy real for the patient. Liquid biopsies isolate and utilize different substrates present in patients' body fluids such as circulating tumor cells, circulating tumor DNA, tumor extracellular vesicles, etc. One of the most-used solid cancers in the...]]></summary>
        <author>
            <name>Maria Palmieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again]]></title>
        <id>pubmed:36648882</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36648882/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is an incurable hematologic malignancy characterized by a multistep evolutionary pathway, with an initial phase called monoclonal gammopathy of undetermined significance (MGUS), potentially evolving into the symptomatic disease, often preceded by an intermediate phase called "smoldering" MM (sMM). From a biological point of view, genomic alterations (translocations/deletions/mutations) are already present at the MGUS phase, thus rendering their role in disease evolution...]]></summary>
        <author>
            <name>Federica Plano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A t(4;13)(q21;q14) translocation in B-cell chronic lymphocytic leukemia causing concomitant homozygous DLEU2/miR15a/miR16-1 and heterozygous ARHGAP24 deletions]]></title>
        <id>pubmed:36641997</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36641997/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[13q14 deletion is the most recurrent chromosomal aberration reported in B-CLL, having a favorable prognostic significance when occurring as the sole cytogenetic alteration. However, its clinical outcome is also related to the deletion size and number of cells with the del(13)(q14) deletion. In 10% of cases, 13q14 deletion arises following a translocation event with multiple partner chromosomes, whose oncogenic impact has not been investigated so far due to the assumption of a possible role as a...]]></summary>
        <author>
            <name>Doron Tolomeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A t(4;13)(q21;q14) translocation in B-cell chronic lymphocytic leukemia causing concomitant homozygous DLEU2/miR15a/miR16-1 and heterozygous ARHGAP24 deletions]]></title>
        <id>pubmed:36641997</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36641997/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[13q14 deletion is the most recurrent chromosomal aberration reported in B-CLL, having a favorable prognostic significance when occurring as the sole cytogenetic alteration. However, its clinical outcome is also related to the deletion size and number of cells with the del(13)(q14) deletion. In 10% of cases, 13q14 deletion arises following a translocation event with multiple partner chromosomes, whose oncogenic impact has not been investigated so far due to the assumption of a possible role as a...]]></summary>
        <author>
            <name>Doron Tolomeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A t(4;13)(q21;q14) translocation in B-cell chronic lymphocytic leukemia causing concomitant homozygous DLEU2/miR15a/miR16-1 and heterozygous ARHGAP24 deletions]]></title>
        <id>pubmed:36641997</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36641997/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[13q14 deletion is the most recurrent chromosomal aberration reported in B-CLL, having a favorable prognostic significance when occurring as the sole cytogenetic alteration. However, its clinical outcome is also related to the deletion size and number of cells with the del(13)(q14) deletion. In 10% of cases, 13q14 deletion arises following a translocation event with multiple partner chromosomes, whose oncogenic impact has not been investigated so far due to the assumption of a possible role as a...]]></summary>
        <author>
            <name>Doron Tolomeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A t(4;13)(q21;q14) translocation in B-cell chronic lymphocytic leukemia causing concomitant homozygous DLEU2/miR15a/miR16-1 and heterozygous ARHGAP24 deletions]]></title>
        <id>pubmed:36641997</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36641997/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[13q14 deletion is the most recurrent chromosomal aberration reported in B-CLL, having a favorable prognostic significance when occurring as the sole cytogenetic alteration. However, its clinical outcome is also related to the deletion size and number of cells with the del(13)(q14) deletion. In 10% of cases, 13q14 deletion arises following a translocation event with multiple partner chromosomes, whose oncogenic impact has not been investigated so far due to the assumption of a possible role as a...]]></summary>
        <author>
            <name>Doron Tolomeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A t(4;13)(q21;q14) translocation in B-cell chronic lymphocytic leukemia causing concomitant homozygous DLEU2/miR15a/miR16-1 and heterozygous ARHGAP24 deletions]]></title>
        <id>pubmed:36641997</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36641997/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[13q14 deletion is the most recurrent chromosomal aberration reported in B-CLL, having a favorable prognostic significance when occurring as the sole cytogenetic alteration. However, its clinical outcome is also related to the deletion size and number of cells with the del(13)(q14) deletion. In 10% of cases, 13q14 deletion arises following a translocation event with multiple partner chromosomes, whose oncogenic impact has not been investigated so far due to the assumption of a possible role as a...]]></summary>
        <author>
            <name>Doron Tolomeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A t(4;13)(q21;q14) translocation in B-cell chronic lymphocytic leukemia causing concomitant homozygous DLEU2/miR15a/miR16-1 and heterozygous ARHGAP24 deletions]]></title>
        <id>pubmed:36641997</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36641997/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[13q14 deletion is the most recurrent chromosomal aberration reported in B-CLL, having a favorable prognostic significance when occurring as the sole cytogenetic alteration. However, its clinical outcome is also related to the deletion size and number of cells with the del(13)(q14) deletion. In 10% of cases, 13q14 deletion arises following a translocation event with multiple partner chromosomes, whose oncogenic impact has not been investigated so far due to the assumption of a possible role as a...]]></summary>
        <author>
            <name>Doron Tolomeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A t(4;13)(q21;q14) translocation in B-cell chronic lymphocytic leukemia causing concomitant homozygous DLEU2/miR15a/miR16-1 and heterozygous ARHGAP24 deletions]]></title>
        <id>pubmed:36641997</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36641997/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[13q14 deletion is the most recurrent chromosomal aberration reported in B-CLL, having a favorable prognostic significance when occurring as the sole cytogenetic alteration. However, its clinical outcome is also related to the deletion size and number of cells with the del(13)(q14) deletion. In 10% of cases, 13q14 deletion arises following a translocation event with multiple partner chromosomes, whose oncogenic impact has not been investigated so far due to the assumption of a possible role as a...]]></summary>
        <author>
            <name>Doron Tolomeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A t(4;13)(q21;q14) translocation in B-cell chronic lymphocytic leukemia causing concomitant homozygous DLEU2/miR15a/miR16-1 and heterozygous ARHGAP24 deletions]]></title>
        <id>pubmed:36641997</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36641997/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[13q14 deletion is the most recurrent chromosomal aberration reported in B-CLL, having a favorable prognostic significance when occurring as the sole cytogenetic alteration. However, its clinical outcome is also related to the deletion size and number of cells with the del(13)(q14) deletion. In 10% of cases, 13q14 deletion arises following a translocation event with multiple partner chromosomes, whose oncogenic impact has not been investigated so far due to the assumption of a possible role as a...]]></summary>
        <author>
            <name>Doron Tolomeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A t(4;13)(q21;q14) translocation in B-cell chronic lymphocytic leukemia causing concomitant homozygous DLEU2/miR15a/miR16-1 and heterozygous ARHGAP24 deletions]]></title>
        <id>pubmed:36641997</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36641997/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[13q14 deletion is the most recurrent chromosomal aberration reported in B-CLL, having a favorable prognostic significance when occurring as the sole cytogenetic alteration. However, its clinical outcome is also related to the deletion size and number of cells with the del(13)(q14) deletion. In 10% of cases, 13q14 deletion arises following a translocation event with multiple partner chromosomes, whose oncogenic impact has not been investigated so far due to the assumption of a possible role as a...]]></summary>
        <author>
            <name>Doron Tolomeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A t(4;13)(q21;q14) translocation in B-cell chronic lymphocytic leukemia causing concomitant homozygous DLEU2/miR15a/miR16-1 and heterozygous ARHGAP24 deletions]]></title>
        <id>pubmed:36641997</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36641997/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[13q14 deletion is the most recurrent chromosomal aberration reported in B-CLL, having a favorable prognostic significance when occurring as the sole cytogenetic alteration. However, its clinical outcome is also related to the deletion size and number of cells with the del(13)(q14) deletion. In 10% of cases, 13q14 deletion arises following a translocation event with multiple partner chromosomes, whose oncogenic impact has not been investigated so far due to the assumption of a possible role as a...]]></summary>
        <author>
            <name>Doron Tolomeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A t(4;13)(q21;q14) translocation in B-cell chronic lymphocytic leukemia causing concomitant homozygous DLEU2/miR15a/miR16-1 and heterozygous ARHGAP24 deletions]]></title>
        <id>pubmed:36641997</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36641997/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230116200008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[13q14 deletion is the most recurrent chromosomal aberration reported in B-CLL, having a favorable prognostic significance when occurring as the sole cytogenetic alteration. However, its clinical outcome is also related to the deletion size and number of cells with the del(13)(q14) deletion. In 10% of cases, 13q14 deletion arises following a translocation event with multiple partner chromosomes, whose oncogenic impact has not been investigated so far due to the assumption of a possible role as a...]]></summary>
        <author>
            <name>Doron Tolomeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases]]></title>
        <id>pubmed:36632253</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36632253/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells with a proliferation of one or more myeloid lineage and mature cell overproduction, while myelodysplastic syndrome (MDS)/MPN simultaneously show aspects of MDS and MPN, leading to partially ineffective hematopoiesis with associated dysplastic changes. This spectrum of disorders includes chronic myeloid leukemia, polycythemia vera, primary myelofibrosis, and essential thrombocythemia. MDS/MPN are classically not...]]></summary>
        <author>
            <name>Hristo Popov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases]]></title>
        <id>pubmed:36632253</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36632253/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells with a proliferation of one or more myeloid lineage and mature cell overproduction, while myelodysplastic syndrome (MDS)/MPN simultaneously show aspects of MDS and MPN, leading to partially ineffective hematopoiesis with associated dysplastic changes. This spectrum of disorders includes chronic myeloid leukemia, polycythemia vera, primary myelofibrosis, and essential thrombocythemia. MDS/MPN are classically not...]]></summary>
        <author>
            <name>Hristo Popov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases]]></title>
        <id>pubmed:36632253</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36632253/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells with a proliferation of one or more myeloid lineage and mature cell overproduction, while myelodysplastic syndrome (MDS)/MPN simultaneously show aspects of MDS and MPN, leading to partially ineffective hematopoiesis with associated dysplastic changes. This spectrum of disorders includes chronic myeloid leukemia, polycythemia vera, primary myelofibrosis, and essential thrombocythemia. MDS/MPN are classically not...]]></summary>
        <author>
            <name>Hristo Popov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases]]></title>
        <id>pubmed:36632253</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36632253/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells with a proliferation of one or more myeloid lineage and mature cell overproduction, while myelodysplastic syndrome (MDS)/MPN simultaneously show aspects of MDS and MPN, leading to partially ineffective hematopoiesis with associated dysplastic changes. This spectrum of disorders includes chronic myeloid leukemia, polycythemia vera, primary myelofibrosis, and essential thrombocythemia. MDS/MPN are classically not...]]></summary>
        <author>
            <name>Hristo Popov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases]]></title>
        <id>pubmed:36632253</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36632253/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells with a proliferation of one or more myeloid lineage and mature cell overproduction, while myelodysplastic syndrome (MDS)/MPN simultaneously show aspects of MDS and MPN, leading to partially ineffective hematopoiesis with associated dysplastic changes. This spectrum of disorders includes chronic myeloid leukemia, polycythemia vera, primary myelofibrosis, and essential thrombocythemia. MDS/MPN are classically not...]]></summary>
        <author>
            <name>Hristo Popov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases]]></title>
        <id>pubmed:36632253</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36632253/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells with a proliferation of one or more myeloid lineage and mature cell overproduction, while myelodysplastic syndrome (MDS)/MPN simultaneously show aspects of MDS and MPN, leading to partially ineffective hematopoiesis with associated dysplastic changes. This spectrum of disorders includes chronic myeloid leukemia, polycythemia vera, primary myelofibrosis, and essential thrombocythemia. MDS/MPN are classically not...]]></summary>
        <author>
            <name>Hristo Popov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases]]></title>
        <id>pubmed:36632253</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36632253/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells with a proliferation of one or more myeloid lineage and mature cell overproduction, while myelodysplastic syndrome (MDS)/MPN simultaneously show aspects of MDS and MPN, leading to partially ineffective hematopoiesis with associated dysplastic changes. This spectrum of disorders includes chronic myeloid leukemia, polycythemia vera, primary myelofibrosis, and essential thrombocythemia. MDS/MPN are classically not...]]></summary>
        <author>
            <name>Hristo Popov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases]]></title>
        <id>pubmed:36632253</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36632253/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells with a proliferation of one or more myeloid lineage and mature cell overproduction, while myelodysplastic syndrome (MDS)/MPN simultaneously show aspects of MDS and MPN, leading to partially ineffective hematopoiesis with associated dysplastic changes. This spectrum of disorders includes chronic myeloid leukemia, polycythemia vera, primary myelofibrosis, and essential thrombocythemia. MDS/MPN are classically not...]]></summary>
        <author>
            <name>Hristo Popov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases]]></title>
        <id>pubmed:36632253</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36632253/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells with a proliferation of one or more myeloid lineage and mature cell overproduction, while myelodysplastic syndrome (MDS)/MPN simultaneously show aspects of MDS and MPN, leading to partially ineffective hematopoiesis with associated dysplastic changes. This spectrum of disorders includes chronic myeloid leukemia, polycythemia vera, primary myelofibrosis, and essential thrombocythemia. MDS/MPN are classically not...]]></summary>
        <author>
            <name>Hristo Popov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases]]></title>
        <id>pubmed:36632253</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36632253/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells with a proliferation of one or more myeloid lineage and mature cell overproduction, while myelodysplastic syndrome (MDS)/MPN simultaneously show aspects of MDS and MPN, leading to partially ineffective hematopoiesis with associated dysplastic changes. This spectrum of disorders includes chronic myeloid leukemia, polycythemia vera, primary myelofibrosis, and essential thrombocythemia. MDS/MPN are classically not...]]></summary>
        <author>
            <name>Hristo Popov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases]]></title>
        <id>pubmed:36632253</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36632253/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells with a proliferation of one or more myeloid lineage and mature cell overproduction, while myelodysplastic syndrome (MDS)/MPN simultaneously show aspects of MDS and MPN, leading to partially ineffective hematopoiesis with associated dysplastic changes. This spectrum of disorders includes chronic myeloid leukemia, polycythemia vera, primary myelofibrosis, and essential thrombocythemia. MDS/MPN are classically not...]]></summary>
        <author>
            <name>Hristo Popov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases]]></title>
        <id>pubmed:36632253</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36632253/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells with a proliferation of one or more myeloid lineage and mature cell overproduction, while myelodysplastic syndrome (MDS)/MPN simultaneously show aspects of MDS and MPN, leading to partially ineffective hematopoiesis with associated dysplastic changes. This spectrum of disorders includes chronic myeloid leukemia, polycythemia vera, primary myelofibrosis, and essential thrombocythemia. MDS/MPN are classically not...]]></summary>
        <author>
            <name>Hristo Popov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases]]></title>
        <id>pubmed:36632253</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36632253/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells with a proliferation of one or more myeloid lineage and mature cell overproduction, while myelodysplastic syndrome (MDS)/MPN simultaneously show aspects of MDS and MPN, leading to partially ineffective hematopoiesis with associated dysplastic changes. This spectrum of disorders includes chronic myeloid leukemia, polycythemia vera, primary myelofibrosis, and essential thrombocythemia. MDS/MPN are classically not...]]></summary>
        <author>
            <name>Hristo Popov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases]]></title>
        <id>pubmed:36632253</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36632253/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells with a proliferation of one or more myeloid lineage and mature cell overproduction, while myelodysplastic syndrome (MDS)/MPN simultaneously show aspects of MDS and MPN, leading to partially ineffective hematopoiesis with associated dysplastic changes. This spectrum of disorders includes chronic myeloid leukemia, polycythemia vera, primary myelofibrosis, and essential thrombocythemia. MDS/MPN are classically not...]]></summary>
        <author>
            <name>Hristo Popov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases]]></title>
        <id>pubmed:36632253</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36632253/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells with a proliferation of one or more myeloid lineage and mature cell overproduction, while myelodysplastic syndrome (MDS)/MPN simultaneously show aspects of MDS and MPN, leading to partially ineffective hematopoiesis with associated dysplastic changes. This spectrum of disorders includes chronic myeloid leukemia, polycythemia vera, primary myelofibrosis, and essential thrombocythemia. MDS/MPN are classically not...]]></summary>
        <author>
            <name>Hristo Popov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases]]></title>
        <id>pubmed:36632253</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36632253/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells with a proliferation of one or more myeloid lineage and mature cell overproduction, while myelodysplastic syndrome (MDS)/MPN simultaneously show aspects of MDS and MPN, leading to partially ineffective hematopoiesis with associated dysplastic changes. This spectrum of disorders includes chronic myeloid leukemia, polycythemia vera, primary myelofibrosis, and essential thrombocythemia. MDS/MPN are classically not...]]></summary>
        <author>
            <name>Hristo Popov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases]]></title>
        <id>pubmed:36632253</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36632253/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230116200009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells with a proliferation of one or more myeloid lineage and mature cell overproduction, while myelodysplastic syndrome (MDS)/MPN simultaneously show aspects of MDS and MPN, leading to partially ineffective hematopoiesis with associated dysplastic changes. This spectrum of disorders includes chronic myeloid leukemia, polycythemia vera, primary myelofibrosis, and essential thrombocythemia. MDS/MPN are classically not...]]></summary>
        <author>
            <name>Hristo Popov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases]]></title>
        <id>pubmed:36632253</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36632253/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells with a proliferation of one or more myeloid lineage and mature cell overproduction, while myelodysplastic syndrome (MDS)/MPN simultaneously show aspects of MDS and MPN, leading to partially ineffective hematopoiesis with associated dysplastic changes. This spectrum of disorders includes chronic myeloid leukemia, polycythemia vera, primary myelofibrosis, and essential thrombocythemia. MDS/MPN are classically not...]]></summary>
        <author>
            <name>Hristo Popov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases]]></title>
        <id>pubmed:36632253</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36632253/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells with a proliferation of one or more myeloid lineage and mature cell overproduction, while myelodysplastic syndrome (MDS)/MPN simultaneously show aspects of MDS and MPN, leading to partially ineffective hematopoiesis with associated dysplastic changes. This spectrum of disorders includes chronic myeloid leukemia, polycythemia vera, primary myelofibrosis, and essential thrombocythemia. MDS/MPN are classically not...]]></summary>
        <author>
            <name>Hristo Popov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases]]></title>
        <id>pubmed:36632253</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36632253/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells with a proliferation of one or more myeloid lineage and mature cell overproduction, while myelodysplastic syndrome (MDS)/MPN simultaneously show aspects of MDS and MPN, leading to partially ineffective hematopoiesis with associated dysplastic changes. This spectrum of disorders includes chronic myeloid leukemia, polycythemia vera, primary myelofibrosis, and essential thrombocythemia. MDS/MPN are classically not...]]></summary>
        <author>
            <name>Hristo Popov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases]]></title>
        <id>pubmed:36632253</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36632253/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells with a proliferation of one or more myeloid lineage and mature cell overproduction, while myelodysplastic syndrome (MDS)/MPN simultaneously show aspects of MDS and MPN, leading to partially ineffective hematopoiesis with associated dysplastic changes. This spectrum of disorders includes chronic myeloid leukemia, polycythemia vera, primary myelofibrosis, and essential thrombocythemia. MDS/MPN are classically not...]]></summary>
        <author>
            <name>Hristo Popov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multi-region sequencing depicts intratumor heterogeneity and clonal evolution in cervical cancer]]></title>
        <id>pubmed:36635412</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36635412/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cervical cancer is a heterogeneous malignancy mainly caused by human papillomavirus (HPV). While a few studies have revealed heterogeneity of cervical cancer in chromosome levels, the correlation between genetic heterogeneity and HPV integration in cervical cancer remains unknown. Here, we applied multi-region whole-exome sequencing and HPV integration analysis to explore intratumor heterogeneity in cervical cancer. We sequenced 20 tumor regions and 5 adjacent normal tissues from 5 cervical...]]></summary>
        <author>
            <name>Chen Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multi-region sequencing depicts intratumor heterogeneity and clonal evolution in cervical cancer]]></title>
        <id>pubmed:36635412</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36635412/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cervical cancer is a heterogeneous malignancy mainly caused by human papillomavirus (HPV). While a few studies have revealed heterogeneity of cervical cancer in chromosome levels, the correlation between genetic heterogeneity and HPV integration in cervical cancer remains unknown. Here, we applied multi-region whole-exome sequencing and HPV integration analysis to explore intratumor heterogeneity in cervical cancer. We sequenced 20 tumor regions and 5 adjacent normal tissues from 5 cervical...]]></summary>
        <author>
            <name>Chen Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multi-region sequencing depicts intratumor heterogeneity and clonal evolution in cervical cancer]]></title>
        <id>pubmed:36635412</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36635412/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cervical cancer is a heterogeneous malignancy mainly caused by human papillomavirus (HPV). While a few studies have revealed heterogeneity of cervical cancer in chromosome levels, the correlation between genetic heterogeneity and HPV integration in cervical cancer remains unknown. Here, we applied multi-region whole-exome sequencing and HPV integration analysis to explore intratumor heterogeneity in cervical cancer. We sequenced 20 tumor regions and 5 adjacent normal tissues from 5 cervical...]]></summary>
        <author>
            <name>Chen Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multi-region sequencing depicts intratumor heterogeneity and clonal evolution in cervical cancer]]></title>
        <id>pubmed:36635412</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36635412/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cervical cancer is a heterogeneous malignancy mainly caused by human papillomavirus (HPV). While a few studies have revealed heterogeneity of cervical cancer in chromosome levels, the correlation between genetic heterogeneity and HPV integration in cervical cancer remains unknown. Here, we applied multi-region whole-exome sequencing and HPV integration analysis to explore intratumor heterogeneity in cervical cancer. We sequenced 20 tumor regions and 5 adjacent normal tissues from 5 cervical...]]></summary>
        <author>
            <name>Chen Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multi-region sequencing depicts intratumor heterogeneity and clonal evolution in cervical cancer]]></title>
        <id>pubmed:36635412</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36635412/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cervical cancer is a heterogeneous malignancy mainly caused by human papillomavirus (HPV). While a few studies have revealed heterogeneity of cervical cancer in chromosome levels, the correlation between genetic heterogeneity and HPV integration in cervical cancer remains unknown. Here, we applied multi-region whole-exome sequencing and HPV integration analysis to explore intratumor heterogeneity in cervical cancer. We sequenced 20 tumor regions and 5 adjacent normal tissues from 5 cervical...]]></summary>
        <author>
            <name>Chen Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multi-region sequencing depicts intratumor heterogeneity and clonal evolution in cervical cancer]]></title>
        <id>pubmed:36635412</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36635412/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cervical cancer is a heterogeneous malignancy mainly caused by human papillomavirus (HPV). While a few studies have revealed heterogeneity of cervical cancer in chromosome levels, the correlation between genetic heterogeneity and HPV integration in cervical cancer remains unknown. Here, we applied multi-region whole-exome sequencing and HPV integration analysis to explore intratumor heterogeneity in cervical cancer. We sequenced 20 tumor regions and 5 adjacent normal tissues from 5 cervical...]]></summary>
        <author>
            <name>Chen Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multi-region sequencing depicts intratumor heterogeneity and clonal evolution in cervical cancer]]></title>
        <id>pubmed:36635412</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36635412/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cervical cancer is a heterogeneous malignancy mainly caused by human papillomavirus (HPV). While a few studies have revealed heterogeneity of cervical cancer in chromosome levels, the correlation between genetic heterogeneity and HPV integration in cervical cancer remains unknown. Here, we applied multi-region whole-exome sequencing and HPV integration analysis to explore intratumor heterogeneity in cervical cancer. We sequenced 20 tumor regions and 5 adjacent normal tissues from 5 cervical...]]></summary>
        <author>
            <name>Chen Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multi-region sequencing depicts intratumor heterogeneity and clonal evolution in cervical cancer]]></title>
        <id>pubmed:36635412</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36635412/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cervical cancer is a heterogeneous malignancy mainly caused by human papillomavirus (HPV). While a few studies have revealed heterogeneity of cervical cancer in chromosome levels, the correlation between genetic heterogeneity and HPV integration in cervical cancer remains unknown. Here, we applied multi-region whole-exome sequencing and HPV integration analysis to explore intratumor heterogeneity in cervical cancer. We sequenced 20 tumor regions and 5 adjacent normal tissues from 5 cervical...]]></summary>
        <author>
            <name>Chen Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multi-region sequencing depicts intratumor heterogeneity and clonal evolution in cervical cancer]]></title>
        <id>pubmed:36635412</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36635412/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cervical cancer is a heterogeneous malignancy mainly caused by human papillomavirus (HPV). While a few studies have revealed heterogeneity of cervical cancer in chromosome levels, the correlation between genetic heterogeneity and HPV integration in cervical cancer remains unknown. Here, we applied multi-region whole-exome sequencing and HPV integration analysis to explore intratumor heterogeneity in cervical cancer. We sequenced 20 tumor regions and 5 adjacent normal tissues from 5 cervical...]]></summary>
        <author>
            <name>Chen Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multi-region sequencing depicts intratumor heterogeneity and clonal evolution in cervical cancer]]></title>
        <id>pubmed:36635412</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36635412/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230116200008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cervical cancer is a heterogeneous malignancy mainly caused by human papillomavirus (HPV). While a few studies have revealed heterogeneity of cervical cancer in chromosome levels, the correlation between genetic heterogeneity and HPV integration in cervical cancer remains unknown. Here, we applied multi-region whole-exome sequencing and HPV integration analysis to explore intratumor heterogeneity in cervical cancer. We sequenced 20 tumor regions and 5 adjacent normal tissues from 5 cervical...]]></summary>
        <author>
            <name>Chen Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multi-region sequencing depicts intratumor heterogeneity and clonal evolution in cervical cancer]]></title>
        <id>pubmed:36635412</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36635412/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cervical cancer is a heterogeneous malignancy mainly caused by human papillomavirus (HPV). While a few studies have revealed heterogeneity of cervical cancer in chromosome levels, the correlation between genetic heterogeneity and HPV integration in cervical cancer remains unknown. Here, we applied multi-region whole-exome sequencing and HPV integration analysis to explore intratumor heterogeneity in cervical cancer. We sequenced 20 tumor regions and 5 adjacent normal tissues from 5 cervical...]]></summary>
        <author>
            <name>Chen Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multi-region sequencing depicts intratumor heterogeneity and clonal evolution in cervical cancer]]></title>
        <id>pubmed:36635412</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36635412/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cervical cancer is a heterogeneous malignancy mainly caused by human papillomavirus (HPV). While a few studies have revealed heterogeneity of cervical cancer in chromosome levels, the correlation between genetic heterogeneity and HPV integration in cervical cancer remains unknown. Here, we applied multi-region whole-exome sequencing and HPV integration analysis to explore intratumor heterogeneity in cervical cancer. We sequenced 20 tumor regions and 5 adjacent normal tissues from 5 cervical...]]></summary>
        <author>
            <name>Chen Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multi-region sequencing depicts intratumor heterogeneity and clonal evolution in cervical cancer]]></title>
        <id>pubmed:36635412</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36635412/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cervical cancer is a heterogeneous malignancy mainly caused by human papillomavirus (HPV). While a few studies have revealed heterogeneity of cervical cancer in chromosome levels, the correlation between genetic heterogeneity and HPV integration in cervical cancer remains unknown. Here, we applied multi-region whole-exome sequencing and HPV integration analysis to explore intratumor heterogeneity in cervical cancer. We sequenced 20 tumor regions and 5 adjacent normal tissues from 5 cervical...]]></summary>
        <author>
            <name>Chen Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult low hypodiploid acute lymphoblastic leukemia emerges from pre-leukemic TP53-mutant clonal hematopoiesis]]></title>
        <id>pubmed:36630200</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36630200/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low hypodiploidy defines a rare subtype of B-cell acute lymphoblastic leukemia (B-ALL) with a dismal outcome. To investigate the genomic basis of low-hypodiploid ALL (LH-ALL) in adults, we analyzed copy-number aberrations, loss-of-heterozygosity, mutations and cytogenetics data in a prospective cohort of Philadelphia-negative B-ALL patients (n=591, aged 18-84y), allowing to identify 80 LH-ALL cases (14%). Genomic analysis was critical for evidencing low hypodiploidy in many cases missed by...]]></summary>
        <author>
            <name>Rathana Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of global research hotspots and trends on ten-eleven translocation 2: visualization and bibliometric analysis]]></title>
        <id>pubmed:36628244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36628244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230201200224&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Research on TET2 is constantly growing and evolving during the last decade. Here, we provide an objective and comprehensive analysis of the global status, research hotspots, and potential trends in the field of TET2 research by using a bibliometric approach. These results will assist researchers in mastering the knowledge structure and guiding the future research directions of TET2.]]></summary>
        <author>
            <name>Hao Lv</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult low hypodiploid acute lymphoblastic leukemia emerges from pre-leukemic TP53-mutant clonal hematopoiesis]]></title>
        <id>pubmed:36630200</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36630200/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low hypodiploidy defines a rare subtype of B-cell acute lymphoblastic leukemia (B-ALL) with a dismal outcome. To investigate the genomic basis of low-hypodiploid ALL (LH-ALL) in adults, we analyzed copy-number aberrations, loss-of-heterozygosity, mutations and cytogenetics data in a prospective cohort of Philadelphia-negative B-ALL patients (n=591, aged 18-84y), allowing to identify 80 LH-ALL cases (14%). Genomic analysis was critical for evidencing low hypodiploidy in many cases missed by...]]></summary>
        <author>
            <name>Rathana Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of global research hotspots and trends on ten-eleven translocation 2: visualization and bibliometric analysis]]></title>
        <id>pubmed:36628244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36628244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230131200903&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Research on TET2 is constantly growing and evolving during the last decade. Here, we provide an objective and comprehensive analysis of the global status, research hotspots, and potential trends in the field of TET2 research by using a bibliometric approach. These results will assist researchers in mastering the knowledge structure and guiding the future research directions of TET2.]]></summary>
        <author>
            <name>Hao Lv</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult low hypodiploid acute lymphoblastic leukemia emerges from pre-leukemic TP53-mutant clonal hematopoiesis]]></title>
        <id>pubmed:36630200</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36630200/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low hypodiploidy defines a rare subtype of B-cell acute lymphoblastic leukemia (B-ALL) with a dismal outcome. To investigate the genomic basis of low-hypodiploid ALL (LH-ALL) in adults, we analyzed copy-number aberrations, loss-of-heterozygosity, mutations and cytogenetics data in a prospective cohort of Philadelphia-negative B-ALL patients (n=591, aged 18-84y), allowing to identify 80 LH-ALL cases (14%). Genomic analysis was critical for evidencing low hypodiploidy in many cases missed by...]]></summary>
        <author>
            <name>Rathana Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of global research hotspots and trends on ten-eleven translocation 2: visualization and bibliometric analysis]]></title>
        <id>pubmed:36628244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36628244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Research on TET2 is constantly growing and evolving during the last decade. Here, we provide an objective and comprehensive analysis of the global status, research hotspots, and potential trends in the field of TET2 research by using a bibliometric approach. These results will assist researchers in mastering the knowledge structure and guiding the future research directions of TET2.]]></summary>
        <author>
            <name>Hao Lv</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult low hypodiploid acute lymphoblastic leukemia emerges from pre-leukemic TP53-mutant clonal hematopoiesis]]></title>
        <id>pubmed:36630200</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36630200/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low hypodiploidy defines a rare subtype of B-cell acute lymphoblastic leukemia (B-ALL) with a dismal outcome. To investigate the genomic basis of low-hypodiploid ALL (LH-ALL) in adults, we analyzed copy-number aberrations, loss-of-heterozygosity, mutations and cytogenetics data in a prospective cohort of Philadelphia-negative B-ALL patients (n=591, aged 18-84y), allowing to identify 80 LH-ALL cases (14%). Genomic analysis was critical for evidencing low hypodiploidy in many cases missed by...]]></summary>
        <author>
            <name>Rathana Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of global research hotspots and trends on ten-eleven translocation 2: visualization and bibliometric analysis]]></title>
        <id>pubmed:36628244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36628244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Research on TET2 is constantly growing and evolving during the last decade. Here, we provide an objective and comprehensive analysis of the global status, research hotspots, and potential trends in the field of TET2 research by using a bibliometric approach. These results will assist researchers in mastering the knowledge structure and guiding the future research directions of TET2.]]></summary>
        <author>
            <name>Hao Lv</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult low hypodiploid acute lymphoblastic leukemia emerges from pre-leukemic TP53-mutant clonal hematopoiesis]]></title>
        <id>pubmed:36630200</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36630200/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low hypodiploidy defines a rare subtype of B-cell acute lymphoblastic leukemia (B-ALL) with a dismal outcome. To investigate the genomic basis of low-hypodiploid ALL (LH-ALL) in adults, we analyzed copy-number aberrations, loss-of-heterozygosity, mutations and cytogenetics data in a prospective cohort of Philadelphia-negative B-ALL patients (n=591, aged 18-84y), allowing to identify 80 LH-ALL cases (14%). Genomic analysis was critical for evidencing low hypodiploidy in many cases missed by...]]></summary>
        <author>
            <name>Rathana Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of global research hotspots and trends on ten-eleven translocation 2: visualization and bibliometric analysis]]></title>
        <id>pubmed:36628244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36628244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Research on TET2 is constantly growing and evolving during the last decade. Here, we provide an objective and comprehensive analysis of the global status, research hotspots, and potential trends in the field of TET2 research by using a bibliometric approach. These results will assist researchers in mastering the knowledge structure and guiding the future research directions of TET2.]]></summary>
        <author>
            <name>Hao Lv</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult low hypodiploid acute lymphoblastic leukemia emerges from pre-leukemic TP53-mutant clonal hematopoiesis]]></title>
        <id>pubmed:36630200</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36630200/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low hypodiploidy defines a rare subtype of B-cell acute lymphoblastic leukemia (B-ALL) with a dismal outcome. To investigate the genomic basis of low-hypodiploid ALL (LH-ALL) in adults, we analyzed copy-number aberrations, loss-of-heterozygosity, mutations and cytogenetics data in a prospective cohort of Philadelphia-negative B-ALL patients (n=591, aged 18-84y), allowing to identify 80 LH-ALL cases (14%). Genomic analysis was critical for evidencing low hypodiploidy in many cases missed by...]]></summary>
        <author>
            <name>Rathana Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of global research hotspots and trends on ten-eleven translocation 2: visualization and bibliometric analysis]]></title>
        <id>pubmed:36628244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36628244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Research on TET2 is constantly growing and evolving during the last decade. Here, we provide an objective and comprehensive analysis of the global status, research hotspots, and potential trends in the field of TET2 research by using a bibliometric approach. These results will assist researchers in mastering the knowledge structure and guiding the future research directions of TET2.]]></summary>
        <author>
            <name>Hao Lv</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult low hypodiploid acute lymphoblastic leukemia emerges from pre-leukemic TP53-mutant clonal hematopoiesis]]></title>
        <id>pubmed:36630200</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36630200/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low hypodiploidy defines a rare subtype of B-cell acute lymphoblastic leukemia (B-ALL) with a dismal outcome. To investigate the genomic basis of low-hypodiploid ALL (LH-ALL) in adults, we analyzed copy-number aberrations, loss-of-heterozygosity, mutations and cytogenetics data in a prospective cohort of Philadelphia-negative B-ALL patients (n=591, aged 18-84y), allowing to identify 80 LH-ALL cases (14%). Genomic analysis was critical for evidencing low hypodiploidy in many cases missed by...]]></summary>
        <author>
            <name>Rathana Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of global research hotspots and trends on ten-eleven translocation 2: visualization and bibliometric analysis]]></title>
        <id>pubmed:36628244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36628244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Research on TET2 is constantly growing and evolving during the last decade. Here, we provide an objective and comprehensive analysis of the global status, research hotspots, and potential trends in the field of TET2 research by using a bibliometric approach. These results will assist researchers in mastering the knowledge structure and guiding the future research directions of TET2.]]></summary>
        <author>
            <name>Hao Lv</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult low hypodiploid acute lymphoblastic leukemia emerges from pre-leukemic TP53-mutant clonal hematopoiesis]]></title>
        <id>pubmed:36630200</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36630200/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low hypodiploidy defines a rare subtype of B-cell acute lymphoblastic leukemia (B-ALL) with a dismal outcome. To investigate the genomic basis of low-hypodiploid ALL (LH-ALL) in adults, we analyzed copy-number aberrations, loss-of-heterozygosity, mutations and cytogenetics data in a prospective cohort of Philadelphia-negative B-ALL patients (n=591, aged 18-84y), allowing to identify 80 LH-ALL cases (14%). Genomic analysis was critical for evidencing low hypodiploidy in many cases missed by...]]></summary>
        <author>
            <name>Rathana Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of global research hotspots and trends on ten-eleven translocation 2: visualization and bibliometric analysis]]></title>
        <id>pubmed:36628244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36628244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Research on TET2 is constantly growing and evolving during the last decade. Here, we provide an objective and comprehensive analysis of the global status, research hotspots, and potential trends in the field of TET2 research by using a bibliometric approach. These results will assist researchers in mastering the knowledge structure and guiding the future research directions of TET2.]]></summary>
        <author>
            <name>Hao Lv</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult low hypodiploid acute lymphoblastic leukemia emerges from pre-leukemic TP53-mutant clonal hematopoiesis]]></title>
        <id>pubmed:36630200</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36630200/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low hypodiploidy defines a rare subtype of B-cell acute lymphoblastic leukemia (B-ALL) with a dismal outcome. To investigate the genomic basis of low-hypodiploid ALL (LH-ALL) in adults, we analyzed copy-number aberrations, loss-of-heterozygosity, mutations and cytogenetics data in a prospective cohort of Philadelphia-negative B-ALL patients (n=591, aged 18-84y), allowing to identify 80 LH-ALL cases (14%). Genomic analysis was critical for evidencing low hypodiploidy in many cases missed by...]]></summary>
        <author>
            <name>Rathana Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of global research hotspots and trends on ten-eleven translocation 2: visualization and bibliometric analysis]]></title>
        <id>pubmed:36628244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36628244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Research on TET2 is constantly growing and evolving during the last decade. Here, we provide an objective and comprehensive analysis of the global status, research hotspots, and potential trends in the field of TET2 research by using a bibliometric approach. These results will assist researchers in mastering the knowledge structure and guiding the future research directions of TET2.]]></summary>
        <author>
            <name>Hao Lv</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult low hypodiploid acute lymphoblastic leukemia emerges from pre-leukemic TP53-mutant clonal hematopoiesis]]></title>
        <id>pubmed:36630200</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36630200/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low hypodiploidy defines a rare subtype of B-cell acute lymphoblastic leukemia (B-ALL) with a dismal outcome. To investigate the genomic basis of low-hypodiploid ALL (LH-ALL) in adults, we analyzed copy-number aberrations, loss-of-heterozygosity, mutations and cytogenetics data in a prospective cohort of Philadelphia-negative B-ALL patients (n=591, aged 18-84y), allowing to identify 80 LH-ALL cases (14%). Genomic analysis was critical for evidencing low hypodiploidy in many cases missed by...]]></summary>
        <author>
            <name>Rathana Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of global research hotspots and trends on ten-eleven translocation 2: visualization and bibliometric analysis]]></title>
        <id>pubmed:36628244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36628244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Research on TET2 is constantly growing and evolving during the last decade. Here, we provide an objective and comprehensive analysis of the global status, research hotspots, and potential trends in the field of TET2 research by using a bibliometric approach. These results will assist researchers in mastering the knowledge structure and guiding the future research directions of TET2.]]></summary>
        <author>
            <name>Hao Lv</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult low hypodiploid acute lymphoblastic leukemia emerges from pre-leukemic TP53-mutant clonal hematopoiesis]]></title>
        <id>pubmed:36630200</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36630200/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low hypodiploidy defines a rare subtype of B-cell acute lymphoblastic leukemia (B-ALL) with a dismal outcome. To investigate the genomic basis of low-hypodiploid ALL (LH-ALL) in adults, we analyzed copy-number aberrations, loss-of-heterozygosity, mutations and cytogenetics data in a prospective cohort of Philadelphia-negative B-ALL patients (n=591, aged 18-84y), allowing to identify 80 LH-ALL cases (14%). Genomic analysis was critical for evidencing low hypodiploidy in many cases missed by...]]></summary>
        <author>
            <name>Rathana Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of global research hotspots and trends on ten-eleven translocation 2: visualization and bibliometric analysis]]></title>
        <id>pubmed:36628244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36628244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Research on TET2 is constantly growing and evolving during the last decade. Here, we provide an objective and comprehensive analysis of the global status, research hotspots, and potential trends in the field of TET2 research by using a bibliometric approach. These results will assist researchers in mastering the knowledge structure and guiding the future research directions of TET2.]]></summary>
        <author>
            <name>Hao Lv</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult low hypodiploid acute lymphoblastic leukemia emerges from pre-leukemic TP53-mutant clonal hematopoiesis]]></title>
        <id>pubmed:36630200</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36630200/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low hypodiploidy defines a rare subtype of B-cell acute lymphoblastic leukemia (B-ALL) with a dismal outcome. To investigate the genomic basis of low-hypodiploid ALL (LH-ALL) in adults, we analyzed copy-number aberrations, loss-of-heterozygosity, mutations and cytogenetics data in a prospective cohort of Philadelphia-negative B-ALL patients (n=591, aged 18-84y), allowing to identify 80 LH-ALL cases (14%). Genomic analysis was critical for evidencing low hypodiploidy in many cases missed by...]]></summary>
        <author>
            <name>Rathana Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of global research hotspots and trends on ten-eleven translocation 2: visualization and bibliometric analysis]]></title>
        <id>pubmed:36628244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36628244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Research on TET2 is constantly growing and evolving during the last decade. Here, we provide an objective and comprehensive analysis of the global status, research hotspots, and potential trends in the field of TET2 research by using a bibliometric approach. These results will assist researchers in mastering the knowledge structure and guiding the future research directions of TET2.]]></summary>
        <author>
            <name>Hao Lv</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult low hypodiploid acute lymphoblastic leukemia emerges from pre-leukemic TP53-mutant clonal hematopoiesis]]></title>
        <id>pubmed:36630200</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36630200/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low hypodiploidy defines a rare subtype of B-cell acute lymphoblastic leukemia (B-ALL) with a dismal outcome. To investigate the genomic basis of low-hypodiploid ALL (LH-ALL) in adults, we analyzed copy-number aberrations, loss-of-heterozygosity, mutations and cytogenetics data in a prospective cohort of Philadelphia-negative B-ALL patients (n=591, aged 18-84y), allowing to identify 80 LH-ALL cases (14%). Genomic analysis was critical for evidencing low hypodiploidy in many cases missed by...]]></summary>
        <author>
            <name>Rathana Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of global research hotspots and trends on ten-eleven translocation 2: visualization and bibliometric analysis]]></title>
        <id>pubmed:36628244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36628244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Research on TET2 is constantly growing and evolving during the last decade. Here, we provide an objective and comprehensive analysis of the global status, research hotspots, and potential trends in the field of TET2 research by using a bibliometric approach. These results will assist researchers in mastering the knowledge structure and guiding the future research directions of TET2.]]></summary>
        <author>
            <name>Hao Lv</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult low hypodiploid acute lymphoblastic leukemia emerges from pre-leukemic TP53-mutant clonal hematopoiesis]]></title>
        <id>pubmed:36630200</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36630200/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low hypodiploidy defines a rare subtype of B-cell acute lymphoblastic leukemia (B-ALL) with a dismal outcome. To investigate the genomic basis of low-hypodiploid ALL (LH-ALL) in adults, we analyzed copy-number aberrations, loss-of-heterozygosity, mutations and cytogenetics data in a prospective cohort of Philadelphia-negative B-ALL patients (n=591, aged 18-84y), allowing to identify 80 LH-ALL cases (14%). Genomic analysis was critical for evidencing low hypodiploidy in many cases missed by...]]></summary>
        <author>
            <name>Rathana Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of global research hotspots and trends on ten-eleven translocation 2: visualization and bibliometric analysis]]></title>
        <id>pubmed:36628244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36628244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Research on TET2 is constantly growing and evolving during the last decade. Here, we provide an objective and comprehensive analysis of the global status, research hotspots, and potential trends in the field of TET2 research by using a bibliometric approach. These results will assist researchers in mastering the knowledge structure and guiding the future research directions of TET2.]]></summary>
        <author>
            <name>Hao Lv</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult low hypodiploid acute lymphoblastic leukemia emerges from pre-leukemic TP53-mutant clonal hematopoiesis]]></title>
        <id>pubmed:36630200</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36630200/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low hypodiploidy defines a rare subtype of B-cell acute lymphoblastic leukemia (B-ALL) with a dismal outcome. To investigate the genomic basis of low-hypodiploid ALL (LH-ALL) in adults, we analyzed copy-number aberrations, loss-of-heterozygosity, mutations and cytogenetics data in a prospective cohort of Philadelphia-negative B-ALL patients (n=591, aged 18-84y), allowing to identify 80 LH-ALL cases (14%). Genomic analysis was critical for evidencing low hypodiploidy in many cases missed by...]]></summary>
        <author>
            <name>Rathana Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of global research hotspots and trends on ten-eleven translocation 2: visualization and bibliometric analysis]]></title>
        <id>pubmed:36628244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36628244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Research on TET2 is constantly growing and evolving during the last decade. Here, we provide an objective and comprehensive analysis of the global status, research hotspots, and potential trends in the field of TET2 research by using a bibliometric approach. These results will assist researchers in mastering the knowledge structure and guiding the future research directions of TET2.]]></summary>
        <author>
            <name>Hao Lv</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult low hypodiploid acute lymphoblastic leukemia emerges from pre-leukemic TP53-mutant clonal hematopoiesis]]></title>
        <id>pubmed:36630200</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36630200/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low hypodiploidy defines a rare subtype of B-cell acute lymphoblastic leukemia (B-ALL) with a dismal outcome. To investigate the genomic basis of low-hypodiploid ALL (LH-ALL) in adults, we analyzed copy-number aberrations, loss-of-heterozygosity, mutations and cytogenetics data in a prospective cohort of Philadelphia-negative B-ALL patients (n=591, aged 18-84y), allowing to identify 80 LH-ALL cases (14%). Genomic analysis was critical for evidencing low hypodiploidy in many cases missed by...]]></summary>
        <author>
            <name>Rathana Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of global research hotspots and trends on ten-eleven translocation 2: visualization and bibliometric analysis]]></title>
        <id>pubmed:36628244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36628244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Research on TET2 is constantly growing and evolving during the last decade. Here, we provide an objective and comprehensive analysis of the global status, research hotspots, and potential trends in the field of TET2 research by using a bibliometric approach. These results will assist researchers in mastering the knowledge structure and guiding the future research directions of TET2.]]></summary>
        <author>
            <name>Hao Lv</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult low hypodiploid acute lymphoblastic leukemia emerges from pre-leukemic TP53-mutant clonal hematopoiesis]]></title>
        <id>pubmed:36630200</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36630200/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230116200009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low hypodiploidy defines a rare subtype of B-cell acute lymphoblastic leukemia (B-ALL) with a dismal outcome. To investigate the genomic basis of low-hypodiploid ALL (LH-ALL) in adults, we analyzed copy-number aberrations, loss-of-heterozygosity, mutations and cytogenetics data in a prospective cohort of Philadelphia-negative B-ALL patients (n=591, aged 18-84y), allowing to identify 80 LH-ALL cases (14%). Genomic analysis was critical for evidencing low hypodiploidy in many cases missed by...]]></summary>
        <author>
            <name>Rathana Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of global research hotspots and trends on ten-eleven translocation 2: visualization and bibliometric analysis]]></title>
        <id>pubmed:36628244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36628244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230116200009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Research on TET2 is constantly growing and evolving during the last decade. Here, we provide an objective and comprehensive analysis of the global status, research hotspots, and potential trends in the field of TET2 research by using a bibliometric approach. These results will assist researchers in mastering the knowledge structure and guiding the future research directions of TET2.]]></summary>
        <author>
            <name>Hao Lv</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult low hypodiploid acute lymphoblastic leukemia emerges from pre-leukemic TP53-mutant clonal hematopoiesis]]></title>
        <id>pubmed:36630200</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36630200/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low hypodiploidy defines a rare subtype of B-cell acute lymphoblastic leukemia (B-ALL) with a dismal outcome. To investigate the genomic basis of low-hypodiploid ALL (LH-ALL) in adults, we analyzed copy-number aberrations, loss-of-heterozygosity, mutations and cytogenetics data in a prospective cohort of Philadelphia-negative B-ALL patients (n=591, aged 18-84y), allowing to identify 80 LH-ALL cases (14%). Genomic analysis was critical for evidencing low hypodiploidy in many cases missed by...]]></summary>
        <author>
            <name>Rathana Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of global research hotspots and trends on ten-eleven translocation 2: visualization and bibliometric analysis]]></title>
        <id>pubmed:36628244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36628244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Research on TET2 is constantly growing and evolving during the last decade. Here, we provide an objective and comprehensive analysis of the global status, research hotspots, and potential trends in the field of TET2 research by using a bibliometric approach. These results will assist researchers in mastering the knowledge structure and guiding the future research directions of TET2.]]></summary>
        <author>
            <name>Hao Lv</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult low hypodiploid acute lymphoblastic leukemia emerges from pre-leukemic TP53-mutant clonal hematopoiesis]]></title>
        <id>pubmed:36630200</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36630200/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low hypodiploidy defines a rare subtype of B-cell acute lymphoblastic leukemia (B-ALL) with a dismal outcome. To investigate the genomic basis of low-hypodiploid ALL (LH-ALL) in adults, we analyzed copy-number aberrations, loss-of-heterozygosity, mutations and cytogenetics data in a prospective cohort of Philadelphia-negative B-ALL patients (n=591, aged 18-84y), allowing to identify 80 LH-ALL cases (14%). Genomic analysis was critical for evidencing low hypodiploidy in many cases missed by...]]></summary>
        <author>
            <name>Rathana Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of global research hotspots and trends on ten-eleven translocation 2: visualization and bibliometric analysis]]></title>
        <id>pubmed:36628244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36628244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Research on TET2 is constantly growing and evolving during the last decade. Here, we provide an objective and comprehensive analysis of the global status, research hotspots, and potential trends in the field of TET2 research by using a bibliometric approach. These results will assist researchers in mastering the knowledge structure and guiding the future research directions of TET2.]]></summary>
        <author>
            <name>Hao Lv</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult low hypodiploid acute lymphoblastic leukemia emerges from pre-leukemic TP53-mutant clonal hematopoiesis]]></title>
        <id>pubmed:36630200</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36630200/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low hypodiploidy defines a rare subtype of B-cell acute lymphoblastic leukemia (B-ALL) with a dismal outcome. To investigate the genomic basis of low-hypodiploid ALL (LH-ALL) in adults, we analyzed copy-number aberrations, loss-of-heterozygosity, mutations and cytogenetics data in a prospective cohort of Philadelphia-negative B-ALL patients (n=591, aged 18-84y), allowing to identify 80 LH-ALL cases (14%). Genomic analysis was critical for evidencing low hypodiploidy in many cases missed by...]]></summary>
        <author>
            <name>Rathana Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of global research hotspots and trends on ten-eleven translocation 2: visualization and bibliometric analysis]]></title>
        <id>pubmed:36628244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36628244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Research on TET2 is constantly growing and evolving during the last decade. Here, we provide an objective and comprehensive analysis of the global status, research hotspots, and potential trends in the field of TET2 research by using a bibliometric approach. These results will assist researchers in mastering the knowledge structure and guiding the future research directions of TET2.]]></summary>
        <author>
            <name>Hao Lv</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult low hypodiploid acute lymphoblastic leukemia emerges from pre-leukemic TP53-mutant clonal hematopoiesis]]></title>
        <id>pubmed:36630200</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36630200/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low hypodiploidy defines a rare subtype of B-cell acute lymphoblastic leukemia (B-ALL) with a dismal outcome. To investigate the genomic basis of low-hypodiploid ALL (LH-ALL) in adults, we analyzed copy-number aberrations, loss-of-heterozygosity, mutations and cytogenetics data in a prospective cohort of Philadelphia-negative B-ALL patients (n=591, aged 18-84y), allowing to identify 80 LH-ALL cases (14%). Genomic analysis was critical for evidencing low hypodiploidy in many cases missed by...]]></summary>
        <author>
            <name>Rathana Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of global research hotspots and trends on ten-eleven translocation 2: visualization and bibliometric analysis]]></title>
        <id>pubmed:36628244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36628244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Research on TET2 is constantly growing and evolving during the last decade. Here, we provide an objective and comprehensive analysis of the global status, research hotspots, and potential trends in the field of TET2 research by using a bibliometric approach. These results will assist researchers in mastering the knowledge structure and guiding the future research directions of TET2.]]></summary>
        <author>
            <name>Hao Lv</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adult low hypodiploid acute lymphoblastic leukemia emerges from pre-leukemic TP53-mutant clonal hematopoiesis]]></title>
        <id>pubmed:36630200</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36630200/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Low hypodiploidy defines a rare subtype of B-cell acute lymphoblastic leukemia (B-ALL) with a dismal outcome. To investigate the genomic basis of low-hypodiploid ALL (LH-ALL) in adults, we analyzed copy-number aberrations, loss-of-heterozygosity, mutations and cytogenetics data in a prospective cohort of Philadelphia-negative B-ALL patients (n=591, aged 18-84y), allowing to identify 80 LH-ALL cases (14%). Genomic analysis was critical for evidencing low hypodiploidy in many cases missed by...]]></summary>
        <author>
            <name>Rathana Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of global research hotspots and trends on ten-eleven translocation 2: visualization and bibliometric analysis]]></title>
        <id>pubmed:36628244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36628244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Research on TET2 is constantly growing and evolving during the last decade. Here, we provide an objective and comprehensive analysis of the global status, research hotspots, and potential trends in the field of TET2 research by using a bibliometric approach. These results will assist researchers in mastering the knowledge structure and guiding the future research directions of TET2.]]></summary>
        <author>
            <name>Hao Lv</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230130200321&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230129195754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230128200551&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230116200009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230110200056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230116200008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures]]></title>
        <id>pubmed:36626250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36626250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230110200057&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted...]]></summary>
        <author>
            <name>Benjamin T Diamond</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors]]></title>
        <id>pubmed:36622391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36622391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230127200119&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[With the advancements in therapeutics for non-Hodgkin lymphoma (NHL), the long-term survival of patients with NHL has markedly increased. Second primary malignancies (SPMs) have become an increasingly relevant long-term concern for NHL survivors. The etiology of SPMs is multifactorial and involves multiple steps. Germline alterations, immune dysregulation, and clonal hematopoiesis contribute to the accumulation of intrinsic adverse factors, and external factors such as lifestyle; exposure to...]]></summary>
        <author>
            <name>Zhumei Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors]]></title>
        <id>pubmed:36622391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36622391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230126200226&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[With the advancements in therapeutics for non-Hodgkin lymphoma (NHL), the long-term survival of patients with NHL has markedly increased. Second primary malignancies (SPMs) have become an increasingly relevant long-term concern for NHL survivors. The etiology of SPMs is multifactorial and involves multiple steps. Germline alterations, immune dysregulation, and clonal hematopoiesis contribute to the accumulation of intrinsic adverse factors, and external factors such as lifestyle; exposure to...]]></summary>
        <author>
            <name>Zhumei Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors]]></title>
        <id>pubmed:36622391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36622391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[With the advancements in therapeutics for non-Hodgkin lymphoma (NHL), the long-term survival of patients with NHL has markedly increased. Second primary malignancies (SPMs) have become an increasingly relevant long-term concern for NHL survivors. The etiology of SPMs is multifactorial and involves multiple steps. Germline alterations, immune dysregulation, and clonal hematopoiesis contribute to the accumulation of intrinsic adverse factors, and external factors such as lifestyle; exposure to...]]></summary>
        <author>
            <name>Zhumei Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors]]></title>
        <id>pubmed:36622391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36622391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[With the advancements in therapeutics for non-Hodgkin lymphoma (NHL), the long-term survival of patients with NHL has markedly increased. Second primary malignancies (SPMs) have become an increasingly relevant long-term concern for NHL survivors. The etiology of SPMs is multifactorial and involves multiple steps. Germline alterations, immune dysregulation, and clonal hematopoiesis contribute to the accumulation of intrinsic adverse factors, and external factors such as lifestyle; exposure to...]]></summary>
        <author>
            <name>Zhumei Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors]]></title>
        <id>pubmed:36622391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36622391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[With the advancements in therapeutics for non-Hodgkin lymphoma (NHL), the long-term survival of patients with NHL has markedly increased. Second primary malignancies (SPMs) have become an increasingly relevant long-term concern for NHL survivors. The etiology of SPMs is multifactorial and involves multiple steps. Germline alterations, immune dysregulation, and clonal hematopoiesis contribute to the accumulation of intrinsic adverse factors, and external factors such as lifestyle; exposure to...]]></summary>
        <author>
            <name>Zhumei Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors]]></title>
        <id>pubmed:36622391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36622391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[With the advancements in therapeutics for non-Hodgkin lymphoma (NHL), the long-term survival of patients with NHL has markedly increased. Second primary malignancies (SPMs) have become an increasingly relevant long-term concern for NHL survivors. The etiology of SPMs is multifactorial and involves multiple steps. Germline alterations, immune dysregulation, and clonal hematopoiesis contribute to the accumulation of intrinsic adverse factors, and external factors such as lifestyle; exposure to...]]></summary>
        <author>
            <name>Zhumei Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors]]></title>
        <id>pubmed:36622391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36622391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[With the advancements in therapeutics for non-Hodgkin lymphoma (NHL), the long-term survival of patients with NHL has markedly increased. Second primary malignancies (SPMs) have become an increasingly relevant long-term concern for NHL survivors. The etiology of SPMs is multifactorial and involves multiple steps. Germline alterations, immune dysregulation, and clonal hematopoiesis contribute to the accumulation of intrinsic adverse factors, and external factors such as lifestyle; exposure to...]]></summary>
        <author>
            <name>Zhumei Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors]]></title>
        <id>pubmed:36622391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36622391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[With the advancements in therapeutics for non-Hodgkin lymphoma (NHL), the long-term survival of patients with NHL has markedly increased. Second primary malignancies (SPMs) have become an increasingly relevant long-term concern for NHL survivors. The etiology of SPMs is multifactorial and involves multiple steps. Germline alterations, immune dysregulation, and clonal hematopoiesis contribute to the accumulation of intrinsic adverse factors, and external factors such as lifestyle; exposure to...]]></summary>
        <author>
            <name>Zhumei Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors]]></title>
        <id>pubmed:36622391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36622391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[With the advancements in therapeutics for non-Hodgkin lymphoma (NHL), the long-term survival of patients with NHL has markedly increased. Second primary malignancies (SPMs) have become an increasingly relevant long-term concern for NHL survivors. The etiology of SPMs is multifactorial and involves multiple steps. Germline alterations, immune dysregulation, and clonal hematopoiesis contribute to the accumulation of intrinsic adverse factors, and external factors such as lifestyle; exposure to...]]></summary>
        <author>
            <name>Zhumei Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors]]></title>
        <id>pubmed:36622391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36622391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[With the advancements in therapeutics for non-Hodgkin lymphoma (NHL), the long-term survival of patients with NHL has markedly increased. Second primary malignancies (SPMs) have become an increasingly relevant long-term concern for NHL survivors. The etiology of SPMs is multifactorial and involves multiple steps. Germline alterations, immune dysregulation, and clonal hematopoiesis contribute to the accumulation of intrinsic adverse factors, and external factors such as lifestyle; exposure to...]]></summary>
        <author>
            <name>Zhumei Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors]]></title>
        <id>pubmed:36622391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36622391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[With the advancements in therapeutics for non-Hodgkin lymphoma (NHL), the long-term survival of patients with NHL has markedly increased. Second primary malignancies (SPMs) have become an increasingly relevant long-term concern for NHL survivors. The etiology of SPMs is multifactorial and involves multiple steps. Germline alterations, immune dysregulation, and clonal hematopoiesis contribute to the accumulation of intrinsic adverse factors, and external factors such as lifestyle; exposure to...]]></summary>
        <author>
            <name>Zhumei Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors]]></title>
        <id>pubmed:36622391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36622391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230116200009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[With the advancements in therapeutics for non-Hodgkin lymphoma (NHL), the long-term survival of patients with NHL has markedly increased. Second primary malignancies (SPMs) have become an increasingly relevant long-term concern for NHL survivors. The etiology of SPMs is multifactorial and involves multiple steps. Germline alterations, immune dysregulation, and clonal hematopoiesis contribute to the accumulation of intrinsic adverse factors, and external factors such as lifestyle; exposure to...]]></summary>
        <author>
            <name>Zhumei Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors]]></title>
        <id>pubmed:36622391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36622391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[With the advancements in therapeutics for non-Hodgkin lymphoma (NHL), the long-term survival of patients with NHL has markedly increased. Second primary malignancies (SPMs) have become an increasingly relevant long-term concern for NHL survivors. The etiology of SPMs is multifactorial and involves multiple steps. Germline alterations, immune dysregulation, and clonal hematopoiesis contribute to the accumulation of intrinsic adverse factors, and external factors such as lifestyle; exposure to...]]></summary>
        <author>
            <name>Zhumei Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors]]></title>
        <id>pubmed:36622391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36622391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[With the advancements in therapeutics for non-Hodgkin lymphoma (NHL), the long-term survival of patients with NHL has markedly increased. Second primary malignancies (SPMs) have become an increasingly relevant long-term concern for NHL survivors. The etiology of SPMs is multifactorial and involves multiple steps. Germline alterations, immune dysregulation, and clonal hematopoiesis contribute to the accumulation of intrinsic adverse factors, and external factors such as lifestyle; exposure to...]]></summary>
        <author>
            <name>Zhumei Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors]]></title>
        <id>pubmed:36622391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36622391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[With the advancements in therapeutics for non-Hodgkin lymphoma (NHL), the long-term survival of patients with NHL has markedly increased. Second primary malignancies (SPMs) have become an increasingly relevant long-term concern for NHL survivors. The etiology of SPMs is multifactorial and involves multiple steps. Germline alterations, immune dysregulation, and clonal hematopoiesis contribute to the accumulation of intrinsic adverse factors, and external factors such as lifestyle; exposure to...]]></summary>
        <author>
            <name>Zhumei Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors]]></title>
        <id>pubmed:36622391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36622391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[With the advancements in therapeutics for non-Hodgkin lymphoma (NHL), the long-term survival of patients with NHL has markedly increased. Second primary malignancies (SPMs) have become an increasingly relevant long-term concern for NHL survivors. The etiology of SPMs is multifactorial and involves multiple steps. Germline alterations, immune dysregulation, and clonal hematopoiesis contribute to the accumulation of intrinsic adverse factors, and external factors such as lifestyle; exposure to...]]></summary>
        <author>
            <name>Zhumei Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors]]></title>
        <id>pubmed:36622391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36622391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[With the advancements in therapeutics for non-Hodgkin lymphoma (NHL), the long-term survival of patients with NHL has markedly increased. Second primary malignancies (SPMs) have become an increasingly relevant long-term concern for NHL survivors. The etiology of SPMs is multifactorial and involves multiple steps. Germline alterations, immune dysregulation, and clonal hematopoiesis contribute to the accumulation of intrinsic adverse factors, and external factors such as lifestyle; exposure to...]]></summary>
        <author>
            <name>Zhumei Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors]]></title>
        <id>pubmed:36622391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36622391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230110200056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[With the advancements in therapeutics for non-Hodgkin lymphoma (NHL), the long-term survival of patients with NHL has markedly increased. Second primary malignancies (SPMs) have become an increasingly relevant long-term concern for NHL survivors. The etiology of SPMs is multifactorial and involves multiple steps. Germline alterations, immune dysregulation, and clonal hematopoiesis contribute to the accumulation of intrinsic adverse factors, and external factors such as lifestyle; exposure to...]]></summary>
        <author>
            <name>Zhumei Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors]]></title>
        <id>pubmed:36622391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36622391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230109200310&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[With the advancements in therapeutics for non-Hodgkin lymphoma (NHL), the long-term survival of patients with NHL has markedly increased. Second primary malignancies (SPMs) have become an increasingly relevant long-term concern for NHL survivors. The etiology of SPMs is multifactorial and involves multiple steps. Germline alterations, immune dysregulation, and clonal hematopoiesis contribute to the accumulation of intrinsic adverse factors, and external factors such as lifestyle; exposure to...]]></summary>
        <author>
            <name>Zhumei Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chimeric antigen receptor T-cell therapy for multiple myeloma]]></title>
        <id>pubmed:36618390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36618390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a malignant plasma cell disorder that remains incurable for most patients, as persistent clonal evolution drives new mutations which confer MM high-risk signatures and resistance to standard care. The past two decades have significantly refashioned the therapeutic options for MM, especially adoptive T cell therapy contributing to impressive response rate and clinical efficacy. Despite great promises achieved from chimeric antigen receptor T-cell (CAR-T) therapy, the poor...]]></summary>
        <author>
            <name>Zehua Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chimeric antigen receptor T-cell therapy for multiple myeloma]]></title>
        <id>pubmed:36618390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36618390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a malignant plasma cell disorder that remains incurable for most patients, as persistent clonal evolution drives new mutations which confer MM high-risk signatures and resistance to standard care. The past two decades have significantly refashioned the therapeutic options for MM, especially adoptive T cell therapy contributing to impressive response rate and clinical efficacy. Despite great promises achieved from chimeric antigen receptor T-cell (CAR-T) therapy, the poor...]]></summary>
        <author>
            <name>Zehua Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chimeric antigen receptor T-cell therapy for multiple myeloma]]></title>
        <id>pubmed:36618390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36618390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a malignant plasma cell disorder that remains incurable for most patients, as persistent clonal evolution drives new mutations which confer MM high-risk signatures and resistance to standard care. The past two decades have significantly refashioned the therapeutic options for MM, especially adoptive T cell therapy contributing to impressive response rate and clinical efficacy. Despite great promises achieved from chimeric antigen receptor T-cell (CAR-T) therapy, the poor...]]></summary>
        <author>
            <name>Zehua Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chimeric antigen receptor T-cell therapy for multiple myeloma]]></title>
        <id>pubmed:36618390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36618390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a malignant plasma cell disorder that remains incurable for most patients, as persistent clonal evolution drives new mutations which confer MM high-risk signatures and resistance to standard care. The past two decades have significantly refashioned the therapeutic options for MM, especially adoptive T cell therapy contributing to impressive response rate and clinical efficacy. Despite great promises achieved from chimeric antigen receptor T-cell (CAR-T) therapy, the poor...]]></summary>
        <author>
            <name>Zehua Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chimeric antigen receptor T-cell therapy for multiple myeloma]]></title>
        <id>pubmed:36618390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36618390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a malignant plasma cell disorder that remains incurable for most patients, as persistent clonal evolution drives new mutations which confer MM high-risk signatures and resistance to standard care. The past two decades have significantly refashioned the therapeutic options for MM, especially adoptive T cell therapy contributing to impressive response rate and clinical efficacy. Despite great promises achieved from chimeric antigen receptor T-cell (CAR-T) therapy, the poor...]]></summary>
        <author>
            <name>Zehua Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chimeric antigen receptor T-cell therapy for multiple myeloma]]></title>
        <id>pubmed:36618390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36618390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a malignant plasma cell disorder that remains incurable for most patients, as persistent clonal evolution drives new mutations which confer MM high-risk signatures and resistance to standard care. The past two decades have significantly refashioned the therapeutic options for MM, especially adoptive T cell therapy contributing to impressive response rate and clinical efficacy. Despite great promises achieved from chimeric antigen receptor T-cell (CAR-T) therapy, the poor...]]></summary>
        <author>
            <name>Zehua Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chimeric antigen receptor T-cell therapy for multiple myeloma]]></title>
        <id>pubmed:36618390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36618390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a malignant plasma cell disorder that remains incurable for most patients, as persistent clonal evolution drives new mutations which confer MM high-risk signatures and resistance to standard care. The past two decades have significantly refashioned the therapeutic options for MM, especially adoptive T cell therapy contributing to impressive response rate and clinical efficacy. Despite great promises achieved from chimeric antigen receptor T-cell (CAR-T) therapy, the poor...]]></summary>
        <author>
            <name>Zehua Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chimeric antigen receptor T-cell therapy for multiple myeloma]]></title>
        <id>pubmed:36618390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36618390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230116200008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a malignant plasma cell disorder that remains incurable for most patients, as persistent clonal evolution drives new mutations which confer MM high-risk signatures and resistance to standard care. The past two decades have significantly refashioned the therapeutic options for MM, especially adoptive T cell therapy contributing to impressive response rate and clinical efficacy. Despite great promises achieved from chimeric antigen receptor T-cell (CAR-T) therapy, the poor...]]></summary>
        <author>
            <name>Zehua Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chimeric antigen receptor T-cell therapy for multiple myeloma]]></title>
        <id>pubmed:36618390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36618390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a malignant plasma cell disorder that remains incurable for most patients, as persistent clonal evolution drives new mutations which confer MM high-risk signatures and resistance to standard care. The past two decades have significantly refashioned the therapeutic options for MM, especially adoptive T cell therapy contributing to impressive response rate and clinical efficacy. Despite great promises achieved from chimeric antigen receptor T-cell (CAR-T) therapy, the poor...]]></summary>
        <author>
            <name>Zehua Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chimeric antigen receptor T-cell therapy for multiple myeloma]]></title>
        <id>pubmed:36618390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36618390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a malignant plasma cell disorder that remains incurable for most patients, as persistent clonal evolution drives new mutations which confer MM high-risk signatures and resistance to standard care. The past two decades have significantly refashioned the therapeutic options for MM, especially adoptive T cell therapy contributing to impressive response rate and clinical efficacy. Despite great promises achieved from chimeric antigen receptor T-cell (CAR-T) therapy, the poor...]]></summary>
        <author>
            <name>Zehua Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chimeric antigen receptor T-cell therapy for multiple myeloma]]></title>
        <id>pubmed:36618390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36618390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a malignant plasma cell disorder that remains incurable for most patients, as persistent clonal evolution drives new mutations which confer MM high-risk signatures and resistance to standard care. The past two decades have significantly refashioned the therapeutic options for MM, especially adoptive T cell therapy contributing to impressive response rate and clinical efficacy. Despite great promises achieved from chimeric antigen receptor T-cell (CAR-T) therapy, the poor...]]></summary>
        <author>
            <name>Zehua Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chimeric antigen receptor T-cell therapy for multiple myeloma]]></title>
        <id>pubmed:36618390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36618390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a malignant plasma cell disorder that remains incurable for most patients, as persistent clonal evolution drives new mutations which confer MM high-risk signatures and resistance to standard care. The past two decades have significantly refashioned the therapeutic options for MM, especially adoptive T cell therapy contributing to impressive response rate and clinical efficacy. Despite great promises achieved from chimeric antigen receptor T-cell (CAR-T) therapy, the poor...]]></summary>
        <author>
            <name>Zehua Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chimeric antigen receptor T-cell therapy for multiple myeloma]]></title>
        <id>pubmed:36618390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36618390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a malignant plasma cell disorder that remains incurable for most patients, as persistent clonal evolution drives new mutations which confer MM high-risk signatures and resistance to standard care. The past two decades have significantly refashioned the therapeutic options for MM, especially adoptive T cell therapy contributing to impressive response rate and clinical efficacy. Despite great promises achieved from chimeric antigen receptor T-cell (CAR-T) therapy, the poor...]]></summary>
        <author>
            <name>Zehua Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chimeric antigen receptor T-cell therapy for multiple myeloma]]></title>
        <id>pubmed:36618390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36618390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230110200057&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a malignant plasma cell disorder that remains incurable for most patients, as persistent clonal evolution drives new mutations which confer MM high-risk signatures and resistance to standard care. The past two decades have significantly refashioned the therapeutic options for MM, especially adoptive T cell therapy contributing to impressive response rate and clinical efficacy. Despite great promises achieved from chimeric antigen receptor T-cell (CAR-T) therapy, the poor...]]></summary>
        <author>
            <name>Zehua Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept]]></title>
        <id>pubmed:36611303</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36611303/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders distinguished by dysplastic bone marrow and peripheral blood cells, ineffective hematopoiesis, and an increased risk of developing acute myeloid leukemia (AML). MDS with ring sideroblasts (MDS-RS) is a favorable outcome subtype with a lower frequency of AML transformation. The FDA recently approved luspatercept for the treatment of patients with very-low-, low-, and intermediate-risk MDS-RS who have failed to correct anemia...]]></summary>
        <author>
            <name>Sigurd Delanghe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept]]></title>
        <id>pubmed:36611303</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36611303/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders distinguished by dysplastic bone marrow and peripheral blood cells, ineffective hematopoiesis, and an increased risk of developing acute myeloid leukemia (AML). MDS with ring sideroblasts (MDS-RS) is a favorable outcome subtype with a lower frequency of AML transformation. The FDA recently approved luspatercept for the treatment of patients with very-low-, low-, and intermediate-risk MDS-RS who have failed to correct anemia...]]></summary>
        <author>
            <name>Sigurd Delanghe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept]]></title>
        <id>pubmed:36611303</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36611303/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders distinguished by dysplastic bone marrow and peripheral blood cells, ineffective hematopoiesis, and an increased risk of developing acute myeloid leukemia (AML). MDS with ring sideroblasts (MDS-RS) is a favorable outcome subtype with a lower frequency of AML transformation. The FDA recently approved luspatercept for the treatment of patients with very-low-, low-, and intermediate-risk MDS-RS who have failed to correct anemia...]]></summary>
        <author>
            <name>Sigurd Delanghe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept]]></title>
        <id>pubmed:36611303</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36611303/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders distinguished by dysplastic bone marrow and peripheral blood cells, ineffective hematopoiesis, and an increased risk of developing acute myeloid leukemia (AML). MDS with ring sideroblasts (MDS-RS) is a favorable outcome subtype with a lower frequency of AML transformation. The FDA recently approved luspatercept for the treatment of patients with very-low-, low-, and intermediate-risk MDS-RS who have failed to correct anemia...]]></summary>
        <author>
            <name>Sigurd Delanghe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept]]></title>
        <id>pubmed:36611303</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36611303/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders distinguished by dysplastic bone marrow and peripheral blood cells, ineffective hematopoiesis, and an increased risk of developing acute myeloid leukemia (AML). MDS with ring sideroblasts (MDS-RS) is a favorable outcome subtype with a lower frequency of AML transformation. The FDA recently approved luspatercept for the treatment of patients with very-low-, low-, and intermediate-risk MDS-RS who have failed to correct anemia...]]></summary>
        <author>
            <name>Sigurd Delanghe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept]]></title>
        <id>pubmed:36611303</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36611303/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders distinguished by dysplastic bone marrow and peripheral blood cells, ineffective hematopoiesis, and an increased risk of developing acute myeloid leukemia (AML). MDS with ring sideroblasts (MDS-RS) is a favorable outcome subtype with a lower frequency of AML transformation. The FDA recently approved luspatercept for the treatment of patients with very-low-, low-, and intermediate-risk MDS-RS who have failed to correct anemia...]]></summary>
        <author>
            <name>Sigurd Delanghe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept]]></title>
        <id>pubmed:36611303</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36611303/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders distinguished by dysplastic bone marrow and peripheral blood cells, ineffective hematopoiesis, and an increased risk of developing acute myeloid leukemia (AML). MDS with ring sideroblasts (MDS-RS) is a favorable outcome subtype with a lower frequency of AML transformation. The FDA recently approved luspatercept for the treatment of patients with very-low-, low-, and intermediate-risk MDS-RS who have failed to correct anemia...]]></summary>
        <author>
            <name>Sigurd Delanghe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept]]></title>
        <id>pubmed:36611303</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36611303/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders distinguished by dysplastic bone marrow and peripheral blood cells, ineffective hematopoiesis, and an increased risk of developing acute myeloid leukemia (AML). MDS with ring sideroblasts (MDS-RS) is a favorable outcome subtype with a lower frequency of AML transformation. The FDA recently approved luspatercept for the treatment of patients with very-low-, low-, and intermediate-risk MDS-RS who have failed to correct anemia...]]></summary>
        <author>
            <name>Sigurd Delanghe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept]]></title>
        <id>pubmed:36611303</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36611303/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders distinguished by dysplastic bone marrow and peripheral blood cells, ineffective hematopoiesis, and an increased risk of developing acute myeloid leukemia (AML). MDS with ring sideroblasts (MDS-RS) is a favorable outcome subtype with a lower frequency of AML transformation. The FDA recently approved luspatercept for the treatment of patients with very-low-, low-, and intermediate-risk MDS-RS who have failed to correct anemia...]]></summary>
        <author>
            <name>Sigurd Delanghe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept]]></title>
        <id>pubmed:36611303</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36611303/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230116200009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders distinguished by dysplastic bone marrow and peripheral blood cells, ineffective hematopoiesis, and an increased risk of developing acute myeloid leukemia (AML). MDS with ring sideroblasts (MDS-RS) is a favorable outcome subtype with a lower frequency of AML transformation. The FDA recently approved luspatercept for the treatment of patients with very-low-, low-, and intermediate-risk MDS-RS who have failed to correct anemia...]]></summary>
        <author>
            <name>Sigurd Delanghe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept]]></title>
        <id>pubmed:36611303</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36611303/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders distinguished by dysplastic bone marrow and peripheral blood cells, ineffective hematopoiesis, and an increased risk of developing acute myeloid leukemia (AML). MDS with ring sideroblasts (MDS-RS) is a favorable outcome subtype with a lower frequency of AML transformation. The FDA recently approved luspatercept for the treatment of patients with very-low-, low-, and intermediate-risk MDS-RS who have failed to correct anemia...]]></summary>
        <author>
            <name>Sigurd Delanghe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept]]></title>
        <id>pubmed:36611303</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36611303/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders distinguished by dysplastic bone marrow and peripheral blood cells, ineffective hematopoiesis, and an increased risk of developing acute myeloid leukemia (AML). MDS with ring sideroblasts (MDS-RS) is a favorable outcome subtype with a lower frequency of AML transformation. The FDA recently approved luspatercept for the treatment of patients with very-low-, low-, and intermediate-risk MDS-RS who have failed to correct anemia...]]></summary>
        <author>
            <name>Sigurd Delanghe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept]]></title>
        <id>pubmed:36611303</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36611303/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders distinguished by dysplastic bone marrow and peripheral blood cells, ineffective hematopoiesis, and an increased risk of developing acute myeloid leukemia (AML). MDS with ring sideroblasts (MDS-RS) is a favorable outcome subtype with a lower frequency of AML transformation. The FDA recently approved luspatercept for the treatment of patients with very-low-, low-, and intermediate-risk MDS-RS who have failed to correct anemia...]]></summary>
        <author>
            <name>Sigurd Delanghe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept]]></title>
        <id>pubmed:36611303</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36611303/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders distinguished by dysplastic bone marrow and peripheral blood cells, ineffective hematopoiesis, and an increased risk of developing acute myeloid leukemia (AML). MDS with ring sideroblasts (MDS-RS) is a favorable outcome subtype with a lower frequency of AML transformation. The FDA recently approved luspatercept for the treatment of patients with very-low-, low-, and intermediate-risk MDS-RS who have failed to correct anemia...]]></summary>
        <author>
            <name>Sigurd Delanghe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept]]></title>
        <id>pubmed:36611303</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36611303/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders distinguished by dysplastic bone marrow and peripheral blood cells, ineffective hematopoiesis, and an increased risk of developing acute myeloid leukemia (AML). MDS with ring sideroblasts (MDS-RS) is a favorable outcome subtype with a lower frequency of AML transformation. The FDA recently approved luspatercept for the treatment of patients with very-low-, low-, and intermediate-risk MDS-RS who have failed to correct anemia...]]></summary>
        <author>
            <name>Sigurd Delanghe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept]]></title>
        <id>pubmed:36611303</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36611303/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230110200056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders distinguished by dysplastic bone marrow and peripheral blood cells, ineffective hematopoiesis, and an increased risk of developing acute myeloid leukemia (AML). MDS with ring sideroblasts (MDS-RS) is a favorable outcome subtype with a lower frequency of AML transformation. The FDA recently approved luspatercept for the treatment of patients with very-low-, low-, and intermediate-risk MDS-RS who have failed to correct anemia...]]></summary>
        <author>
            <name>Sigurd Delanghe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept]]></title>
        <id>pubmed:36611303</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36611303/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230109200310&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders distinguished by dysplastic bone marrow and peripheral blood cells, ineffective hematopoiesis, and an increased risk of developing acute myeloid leukemia (AML). MDS with ring sideroblasts (MDS-RS) is a favorable outcome subtype with a lower frequency of AML transformation. The FDA recently approved luspatercept for the treatment of patients with very-low-, low-, and intermediate-risk MDS-RS who have failed to correct anemia...]]></summary>
        <author>
            <name>Sigurd Delanghe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept]]></title>
        <id>pubmed:36611303</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36611303/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230108195940&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders distinguished by dysplastic bone marrow and peripheral blood cells, ineffective hematopoiesis, and an increased risk of developing acute myeloid leukemia (AML). MDS with ring sideroblasts (MDS-RS) is a favorable outcome subtype with a lower frequency of AML transformation. The FDA recently approved luspatercept for the treatment of patients with very-low-, low-, and intermediate-risk MDS-RS who have failed to correct anemia...]]></summary>
        <author>
            <name>Sigurd Delanghe</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A polygenic two-hit hypothesis for prostate cancer]]></title>
        <id>pubmed:36610996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36610996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Prostate cancer is one of the most heritable cancers. Hundreds of germline polymorphisms have been linked to prostate cancer diagnosis and prognosis. Polygenic risk scores can predict genetic risk of a prostate cancer diagnosis. While these scores inform on the probability of developing a tumor, it remains unknown how germline risk influences the tumor molecular evolution. We cultivated a cohort of 1,250 localized European-descent patients with germline and somatic DNA profiling. Men of European...]]></summary>
        <author>
            <name>Kathleen E Houlahan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A polygenic two-hit hypothesis for prostate cancer]]></title>
        <id>pubmed:36610996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36610996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Prostate cancer is one of the most heritable cancers. Hundreds of germline polymorphisms have been linked to prostate cancer diagnosis and prognosis. Polygenic risk scores can predict genetic risk of a prostate cancer diagnosis. While these scores inform on the probability of developing a tumor, it remains unknown how germline risk influences the tumor molecular evolution. We cultivated a cohort of 1,250 localized European-descent patients with germline and somatic DNA profiling. Men of European...]]></summary>
        <author>
            <name>Kathleen E Houlahan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A polygenic two-hit hypothesis for prostate cancer]]></title>
        <id>pubmed:36610996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36610996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Prostate cancer is one of the most heritable cancers. Hundreds of germline polymorphisms have been linked to prostate cancer diagnosis and prognosis. Polygenic risk scores can predict genetic risk of a prostate cancer diagnosis. While these scores inform on the probability of developing a tumor, it remains unknown how germline risk influences the tumor molecular evolution. We cultivated a cohort of 1,250 localized European-descent patients with germline and somatic DNA profiling. Men of European...]]></summary>
        <author>
            <name>Kathleen E Houlahan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A polygenic two-hit hypothesis for prostate cancer]]></title>
        <id>pubmed:36610996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36610996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Prostate cancer is one of the most heritable cancers. Hundreds of germline polymorphisms have been linked to prostate cancer diagnosis and prognosis. Polygenic risk scores can predict genetic risk of a prostate cancer diagnosis. While these scores inform on the probability of developing a tumor, it remains unknown how germline risk influences the tumor molecular evolution. We cultivated a cohort of 1,250 localized European-descent patients with germline and somatic DNA profiling. Men of European...]]></summary>
        <author>
            <name>Kathleen E Houlahan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A polygenic two-hit hypothesis for prostate cancer]]></title>
        <id>pubmed:36610996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36610996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Prostate cancer is one of the most heritable cancers. Hundreds of germline polymorphisms have been linked to prostate cancer diagnosis and prognosis. Polygenic risk scores can predict genetic risk of a prostate cancer diagnosis. While these scores inform on the probability of developing a tumor, it remains unknown how germline risk influences the tumor molecular evolution. We cultivated a cohort of 1,250 localized European-descent patients with germline and somatic DNA profiling. Men of European...]]></summary>
        <author>
            <name>Kathleen E Houlahan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A polygenic two-hit hypothesis for prostate cancer]]></title>
        <id>pubmed:36610996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36610996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Prostate cancer is one of the most heritable cancers. Hundreds of germline polymorphisms have been linked to prostate cancer diagnosis and prognosis. Polygenic risk scores can predict genetic risk of a prostate cancer diagnosis. While these scores inform on the probability of developing a tumor, it remains unknown how germline risk influences the tumor molecular evolution. We cultivated a cohort of 1,250 localized European-descent patients with germline and somatic DNA profiling. Men of European...]]></summary>
        <author>
            <name>Kathleen E Houlahan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A polygenic two-hit hypothesis for prostate cancer]]></title>
        <id>pubmed:36610996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36610996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Prostate cancer is one of the most heritable cancers. Hundreds of germline polymorphisms have been linked to prostate cancer diagnosis and prognosis. Polygenic risk scores can predict genetic risk of a prostate cancer diagnosis. While these scores inform on the probability of developing a tumor, it remains unknown how germline risk influences the tumor molecular evolution. We cultivated a cohort of 1,250 localized European-descent patients with germline and somatic DNA profiling. Men of European...]]></summary>
        <author>
            <name>Kathleen E Houlahan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A polygenic two-hit hypothesis for prostate cancer]]></title>
        <id>pubmed:36610996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36610996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230116200008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Prostate cancer is one of the most heritable cancers. Hundreds of germline polymorphisms have been linked to prostate cancer diagnosis and prognosis. Polygenic risk scores can predict genetic risk of a prostate cancer diagnosis. While these scores inform on the probability of developing a tumor, it remains unknown how germline risk influences the tumor molecular evolution. We cultivated a cohort of 1,250 localized European-descent patients with germline and somatic DNA profiling. Men of European...]]></summary>
        <author>
            <name>Kathleen E Houlahan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A polygenic two-hit hypothesis for prostate cancer]]></title>
        <id>pubmed:36610996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36610996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Prostate cancer is one of the most heritable cancers. Hundreds of germline polymorphisms have been linked to prostate cancer diagnosis and prognosis. Polygenic risk scores can predict genetic risk of a prostate cancer diagnosis. While these scores inform on the probability of developing a tumor, it remains unknown how germline risk influences the tumor molecular evolution. We cultivated a cohort of 1,250 localized European-descent patients with germline and somatic DNA profiling. Men of European...]]></summary>
        <author>
            <name>Kathleen E Houlahan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A polygenic two-hit hypothesis for prostate cancer]]></title>
        <id>pubmed:36610996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36610996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Prostate cancer is one of the most heritable cancers. Hundreds of germline polymorphisms have been linked to prostate cancer diagnosis and prognosis. Polygenic risk scores can predict genetic risk of a prostate cancer diagnosis. While these scores inform on the probability of developing a tumor, it remains unknown how germline risk influences the tumor molecular evolution. We cultivated a cohort of 1,250 localized European-descent patients with germline and somatic DNA profiling. Men of European...]]></summary>
        <author>
            <name>Kathleen E Houlahan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A polygenic two-hit hypothesis for prostate cancer]]></title>
        <id>pubmed:36610996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36610996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Prostate cancer is one of the most heritable cancers. Hundreds of germline polymorphisms have been linked to prostate cancer diagnosis and prognosis. Polygenic risk scores can predict genetic risk of a prostate cancer diagnosis. While these scores inform on the probability of developing a tumor, it remains unknown how germline risk influences the tumor molecular evolution. We cultivated a cohort of 1,250 localized European-descent patients with germline and somatic DNA profiling. Men of European...]]></summary>
        <author>
            <name>Kathleen E Houlahan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A polygenic two-hit hypothesis for prostate cancer]]></title>
        <id>pubmed:36610996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36610996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Prostate cancer is one of the most heritable cancers. Hundreds of germline polymorphisms have been linked to prostate cancer diagnosis and prognosis. Polygenic risk scores can predict genetic risk of a prostate cancer diagnosis. While these scores inform on the probability of developing a tumor, it remains unknown how germline risk influences the tumor molecular evolution. We cultivated a cohort of 1,250 localized European-descent patients with germline and somatic DNA profiling. Men of European...]]></summary>
        <author>
            <name>Kathleen E Houlahan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A polygenic two-hit hypothesis for prostate cancer]]></title>
        <id>pubmed:36610996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36610996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Prostate cancer is one of the most heritable cancers. Hundreds of germline polymorphisms have been linked to prostate cancer diagnosis and prognosis. Polygenic risk scores can predict genetic risk of a prostate cancer diagnosis. While these scores inform on the probability of developing a tumor, it remains unknown how germline risk influences the tumor molecular evolution. We cultivated a cohort of 1,250 localized European-descent patients with germline and somatic DNA profiling. Men of European...]]></summary>
        <author>
            <name>Kathleen E Houlahan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A polygenic two-hit hypothesis for prostate cancer]]></title>
        <id>pubmed:36610996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36610996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230110200057&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Prostate cancer is one of the most heritable cancers. Hundreds of germline polymorphisms have been linked to prostate cancer diagnosis and prognosis. Polygenic risk scores can predict genetic risk of a prostate cancer diagnosis. While these scores inform on the probability of developing a tumor, it remains unknown how germline risk influences the tumor molecular evolution. We cultivated a cohort of 1,250 localized European-descent patients with germline and somatic DNA profiling. Men of European...]]></summary>
        <author>
            <name>Kathleen E Houlahan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A polygenic two-hit hypothesis for prostate cancer]]></title>
        <id>pubmed:36610996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36610996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230109200310&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Prostate cancer is one of the most heritable cancers. Hundreds of germline polymorphisms have been linked to prostate cancer diagnosis and prognosis. Polygenic risk scores can predict genetic risk of a prostate cancer diagnosis. While these scores inform on the probability of developing a tumor, it remains unknown how germline risk influences the tumor molecular evolution. We cultivated a cohort of 1,250 localized European-descent patients with germline and somatic DNA profiling. Men of European...]]></summary>
        <author>
            <name>Kathleen E Houlahan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A polygenic two-hit hypothesis for prostate cancer]]></title>
        <id>pubmed:36610996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36610996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230108195940&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Prostate cancer is one of the most heritable cancers. Hundreds of germline polymorphisms have been linked to prostate cancer diagnosis and prognosis. Polygenic risk scores can predict genetic risk of a prostate cancer diagnosis. While these scores inform on the probability of developing a tumor, it remains unknown how germline risk influences the tumor molecular evolution. We cultivated a cohort of 1,250 localized European-descent patients with germline and somatic DNA profiling. Men of European...]]></summary>
        <author>
            <name>Kathleen E Houlahan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report]]></title>
        <id>pubmed:36604730</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604730/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this patient, longitudinal WES analysis revealed a sequential and cumulative pattern of genetic alterations, where germline and nevi somatic events contributed early to its rapid clinical progression. In this case report, we found tumor-associated nevi as genetically heterogeneous precursor entities, in which potential prognostic biomarkers should be studied prospectively.]]></summary>
        <author>
            <name>Ana Mordoh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis]]></title>
        <id>pubmed:36604421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome associated with germline TP53 pathogenic variants. Here, we perform whole-genome sequence (WGS) analysis of tumors from 22 patients with TP53 germline pathogenic variants. We observe somatic mutations affecting Wnt, PI3K/AKT signaling, epigenetic modifiers and homologous recombination genes as well as mutational signatures associated with prior chemotherapy. We identify near-ubiquitous early loss of heterozygosity of TP53,...]]></summary>
        <author>
            <name>Nicholas Light</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report]]></title>
        <id>pubmed:36604730</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604730/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this patient, longitudinal WES analysis revealed a sequential and cumulative pattern of genetic alterations, where germline and nevi somatic events contributed early to its rapid clinical progression. In this case report, we found tumor-associated nevi as genetically heterogeneous precursor entities, in which potential prognostic biomarkers should be studied prospectively.]]></summary>
        <author>
            <name>Ana Mordoh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis]]></title>
        <id>pubmed:36604421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome associated with germline TP53 pathogenic variants. Here, we perform whole-genome sequence (WGS) analysis of tumors from 22 patients with TP53 germline pathogenic variants. We observe somatic mutations affecting Wnt, PI3K/AKT signaling, epigenetic modifiers and homologous recombination genes as well as mutational signatures associated with prior chemotherapy. We identify near-ubiquitous early loss of heterozygosity of TP53,...]]></summary>
        <author>
            <name>Nicholas Light</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report]]></title>
        <id>pubmed:36604730</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604730/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this patient, longitudinal WES analysis revealed a sequential and cumulative pattern of genetic alterations, where germline and nevi somatic events contributed early to its rapid clinical progression. In this case report, we found tumor-associated nevi as genetically heterogeneous precursor entities, in which potential prognostic biomarkers should be studied prospectively.]]></summary>
        <author>
            <name>Ana Mordoh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis]]></title>
        <id>pubmed:36604421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome associated with germline TP53 pathogenic variants. Here, we perform whole-genome sequence (WGS) analysis of tumors from 22 patients with TP53 germline pathogenic variants. We observe somatic mutations affecting Wnt, PI3K/AKT signaling, epigenetic modifiers and homologous recombination genes as well as mutational signatures associated with prior chemotherapy. We identify near-ubiquitous early loss of heterozygosity of TP53,...]]></summary>
        <author>
            <name>Nicholas Light</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report]]></title>
        <id>pubmed:36604730</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604730/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this patient, longitudinal WES analysis revealed a sequential and cumulative pattern of genetic alterations, where germline and nevi somatic events contributed early to its rapid clinical progression. In this case report, we found tumor-associated nevi as genetically heterogeneous precursor entities, in which potential prognostic biomarkers should be studied prospectively.]]></summary>
        <author>
            <name>Ana Mordoh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis]]></title>
        <id>pubmed:36604421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome associated with germline TP53 pathogenic variants. Here, we perform whole-genome sequence (WGS) analysis of tumors from 22 patients with TP53 germline pathogenic variants. We observe somatic mutations affecting Wnt, PI3K/AKT signaling, epigenetic modifiers and homologous recombination genes as well as mutational signatures associated with prior chemotherapy. We identify near-ubiquitous early loss of heterozygosity of TP53,...]]></summary>
        <author>
            <name>Nicholas Light</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report]]></title>
        <id>pubmed:36604730</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604730/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this patient, longitudinal WES analysis revealed a sequential and cumulative pattern of genetic alterations, where germline and nevi somatic events contributed early to its rapid clinical progression. In this case report, we found tumor-associated nevi as genetically heterogeneous precursor entities, in which potential prognostic biomarkers should be studied prospectively.]]></summary>
        <author>
            <name>Ana Mordoh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis]]></title>
        <id>pubmed:36604421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome associated with germline TP53 pathogenic variants. Here, we perform whole-genome sequence (WGS) analysis of tumors from 22 patients with TP53 germline pathogenic variants. We observe somatic mutations affecting Wnt, PI3K/AKT signaling, epigenetic modifiers and homologous recombination genes as well as mutational signatures associated with prior chemotherapy. We identify near-ubiquitous early loss of heterozygosity of TP53,...]]></summary>
        <author>
            <name>Nicholas Light</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report]]></title>
        <id>pubmed:36604730</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604730/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this patient, longitudinal WES analysis revealed a sequential and cumulative pattern of genetic alterations, where germline and nevi somatic events contributed early to its rapid clinical progression. In this case report, we found tumor-associated nevi as genetically heterogeneous precursor entities, in which potential prognostic biomarkers should be studied prospectively.]]></summary>
        <author>
            <name>Ana Mordoh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis]]></title>
        <id>pubmed:36604421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome associated with germline TP53 pathogenic variants. Here, we perform whole-genome sequence (WGS) analysis of tumors from 22 patients with TP53 germline pathogenic variants. We observe somatic mutations affecting Wnt, PI3K/AKT signaling, epigenetic modifiers and homologous recombination genes as well as mutational signatures associated with prior chemotherapy. We identify near-ubiquitous early loss of heterozygosity of TP53,...]]></summary>
        <author>
            <name>Nicholas Light</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report]]></title>
        <id>pubmed:36604730</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604730/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230116200008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this patient, longitudinal WES analysis revealed a sequential and cumulative pattern of genetic alterations, where germline and nevi somatic events contributed early to its rapid clinical progression. In this case report, we found tumor-associated nevi as genetically heterogeneous precursor entities, in which potential prognostic biomarkers should be studied prospectively.]]></summary>
        <author>
            <name>Ana Mordoh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis]]></title>
        <id>pubmed:36604421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230116200008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome associated with germline TP53 pathogenic variants. Here, we perform whole-genome sequence (WGS) analysis of tumors from 22 patients with TP53 germline pathogenic variants. We observe somatic mutations affecting Wnt, PI3K/AKT signaling, epigenetic modifiers and homologous recombination genes as well as mutational signatures associated with prior chemotherapy. We identify near-ubiquitous early loss of heterozygosity of TP53,...]]></summary>
        <author>
            <name>Nicholas Light</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report]]></title>
        <id>pubmed:36604730</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604730/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this patient, longitudinal WES analysis revealed a sequential and cumulative pattern of genetic alterations, where germline and nevi somatic events contributed early to its rapid clinical progression. In this case report, we found tumor-associated nevi as genetically heterogeneous precursor entities, in which potential prognostic biomarkers should be studied prospectively.]]></summary>
        <author>
            <name>Ana Mordoh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis]]></title>
        <id>pubmed:36604421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome associated with germline TP53 pathogenic variants. Here, we perform whole-genome sequence (WGS) analysis of tumors from 22 patients with TP53 germline pathogenic variants. We observe somatic mutations affecting Wnt, PI3K/AKT signaling, epigenetic modifiers and homologous recombination genes as well as mutational signatures associated with prior chemotherapy. We identify near-ubiquitous early loss of heterozygosity of TP53,...]]></summary>
        <author>
            <name>Nicholas Light</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report]]></title>
        <id>pubmed:36604730</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604730/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this patient, longitudinal WES analysis revealed a sequential and cumulative pattern of genetic alterations, where germline and nevi somatic events contributed early to its rapid clinical progression. In this case report, we found tumor-associated nevi as genetically heterogeneous precursor entities, in which potential prognostic biomarkers should be studied prospectively.]]></summary>
        <author>
            <name>Ana Mordoh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis]]></title>
        <id>pubmed:36604421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome associated with germline TP53 pathogenic variants. Here, we perform whole-genome sequence (WGS) analysis of tumors from 22 patients with TP53 germline pathogenic variants. We observe somatic mutations affecting Wnt, PI3K/AKT signaling, epigenetic modifiers and homologous recombination genes as well as mutational signatures associated with prior chemotherapy. We identify near-ubiquitous early loss of heterozygosity of TP53,...]]></summary>
        <author>
            <name>Nicholas Light</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report]]></title>
        <id>pubmed:36604730</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604730/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this patient, longitudinal WES analysis revealed a sequential and cumulative pattern of genetic alterations, where germline and nevi somatic events contributed early to its rapid clinical progression. In this case report, we found tumor-associated nevi as genetically heterogeneous precursor entities, in which potential prognostic biomarkers should be studied prospectively.]]></summary>
        <author>
            <name>Ana Mordoh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis]]></title>
        <id>pubmed:36604421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome associated with germline TP53 pathogenic variants. Here, we perform whole-genome sequence (WGS) analysis of tumors from 22 patients with TP53 germline pathogenic variants. We observe somatic mutations affecting Wnt, PI3K/AKT signaling, epigenetic modifiers and homologous recombination genes as well as mutational signatures associated with prior chemotherapy. We identify near-ubiquitous early loss of heterozygosity of TP53,...]]></summary>
        <author>
            <name>Nicholas Light</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report]]></title>
        <id>pubmed:36604730</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604730/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this patient, longitudinal WES analysis revealed a sequential and cumulative pattern of genetic alterations, where germline and nevi somatic events contributed early to its rapid clinical progression. In this case report, we found tumor-associated nevi as genetically heterogeneous precursor entities, in which potential prognostic biomarkers should be studied prospectively.]]></summary>
        <author>
            <name>Ana Mordoh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis]]></title>
        <id>pubmed:36604421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome associated with germline TP53 pathogenic variants. Here, we perform whole-genome sequence (WGS) analysis of tumors from 22 patients with TP53 germline pathogenic variants. We observe somatic mutations affecting Wnt, PI3K/AKT signaling, epigenetic modifiers and homologous recombination genes as well as mutational signatures associated with prior chemotherapy. We identify near-ubiquitous early loss of heterozygosity of TP53,...]]></summary>
        <author>
            <name>Nicholas Light</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report]]></title>
        <id>pubmed:36604730</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604730/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this patient, longitudinal WES analysis revealed a sequential and cumulative pattern of genetic alterations, where germline and nevi somatic events contributed early to its rapid clinical progression. In this case report, we found tumor-associated nevi as genetically heterogeneous precursor entities, in which potential prognostic biomarkers should be studied prospectively.]]></summary>
        <author>
            <name>Ana Mordoh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis]]></title>
        <id>pubmed:36604421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome associated with germline TP53 pathogenic variants. Here, we perform whole-genome sequence (WGS) analysis of tumors from 22 patients with TP53 germline pathogenic variants. We observe somatic mutations affecting Wnt, PI3K/AKT signaling, epigenetic modifiers and homologous recombination genes as well as mutational signatures associated with prior chemotherapy. We identify near-ubiquitous early loss of heterozygosity of TP53,...]]></summary>
        <author>
            <name>Nicholas Light</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report]]></title>
        <id>pubmed:36604730</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604730/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230110200057&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this patient, longitudinal WES analysis revealed a sequential and cumulative pattern of genetic alterations, where germline and nevi somatic events contributed early to its rapid clinical progression. In this case report, we found tumor-associated nevi as genetically heterogeneous precursor entities, in which potential prognostic biomarkers should be studied prospectively.]]></summary>
        <author>
            <name>Ana Mordoh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis]]></title>
        <id>pubmed:36604421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230110200057&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome associated with germline TP53 pathogenic variants. Here, we perform whole-genome sequence (WGS) analysis of tumors from 22 patients with TP53 germline pathogenic variants. We observe somatic mutations affecting Wnt, PI3K/AKT signaling, epigenetic modifiers and homologous recombination genes as well as mutational signatures associated with prior chemotherapy. We identify near-ubiquitous early loss of heterozygosity of TP53,...]]></summary>
        <author>
            <name>Nicholas Light</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report]]></title>
        <id>pubmed:36604730</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604730/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230109200310&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this patient, longitudinal WES analysis revealed a sequential and cumulative pattern of genetic alterations, where germline and nevi somatic events contributed early to its rapid clinical progression. In this case report, we found tumor-associated nevi as genetically heterogeneous precursor entities, in which potential prognostic biomarkers should be studied prospectively.]]></summary>
        <author>
            <name>Ana Mordoh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis]]></title>
        <id>pubmed:36604421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230109200310&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome associated with germline TP53 pathogenic variants. Here, we perform whole-genome sequence (WGS) analysis of tumors from 22 patients with TP53 germline pathogenic variants. We observe somatic mutations affecting Wnt, PI3K/AKT signaling, epigenetic modifiers and homologous recombination genes as well as mutational signatures associated with prior chemotherapy. We identify near-ubiquitous early loss of heterozygosity of TP53,...]]></summary>
        <author>
            <name>Nicholas Light</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report]]></title>
        <id>pubmed:36604730</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604730/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230108195940&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this patient, longitudinal WES analysis revealed a sequential and cumulative pattern of genetic alterations, where germline and nevi somatic events contributed early to its rapid clinical progression. In this case report, we found tumor-associated nevi as genetically heterogeneous precursor entities, in which potential prognostic biomarkers should be studied prospectively.]]></summary>
        <author>
            <name>Ana Mordoh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis]]></title>
        <id>pubmed:36604421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230108195940&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome associated with germline TP53 pathogenic variants. Here, we perform whole-genome sequence (WGS) analysis of tumors from 22 patients with TP53 germline pathogenic variants. We observe somatic mutations affecting Wnt, PI3K/AKT signaling, epigenetic modifiers and homologous recombination genes as well as mutational signatures associated with prior chemotherapy. We identify near-ubiquitous early loss of heterozygosity of TP53,...]]></summary>
        <author>
            <name>Nicholas Light</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report]]></title>
        <id>pubmed:36604730</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604730/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230107200413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this patient, longitudinal WES analysis revealed a sequential and cumulative pattern of genetic alterations, where germline and nevi somatic events contributed early to its rapid clinical progression. In this case report, we found tumor-associated nevi as genetically heterogeneous precursor entities, in which potential prognostic biomarkers should be studied prospectively.]]></summary>
        <author>
            <name>Ana Mordoh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis]]></title>
        <id>pubmed:36604421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230107200413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome associated with germline TP53 pathogenic variants. Here, we perform whole-genome sequence (WGS) analysis of tumors from 22 patients with TP53 germline pathogenic variants. We observe somatic mutations affecting Wnt, PI3K/AKT signaling, epigenetic modifiers and homologous recombination genes as well as mutational signatures associated with prior chemotherapy. We identify near-ubiquitous early loss of heterozygosity of TP53,...]]></summary>
        <author>
            <name>Nicholas Light</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230125200117&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230124195847&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230123200236&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230116200009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230110200056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230109200310&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230108195940&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230107200413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA]]></title>
        <id>pubmed:36598417</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36598417/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Malignant peripheral nerve sheath tumor (MPNST), an aggressive soft-tissue sarcoma, occurs in people with neurofibromatosis type 1 (NF1) and sporadically. Whole-genome and multi-regional exome sequencing, transcriptomic, and methylation profiling of 95 tumor samples revealed the order of genomic events in tumor evolution. Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy number...]]></summary>
        <author>
            <name>Isidro Cortes-Ciriano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA]]></title>
        <id>pubmed:36598417</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36598417/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Malignant peripheral nerve sheath tumor (MPNST), an aggressive soft-tissue sarcoma, occurs in people with neurofibromatosis type 1 (NF1) and sporadically. Whole-genome and multi-regional exome sequencing, transcriptomic, and methylation profiling of 95 tumor samples revealed the order of genomic events in tumor evolution. Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy number...]]></summary>
        <author>
            <name>Isidro Cortes-Ciriano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA]]></title>
        <id>pubmed:36598417</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36598417/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Malignant peripheral nerve sheath tumor (MPNST), an aggressive soft-tissue sarcoma, occurs in people with neurofibromatosis type 1 (NF1) and sporadically. Whole-genome and multi-regional exome sequencing, transcriptomic, and methylation profiling of 95 tumor samples revealed the order of genomic events in tumor evolution. Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy number...]]></summary>
        <author>
            <name>Isidro Cortes-Ciriano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA]]></title>
        <id>pubmed:36598417</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36598417/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Malignant peripheral nerve sheath tumor (MPNST), an aggressive soft-tissue sarcoma, occurs in people with neurofibromatosis type 1 (NF1) and sporadically. Whole-genome and multi-regional exome sequencing, transcriptomic, and methylation profiling of 95 tumor samples revealed the order of genomic events in tumor evolution. Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy number...]]></summary>
        <author>
            <name>Isidro Cortes-Ciriano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230116200008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA]]></title>
        <id>pubmed:36598417</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36598417/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230116200008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Malignant peripheral nerve sheath tumor (MPNST), an aggressive soft-tissue sarcoma, occurs in people with neurofibromatosis type 1 (NF1) and sporadically. Whole-genome and multi-regional exome sequencing, transcriptomic, and methylation profiling of 95 tumor samples revealed the order of genomic events in tumor evolution. Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy number...]]></summary>
        <author>
            <name>Isidro Cortes-Ciriano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA]]></title>
        <id>pubmed:36598417</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36598417/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Malignant peripheral nerve sheath tumor (MPNST), an aggressive soft-tissue sarcoma, occurs in people with neurofibromatosis type 1 (NF1) and sporadically. Whole-genome and multi-regional exome sequencing, transcriptomic, and methylation profiling of 95 tumor samples revealed the order of genomic events in tumor evolution. Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy number...]]></summary>
        <author>
            <name>Isidro Cortes-Ciriano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA]]></title>
        <id>pubmed:36598417</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36598417/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Malignant peripheral nerve sheath tumor (MPNST), an aggressive soft-tissue sarcoma, occurs in people with neurofibromatosis type 1 (NF1) and sporadically. Whole-genome and multi-regional exome sequencing, transcriptomic, and methylation profiling of 95 tumor samples revealed the order of genomic events in tumor evolution. Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy number...]]></summary>
        <author>
            <name>Isidro Cortes-Ciriano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA]]></title>
        <id>pubmed:36598417</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36598417/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Malignant peripheral nerve sheath tumor (MPNST), an aggressive soft-tissue sarcoma, occurs in people with neurofibromatosis type 1 (NF1) and sporadically. Whole-genome and multi-regional exome sequencing, transcriptomic, and methylation profiling of 95 tumor samples revealed the order of genomic events in tumor evolution. Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy number...]]></summary>
        <author>
            <name>Isidro Cortes-Ciriano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA]]></title>
        <id>pubmed:36598417</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36598417/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Malignant peripheral nerve sheath tumor (MPNST), an aggressive soft-tissue sarcoma, occurs in people with neurofibromatosis type 1 (NF1) and sporadically. Whole-genome and multi-regional exome sequencing, transcriptomic, and methylation profiling of 95 tumor samples revealed the order of genomic events in tumor evolution. Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy number...]]></summary>
        <author>
            <name>Isidro Cortes-Ciriano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA]]></title>
        <id>pubmed:36598417</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36598417/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Malignant peripheral nerve sheath tumor (MPNST), an aggressive soft-tissue sarcoma, occurs in people with neurofibromatosis type 1 (NF1) and sporadically. Whole-genome and multi-regional exome sequencing, transcriptomic, and methylation profiling of 95 tumor samples revealed the order of genomic events in tumor evolution. Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy number...]]></summary>
        <author>
            <name>Isidro Cortes-Ciriano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230110200057&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA]]></title>
        <id>pubmed:36598417</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36598417/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230110200057&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Malignant peripheral nerve sheath tumor (MPNST), an aggressive soft-tissue sarcoma, occurs in people with neurofibromatosis type 1 (NF1) and sporadically. Whole-genome and multi-regional exome sequencing, transcriptomic, and methylation profiling of 95 tumor samples revealed the order of genomic events in tumor evolution. Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy number...]]></summary>
        <author>
            <name>Isidro Cortes-Ciriano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230109200310&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA]]></title>
        <id>pubmed:36598417</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36598417/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230109200310&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Malignant peripheral nerve sheath tumor (MPNST), an aggressive soft-tissue sarcoma, occurs in people with neurofibromatosis type 1 (NF1) and sporadically. Whole-genome and multi-regional exome sequencing, transcriptomic, and methylation profiling of 95 tumor samples revealed the order of genomic events in tumor evolution. Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy number...]]></summary>
        <author>
            <name>Isidro Cortes-Ciriano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230108195940&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA]]></title>
        <id>pubmed:36598417</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36598417/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230108195940&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Malignant peripheral nerve sheath tumor (MPNST), an aggressive soft-tissue sarcoma, occurs in people with neurofibromatosis type 1 (NF1) and sporadically. Whole-genome and multi-regional exome sequencing, transcriptomic, and methylation profiling of 95 tumor samples revealed the order of genomic events in tumor evolution. Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy number...]]></summary>
        <author>
            <name>Isidro Cortes-Ciriano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230107200413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA]]></title>
        <id>pubmed:36598417</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36598417/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230107200413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Malignant peripheral nerve sheath tumor (MPNST), an aggressive soft-tissue sarcoma, occurs in people with neurofibromatosis type 1 (NF1) and sporadically. Whole-genome and multi-regional exome sequencing, transcriptomic, and methylation profiling of 95 tumor samples revealed the order of genomic events in tumor evolution. Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy number...]]></summary>
        <author>
            <name>Isidro Cortes-Ciriano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA]]></title>
        <id>pubmed:36598417</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36598417/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Malignant peripheral nerve sheath tumor (MPNST), an aggressive soft-tissue sarcoma, occurs in people with neurofibromatosis type 1 (NF1) and sporadically. Whole-genome and multi-regional exome sequencing, transcriptomic, and methylation profiling of 95 tumor samples revealed the order of genomic events in tumor evolution. Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy number...]]></summary>
        <author>
            <name>Isidro Cortes-Ciriano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA]]></title>
        <id>pubmed:36598417</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36598417/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Malignant peripheral nerve sheath tumor (MPNST), an aggressive soft-tissue sarcoma, occurs in people with neurofibromatosis type 1 (NF1) and sporadically. Whole-genome and multi-regional exome sequencing, transcriptomic, and methylation profiling of 95 tumor samples revealed the order of genomic events in tumor evolution. Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy number...]]></summary>
        <author>
            <name>Isidro Cortes-Ciriano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In vivo clonal tracking reveals evidence of haemangioblast and haematomesoblast contribution to yolk sac haematopoiesis]]></title>
        <id>pubmed:36596806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36596806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230122195914&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[During embryogenesis, haematopoietic and endothelial lineages emerge closely in time and space. It is thought that the first blood and endothelium derive from a common clonal ancestor, the haemangioblast. However, investigation of candidate haemangioblasts in vitro revealed the capacity for mesenchymal differentiation, a feature more compatible with an earlier mesodermal precursor. To date, no evidence for an in vivo haemangioblast has been discovered. Using single cell RNA-Sequencing and in...]]></summary>
        <author>
            <name>C Biben</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In vivo clonal tracking reveals evidence of haemangioblast and haematomesoblast contribution to yolk sac haematopoiesis]]></title>
        <id>pubmed:36596806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36596806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230121200342&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[During embryogenesis, haematopoietic and endothelial lineages emerge closely in time and space. It is thought that the first blood and endothelium derive from a common clonal ancestor, the haemangioblast. However, investigation of candidate haemangioblasts in vitro revealed the capacity for mesenchymal differentiation, a feature more compatible with an earlier mesodermal precursor. To date, no evidence for an in vivo haemangioblast has been discovered. Using single cell RNA-Sequencing and in...]]></summary>
        <author>
            <name>C Biben</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In vivo clonal tracking reveals evidence of haemangioblast and haematomesoblast contribution to yolk sac haematopoiesis]]></title>
        <id>pubmed:36596806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36596806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[During embryogenesis, haematopoietic and endothelial lineages emerge closely in time and space. It is thought that the first blood and endothelium derive from a common clonal ancestor, the haemangioblast. However, investigation of candidate haemangioblasts in vitro revealed the capacity for mesenchymal differentiation, a feature more compatible with an earlier mesodermal precursor. To date, no evidence for an in vivo haemangioblast has been discovered. Using single cell RNA-Sequencing and in...]]></summary>
        <author>
            <name>C Biben</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A new risk factor associated with cardiovascular disease: clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:36595120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36595120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a prevalent disease associated with all-cause death. Not only because it can be a precancerous lesion of blood system diseases but also has a strong association with cardiovascular disease. A narrow term, clonal hematopoiesis of indeterminate potential (CHIP), was proposed by Steensma et al. [1] to describe individuals with detectable somatic clonal mutations in their genes in blood or bone marrow but without a diagnosis of hematological disease or unexplained cytopenia....]]></summary>
        <author>
            <name>Xiongkai Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In vivo clonal tracking reveals evidence of haemangioblast and haematomesoblast contribution to yolk sac haematopoiesis]]></title>
        <id>pubmed:36596806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36596806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[During embryogenesis, haematopoietic and endothelial lineages emerge closely in time and space. It is thought that the first blood and endothelium derive from a common clonal ancestor, the haemangioblast. However, investigation of candidate haemangioblasts in vitro revealed the capacity for mesenchymal differentiation, a feature more compatible with an earlier mesodermal precursor. To date, no evidence for an in vivo haemangioblast has been discovered. Using single cell RNA-Sequencing and in...]]></summary>
        <author>
            <name>C Biben</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A new risk factor associated with cardiovascular disease: clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:36595120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36595120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a prevalent disease associated with all-cause death. Not only because it can be a precancerous lesion of blood system diseases but also has a strong association with cardiovascular disease. A narrow term, clonal hematopoiesis of indeterminate potential (CHIP), was proposed by Steensma et al. [1] to describe individuals with detectable somatic clonal mutations in their genes in blood or bone marrow but without a diagnosis of hematological disease or unexplained cytopenia....]]></summary>
        <author>
            <name>Xiongkai Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In vivo clonal tracking reveals evidence of haemangioblast and haematomesoblast contribution to yolk sac haematopoiesis]]></title>
        <id>pubmed:36596806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36596806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[During embryogenesis, haematopoietic and endothelial lineages emerge closely in time and space. It is thought that the first blood and endothelium derive from a common clonal ancestor, the haemangioblast. However, investigation of candidate haemangioblasts in vitro revealed the capacity for mesenchymal differentiation, a feature more compatible with an earlier mesodermal precursor. To date, no evidence for an in vivo haemangioblast has been discovered. Using single cell RNA-Sequencing and in...]]></summary>
        <author>
            <name>C Biben</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A new risk factor associated with cardiovascular disease: clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:36595120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36595120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a prevalent disease associated with all-cause death. Not only because it can be a precancerous lesion of blood system diseases but also has a strong association with cardiovascular disease. A narrow term, clonal hematopoiesis of indeterminate potential (CHIP), was proposed by Steensma et al. [1] to describe individuals with detectable somatic clonal mutations in their genes in blood or bone marrow but without a diagnosis of hematological disease or unexplained cytopenia....]]></summary>
        <author>
            <name>Xiongkai Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In vivo clonal tracking reveals evidence of haemangioblast and haematomesoblast contribution to yolk sac haematopoiesis]]></title>
        <id>pubmed:36596806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36596806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[During embryogenesis, haematopoietic and endothelial lineages emerge closely in time and space. It is thought that the first blood and endothelium derive from a common clonal ancestor, the haemangioblast. However, investigation of candidate haemangioblasts in vitro revealed the capacity for mesenchymal differentiation, a feature more compatible with an earlier mesodermal precursor. To date, no evidence for an in vivo haemangioblast has been discovered. Using single cell RNA-Sequencing and in...]]></summary>
        <author>
            <name>C Biben</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A new risk factor associated with cardiovascular disease: clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:36595120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36595120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a prevalent disease associated with all-cause death. Not only because it can be a precancerous lesion of blood system diseases but also has a strong association with cardiovascular disease. A narrow term, clonal hematopoiesis of indeterminate potential (CHIP), was proposed by Steensma et al. [1] to describe individuals with detectable somatic clonal mutations in their genes in blood or bone marrow but without a diagnosis of hematological disease or unexplained cytopenia....]]></summary>
        <author>
            <name>Xiongkai Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In vivo clonal tracking reveals evidence of haemangioblast and haematomesoblast contribution to yolk sac haematopoiesis]]></title>
        <id>pubmed:36596806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36596806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230116200009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[During embryogenesis, haematopoietic and endothelial lineages emerge closely in time and space. It is thought that the first blood and endothelium derive from a common clonal ancestor, the haemangioblast. However, investigation of candidate haemangioblasts in vitro revealed the capacity for mesenchymal differentiation, a feature more compatible with an earlier mesodermal precursor. To date, no evidence for an in vivo haemangioblast has been discovered. Using single cell RNA-Sequencing and in...]]></summary>
        <author>
            <name>C Biben</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A new risk factor associated with cardiovascular disease: clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:36595120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36595120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230116200009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a prevalent disease associated with all-cause death. Not only because it can be a precancerous lesion of blood system diseases but also has a strong association with cardiovascular disease. A narrow term, clonal hematopoiesis of indeterminate potential (CHIP), was proposed by Steensma et al. [1] to describe individuals with detectable somatic clonal mutations in their genes in blood or bone marrow but without a diagnosis of hematological disease or unexplained cytopenia....]]></summary>
        <author>
            <name>Xiongkai Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In vivo clonal tracking reveals evidence of haemangioblast and haematomesoblast contribution to yolk sac haematopoiesis]]></title>
        <id>pubmed:36596806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36596806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[During embryogenesis, haematopoietic and endothelial lineages emerge closely in time and space. It is thought that the first blood and endothelium derive from a common clonal ancestor, the haemangioblast. However, investigation of candidate haemangioblasts in vitro revealed the capacity for mesenchymal differentiation, a feature more compatible with an earlier mesodermal precursor. To date, no evidence for an in vivo haemangioblast has been discovered. Using single cell RNA-Sequencing and in...]]></summary>
        <author>
            <name>C Biben</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A new risk factor associated with cardiovascular disease: clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:36595120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36595120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a prevalent disease associated with all-cause death. Not only because it can be a precancerous lesion of blood system diseases but also has a strong association with cardiovascular disease. A narrow term, clonal hematopoiesis of indeterminate potential (CHIP), was proposed by Steensma et al. [1] to describe individuals with detectable somatic clonal mutations in their genes in blood or bone marrow but without a diagnosis of hematological disease or unexplained cytopenia....]]></summary>
        <author>
            <name>Xiongkai Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In vivo clonal tracking reveals evidence of haemangioblast and haematomesoblast contribution to yolk sac haematopoiesis]]></title>
        <id>pubmed:36596806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36596806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[During embryogenesis, haematopoietic and endothelial lineages emerge closely in time and space. It is thought that the first blood and endothelium derive from a common clonal ancestor, the haemangioblast. However, investigation of candidate haemangioblasts in vitro revealed the capacity for mesenchymal differentiation, a feature more compatible with an earlier mesodermal precursor. To date, no evidence for an in vivo haemangioblast has been discovered. Using single cell RNA-Sequencing and in...]]></summary>
        <author>
            <name>C Biben</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A new risk factor associated with cardiovascular disease: clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:36595120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36595120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a prevalent disease associated with all-cause death. Not only because it can be a precancerous lesion of blood system diseases but also has a strong association with cardiovascular disease. A narrow term, clonal hematopoiesis of indeterminate potential (CHIP), was proposed by Steensma et al. [1] to describe individuals with detectable somatic clonal mutations in their genes in blood or bone marrow but without a diagnosis of hematological disease or unexplained cytopenia....]]></summary>
        <author>
            <name>Xiongkai Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In vivo clonal tracking reveals evidence of haemangioblast and haematomesoblast contribution to yolk sac haematopoiesis]]></title>
        <id>pubmed:36596806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36596806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[During embryogenesis, haematopoietic and endothelial lineages emerge closely in time and space. It is thought that the first blood and endothelium derive from a common clonal ancestor, the haemangioblast. However, investigation of candidate haemangioblasts in vitro revealed the capacity for mesenchymal differentiation, a feature more compatible with an earlier mesodermal precursor. To date, no evidence for an in vivo haemangioblast has been discovered. Using single cell RNA-Sequencing and in...]]></summary>
        <author>
            <name>C Biben</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A new risk factor associated with cardiovascular disease: clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:36595120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36595120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a prevalent disease associated with all-cause death. Not only because it can be a precancerous lesion of blood system diseases but also has a strong association with cardiovascular disease. A narrow term, clonal hematopoiesis of indeterminate potential (CHIP), was proposed by Steensma et al. [1] to describe individuals with detectable somatic clonal mutations in their genes in blood or bone marrow but without a diagnosis of hematological disease or unexplained cytopenia....]]></summary>
        <author>
            <name>Xiongkai Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In vivo clonal tracking reveals evidence of haemangioblast and haematomesoblast contribution to yolk sac haematopoiesis]]></title>
        <id>pubmed:36596806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36596806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[During embryogenesis, haematopoietic and endothelial lineages emerge closely in time and space. It is thought that the first blood and endothelium derive from a common clonal ancestor, the haemangioblast. However, investigation of candidate haemangioblasts in vitro revealed the capacity for mesenchymal differentiation, a feature more compatible with an earlier mesodermal precursor. To date, no evidence for an in vivo haemangioblast has been discovered. Using single cell RNA-Sequencing and in...]]></summary>
        <author>
            <name>C Biben</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A new risk factor associated with cardiovascular disease: clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:36595120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36595120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a prevalent disease associated with all-cause death. Not only because it can be a precancerous lesion of blood system diseases but also has a strong association with cardiovascular disease. A narrow term, clonal hematopoiesis of indeterminate potential (CHIP), was proposed by Steensma et al. [1] to describe individuals with detectable somatic clonal mutations in their genes in blood or bone marrow but without a diagnosis of hematological disease or unexplained cytopenia....]]></summary>
        <author>
            <name>Xiongkai Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In vivo clonal tracking reveals evidence of haemangioblast and haematomesoblast contribution to yolk sac haematopoiesis]]></title>
        <id>pubmed:36596806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36596806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[During embryogenesis, haematopoietic and endothelial lineages emerge closely in time and space. It is thought that the first blood and endothelium derive from a common clonal ancestor, the haemangioblast. However, investigation of candidate haemangioblasts in vitro revealed the capacity for mesenchymal differentiation, a feature more compatible with an earlier mesodermal precursor. To date, no evidence for an in vivo haemangioblast has been discovered. Using single cell RNA-Sequencing and in...]]></summary>
        <author>
            <name>C Biben</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A new risk factor associated with cardiovascular disease: clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:36595120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36595120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a prevalent disease associated with all-cause death. Not only because it can be a precancerous lesion of blood system diseases but also has a strong association with cardiovascular disease. A narrow term, clonal hematopoiesis of indeterminate potential (CHIP), was proposed by Steensma et al. [1] to describe individuals with detectable somatic clonal mutations in their genes in blood or bone marrow but without a diagnosis of hematological disease or unexplained cytopenia....]]></summary>
        <author>
            <name>Xiongkai Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In vivo clonal tracking reveals evidence of haemangioblast and haematomesoblast contribution to yolk sac haematopoiesis]]></title>
        <id>pubmed:36596806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36596806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230110200056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[During embryogenesis, haematopoietic and endothelial lineages emerge closely in time and space. It is thought that the first blood and endothelium derive from a common clonal ancestor, the haemangioblast. However, investigation of candidate haemangioblasts in vitro revealed the capacity for mesenchymal differentiation, a feature more compatible with an earlier mesodermal precursor. To date, no evidence for an in vivo haemangioblast has been discovered. Using single cell RNA-Sequencing and in...]]></summary>
        <author>
            <name>C Biben</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A new risk factor associated with cardiovascular disease: clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:36595120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36595120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230110200056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a prevalent disease associated with all-cause death. Not only because it can be a precancerous lesion of blood system diseases but also has a strong association with cardiovascular disease. A narrow term, clonal hematopoiesis of indeterminate potential (CHIP), was proposed by Steensma et al. [1] to describe individuals with detectable somatic clonal mutations in their genes in blood or bone marrow but without a diagnosis of hematological disease or unexplained cytopenia....]]></summary>
        <author>
            <name>Xiongkai Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In vivo clonal tracking reveals evidence of haemangioblast and haematomesoblast contribution to yolk sac haematopoiesis]]></title>
        <id>pubmed:36596806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36596806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230109200310&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[During embryogenesis, haematopoietic and endothelial lineages emerge closely in time and space. It is thought that the first blood and endothelium derive from a common clonal ancestor, the haemangioblast. However, investigation of candidate haemangioblasts in vitro revealed the capacity for mesenchymal differentiation, a feature more compatible with an earlier mesodermal precursor. To date, no evidence for an in vivo haemangioblast has been discovered. Using single cell RNA-Sequencing and in...]]></summary>
        <author>
            <name>C Biben</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A new risk factor associated with cardiovascular disease: clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:36595120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36595120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230109200310&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a prevalent disease associated with all-cause death. Not only because it can be a precancerous lesion of blood system diseases but also has a strong association with cardiovascular disease. A narrow term, clonal hematopoiesis of indeterminate potential (CHIP), was proposed by Steensma et al. [1] to describe individuals with detectable somatic clonal mutations in their genes in blood or bone marrow but without a diagnosis of hematological disease or unexplained cytopenia....]]></summary>
        <author>
            <name>Xiongkai Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In vivo clonal tracking reveals evidence of haemangioblast and haematomesoblast contribution to yolk sac haematopoiesis]]></title>
        <id>pubmed:36596806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36596806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230108195940&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[During embryogenesis, haematopoietic and endothelial lineages emerge closely in time and space. It is thought that the first blood and endothelium derive from a common clonal ancestor, the haemangioblast. However, investigation of candidate haemangioblasts in vitro revealed the capacity for mesenchymal differentiation, a feature more compatible with an earlier mesodermal precursor. To date, no evidence for an in vivo haemangioblast has been discovered. Using single cell RNA-Sequencing and in...]]></summary>
        <author>
            <name>C Biben</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A new risk factor associated with cardiovascular disease: clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:36595120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36595120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230108195940&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a prevalent disease associated with all-cause death. Not only because it can be a precancerous lesion of blood system diseases but also has a strong association with cardiovascular disease. A narrow term, clonal hematopoiesis of indeterminate potential (CHIP), was proposed by Steensma et al. [1] to describe individuals with detectable somatic clonal mutations in their genes in blood or bone marrow but without a diagnosis of hematological disease or unexplained cytopenia....]]></summary>
        <author>
            <name>Xiongkai Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In vivo clonal tracking reveals evidence of haemangioblast and haematomesoblast contribution to yolk sac haematopoiesis]]></title>
        <id>pubmed:36596806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36596806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230107200413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[During embryogenesis, haematopoietic and endothelial lineages emerge closely in time and space. It is thought that the first blood and endothelium derive from a common clonal ancestor, the haemangioblast. However, investigation of candidate haemangioblasts in vitro revealed the capacity for mesenchymal differentiation, a feature more compatible with an earlier mesodermal precursor. To date, no evidence for an in vivo haemangioblast has been discovered. Using single cell RNA-Sequencing and in...]]></summary>
        <author>
            <name>C Biben</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A new risk factor associated with cardiovascular disease: clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:36595120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36595120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230107200413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a prevalent disease associated with all-cause death. Not only because it can be a precancerous lesion of blood system diseases but also has a strong association with cardiovascular disease. A narrow term, clonal hematopoiesis of indeterminate potential (CHIP), was proposed by Steensma et al. [1] to describe individuals with detectable somatic clonal mutations in their genes in blood or bone marrow but without a diagnosis of hematological disease or unexplained cytopenia....]]></summary>
        <author>
            <name>Xiongkai Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In vivo clonal tracking reveals evidence of haemangioblast and haematomesoblast contribution to yolk sac haematopoiesis]]></title>
        <id>pubmed:36596806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36596806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[During embryogenesis, haematopoietic and endothelial lineages emerge closely in time and space. It is thought that the first blood and endothelium derive from a common clonal ancestor, the haemangioblast. However, investigation of candidate haemangioblasts in vitro revealed the capacity for mesenchymal differentiation, a feature more compatible with an earlier mesodermal precursor. To date, no evidence for an in vivo haemangioblast has been discovered. Using single cell RNA-Sequencing and in...]]></summary>
        <author>
            <name>C Biben</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A new risk factor associated with cardiovascular disease: clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:36595120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36595120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a prevalent disease associated with all-cause death. Not only because it can be a precancerous lesion of blood system diseases but also has a strong association with cardiovascular disease. A narrow term, clonal hematopoiesis of indeterminate potential (CHIP), was proposed by Steensma et al. [1] to describe individuals with detectable somatic clonal mutations in their genes in blood or bone marrow but without a diagnosis of hematological disease or unexplained cytopenia....]]></summary>
        <author>
            <name>Xiongkai Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A new risk factor associated with cardiovascular disease: clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:36595120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36595120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a prevalent disease associated with all-cause death. Not only because it can be a precancerous lesion of blood system diseases but also has a strong association with cardiovascular disease. A narrow term, clonal hematopoiesis of indeterminate potential (CHIP), was proposed by Steensma et al. [1] to describe individuals with detectable somatic clonal mutations in their genes in blood or bone marrow but without a diagnosis of hematological disease or unexplained cytopenia....]]></summary>
        <author>
            <name>Xiongkai Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A new risk factor associated with cardiovascular disease: clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:36595120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36595120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a prevalent disease associated with all-cause death. Not only because it can be a precancerous lesion of blood system diseases but also has a strong association with cardiovascular disease. A narrow term, clonal hematopoiesis of indeterminate potential (CHIP), was proposed by Steensma et al. [1] to describe individuals with detectable somatic clonal mutations in their genes in blood or bone marrow but without a diagnosis of hematological disease or unexplained cytopenia....]]></summary>
        <author>
            <name>Xiongkai Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and inflammation - the perpetual cycle]]></title>
        <id>pubmed:36593155</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36593155/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired genetic or cytogenetic alterations in a blood stem cell that confer clonal fitness promote its relative expansion leading to clonal hematopoiesis (CH). Despite a largely intact hematopoietic output, CH is associated with a heightened risk of progression to hematologic malignancies and with non-hematologic health manifestations, including cardiovascular disease and overall mortality. We focus on the evidence for the role of inflammation in establishing, maintaining and reciprocally being...]]></summary>
        <author>
            <name>Serine Avagyan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and inflammation - the perpetual cycle]]></title>
        <id>pubmed:36593155</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36593155/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired genetic or cytogenetic alterations in a blood stem cell that confer clonal fitness promote its relative expansion leading to clonal hematopoiesis (CH). Despite a largely intact hematopoietic output, CH is associated with a heightened risk of progression to hematologic malignancies and with non-hematologic health manifestations, including cardiovascular disease and overall mortality. We focus on the evidence for the role of inflammation in establishing, maintaining and reciprocally being...]]></summary>
        <author>
            <name>Serine Avagyan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and inflammation - the perpetual cycle]]></title>
        <id>pubmed:36593155</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36593155/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired genetic or cytogenetic alterations in a blood stem cell that confer clonal fitness promote its relative expansion leading to clonal hematopoiesis (CH). Despite a largely intact hematopoietic output, CH is associated with a heightened risk of progression to hematologic malignancies and with non-hematologic health manifestations, including cardiovascular disease and overall mortality. We focus on the evidence for the role of inflammation in establishing, maintaining and reciprocally being...]]></summary>
        <author>
            <name>Serine Avagyan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and inflammation - the perpetual cycle]]></title>
        <id>pubmed:36593155</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36593155/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired genetic or cytogenetic alterations in a blood stem cell that confer clonal fitness promote its relative expansion leading to clonal hematopoiesis (CH). Despite a largely intact hematopoietic output, CH is associated with a heightened risk of progression to hematologic malignancies and with non-hematologic health manifestations, including cardiovascular disease and overall mortality. We focus on the evidence for the role of inflammation in establishing, maintaining and reciprocally being...]]></summary>
        <author>
            <name>Serine Avagyan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and inflammation - the perpetual cycle]]></title>
        <id>pubmed:36593155</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36593155/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230116200009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired genetic or cytogenetic alterations in a blood stem cell that confer clonal fitness promote its relative expansion leading to clonal hematopoiesis (CH). Despite a largely intact hematopoietic output, CH is associated with a heightened risk of progression to hematologic malignancies and with non-hematologic health manifestations, including cardiovascular disease and overall mortality. We focus on the evidence for the role of inflammation in establishing, maintaining and reciprocally being...]]></summary>
        <author>
            <name>Serine Avagyan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and inflammation - the perpetual cycle]]></title>
        <id>pubmed:36593155</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36593155/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired genetic or cytogenetic alterations in a blood stem cell that confer clonal fitness promote its relative expansion leading to clonal hematopoiesis (CH). Despite a largely intact hematopoietic output, CH is associated with a heightened risk of progression to hematologic malignancies and with non-hematologic health manifestations, including cardiovascular disease and overall mortality. We focus on the evidence for the role of inflammation in establishing, maintaining and reciprocally being...]]></summary>
        <author>
            <name>Serine Avagyan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and inflammation - the perpetual cycle]]></title>
        <id>pubmed:36593155</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36593155/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired genetic or cytogenetic alterations in a blood stem cell that confer clonal fitness promote its relative expansion leading to clonal hematopoiesis (CH). Despite a largely intact hematopoietic output, CH is associated with a heightened risk of progression to hematologic malignancies and with non-hematologic health manifestations, including cardiovascular disease and overall mortality. We focus on the evidence for the role of inflammation in establishing, maintaining and reciprocally being...]]></summary>
        <author>
            <name>Serine Avagyan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and inflammation - the perpetual cycle]]></title>
        <id>pubmed:36593155</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36593155/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired genetic or cytogenetic alterations in a blood stem cell that confer clonal fitness promote its relative expansion leading to clonal hematopoiesis (CH). Despite a largely intact hematopoietic output, CH is associated with a heightened risk of progression to hematologic malignancies and with non-hematologic health manifestations, including cardiovascular disease and overall mortality. We focus on the evidence for the role of inflammation in establishing, maintaining and reciprocally being...]]></summary>
        <author>
            <name>Serine Avagyan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and inflammation - the perpetual cycle]]></title>
        <id>pubmed:36593155</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36593155/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired genetic or cytogenetic alterations in a blood stem cell that confer clonal fitness promote its relative expansion leading to clonal hematopoiesis (CH). Despite a largely intact hematopoietic output, CH is associated with a heightened risk of progression to hematologic malignancies and with non-hematologic health manifestations, including cardiovascular disease and overall mortality. We focus on the evidence for the role of inflammation in establishing, maintaining and reciprocally being...]]></summary>
        <author>
            <name>Serine Avagyan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and inflammation - the perpetual cycle]]></title>
        <id>pubmed:36593155</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36593155/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired genetic or cytogenetic alterations in a blood stem cell that confer clonal fitness promote its relative expansion leading to clonal hematopoiesis (CH). Despite a largely intact hematopoietic output, CH is associated with a heightened risk of progression to hematologic malignancies and with non-hematologic health manifestations, including cardiovascular disease and overall mortality. We focus on the evidence for the role of inflammation in establishing, maintaining and reciprocally being...]]></summary>
        <author>
            <name>Serine Avagyan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and inflammation - the perpetual cycle]]></title>
        <id>pubmed:36593155</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36593155/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230110200056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired genetic or cytogenetic alterations in a blood stem cell that confer clonal fitness promote its relative expansion leading to clonal hematopoiesis (CH). Despite a largely intact hematopoietic output, CH is associated with a heightened risk of progression to hematologic malignancies and with non-hematologic health manifestations, including cardiovascular disease and overall mortality. We focus on the evidence for the role of inflammation in establishing, maintaining and reciprocally being...]]></summary>
        <author>
            <name>Serine Avagyan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and inflammation - the perpetual cycle]]></title>
        <id>pubmed:36593155</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36593155/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230109200310&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired genetic or cytogenetic alterations in a blood stem cell that confer clonal fitness promote its relative expansion leading to clonal hematopoiesis (CH). Despite a largely intact hematopoietic output, CH is associated with a heightened risk of progression to hematologic malignancies and with non-hematologic health manifestations, including cardiovascular disease and overall mortality. We focus on the evidence for the role of inflammation in establishing, maintaining and reciprocally being...]]></summary>
        <author>
            <name>Serine Avagyan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and inflammation - the perpetual cycle]]></title>
        <id>pubmed:36593155</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36593155/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230108195940&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired genetic or cytogenetic alterations in a blood stem cell that confer clonal fitness promote its relative expansion leading to clonal hematopoiesis (CH). Despite a largely intact hematopoietic output, CH is associated with a heightened risk of progression to hematologic malignancies and with non-hematologic health manifestations, including cardiovascular disease and overall mortality. We focus on the evidence for the role of inflammation in establishing, maintaining and reciprocally being...]]></summary>
        <author>
            <name>Serine Avagyan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and inflammation - the perpetual cycle]]></title>
        <id>pubmed:36593155</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36593155/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230107200413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired genetic or cytogenetic alterations in a blood stem cell that confer clonal fitness promote its relative expansion leading to clonal hematopoiesis (CH). Despite a largely intact hematopoietic output, CH is associated with a heightened risk of progression to hematologic malignancies and with non-hematologic health manifestations, including cardiovascular disease and overall mortality. We focus on the evidence for the role of inflammation in establishing, maintaining and reciprocally being...]]></summary>
        <author>
            <name>Serine Avagyan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and inflammation - the perpetual cycle]]></title>
        <id>pubmed:36593155</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36593155/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired genetic or cytogenetic alterations in a blood stem cell that confer clonal fitness promote its relative expansion leading to clonal hematopoiesis (CH). Despite a largely intact hematopoietic output, CH is associated with a heightened risk of progression to hematologic malignancies and with non-hematologic health manifestations, including cardiovascular disease and overall mortality. We focus on the evidence for the role of inflammation in establishing, maintaining and reciprocally being...]]></summary>
        <author>
            <name>Serine Avagyan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and inflammation - the perpetual cycle]]></title>
        <id>pubmed:36593155</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36593155/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired genetic or cytogenetic alterations in a blood stem cell that confer clonal fitness promote its relative expansion leading to clonal hematopoiesis (CH). Despite a largely intact hematopoietic output, CH is associated with a heightened risk of progression to hematologic malignancies and with non-hematologic health manifestations, including cardiovascular disease and overall mortality. We focus on the evidence for the role of inflammation in establishing, maintaining and reciprocally being...]]></summary>
        <author>
            <name>Serine Avagyan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and inflammation - the perpetual cycle]]></title>
        <id>pubmed:36593155</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36593155/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired genetic or cytogenetic alterations in a blood stem cell that confer clonal fitness promote its relative expansion leading to clonal hematopoiesis (CH). Despite a largely intact hematopoietic output, CH is associated with a heightened risk of progression to hematologic malignancies and with non-hematologic health manifestations, including cardiovascular disease and overall mortality. We focus on the evidence for the role of inflammation in establishing, maintaining and reciprocally being...]]></summary>
        <author>
            <name>Serine Avagyan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36587837</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587837/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36587837</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587837/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36587837</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587837/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36587837</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587837/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230116200008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36587837</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587837/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36587837</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587837/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36587837</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587837/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36587837</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587837/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36587837</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587837/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36587837</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587837/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230110200057&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36587837</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587837/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230109200310&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36587837</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587837/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230108195940&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36587837</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587837/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230107200413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36587837</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587837/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36587837</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587837/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36587837</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587837/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36587837</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587837/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging evidence on the role of clonal hematopoiesis of indeterminate potential in chronic kidney disease]]></title>
        <id>pubmed:36586535</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36586535/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230120200101&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic kidney disease (CKD) was responsible for 1.2 million deaths globally in 2016. Despite the large and growing burden of CKD, treatment options are limited and generally only preserve kidney function. Characterizing molecular precursors to incident and progressive CKD could point to critically needed prevention and treatment strategies. Clonal hematopoiesis of indeterminate potential (CHIP) is typically characterized by the clonal expansion of blood cells carrying somatic mutations in...]]></summary>
        <author>
            <name>Zhijie Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging evidence on the role of clonal hematopoiesis of indeterminate potential in chronic kidney disease]]></title>
        <id>pubmed:36586535</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36586535/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic kidney disease (CKD) was responsible for 1.2 million deaths globally in 2016. Despite the large and growing burden of CKD, treatment options are limited and generally only preserve kidney function. Characterizing molecular precursors to incident and progressive CKD could point to critically needed prevention and treatment strategies. Clonal hematopoiesis of indeterminate potential (CHIP) is typically characterized by the clonal expansion of blood cells carrying somatic mutations in...]]></summary>
        <author>
            <name>Zhijie Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging evidence on the role of clonal hematopoiesis of indeterminate potential in chronic kidney disease]]></title>
        <id>pubmed:36586535</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36586535/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic kidney disease (CKD) was responsible for 1.2 million deaths globally in 2016. Despite the large and growing burden of CKD, treatment options are limited and generally only preserve kidney function. Characterizing molecular precursors to incident and progressive CKD could point to critically needed prevention and treatment strategies. Clonal hematopoiesis of indeterminate potential (CHIP) is typically characterized by the clonal expansion of blood cells carrying somatic mutations in...]]></summary>
        <author>
            <name>Zhijie Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging evidence on the role of clonal hematopoiesis of indeterminate potential in chronic kidney disease]]></title>
        <id>pubmed:36586535</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36586535/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic kidney disease (CKD) was responsible for 1.2 million deaths globally in 2016. Despite the large and growing burden of CKD, treatment options are limited and generally only preserve kidney function. Characterizing molecular precursors to incident and progressive CKD could point to critically needed prevention and treatment strategies. Clonal hematopoiesis of indeterminate potential (CHIP) is typically characterized by the clonal expansion of blood cells carrying somatic mutations in...]]></summary>
        <author>
            <name>Zhijie Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging evidence on the role of clonal hematopoiesis of indeterminate potential in chronic kidney disease]]></title>
        <id>pubmed:36586535</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36586535/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230116200009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic kidney disease (CKD) was responsible for 1.2 million deaths globally in 2016. Despite the large and growing burden of CKD, treatment options are limited and generally only preserve kidney function. Characterizing molecular precursors to incident and progressive CKD could point to critically needed prevention and treatment strategies. Clonal hematopoiesis of indeterminate potential (CHIP) is typically characterized by the clonal expansion of blood cells carrying somatic mutations in...]]></summary>
        <author>
            <name>Zhijie Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging evidence on the role of clonal hematopoiesis of indeterminate potential in chronic kidney disease]]></title>
        <id>pubmed:36586535</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36586535/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic kidney disease (CKD) was responsible for 1.2 million deaths globally in 2016. Despite the large and growing burden of CKD, treatment options are limited and generally only preserve kidney function. Characterizing molecular precursors to incident and progressive CKD could point to critically needed prevention and treatment strategies. Clonal hematopoiesis of indeterminate potential (CHIP) is typically characterized by the clonal expansion of blood cells carrying somatic mutations in...]]></summary>
        <author>
            <name>Zhijie Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging evidence on the role of clonal hematopoiesis of indeterminate potential in chronic kidney disease]]></title>
        <id>pubmed:36586535</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36586535/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic kidney disease (CKD) was responsible for 1.2 million deaths globally in 2016. Despite the large and growing burden of CKD, treatment options are limited and generally only preserve kidney function. Characterizing molecular precursors to incident and progressive CKD could point to critically needed prevention and treatment strategies. Clonal hematopoiesis of indeterminate potential (CHIP) is typically characterized by the clonal expansion of blood cells carrying somatic mutations in...]]></summary>
        <author>
            <name>Zhijie Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging evidence on the role of clonal hematopoiesis of indeterminate potential in chronic kidney disease]]></title>
        <id>pubmed:36586535</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36586535/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic kidney disease (CKD) was responsible for 1.2 million deaths globally in 2016. Despite the large and growing burden of CKD, treatment options are limited and generally only preserve kidney function. Characterizing molecular precursors to incident and progressive CKD could point to critically needed prevention and treatment strategies. Clonal hematopoiesis of indeterminate potential (CHIP) is typically characterized by the clonal expansion of blood cells carrying somatic mutations in...]]></summary>
        <author>
            <name>Zhijie Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging evidence on the role of clonal hematopoiesis of indeterminate potential in chronic kidney disease]]></title>
        <id>pubmed:36586535</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36586535/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic kidney disease (CKD) was responsible for 1.2 million deaths globally in 2016. Despite the large and growing burden of CKD, treatment options are limited and generally only preserve kidney function. Characterizing molecular precursors to incident and progressive CKD could point to critically needed prevention and treatment strategies. Clonal hematopoiesis of indeterminate potential (CHIP) is typically characterized by the clonal expansion of blood cells carrying somatic mutations in...]]></summary>
        <author>
            <name>Zhijie Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging evidence on the role of clonal hematopoiesis of indeterminate potential in chronic kidney disease]]></title>
        <id>pubmed:36586535</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36586535/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic kidney disease (CKD) was responsible for 1.2 million deaths globally in 2016. Despite the large and growing burden of CKD, treatment options are limited and generally only preserve kidney function. Characterizing molecular precursors to incident and progressive CKD could point to critically needed prevention and treatment strategies. Clonal hematopoiesis of indeterminate potential (CHIP) is typically characterized by the clonal expansion of blood cells carrying somatic mutations in...]]></summary>
        <author>
            <name>Zhijie Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Evidence on the Role of Clonal Hematopoiesis of Indeterminate Potential in Chronic Kidney Disease]]></title>
        <id>pubmed:36586535</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36586535/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230110200056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic kidney disease (CKD) was responsible for 1.2 million deaths globally in 2016. Despite the large and growing burden of CKD, treatment options are limited and generally only preserve kidney function. Characterizing molecular precursors to incident and progressive CKD could point to critically needed prevention and treatment strategies. Clonal hematopoiesis of indeterminate potential (CHIP) is typically characterized by the clonal expansion of blood cells carrying somatic mutations in...]]></summary>
        <author>
            <name>Zhijie Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Evidence on the Role of Clonal Hematopoiesis of Indeterminate Potential in Chronic Kidney Disease]]></title>
        <id>pubmed:36586535</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36586535/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230109200310&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic kidney disease (CKD) was responsible for 1.2 million deaths globally in 2016. Despite the large and growing burden of CKD, treatment options are limited and generally only preserve kidney function. Characterizing molecular precursors to incident and progressive CKD could point to critically needed prevention and treatment strategies. Clonal hematopoiesis of indeterminate potential (CHIP) is typically characterized by the clonal expansion of blood cells carrying somatic mutations in...]]></summary>
        <author>
            <name>Zhijie Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Evidence on the Role of Clonal Hematopoiesis of Indeterminate Potential in Chronic Kidney Disease]]></title>
        <id>pubmed:36586535</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36586535/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230108195940&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic kidney disease (CKD) was responsible for 1.2 million deaths globally in 2016. Despite the large and growing burden of CKD, treatment options are limited and generally only preserve kidney function. Characterizing molecular precursors to incident and progressive CKD could point to critically needed prevention and treatment strategies. Clonal hematopoiesis of indeterminate potential (CHIP) is typically characterized by the clonal expansion of blood cells carrying somatic mutations in...]]></summary>
        <author>
            <name>Zhijie Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Evidence on the Role of Clonal Hematopoiesis of Indeterminate Potential in Chronic Kidney Disease]]></title>
        <id>pubmed:36586535</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36586535/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230107200413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic kidney disease (CKD) was responsible for 1.2 million deaths globally in 2016. Despite the large and growing burden of CKD, treatment options are limited and generally only preserve kidney function. Characterizing molecular precursors to incident and progressive CKD could point to critically needed prevention and treatment strategies. Clonal hematopoiesis of indeterminate potential (CHIP) is typically characterized by the clonal expansion of blood cells carrying somatic mutations in...]]></summary>
        <author>
            <name>Zhijie Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Evidence on the Role of Clonal Hematopoiesis of Indeterminate Potential in Chronic Kidney Disease]]></title>
        <id>pubmed:36586535</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36586535/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic kidney disease (CKD) was responsible for 1.2 million deaths globally in 2016. Despite the large and growing burden of CKD, treatment options are limited and generally only preserve kidney function. Characterizing molecular precursors to incident and progressive CKD could point to critically needed prevention and treatment strategies. Clonal hematopoiesis of indeterminate potential (CHIP) is typically characterized by the clonal expansion of blood cells carrying somatic mutations in...]]></summary>
        <author>
            <name>Zhijie Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Evidence on the Role of Clonal Hematopoiesis of Indeterminate Potential in Chronic Kidney Disease]]></title>
        <id>pubmed:36586535</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36586535/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic kidney disease (CKD) was responsible for 1.2 million deaths globally in 2016. Despite the large and growing burden of CKD, treatment options are limited and generally only preserve kidney function. Characterizing molecular precursors to incident and progressive CKD could point to critically needed prevention and treatment strategies. Clonal hematopoiesis of indeterminate potential (CHIP) is typically characterized by the clonal expansion of blood cells carrying somatic mutations in...]]></summary>
        <author>
            <name>Zhijie Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Evidence on the Role of Clonal Hematopoiesis of Indeterminate Potential in Chronic Kidney Disease]]></title>
        <id>pubmed:36586535</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36586535/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic kidney disease (CKD) was responsible for 1.2 million deaths globally in 2016. Despite the large and growing burden of CKD, treatment options are limited and generally only preserve kidney function. Characterizing molecular precursors to incident and progressive CKD could point to critically needed prevention and treatment strategies. Clonal hematopoiesis of indeterminate potential (CHIP) is typically characterized by the clonal expansion of blood cells carrying somatic mutations in...]]></summary>
        <author>
            <name>Zhijie Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Evidence on the Role of Clonal Hematopoiesis of Indeterminate Potential in Chronic Kidney Disease]]></title>
        <id>pubmed:36586535</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36586535/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic kidney disease (CKD) was responsible for 1.2 million deaths globally in 2016. Despite the large and growing burden of CKD, treatment options are limited and generally only preserve kidney function. Characterizing molecular precursors to incident and progressive CKD could point to critically needed prevention and treatment strategies. Clonal hematopoiesis of indeterminate potential (CHIP) is typically characterized by the clonal expansion of blood cells carrying somatic mutations in...]]></summary>
        <author>
            <name>Zhijie Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Evidence on the Role of Clonal Hematopoiesis of Indeterminate Potential in Chronic Kidney Disease]]></title>
        <id>pubmed:36586535</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36586535/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic kidney disease (CKD) was responsible for 1.2 million deaths globally in 2016. Despite the large and growing burden of CKD, treatment options are limited and generally only preserve kidney function. Characterizing molecular precursors to incident and progressive CKD could point to critically needed prevention and treatment strategies. Clonal hematopoiesis of indeterminate potential (CHIP) is typically characterized by the clonal expansion of blood cells carrying somatic mutations in...]]></summary>
        <author>
            <name>Zhijie Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell resolved ploidy and chromosomal aberrations in nonalcoholic steatohepatitis-(NASH) induced hepatocellular carcinoma and its precursor lesions]]></title>
        <id>pubmed:36587184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nonalcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC) and its precursor, nonalcoholic fatty liver disease (NAFLD) are an unmet health issue due to widespread obesity. We assessed copy number changes of genes associated with hepatocarcinogenesis and oxidative pathways at a single-cell level. Eleven patients with NASH-HCC and 11 patients with NAFLD were included. Eight probes were analyzed using multiplex interphase fluorescence in situ hybridization (miFISH), single-cell...]]></summary>
        <author>
            <name>Juliane Friemel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell resolved ploidy and chromosomal aberrations in nonalcoholic steatohepatitis-(NASH) induced hepatocellular carcinoma and its precursor lesions]]></title>
        <id>pubmed:36587184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nonalcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC) and its precursor, nonalcoholic fatty liver disease (NAFLD) are an unmet health issue due to widespread obesity. We assessed copy number changes of genes associated with hepatocarcinogenesis and oxidative pathways at a single-cell level. Eleven patients with NASH-HCC and 11 patients with NAFLD were included. Eight probes were analyzed using multiplex interphase fluorescence in situ hybridization (miFISH), single-cell...]]></summary>
        <author>
            <name>Juliane Friemel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell resolved ploidy and chromosomal aberrations in nonalcoholic steatohepatitis-(NASH) induced hepatocellular carcinoma and its precursor lesions]]></title>
        <id>pubmed:36587184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230116200008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nonalcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC) and its precursor, nonalcoholic fatty liver disease (NAFLD) are an unmet health issue due to widespread obesity. We assessed copy number changes of genes associated with hepatocarcinogenesis and oxidative pathways at a single-cell level. Eleven patients with NASH-HCC and 11 patients with NAFLD were included. Eight probes were analyzed using multiplex interphase fluorescence in situ hybridization (miFISH), single-cell...]]></summary>
        <author>
            <name>Juliane Friemel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell resolved ploidy and chromosomal aberrations in nonalcoholic steatohepatitis-(NASH) induced hepatocellular carcinoma and its precursor lesions]]></title>
        <id>pubmed:36587184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nonalcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC) and its precursor, nonalcoholic fatty liver disease (NAFLD) are an unmet health issue due to widespread obesity. We assessed copy number changes of genes associated with hepatocarcinogenesis and oxidative pathways at a single-cell level. Eleven patients with NASH-HCC and 11 patients with NAFLD were included. Eight probes were analyzed using multiplex interphase fluorescence in situ hybridization (miFISH), single-cell...]]></summary>
        <author>
            <name>Juliane Friemel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell resolved ploidy and chromosomal aberrations in nonalcoholic steatohepatitis-(NASH) induced hepatocellular carcinoma and its precursor lesions]]></title>
        <id>pubmed:36587184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nonalcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC) and its precursor, nonalcoholic fatty liver disease (NAFLD) are an unmet health issue due to widespread obesity. We assessed copy number changes of genes associated with hepatocarcinogenesis and oxidative pathways at a single-cell level. Eleven patients with NASH-HCC and 11 patients with NAFLD were included. Eight probes were analyzed using multiplex interphase fluorescence in situ hybridization (miFISH), single-cell...]]></summary>
        <author>
            <name>Juliane Friemel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell resolved ploidy and chromosomal aberrations in nonalcoholic steatohepatitis-(NASH) induced hepatocellular carcinoma and its precursor lesions]]></title>
        <id>pubmed:36587184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nonalcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC) and its precursor, nonalcoholic fatty liver disease (NAFLD) are an unmet health issue due to widespread obesity. We assessed copy number changes of genes associated with hepatocarcinogenesis and oxidative pathways at a single-cell level. Eleven patients with NASH-HCC and 11 patients with NAFLD were included. Eight probes were analyzed using multiplex interphase fluorescence in situ hybridization (miFISH), single-cell...]]></summary>
        <author>
            <name>Juliane Friemel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell resolved ploidy and chromosomal aberrations in nonalcoholic steatohepatitis-(NASH) induced hepatocellular carcinoma and its precursor lesions]]></title>
        <id>pubmed:36587184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nonalcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC) and its precursor, nonalcoholic fatty liver disease (NAFLD) are an unmet health issue due to widespread obesity. We assessed copy number changes of genes associated with hepatocarcinogenesis and oxidative pathways at a single-cell level. Eleven patients with NASH-HCC and 11 patients with NAFLD were included. Eight probes were analyzed using multiplex interphase fluorescence in situ hybridization (miFISH), single-cell...]]></summary>
        <author>
            <name>Juliane Friemel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell resolved ploidy and chromosomal aberrations in nonalcoholic steatohepatitis-(NASH) induced hepatocellular carcinoma and its precursor lesions]]></title>
        <id>pubmed:36587184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nonalcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC) and its precursor, nonalcoholic fatty liver disease (NAFLD) are an unmet health issue due to widespread obesity. We assessed copy number changes of genes associated with hepatocarcinogenesis and oxidative pathways at a single-cell level. Eleven patients with NASH-HCC and 11 patients with NAFLD were included. Eight probes were analyzed using multiplex interphase fluorescence in situ hybridization (miFISH), single-cell...]]></summary>
        <author>
            <name>Juliane Friemel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell resolved ploidy and chromosomal aberrations in nonalcoholic steatohepatitis-(NASH) induced hepatocellular carcinoma and its precursor lesions]]></title>
        <id>pubmed:36587184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230110200057&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nonalcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC) and its precursor, nonalcoholic fatty liver disease (NAFLD) are an unmet health issue due to widespread obesity. We assessed copy number changes of genes associated with hepatocarcinogenesis and oxidative pathways at a single-cell level. Eleven patients with NASH-HCC and 11 patients with NAFLD were included. Eight probes were analyzed using multiplex interphase fluorescence in situ hybridization (miFISH), single-cell...]]></summary>
        <author>
            <name>Juliane Friemel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell resolved ploidy and chromosomal aberrations in nonalcoholic steatohepatitis-(NASH) induced hepatocellular carcinoma and its precursor lesions]]></title>
        <id>pubmed:36587184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230109200310&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nonalcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC) and its precursor, nonalcoholic fatty liver disease (NAFLD) are an unmet health issue due to widespread obesity. We assessed copy number changes of genes associated with hepatocarcinogenesis and oxidative pathways at a single-cell level. Eleven patients with NASH-HCC and 11 patients with NAFLD were included. Eight probes were analyzed using multiplex interphase fluorescence in situ hybridization (miFISH), single-cell...]]></summary>
        <author>
            <name>Juliane Friemel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell resolved ploidy and chromosomal aberrations in nonalcoholic steatohepatitis-(NASH) induced hepatocellular carcinoma and its precursor lesions]]></title>
        <id>pubmed:36587184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230108195940&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nonalcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC) and its precursor, nonalcoholic fatty liver disease (NAFLD) are an unmet health issue due to widespread obesity. We assessed copy number changes of genes associated with hepatocarcinogenesis and oxidative pathways at a single-cell level. Eleven patients with NASH-HCC and 11 patients with NAFLD were included. Eight probes were analyzed using multiplex interphase fluorescence in situ hybridization (miFISH), single-cell...]]></summary>
        <author>
            <name>Juliane Friemel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell resolved ploidy and chromosomal aberrations in nonalcoholic steatohepatitis-(NASH) induced hepatocellular carcinoma and its precursor lesions]]></title>
        <id>pubmed:36587184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230107200413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nonalcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC) and its precursor, nonalcoholic fatty liver disease (NAFLD) are an unmet health issue due to widespread obesity. We assessed copy number changes of genes associated with hepatocarcinogenesis and oxidative pathways at a single-cell level. Eleven patients with NASH-HCC and 11 patients with NAFLD were included. Eight probes were analyzed using multiplex interphase fluorescence in situ hybridization (miFISH), single-cell...]]></summary>
        <author>
            <name>Juliane Friemel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell resolved ploidy and chromosomal aberrations in nonalcoholic steatohepatitis-(NASH) induced hepatocellular carcinoma and its precursor lesions]]></title>
        <id>pubmed:36587184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nonalcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC) and its precursor, nonalcoholic fatty liver disease (NAFLD) are an unmet health issue due to widespread obesity. We assessed copy number changes of genes associated with hepatocarcinogenesis and oxidative pathways at a single-cell level. Eleven patients with NASH-HCC and 11 patients with NAFLD were included. Eight probes were analyzed using multiplex interphase fluorescence in situ hybridization (miFISH), single-cell...]]></summary>
        <author>
            <name>Juliane Friemel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell resolved ploidy and chromosomal aberrations in nonalcoholic steatohepatitis-(NASH) induced hepatocellular carcinoma and its precursor lesions]]></title>
        <id>pubmed:36587184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nonalcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC) and its precursor, nonalcoholic fatty liver disease (NAFLD) are an unmet health issue due to widespread obesity. We assessed copy number changes of genes associated with hepatocarcinogenesis and oxidative pathways at a single-cell level. Eleven patients with NASH-HCC and 11 patients with NAFLD were included. Eight probes were analyzed using multiplex interphase fluorescence in situ hybridization (miFISH), single-cell...]]></summary>
        <author>
            <name>Juliane Friemel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell resolved ploidy and chromosomal aberrations in nonalcoholic steatohepatitis-(NASH) induced hepatocellular carcinoma and its precursor lesions]]></title>
        <id>pubmed:36587184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nonalcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC) and its precursor, nonalcoholic fatty liver disease (NAFLD) are an unmet health issue due to widespread obesity. We assessed copy number changes of genes associated with hepatocarcinogenesis and oxidative pathways at a single-cell level. Eleven patients with NASH-HCC and 11 patients with NAFLD were included. Eight probes were analyzed using multiplex interphase fluorescence in situ hybridization (miFISH), single-cell...]]></summary>
        <author>
            <name>Juliane Friemel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell resolved ploidy and chromosomal aberrations in nonalcoholic steatohepatitis-(NASH) induced hepatocellular carcinoma and its precursor lesions]]></title>
        <id>pubmed:36587184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nonalcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC) and its precursor, nonalcoholic fatty liver disease (NAFLD) are an unmet health issue due to widespread obesity. We assessed copy number changes of genes associated with hepatocarcinogenesis and oxidative pathways at a single-cell level. Eleven patients with NASH-HCC and 11 patients with NAFLD were included. Eight probes were analyzed using multiplex interphase fluorescence in situ hybridization (miFISH), single-cell...]]></summary>
        <author>
            <name>Juliane Friemel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell resolved ploidy and chromosomal aberrations in nonalcoholic steatohepatitis-(NASH) induced hepatocellular carcinoma and its precursor lesions]]></title>
        <id>pubmed:36587184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nonalcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC) and its precursor, nonalcoholic fatty liver disease (NAFLD) are an unmet health issue due to widespread obesity. We assessed copy number changes of genes associated with hepatocarcinogenesis and oxidative pathways at a single-cell level. Eleven patients with NASH-HCC and 11 patients with NAFLD were included. Eight probes were analyzed using multiplex interphase fluorescence in situ hybridization (miFISH), single-cell...]]></summary>
        <author>
            <name>Juliane Friemel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230116200009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230110200056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230109200310&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230108195940&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230107200413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36584935</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36584935/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36584935</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36584935/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36584935</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36584935/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230116200008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36584935</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36584935/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36584935</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36584935/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36584935</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36584935/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36584935</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36584935/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36584935</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36584935/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36584935</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36584935/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230110200057&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36584935</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36584935/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230109200310&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36584935</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36584935/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230108195940&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36584935</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36584935/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230107200413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36584935</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36584935/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36584935</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36584935/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36584935</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36584935/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36584935</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36584935/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36584935</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36584935/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36584935</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36584935/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230116200008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230110200057&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230109200310&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230108195940&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230107200413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230119200127&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230116200009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230110200056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230109200310&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230108195940&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230107200413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230118200219&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230117200313&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230116200009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230110200056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230109200310&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230108195940&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230107200413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230116200008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230116200008&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230115200000&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230114200358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230113195729&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230112200146&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230111200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230110200057&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230110200057&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230110200057&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230110200057&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230109200310&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230109200310&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230109200310&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230109200310&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230109200310&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230109200310&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230108195940&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230108195940&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230108195940&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230108195940&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230108195940&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230108195940&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230107200413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230107200413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230107200413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230107200413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230107200413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230107200413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Nodal interferon exposure drives tumour-specific tolerance]]></title>
        <id>72a3a11d39c217b1a80cbb551444e6f6</id>
        <link href="https://twitter.com/NatureRevCancer/status/1533878403463405569"/>
        <updated>2022-06-06T18:28:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Nodal interferon exposure drives tumour-specific tolerance https://t.co/FT4NeBcFTg pic.twitter.com/NRHkVDUsOr
 NatureReviewsCancer (@NatureRevCancer) June 6, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@VIBConferences: #Cancer #immunotherapy has become a crucial pillar of anticancer therapy. 19 leading researchers at #ImmunoOnco22 will give new insights into the immune response to tumors and tackle unresolved questions.Registration Deadline: Thursday 2 June. Read more]]></title>
        <id>bb6bc242bcbc356c4a38db850e74d812</id>
        <link href="https://twitter.com/VIBConferences/status/1531132720952266752"/>
        <updated>2022-05-30T04:37:42.000Z</updated>
        <summary type="html"><![CDATA[#Cancer #immunotherapy has become a crucial pillar of anticancer therapy. 19 leading researchers at #ImmunoOnco22 will give new insights into the immune response to tumors and tackle unresolved questions.
Registration Deadline: Thursday 2 June. Read more https://t.co/cc0HC5cj6W pic.twitter.com/u8LFuzBbsV
 VIB Conferences (@VIBConferences) May 30, 2022]]></summary>
        <author>
            <name>@VIBConferences</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Nonsense-mediated RNA decay: an emerging modulator of malignancy]]></title>
        <id>ed6c996dc1a718afb523de6229a53131</id>
        <link href="https://twitter.com/NatureRevCancer/status/1530198403686072320"/>
        <updated>2022-05-27T14:45:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Nonsense-mediated RNA decay: an emerging modulator of malignancy https://t.co/wjuHplkpof pic.twitter.com/1SoKYhRsPO
 NatureReviewsCancer (@NatureRevCancer) May 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Our June issue, out NOW! With articles on #therapyresistance, #senescence & targeting CDK4 & CDK6 in #cancer! Plus, a Comment on cancer mRNA vaccines as well as the launch of our new Tools of the Trade articles #NRCToT. So much content ]]></title>
        <id>d15a3a4b24853812d7fa21fd56de5815</id>
        <link href="https://twitter.com/NatureRevCancer/status/1530174481313972224"/>
        <updated>2022-05-27T13:10:00.000Z</updated>
        <summary type="html"><![CDATA[Our June issue, out NOW! With articles on #therapyresistance, #senescence & targeting CDK4 & CDK6 in #cancer! Plus, a Comment on cancer mRNA vaccines as well as the launch of our new Tools of the Trade articles #NRCToT. So much content 
 https://t.co/Fo6XRWV3OZ@natrescancer pic.twitter.com/rbxRPqLV6g
 NatureReviewsCancer (@NatureRevCancer) May 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@UlrikeHarjes: This Review by @MarcusDGon @cantleylab is part of the @NatureRevCancer series on #Diet & #SystemicMetabolism in cancer:  do love this topic in general plus I am handling research at @NatureMedicine now.. get in touch if you have something of interest]]></title>
        <id>fe13755a2693ea65459e5e21df097d2a</id>
        <link href="https://twitter.com/UlrikeHarjes/status/1529747629936193537"/>
        <updated>2022-05-26T08:53:50.000Z</updated>
        <summary type="html"><![CDATA[This Review by @MarcusDGon @cantleylab is part of the @NatureRevCancer series on #Diet & #SystemicMetabolism in cancer: https://t.co/p3Y2cdNhco
I do love this topic in general plus I am handling research at @NatureMedicine now.. get in touch if you have something of interest https://t.co/qWH2dTv8j9
 Ulrike Harjes (@UlrikeHarjes) May 26, 2022]]></summary>
        <author>
            <name>@UlrikeHarjes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Developing dietary interventions as therapy for cancer]]></title>
        <id>9ba5279424b31b0122a4ae20c18e6d03</id>
        <link href="https://twitter.com/NatureRevCancer/status/1529516411059437568"/>
        <updated>2022-05-25T17:35:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Developing dietary interventions as therapy for cancer https://t.co/ijuqctk1wJ pic.twitter.com/KHPpMKnCFa
 NatureReviewsCancer (@NatureRevCancer) May 25, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Digging for treasures in the tumour interactome]]></title>
        <id>611d40f2e6ea2796b028bebda41a86dd</id>
        <link href="https://twitter.com/NatureRevCancer/status/1526928478490095616"/>
        <updated>2022-05-18T14:11:32.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Digging for treasures in the tumour interactome https://t.co/NhHYAwUgLE
 NatureReviewsCancer (@NatureRevCancer) May 18, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: As part of our overall commitment to diversity, equity and inclusion at Springer Nature, wed like to better understand what DEI means within the global research community. Take the survey here]]></title>
        <id>9590a971b00448cd312078183965b21d</id>
        <link href="https://twitter.com/NatureRevCancer/status/1526560254091313156"/>
        <updated>2022-05-17T13:48:21.000Z</updated>
        <summary type="html"><![CDATA[As part of our overall commitment to diversity, equity and inclusion at Springer Nature, wed like to better understand what DEI means within the global research community. Take the survey here https://t.co/03yLiUxFTq
 NatureReviewsCancer (@NatureRevCancer) May 17, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Newsflash! We have a new article type in the journal - Tools of the Trade #NRCToT   where we hope to enable more #ECRs to interact with the editorial team & have a bigger voice in our content. For more info, check out the Editorial ]]></title>
        <id>aa38ff4245b93e964773f191844ddc7a</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524772831904509953"/>
        <updated>2022-05-12T15:25:46.000Z</updated>
        <summary type="html"><![CDATA[Newsflash! We have a new article type in the journal - Tools of the Trade #NRCToT   where we hope to enable more #ECRs to interact with the editorial team & have a bigger voice in our content. For more info, check out the Editorial  https://t.co/VbyoUJmTRJ
 NatureReviewsCancer (@NatureRevCancer) May 12, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Tools for the next generation]]></title>
        <id>65aca76b9f794aaa668d84ad32dca4a0</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524068259712036864"/>
        <updated>2022-05-10T16:46:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Tools for the next generation https://t.co/lEzTPFYDf5
 NatureReviewsCancer (@NatureRevCancer) May 10, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Hunting down rare drug-tolerant cycling cells with Watermelon]]></title>
        <id>afa9b6784b4ccc7c05ed4efd26ddfb2d</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524022709386190856"/>
        <updated>2022-05-10T13:45:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Hunting down rare drug-tolerant cycling cells with Watermelon https://t.co/XXT0c9SAYX
 NatureReviewsCancer (@NatureRevCancer) May 10, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@VarunVenkatara2: Very happy that our latest Perspective is now online @NatureRevCancer ! We discuss implications of malignant, multicellular networks and potential therapeutic strategies how to disconnect them. Thanks to everyone involved ! #CancerNeuroscience #TumorMicrotubes #neurotwitter]]></title>
        <id>43e2d5ccebc9030f737d656f47ac9d98</id>
        <link href="https://twitter.com/VarunVenkatara2/status/1520050291986604033"/>
        <updated>2022-04-29T14:40:05.000Z</updated>
        <summary type="html"><![CDATA[Very happy that our latest Perspective is now online @NatureRevCancer ! We discuss implications of malignant, multicellular networks and potential therapeutic strategies how to disconnect them. Thanks to everyone involved ! #CancerNeuroscience #TumorMicrotubes #neurotwitter https://t.co/S55cKTGNFd
 Varun Venkataramani (@VarunVenkatara2) April 29, 2022]]></summary>
        <author>
            <name>@VarunVenkatara2</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! An inhospitable site]]></title>
        <id>9f6b8644378881f4c2e6b6833c93fc2f</id>
        <link href="https://twitter.com/NatureRevCancer/status/1520020349068316673"/>
        <updated>2022-04-29T12:41:06.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! An inhospitable site https://t.co/0dvqIKCWxh pic.twitter.com/PtY8J9Fz7r
 NatureReviewsCancer (@NatureRevCancer) April 29, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Disconnecting multicellular networks in brain tumours]]></title>
        <id>f6d91efcd60dae769e2722585bdfa8df</id>
        <link href="https://twitter.com/NatureRevCancer/status/1520020340201598978"/>
        <updated>2022-04-29T12:41:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Disconnecting multicellular networks in brain tumours https://t.co/LJrzy8bRma pic.twitter.com/CO7BnooP0r
 NatureReviewsCancer (@NatureRevCancer) April 29, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Our May issue, out NOW! With Reviews on #CRISPR in cancer biology & #therapy, ROS in tumour development & progression, and cancer #proteogenomics, and Comments on esophageal cancer research in Eastern Africa and on Critical Race Theory.]]></title>
        <id>76e3b436bc8e43ad21366a80c120e395</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519678964364623872"/>
        <updated>2022-04-28T14:04:34.000Z</updated>
        <summary type="html"><![CDATA[Our May issue, out NOW! With Reviews on #CRISPR in cancer biology & #therapy, ROS in tumour development & progression, and cancer #proteogenomics, and Comments on esophageal cancer research in Eastern Africa and on Critical Race Theory.
 https://t.co/vQwHFJhpwv@natrescancer pic.twitter.com/6kYgjRYhdT
 NatureReviewsCancer (@NatureRevCancer) April 28, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@tmurraystewart: Our latest publication on #polyamines is online!@HopkinsMedicine]]></title>
        <id>fdf224ea293cdf039086d16e5699a59a</id>
        <link href="https://twitter.com/tmurraystewart/status/1519413460978704384"/>
        <updated>2022-04-27T20:29:33.000Z</updated>
        <summary type="html"><![CDATA[Our latest publication on #polyamines is online!@HopkinsMedicine https://t.co/ehRGgN1w9R
 Tracy Murray Stewart (@tmurraystewart) April 27, 2022]]></summary>
        <author>
            <name>@tmurraystewart</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Polyamines in cancer: integrating organismal metabolism and antitumour immunity]]></title>
        <id>4f43226ec4dc8e531ff6e64a9c5ab8e6</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519381375874265088"/>
        <updated>2022-04-27T18:22:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Polyamines in cancer: integrating organismal metabolism and antitumour immunity https://t.co/YCJX1hRQLO pic.twitter.com/zRUCRNXyxH
 NatureReviewsCancer (@NatureRevCancer) April 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW #ResearchHighlight! Lv, Liu, Mo & co demonstrate that in pancreatic #PDAC cells, gasdermin E transports YBX1 to the nucleus, which promotes mucin expression, thereby providing tumour cells with a barrier against digestive enzymes.]]></title>
        <id>a44ed79b9f76aad377b9272fb392f553</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519317944995569664"/>
        <updated>2022-04-27T14:10:00.000Z</updated>
        <summary type="html"><![CDATA[NEW #ResearchHighlight! Lv, Liu, Mo & co demonstrate that in pancreatic #PDAC cells, gasdermin E transports YBX1 to the nucleus, which promotes mucin expression, thereby providing tumour cells with a barrier against digestive enzymes.
 https://t.co/JTUhX0DHQ1@natrescancer pic.twitter.com/2PdCmsDu2p
 NatureReviewsCancer (@NatureRevCancer) April 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: In the April issue of @NatureRevCancer | Comment, Reimagining cancer research with art, by @CancerSciArtist, Stefani Shoreibah & @tdanino  @natrescancer @Columbia]]></title>
        <id>06ff7641d8f5fcc0dff91f835ac3bbc1</id>
        <link href="https://twitter.com/NatureRevCancer/status/1518967636561956865"/>
        <updated>2022-04-26T14:58:00.000Z</updated>
        <summary type="html"><![CDATA[In the April issue of @NatureRevCancer | Comment, Reimagining cancer research with art, by @CancerSciArtist, Stefani Shoreibah & @tdanino
 https://t.co/GeTVCMJQsp @natrescancer
 @Columbia pic.twitter.com/ZXW6A0Fe0c
 NatureReviewsCancer (@NatureRevCancer) April 26, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Tracking dormant disseminated tumour cells]]></title>
        <id>96b2ddff4eb269cf343213c6a1b1ce95</id>
        <link href="https://twitter.com/NatureRevCancer/status/1518563607440621569"/>
        <updated>2022-04-25T12:12:32.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Tracking dormant disseminated tumour cells https://t.co/kSXyWAvCxF
 NatureReviewsCancer (@NatureRevCancer) April 25, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
</feed>